Screening for cofactors in Roquin-mediated post-transcriptional gene regulation by Rehage, Nina Beate
	Aus	dem	Institut	für	Immunologie	der	Ludwig-Maximilians-Universität	München	 Leitung:	Prof.	Dr.	Thomas	Brocker	
 
Screening	for	cofactors	in	Roquin-mediated	
post-transcriptional	gene	regulation	
	
Dissertation	zum	Erwerb	des	Doktorgrades		der	Naturwissenschaften	(Dr.	rer.	nat.)	
		an	der	Medizinischen	Fakultät	der		Ludwig-Maximilians-Universität	zu	München		vorgelegt	von	
	Nina	Beate	Rehage	aus	Bayreuth		München,	2016	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	 Für	meine	Eltern	
	
	
	
Gedruckt	mit	Genehmigung	der	Medizinischen	Fakultät	der	
Ludwig-Maximilians-Universität	München 		Betreuer:		 	 	 	 	 Prof.	Dr.	Vigo	Heissmeyer Zweitgutachter:		 	 	 	 Prof.	Dr.	Peter	Becker Dekan:		 	 	 	 	 Prof.	Dr.	med.	dent.	Reinhard	Hickel	Tag	der	mündlichen	Prüfung:		 	 08.11.2016	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
									
Eidesstattliche	Versicherung	 5		
Eidesstattliche	Versicherung	
Rehage,	Nina	_____________________________________	
Name,	Vorname		
 Ich	erkläre	hiermit	an	Eides	statt,	dass	ich	die	vorliegende	Dissertation	mit	dem	Thema		
	“Screening	for	cofactors	in	Roquin-mediated	post-transcriptional	
gene	regulation”		
 selbständig	verfasst,	mich	außer	der	angegebenen	keiner	weiteren	Hilfsmittel	bedient	und	alle	Erkenntnisse,	die	aus	dem	Schrifttum	ganz	oder	annähernd	übernommen	sind,	als	solche	kenntlich	gemacht	und	nach	ihrer	Herkunft	unter	Bezeichnung	der	Fundstelle	einzeln	nachgewiesen	habe.		
 Ich	erkläre	des	Weiteren,	dass	die	hier	vorgelegte	Dissertation	nicht	in	gleicher	oder	in	ähnlicher	Form	bei	einer	anderen	Stelle	zur	Erlangung	eines	akademischen	Grades	eingereicht	wurde.					___________________	 	 ______________________________	
Ort,	Datum		 	 	 	 Unterschrift	Doktorandin		
	
		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Summary	 	 7	 		
Summary	
Roquin	 paralogs	 are	 RNA-binding	 proteins	 and	 crucial	 regulators	 of	 T	 cell	differentiation.	Roquin-1	binds	to	the	3’	UTR	of	its	target	mRNAs,	which	are	cytokines,	costimulatory	 receptors	 and	 transcription	 factors	 or	 modulators,	 leading	 to	 post-transcriptional	repression	of	mRNA	expression.	Mutation	of	Roquin-1	or	T	cell-specific	ablation	of	Roquin-1	and	its	paralog	Roquin-2	in	mice	causes	spontaneous	activation	of	T	cells	and	the	accumulation	of	T	follicular	helper	cells	and	Th17	cells.	The	resulting	autoimmune	 phenotypes	 and	 pathology	 in	 mice	 are	 similar	 to	 systemic	 lupus	erythematosus	(SLE)	for	the	Roquin-1	point	mutant	or	show	lung	pathology	for	mice	that	 lack	 Roquin	 proteins	 in	 T	 cells.	 Still,	 the	 mechanism	 of	 Roquin-mediated	 post-transcriptional	 gene	 regulation	 and	 especially	 the	 identities	 of	 regulators	 and	cofactors	of	Roquin	have	not	been	resolved.		In	 order	 to	 identify	 cofactors	 of	 Roquin-1	 in	 its	 gene	 regulatory	 pathway,	 we	performed	two	high-throughput	screens	with	reporter	cell	 lines.	First,	new	cofactors	of	 Roquin-1	 in	 post-transcriptional	 gene	 regulation	 of	 the	 T	 cell	 costimulatory	receptor	 ICOS	 were	 identified	 in	 a	 targeted	 RNAi	 screen.	 In	 a	 second	 approach,	 a	genome-wide	 CRISPR/Cas9	 screen	 led	 to	 the	 identification	 of	 protein	 networks	involved	 in	 a	 new	 pathway	 of	 Roquin-induced	 cell	 death.	 Focusing	 on	 RNA-binding	proteins,	I	developed	a	hit	validation	strategy	and	could	confirm	the	uncharacterized	protein	Nufip2	as	a	novel	player	 in	this	pathway.	The	burning	question	how	Roquin-mediated	 ICOS	 repression	 involves	 Nufip2	 was	 subsequently	 addressed	 in	 in-depth	analyses.	 These	 uncovered	 that	 Nufip2	 interacts	 with	 Roquin-1	 in	 cells.	 This	interaction	was	direct	and	showed	high	affinity.	The	cis-elements	in	human	ICOS	that	are	 targeted	 by	 Roquin-1	 and	 which	 are	 potentially	 coregulated	 by	 Nufip2	 were	mapped	and	 the	kinetics	of	 Icos	 regulation	during	 effector	T	 cell	 differentiation	was	determined.	 In	 this	 time	 course	 of	 T	 cell	 activation	 Nufip2	 and	 other	 potential	cofactors	of	Roquin-1	showed	strikingly	different	expression	patterns,	suggesting	that	different	 cofactors	 contribute	 to	 Roquin’s	 function	 and	 Icos	 regulation	 in	 a	 dynamic	manner.	Overall,	the	identification	and	validation	of	new	cofactors	of	Roquin-1	in	this	research	 project	 strongly	 expands	 current	 knowledge	 on	 the	 assembly	 of	 mRNA-protein	 complexes	 that	 coordinate	 Roquin-mediated	 mRNA	 degradation,	 and	 thus	contributes	to	our	understanding	of	its	role	in	mediating	immunological	tolerance.	
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Zusammenfassung	
Die	 Paraloge	 Roquin-1	 und	 Roquin-2	 sind	 RNS-bindende	 Proteine,	 welche	 einen	wichtigen	 Beitrag	 zur	 Kontrolle	 der	 T-Helferzell-Differenzierung	 leisten.	 Roquin-1	bindet	an	Sekundärstrukturen	im	untranslatierten	Bereichen	seiner	Ziel-mRNS,	die	für	Zytokine,	 kostimulatorische	 Rezeptoren,	 Transkriptionsfaktoren	 und	Transkriptionsmodulatoren	 kodieren,	 und	 induziert	 eine	 post-transkriptionelle	Repression	der	mRNS-Expression.	Eine	Punktmutation	in	Roquin-1	oder	die	Deletion	beider	 Roquin-Paraloge	 in	 T-Zellen	 führt	 in	 Mausmodellen	 zu	 einem	 spontanen	 T-Zellaktivierungs-Phänotyp	 und	 einer	 Anreicherung	 von	 follikulären	 T-Helferzellen	beziehungsweise	 von	 Th17	 Zellen.	 Im	 Falle	 der	 Roquin-Punktmutation	 kommt	 es	hierdurch	zu	Lupus-ähnlicher	Autoimmunität,	während	das	Fehlen	von	Roquin	 in	T-Zellen	 krankhafte	 Veränderungen	 des	 Lungengewebes	 hervorruft.	 Der	Mechanismus	der	 Roquin-vermittelten	 post-transkriptionellen	 Genregulation	 ist	 jedoch	 noch	 nicht	vollständig	aufgeklärt,	und	 insbesondere	essentielle	Kofaktoren	und	Regulatoren	der	Roquin-Funktion	sind	weitestgehend	unbekannt.		Um	 neue	 Kofaktoren	 von	 Roquin-1	 in	 seinem	 genregulatorischen	 Signalweg	 zu	identifizieren,	 wurden	 im	 Zuge	 dieser	 Arbeit	 zwei	 verschiedene	 Hochdurchsatz-Screenings	mit	Reporter-Zelllinien	durchgeführt.	In	einem	RNS-Interferenz-Screening	wurden	 sieben	 verschiedene	 Kategorien	 von	 Genen	 nach	 Kofaktoren	 der	 Roquin-1-vermittelten	 Inhibition	 des	 T-Zell-Kostimulators	 ICOS	 systematisch	 durchsucht,	während	 die	 CRISPR/Cas	 Screening-Technologie	 angewandt	 wurde,	 um	 Protein-Netzwerke	zu	identifizieren,	welche	an	Roquin-vermitteltem	Zelltod	beteiligt	sind.	Im	Zuge	 der	 Entwicklung	 einer	 Hit-Validierungs-Strategie	 wurde	 ein	 RNS-bindender	Kandidat,	 das	 noch	 unerforschte	 Protein	 Nufip2,	 als	 neuer	 Kofaktor	 von	 Roquin-1	bestätigt.	 Um	 die	 noch	 unbekannte	 Rolle	 von	 Nufip2	 in	 der	 durch	 Roquin-1	vermittelten	 Genregulation	 weiter	 aufzuschlüsseln,	 wurden	 detaillierte	Funktionsstudien	durchgeführt.	In	diesen	wurde	gezeigt,	dass	Nufip2	eine	direkte	und	hochaffine	Protein-Protein-Wechselwirkung	mit	Roquin-1	eingeht.	Außerdem	wurden	die	wichtigsten	Roquin-1-regulierten	Cis-Elemente	im	3’	untranslatierten	Bereich	der	ICOS	mRNS	als	Orte	potenzieller	Nufip2-Koregulation	bestimmt.	Abschließend	wurde	in	einer	detaillierten	Kinetik	dargestellt,	wie	Icos	in	der	Effektor-T-Zelldifferenzierung	reguliert	 wird.	 Nufip2	 und	 weitere	 potentielle	 Kofaktoren	 von	 Roquin-1	 wiesen	 in	diesem	 Zeitraum	 unterschiedliche	 Expressionsmuster	 auf.	 Hieraus	 ergibt	 sich	 ein	
10	 	 Zusammenfassung		neues	 Modell	 zur	 Regulation	 der	 Roquin-1-Funktion	 und	 der	 Expression	 von	 Icos	durch	den	dynamischen	Beitrag	verschiedener	Kofaktoren	von	Roquin-1.		Insgesamt	wurden	 im	 Zuge	 dieser	 Arbeit	 neue	Kofaktoren	 von	Roquin-1	 erfolgreich	identifiziert	 und	 validiert.	 Die	 so	 gewonnenen	 Erkenntnisse	 sind	 bedeutsam	 für	 die	Aufklärung	 der	 dynamischen	 Ausbildung	 von	 Proteinkomplexen	 mit	 mRNS	 als	Koordinatoren	der	Roquin-Funktion	und	tragen	somit	zum	Verständnis	der	Rolle	von	Roquin-1	im	Kontext	der	Entstehung	immunologischer	Toleranz	bei.			
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Abbreviations	
Table	1:	Abbreviations	
Abbreviation	 Full	name	
aa	 Amino	acid	
AF488	 Alexa	Fluor	488	
Ago/AGO	 Mouse/human	argonaute	protein	
APC		 Antigen-presenting	cell		
APS	 Ammonium	persulfate	
ARE		 AU-rich	element		
Ascl2		 Mouse	achaete-scute	complex	homolog	2	
Ask-1/ASK-1		 Mouse/human	apoptosis-signal	regulating	kinase	1		
ATP2A	 Ca++	transporting	ATPase	in	the	cardiac	muscle	
b-isox		 Isoxazole		
B3galt	 Mouse	beta-1,3-galactosyltransferase	
Bcl-6/BCL-6	 Mouse/human	B	cell	lymphoma	6	
BCR	 B	cell	receptor		
Blast	 Blasticidin	
BSA		 Bovine	serum	albumin		
C-terminus	 Carboxy-terminus	
Cacybp		 Mouse	calcyclin	binding	protein	
CAR	 Coxsackie	virus	and	adenovirus	receptor		
Cas	 CRISPR-associated	nuclease		
CCR	 C-C	chemokine	receptor	type		
CD	 Cluster	of	differentiation	
CDE	 Constitutive	decay	element	
CDE260	 The	last	260	nts	of	TNF	3'	UTR	including	the	CDE	
cDNA	 Complementary	DNA	
CDS	 Coding	sequence	
Cerk/CERK		 Mouse/human	ceramide	kinase	
CLIP		 Crosslinking	and	immunoprecipitation		
CMV		 Cytomegalovirus	
Cnot/CNOT	 Mouse/human	CCR4-NOT	complex	subunit	
conc		 Concentration	
CRISPR	 Clustered	regularly	interspaced	short	palindromic	repeats	
crRNA		 CRISPR-derived	RNA		
CSTF	 Cleavage	stimulation	factor	
CTLA-4		 Cytotoxic	T	lymphocyte-associated	protein	4	
CVID		 Common	variable	antibody	deficiency		
CXCR	 Chemokine	(C-X-C	Motif)	receptor	
Cy5	 Cyanine	5	
DNA	 Deoxyribonucleic	acid	
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Dcp/DCP	 Mouse/Human	decapping	protein		
DEPC		 Diethylpyrocarbonate	
DEST		 Destination	vector	
DMEM		 Dulbecco's	Modified	Eagle's	Medium	
dNTP		 Deoxynucleotide	
dox	 Doxycyclin		
dsDNA		 Double-stranded	DNA	
DSRM	 Double-stranded	RNA	binding	motif		
DTT		 Dithiothreitol		
DUB		 Deubiquitination	enzyme	
E.	coli	 Escherichia	coli	
ECL		 Enhanced	chemiluminescence	
Edc/EDC	 Mouse/Human	enhancer	of	mRNA	decapping	
EDTA		 Ethylenediaminetetraacetic	acid	
eIF	 Eukaryotic	translation	initiation	factor	
env	 Envelope	gene	
ER	 Endoplasmatic	reticulum	
EtBr	 Ethidium	bromide	
Ext/EXT	 Mouse/human	exostosin	protein	
FACS	 Fluorescence-activated	cell	sorting	
FBS	 Fetal	bovine	serum	
Fbxl/FBXL	 Mouse/human	F-Box	and	leucine-rich	repeat	protein	
Fchange		 Fold	change	
FDR		 False	discovery	rate		
FL	 Full-length	
Fmr/FMR	 Mouse/human	fragile	X	mental	retardation	gene	family	
Fmrp/FMRP	 Mouse/human	fragile	X	mental	retardation	protein	
4-OH-TAM	 4-OH-tamoxifen		
Foxo1		 Mouse	forkhead	box	protein	O1	
Foxp3/FOXP3	 Mouse/human	forkhead-box-protein	P3	
FSC	 Forward	scatter	
Fxr/FXR	 Mouse/human	fragile	X	mental	retardation	autosomal	homolog	
G3bp/G3BP	 Mouse/human	GTPase	activating	protein		
gag	 Group-specific	antigen		
GAPDH	 Glyceraldehyde-3-phosphate	dehydrogenase	
Gata	 Mouse	GATA	binding	protein	
GC		 Germinal	center		
gDNA		 Genomic	DNA		
GeCKO		 Genome-scale	CRISPR/Cas9	knockout		
GESS		 Genome-wide	enrichment	for	seed	sequence	match		
GFP	 Green	fluorescent	protein	
GPCR		 G-protein	coupled	receptor	
H2O	 Water	
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HA		 Human	influenza	hemagglutinin	
HBS	 Hepes	buffered	saline	
HCl		 Hydrochloric	acid	
HEK293T	 Human	embryonic	kidney	cells	
HELA	 Human	cervical	cancer	cells	
HEPES	 N-2-hydroxyethylpiperazine-N-2-ethane	sulfonic	acid	
HEPN	 Higher	eukaryotes	and	prokaryotes	nucleotide-binding	domain	
His6	 Hexa	histidine-tag	
HMO		 Hereditary	multiple	osteochondromas		
Hprt/HPRT		 Mouse/human	hypoxanthine	phosphoribosyltransferase	
HR		 Homology-directed	repair		
HRP	 Horseradish	peroxidase	
HTS	 High-throughput	screening	
Hygro		 Hygromycin		
Icos/ICOS	 Mouse/human	inducible	T	cell	costimulator	
Icosl/ICOSL	 Mouse/human	inducible	T	cell	costimulatory	ligand	
IFNγ		 Interferon	γ		
Ig		 Immunoglobulin	
IL	 Interleukin	
Indel	 Insertions	or	deletion	
Iono	 Ionomycin		
IP	 Immunoprecipitation	
IPTG		 Isopropyl-β-D-thiogalactopyranosid		
IRES		 Internal	ribosomal	entry	site	
Irf/IRF	 Mouse/Human	interferon	regulatory	factor		
iTreg		 Induced	regulatory	T	cells	
kb	 kilobase	
KD		 knockdown	
Kda	 Kilodalton	
KH		 K-homology	domain	
Klf2		 Mouse	Krüppel-like	Factor	2	
KO	 knockout	
LB	medium		 lysogeny	broth	
LC		 low	complexity		
LC3-I	 Microtubule-associated	protein	1	light	chain	3	
LC3-II		 PE-conjugated	microtubule-associated	protein	1	light	chain	3	
Lsm/LSM	 Mouse/human	Like	sm	protein	
LTR		 Long	terminal	repeats		
M199R		 Methionine	to	arginine	mutation	at	amino	acid	position	199	
m7G	cap	 7-methylguanosine	cap	
MAGeCK		 Model-based	analysis	of	genome-wide	CRISPR/Cas9	knockout	
March/MARCH	 Mouse/human	membrane-associated	RING	finger	(C3HC4)	
MCPIP	 Monocyte	chemotactic	protein-induced	protein	
Abbreviations	 21	 		
Mdm2		 Mouse	double	minute	2	homolog	
Med		 Mediator	complex	subunit	
MEF	 Mouse	embryonic	fibroblast		
MFI	 Mean	fluorescence	intensity	
MgCl2	 Magnesium	chloride		
MHC	 Major	histocompatibility	complex	
μl	 Microliter	
μc		 Mean	of	control	data		
μs	 Mean	of	sample	data		
min	 Minute	
miRNA	or	miR	 MicroRNA	
miRISC	 MicroRNA-induced	silencing	complex	
ml	 Milliliter	
MMR		 DNA	mismatch	repair		
MOI	 Multiplicity	of	infection	
mRNA	 Messenger	RNA	
mRNP	 Messenger	ribonucleoprotein	
mTOR		 Mechanistic	target	of	rapamycin	(serine/threonine	kinase)	
N-terminus	 Amino-terminus	
NaCl		 Sodium	chloride	
Neo		 Neomycin		
NFkB	 Nuclear	factor	'kappa-light-chain-enhancer'	of	activated	B	cells	
Nfκbid/NFκBID	 Nuclear	factor	'kappa-light-chain-enhancer'	of	activated	B	cells	inhibitor,	delta	
Nfκbiz/NFκBID	 Nuclear	factor	'kappa-light-chain-enhancer'	of	activated	B	cells	inhibitor,	zeta	
ng	 Nanogram	
NGS		 Next-generation	sequencing		
NHEJ		 Non-homologous	end-joining		
NLS		 Nuclear	localization	signal		
nM	 Nanomolar	
NMD	 Nonsense-mediated	mRNA	decay	
NMR		 Nuclear	magnetic	resonance	
nTreg		 Natural	regulatory	T	cell	
nts	 Nucleotides	
Nufip2/NUFIP2	 Mouse/human	nuclear	FMRP	interaction	partner		
#	 Number	
OD600		 Optical	density	of	a	sample	measured	at	a	wavelength	of	600	nm	
Ox40	 Mouse	tumor	necrosis	factor	receptor	superfamily,	member	4	
Ox40l	 Mouse	tumor	necrosis	factor	receptor	superfamily,	member	4	ligand	
P	body	 Processing	body	
P2A		 Porcine	teschovirus-1	self-cleaving	peptide	2A	
PABP	 Poly(A)-binding	protein	
PAM	 Protospacer	adjacant	motif	
PAMP	 Pathogen	associated	molecular	pattern	
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Pan/PAN	 Mouse/human	poly(A)	specific	ribonuclease	
PB	 Pacific	blue	
P	body	 Processing	body	
PBS	 Phosphate	buffered	saline	
PCR	 Polymerase	chain	reaction	
PD-1	 Programmed	cell	death	1	
%	 Percent	
PI3K		 Phosphatidylinositol	3-kinase		
PI4KA	 Phosphatidylinositol	4-kinase	α	
pg	 Picogram	
PMA		 Phorbol-12-myristate-13-acetate		
pMol	 Picomolar	
pol		 Polymerase		
polyA	 Multiple	adenosine	monophosphates	
pri-miRNA	 Primary	microRNA	
PRR	 Pattern	recognition	receptor		
PSGL	 P-selectin	glycoprotein	ligand	
PTBP	 Polypyrimidine	tract	binding	protein	
puro	 Puromycin	
PVDF		 Polyvinylidene	fluoride	
Q/N	rich		 Rich	in	glutamine	and	asparagine	residues		
qPCR	 Real-time	quantitative	PCR	
Rab	 Member	of	the	RAS	oncogene	family	
RBD	 RNA-binding	domain	
RBP	 RNA-binding	protein	
Rck/Ddx6	 DEAD	(Asp-Glu-Ala-Asp)	box	helicase	6	
rev		 Regulator	of	expression	of	virion	proteins		
RG-rich		 Arginine-glycine	rich	
RING		 Really	interesting	new	gene	
RIP	kinase	 Receptor-interacting	serine-threonine	kinase	
RLR		 RIG-I-like	receptor		
RNA	 Ribonucleic	acid	
RNAi	 RNA-mediated	interference	
Rnf/RNF	 Mouse/human	RING	finger	protein	
RNP	 Ribonucleoprotein	
RNS	 Ribonukleinsäure	
RORγt	 Retinoic	acid	receptor-related	orphan	receptor	gamma	
RPMI		 Roswell	Park	Memorial	Institute	medium	
RRM	 RNA	recognition	motif	
RT	 Room	temperature	
RU	 Response	units	
rtTA3		 TET-ON	transactivator		
S1PR	 Sphingosine-1-phosphate	receptor	
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san	 Sanroque	mutation	(Roquin	M199R)	
SAP		 SLAM-associated	protein	
SD	 Standard	deviation	
SDS	PAGE	 Sodium	dodecyl	sulfate	polyacrylamide	gel	electrophoresis	
sec	 Seconds	
SG		 Stress	granule	
sgRNA	 Single	guide	RNA	
SHM		 Somatic	hypermutation		
shRNA	 Short	hairpin	RNA	
siCtrl		 Non-targeting	siRNA		
σc		 Standard	deviation	of	control	data		
σs		 Standard	deviation	of	sample	data		
siNUFIP2	 NUFIP2-targeting	siRNA	
siRNA	 Small	interfering	RNA	
siRoquin-1		 Roquin-1-targeting	siRNA	
Slc35	 Solute	carrier	family	35	(adenosine	3'-phospho	5'-phosphosulfate	transporter)	
SLE	 Systemic	lupus	erythemoatosus	
SM	 Stem-loop	mutant	
SOC	 Super	optimal	broth	
SRP	 Surface	plasmon	resonance	
SSC	 Side	scatter	
Stat/STAT	 Mouse/human	signal	transducer	and	activator	of	transcription		
Stau/STAU	 Mouse/human	Staufen	double-stranded	RNA	binding	protein	
Stk/STK	 Mouse/human	serine/threonine	kinase	
SUMO		 Small	ubiquitin-related	modifier	
TAC		 Tetradecyldimethylbenzylammonium	chloride	
Taq	 Thermus	aquaticus	polymerase	
TBE	 Tris-borate-EDTA	
TBS	 Tris	buffered	saline	
TCR		 T	cell	receptor		
TE	 Tris-EDTA	
TEMED		 Tetramethylethylenediamine		
Temp	 Temperature	
TES		 Testin	LIM	domain	protein	
TFH	cell		 T	follicular	helper	cell	
TGF-β		 Transforming	growth	factor	beta	
Th	 T	helper	cell	
Thy1.1		 Thymus	cell	antigen-1	
TLR	 Toll-like	receptor		
Tm	 Melting	temperature	
TNF	 Tumor	necrosis	factor	
TNRC6	 Trinucleotide	repeat	containing	protein	6	
tracrRNA		 Trans-acting	antisense	RNA		
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TRE		 Tet-response	element		
Treg		 Regulatory	T	cell		
TRIM		 Tripartite	motif	containing	protein	
TRUB	 TruB	pseudouridine	(Psi)	synthase	family	member		
TS	 Target	site	
TTP		 Tristetraprolin	
TYW	 tRNA-YW	synthesizing	protein		
Upf/UPF	 Mouse/human	regulator	of	nonsense	transcripts	homolog	(Yeast)	
Usp/USP	 Mouse/human	ubiquitin	specific	peptidase	
UTR	 Untranslated	region	
wt	 Wildtype	
Xrn/XRN	 Mouse/human	exoribonuclease	
YTHDC	 YTH	domain	containing	protein	
Ywhaz/YWHAZ		 Tyrosine	3-monooxygenase/tryptophan	5-monooxygenase	activation	protein,	zeta	
ZnCl2		 Zinc	dichloride	
ZnF	 Zinc	finger	
Zyx/ZYX		 Mouse/human	Zyxin			
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1 Introduction	
The	work	presented	in	this	thesis	centers	around	the	RNA-binding	protein	Roquin-1,	which	controls	T	cell	differentiation	to	prevent	autoimmunity.	Two	large-scale	screens	were	performed	 to	 explore	 functional	 interactions	of	Roquin-1.	An	RNAi	 screen	was	set	up	to	identify	cofactors	of	Roquin-1	protein	in	the	process	of	post-transcriptional	repression	 of	 the	 important	 T	 cell	 costimulatory	 receptor	 ICOS.	 In	 a	 CRISPR/Cas9-mediated	whole-genome	knockout	screen,	we	explored	the	newly	discovered	function	of	Roquin-1	 to	 induce	cell	death.	Before	 I	start	 to	describe	 the	results	of	my	work	 in	detail,	I	will	begin	by	introducing	the	principles	of	post-transcriptional	gene	regulation	in	general,	and	the	function	of	the	RNA-binding	proteins	Roquin-1,	its	paralog	Roquin-2	and	their	putative	cofactors	Regnase-1	and	Fmrp	in	more	detail.	After	describing	the	aspects	of	adaptive	immunity	including	the	differentiation	of	distinct	T	helper	subsets	and	 the	 special	 role	of	 the	T	cell	 costimulator	 Icos	 in	 linking	T-	and	B	cell	 immunity	that	are	relevant	to	this	study,	I	will	end	the	introduction	by	providing	examples	from	the	current	literature	to	show	how	post-transcriptional	repression	mediated	by	RNA-binding	proteins	influences	functions	and	fate	of	immune	cells.		
1.1 Post-transcriptional	gene	regulation	
Gene	expression	in	mammalian	cells	is	a	tightly	controlled	process	ensuring	that	each	living	cell	expresses	a	specific	RNA	and	protein	repertoire	at	the	correct	level	and	in	a	spatial	and	time-dependent	manner.	The	first	level	of	gene	regulation	is	the	initiation	of	transcription.	Since	eukaryotic	DNA	is	wrapped	in	chromatin,	access	to	the	genomic	region	of	interest	by	epigenetic	regulatory	mechanisms	is	a	first	requirement	for	gene	expression.	Next,	 the	DNA	polymerase	needs	 to	be	guided	 to	 the	promoter	 region,	 a	regulatory	 DNA	 sequence	 located	 upstream	 of	 the	 protein	 coding	 sequence.	 This	 is	accomplished	 by	 sequence-specific	 transcription	 factors,	 which	 are	 supported	 or	inhibited	 by	 transcriptional	 enhancers	 and	 silencers,	 respectively	 (Phillips,	 2008).	During	 the	 course	 of	 transcription,	 the	 polymerase	 generates	 a	 primary	 pre-mRNA	transcript,	which	 is	 co-transcriptionally	 spliced,	 removing	 the	non-coding	 sequences	(introns),	 and	 capped,	 by	 the	 addition	of	 a	7-methyl-guanonsine	 (m7G)	 cap	 to	 the	5’	end.	The	 final	modification	of	 the	nascent	mRNA	 is	 the	addition	of	 a	poly-adenosine	(poly(A))	tail	at	the	3’	end	(McKee	&	Silver,	2007).	Mature	messenger	RNAs	(mRNAs)	thus	consist	of	a	5’	cap,	followed	by	a	5’	untranslated	sequence	(5’	UTR),	the	protein-coding	sequence	(CDS),	a	3’	untranslated	region	(3’	UTR)	and	the	poly(A)	tail.	Mature	
26	 Introduction			mRNAs	are	 translocated	 from	the	nucleus	 to	 the	cytoplasm	 for	 the	pioneer	 round	of	translation.	During	this	process	mRNAs	are	subjected	to	quality	control	mechanisms,	such	 as	 nonsense-mediated	 RNA	 decay	 (NMD),	 which	 acts	 to	 eliminate	 all	 mRNAs	containing	premature	stop	codons	(Hug	et	al.,	2016).	After	5’	cap-binding	proteins	and	poly(A)-binding	 proteins	 (PABPs)	 interact	 to	 circularize	 the	 mRNA	 and	 enable	 the	recruitment	 of	 translation	 initiation	 factors,	 ribosomes	 can	 bind	 to	 the	mRNAs	 and	start	translation	(Wells	et	al.,	1998).	Several	ribosomes	can	translate	the	same	mRNA	at	the	same	time	and	arrange	in	so-called	polysomes,	which	cover	the	whole	length	of	the	coding	sequence,	and	synthesize	growing	polypeptide	chains	 in	parallel	 (Warner	et	 al.,	 1963).	 After	 termination	 of	 translation	 the	 newly	 synthesized	 full-length	proteins	 are	 folded,	 mostly	 with	 the	 help	 of	 chaperones	 (Ellis,	 1996),	 to	 become	functional.	Different	mechanisms	of	post-transcriptional	gene	regulation	can	interfere	with	translation,	resulting	in	silencing	or	degradation	of	the	respective	transcripts.		Overall,	 it	is	thought	that	transcriptional	gene	regulation	is	responsible	for	long-term	changes	 in	 the	mRNA	 profiles,	while	 quick	 adaptations	 in	 the	 expression	 of	 specific	genes	 is	 performed	 via	 regulation	 of	 translation	 efficiencies	 of	 existing	 mRNAs	 by	post-transcriptional	gene	regulation	(Rabani	et	al.,	2011).	Genes	 that	are	extensively	regulated	on	the	post-transcriptional	level	often	possess	long	3’	UTRs	(e.g.	ICOS,	1948	nts),	which	 accommodate	multiple	 different	 cis-regulatory	 elements.	 This	 is	 in	 stark	contrast	 to	 so-called	 housekeeping	 genes,	 which	 are	 constitutively	 expressed	 (e.g.	GAPDH,	 224	 nts).	 Cis-elements	 can	 occur	 as	 linear	 or	 structured	 motives	 and	 are	regulated	 by	 trans-acting	 factors,	 such	 as	 short	 regulatory	 RNAs	 or	 RNA-binding	proteins.	 Different	 trans-acting	 factors	might	 either	 inhibit	 each	 other’s	 function,	 or	coregulate	 the	 same	 mRNA	 independently	 or	 in	 a	 cooperative	 manner.	 These	interactions	impose	a	high	level	of	complexity	to	expression-promoting	or	-repressing	networks	(Jeltsch	&	Heissmeyer,	2016).		
1.1.1 Deadenylation-	and	decapping-dependent	mRNA	decay	Trans-acting	 factors	 can	 adjust	 the	 translation	 efficiency	 of	 mature	 mRNAs	 by	inhibition	 of	 translation	 or	 mRNA	 degradation,	 or	 a	 combination	 thereof.	 mRNA	degradation	 in	 eukaryotic	 cells	 is	 achieved	 via	 two	 possible	 pathways	 of	deadenylation-dependent	mRNA	decay	(Figure	1).		
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Figure	1:	Mechanisms	of	deadenylation-dependent	mRNA	decay.		
Schematic	 representation	 of	 eukaryotic	 deadenylation-dependent	 mRNA	 degradation	 pathways.	
Actively	 translated	 polysomal	 mRNAs	 form	 a	 circle,	 which	 is	 mediated	 by	 an	 interaction	 between	
poly(A)	 binding	 proteins	 (PABPs)	 bound	 to	 the	 poly(A)	 tail	 of	 the	 transcript	 and	 the	 cap-binding	
protein	eIF4E	via	the	scaffolding	factor	eIF4G.	Upon	initiation	of	deadenylation,	PABPs	are	displaced	
and	 translation	 rates	 decrease.	 Shortening	 of	 the	 poly(A)	 tail	 by	 the	 deadenylases	 PAN2,	 CCR4	
(CNOT6/CNOT6L)	and	CAF1	(CNOT7/CNOT8)	is	either	followed	by	3’-5’	degradation	by	the	exosome,	
or	by	5’-3’	directed	decay	via	mRNA	decapping.	Hydrolysis	of	 the	7-methyl-guanosine	cap	(m7G-cap)	
by	the	decapping	enzyme	DCP2	results	in	XRN1-mediated	5’-3’	decay	(Braun	et	al.,	2012;	Chen	&	Shyu,	
2011;	 Huntzinger	&	 Izaurralde,	 2011;	 Jonas	&	 Izaurralde,	 2015;	 Sharif	 &	 Conti,	 2013;	 Shirai	 et	 al.,	
2014;	Zheng	et	al.,	2008).		
Both	 start	with	 the	 degradation	 of	 the	 poly(A)	 tail	 of	 actively	 translated,	 polysomal	mRNAs	performed	by	the	CCR4-CAF1-NOT	multi-protein	deadenylase	complex,	which	assembles	around	the	large	scaffolding	subunit	CNOT1	(Shirai	et	al.,	2014).	The	CCR4-CAF1-NOT	complex	contains	two	catalytic	subunits	CCR4	(CNOT6/CNOT6L)	and	CAF1	(CNOT7/CNOT8)	and	can	additionally	engage	in	a	supercomplex	with	the	deadenylase	PAN2	and	its	binding	partner	PAN3	(Chen	&	Shyu,	2011;	Zheng	et	al.,	2008).	PAN2	is	responsible	 for	an	 initial	 shortening	of	 the	poly(A)	 tail,	while	 further	degradation	 to	<	25	 oligo(A)	 is	 accomplished	 by	 CCR4	 and	 CAF1.	 Loss	 of	 PAN2/PAN3	 can	 be	compensated	by	CCR4	and	CAF1	(Chen	&	Shyu,	2011;	Yamashita	et	al.,	2005),	whereas	knockdown	 of	 CAF1	 severely	 impairs	 deadenylation,	 indicating	 that	 the	 function	 of	
28	 Introduction			this	catalytic	subunit	of	the	CCR4-CAF1-NOT	complex	is	non-redundant	(Zheng	et	al.,	2008).	As	a	result	of	deadenylation,	PABPs	are	displaced	from	the	mRNA	tail,	thereby	weakening	 the	 interaction	 with	 the	 cap-binding	 protein	 eIF4E.	 The	 resulting	 de-circularization	of	the	transcript	leads	to	a	lower	translation	efficiency,	as	well	as	a	high	accessibility	 to	degradation	enzymes	 (Huntzinger	&	 Izaurralde,	2011).	Deadenylated	transcripts	 can	 now	 be	 degraded	 by	 the	 exosome	 in	 3’-5’	 directed	 mRNA	 decay.	However,	the	5’-3’	degradation	pathway	prevails,	because	in	most	cases	the	decapping	activator	complex	LSM1-7	binds	to	oligo(A)	tails	and	thereby	inhibits	exosomal	access	to	 the	 3’	 end	 (Tharun,	 2009).	 Together	 with	 PAT1	 the	 heteroheptameric	 LSM1-7	complex	 recruits	 components	 of	 the	 decapping	 complex,	 such	 as	 RCK,	 EDC3,	 EDC4,	DCP1	and	DCP2	(Jonas	&	Izaurralde,	2015;	Sharif	&	Conti,	2013).	During	the	course	of	decapping,	DCP2	as	well	as	XRN1	directly	bind	to	the	scaffolding	protein	EDC4	(Braun	et	al.,	2012).	While	the	enzymatic	activity	of	DCP2	causes	the	hydrolysis	of	the	5’	m7G-cap,	 the	exonuclease	XRN1	degrades	 the	mRNA	 in	 the	5’-3’	direction.	This	molecular	pathway	 holds	 the	 advantage	 that	 ribosomes,	 which	 have	 undergone	 translation	initiation,	 will	 always	 be	 able	 to	 produce	 a	 functional	 full-length	 protein	 without	running	off	a	partially	degraded	transcript.		
1.1.2 Storage	 of	 translationally	 silenced	 mRNAs	 in	 granule-like	
structures	Translational	 repression	 of	 transcripts	 can	 be	 achieved	 by	 a	 variety	 of	 different	mechanisms.	The	frequently	observed	inhibition	of	the	translation	initiation	step	can	be	 monitored	 by	 a	 shift	 of	 the	 respective	 target	 mRNAs	 from	 the	 polysomal	 into	monosomal	 fractions	 after	 separation	 of	 ribosomes	 in	 sucrose	 gradients,	 whereas	blockage	 of	 the	 elongation	 step	 would	 lead	 to	 an	 accumulation	 of	 target	 mRNAs	 in	higher-molecular	 weight	 fractions	 (Huntzinger	 &	 Izaurralde,	 2011).	 Translationally	silenced	 transcripts	 can	 accumulate	 in	 two	 different	 types	 of	 cytoplasmic	 granules,	stress	granules	and	P	bodies.	Following	treatment	with	arsenite,	a	chemical	substance	that	causes	oxidative	stress	 (Li	et	al.,	2013),	 the	 translation	 initiation	 factor	eIF2α	 is	phosphorylated	 and	 thereby	 converted	 into	 an	 inhibitor	 of	 the	 translation	 initiation	complex.	As	a	result,	cellular	protein	synthesis	is	globally	stalled	at	the	initiation	stage	(Ivanov	&	Anderson,	2013).	Ribosomes	stop	 translation	and	polysomes	disassemble,	which	 is	 followed	 by	 an	 aggregation	 of	 the	 respective	 mRNAs	 and	 their	 bound	translation	 initiation	 components	 in	 large	 cytoplasmic	 aggregates	 called	 stress	granules	 (SG)	 (Anderson	 &	 Kedersha,	 2009).	 Essential	 SG	 components	 are	 the	
Introduction	 29	 		structurally	highly	similar	RNA-binding	proteins	TIA1	and	TIAR,	and	the	RNA-binding	protein	G3BP1,	which	 forms	a	 complex	with	 the	deubiquitinase	USP10	 (Anderson	&	Kedersha,	 2009).	 The	 glutamine-	 and	 asparagine-	 (Q/N)-rich	 prion-like	 protein	domains	 of	 TIA1/TIAR	 and	 the	 glycine-rich	 RGG	 domain	 of	 G3BP1	 promote	 self-aggregation	and	thereby	strongly	contribute	to	the	formation	of	higher-order	protein	complexes,	 such	 that	 overexpression	 of	 any	 of	 the	 three	 proteins	 can	 induce	 SG	formation	even	in	the	absence	of	cellular	stress	(Gilks	et	al.,	2004).	Other	essential	SG	components	are	translation	initiation	factors	like	eIF3,	ribosomal	subunits,	and	PABPs	(Anderson	&	Kedersha,	2009;	Ohn	et	 al.,	 2008).	 Furthermore,	proteins	 implicated	 in	translational	 repression,	 such	 as	 the	 RNA-binding	 protein	 FMRP,	 proved	 to	 be	important	for	stress	granule	formation	(Didiot	et	al.,	2009).		Another	kind	of	cytoplasmic	granules	are	 the	so-called	processing	bodies	(P	bodies),	which	 are	 even	 present	 in	 unstressed	 cells.	 P	 body	 formation	 is	 initiated	 by	mRNA	deadenylation	(Zheng	et	al.,	2008).	Degradation	of	the	poly(A)	tail	of	an	mRNA	leads	to	the	disruption	of	the	interaction	between	PABPs	and	cap-binding	proteins,	resulting	in	linear	mRNAs	with	 lower	translation	efficiency.	Subsequently,	polysome	disassembly	is	accompanied	by	the	translocation	of	the	mRNP	complexes	from	the	cytoplasm	into	P	bodies.	Some	stress	granule	components	are	also	found	in	P	bodies,	such	as	the	RNA	helicase	RCK	(Bish	et	al.,	2015),	the	cap-binding	protein	eIF4E	or	the	5’-3’	exonuclease	XRN1	 (Kedersha	 et	 al.,	 2005).	 However,	 as	 a	 general	 rule,	 components	 of	 the	translation	initiation	complex	are	missing	in	P	bodies,	which	are	instead	characterized	by	 an	 accumulation	 of	 mRNA	 deadenylation/decapping/decay	 factors	 (Bish	 et	 al.,	2015;	Decker	&	Parker,	2012).	Essential	P	body	components	are	LSM	proteins,	as	well	as	 GW182,	 a	 well-characterized	 translational	 silencer	 after	 which	 P	 bodies	 were	originally	 named	 (GW	 bodies)	 (Ohn	 et	 al.,	 2008).	 Similar	 to	 stress	 granules,	 P	 body	assembly	is	also	believed	to	be	mediated	by	protein	aggregation	domains	(Reijns	et	al.,	2008).		Overall,	 sequestration	 into	stress	granules	 is	 thought	 to	provide	a	storage	possibility	for	 mRNA	 molecules	 whose	 translation	 became	 disadvantageous,	 while	 the	 high	density	 of	mRNA	 decay	 proteins	 in	 P	 bodies	 indicates	 a	 strong	 bias	 towards	mRNA	turnover.	 Although	mRNA	decay	 can	 occur	 in	 P	 bodies,	 translational	 repression	 and	mRNA	 decay	 are	 not	 dependent	 on	 P	 body	 formation	 (Eulalio	 et	 al.,	 2007).	 The	functional	difference	between	P	bodies	and	stress	granules	is	still	not	well	understood	and	awaits	further	investigation	(Decker	&	Parker,	2012).		
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1.1.3 Mechanisms	of	RNA-interference	Important	 players	 of	 post-transcriptional	 gene	 regulation	 are	~22	nts	 short	 double-stranded	microRNAs	 (miRNAs),	 which	 bind	 in	 a	 sequence-specific	manner	 to	 linear	
cis-elements	 in	 the	 3’	 untranslated	 region	 (UTR)	 of	 mRNAs	 to	 induce	 translational	inhibition	 and	 RNA	 degradation.	 This	 prominent	 pathway	 is	 called	 RNA-mediated	interference	(RNAi).			
	
Figure	2:	miRNA	biogenesis	and	RNA-interference.		
In	 the	 nucleus,	 long	 primary	 miRNAs	 (pri-miRNAs)	 arise	 from	 polymerase	 II	 or	 polymerase	 III	
transcription	of	genomic	sequences	(gDNA).	Pri-miRNAs	are	cleaved	by	Drosha	and	DGCR8	into	pre-
miRNAs,	which	are	exported	into	the	cytoplasm	as	short	hairpins.	Here,	Dicer	processing	results	in	the	
generation	 of	 mature	 miRNA	 duplexes.	 One	 strand	 is	 loaded	 onto	 Ago	 to	 form	 a	 miRNA-induced	
silencing	 complex	 (miRISC),	 which	 scans	 3’	UTRs	 of	 potential	 target	 mRNAs	 for	 complementary	
sequences.	Perfect	complementarity	can	induce	endonucleolytic	cleavage	of	the	target,	while	the	more	
frequently	observed	partial	 complementarity	 induces	deadenylation-dependent	mRNA	decay	 (Hoefig	
&	Heissmeyer,	2008;	Huntzinger	&	Izaurralde,	2011).	Synthetic	RNAi	reagents	are	delivered	as	short	
interfering	 RNA	 (siRNA)	 or	 short	 hairpin	 RNA	 (shRNA).	 Retrovirally	 delivered	 shRNA-encoding	
sequences	integrate	into	the	host	genome	and	enable	the	transcription	of	shRNA	hairpins,	which	are	
cleaved	into	mature	duplexes	by	Dicer.	siRNAs,	on	the	other	hand,	are	delivered	as	mature	21	nt-long	
duplexes	by	transient	transfection.	One	strand	of	the	mature	siRNA	or	shRNA	duplex	 is	 incorporated	
into	 the	 RISC	 complex	 and	 induces	 endonucleolytic	 cleavage	 of	 a	 perfectly	 complementary	 target	
sequence	 in	 the	CDS	or	3’	UTR	of	 its	 target	mRNA	(Sharma	&	Rao,	2009).	This	 scheme	was	adapted	
from	(Hoefig	&	Heissmeyer,	2008).		
Introduction	 31	 		miRNAs	 are	 transcribed	 as	 long	 primary	 transcripts	 (pri-miRNAs)	 in	 the	 nucleus	(Figure	 2).	 Pri-miRNAs	 are	 processed	 by	 the	 RNAse	 Drosha,	 assisted	 by	 the	 RNA-binding	 protein	 DGCR8	 (Han	 et	 al.,	 2004),	 into	 pre-miRNAs,	 hairpin	 structures	 of	∼70	nts,	which	 are	 exported	 from	 the	 nucleus	 into	 the	 cytoplasm	 (Lee	 et	 al.,	 2003).	Further	processing	is	accomplished	by	the	RNAse	Dicer,	which	cleaves	off	the	loop	of	the	 hairpin	 structure	 to	 result	 in	 a	 18-25	nt-long	 double-stranded	 RNA	 sequence	(Bernstein	et	al.,	2001).	One	strand	of	the	duplex	is	loaded	onto	an	Ago	protein	to	form	the	 miRNA-induced	 silencing	 complex	 (miRISC),	 which	 scans	 the	 transcriptome	 for	target	mRNAs	(Schwarz	et	al.,	2003).	Target	recognition	is	mediated	by	Watson-Crick	base	pairing	between	the	miRNA	and	a	 fully	or	partially	complementary	sequence	 in	the	 3’	UTR	 of	 target	mRNAs.	 Although	 fully	 complementary	 base-pairing	 is	 possible	and	 results	 in	 Ago-mediated	 endonucleolytic	 mRNA	 cleavage	 of	 some	 transcripts,	miRNAs	 can	 additionally	 target	 hundreds	 of	 partially	 complementary	 sequences	where	target	complementarity	is	limited	to	the	miRNA	seed	region	(nts	2-7)	(Hoefig	&	Heissmeyer,	 2008).	 Repression	 of	 target	 mRNAs	 with	 partially	 complementary	sequences	 involves	 the	recruitment	of	GW182	proteins	and	subsequent	 translational	inhibition	and	mRNA	decay	(Chapter	1.1.1)	(Huntzinger	&	Izaurralde,	2011).		The	endogenous	RNAi	pathway	can	be	harnessed	to	create	targeted	gene	knockdowns.	In	mammals,	 synthetic	RNAi	reagents	comprise	short	 interfering	RNAs	(siRNAs)	and	short	 hairpin	 RNAs	 (shRNAs).	 shRNAs	 are	 usually	 delivered	 retro-	 or	 lentivirally	 as	pre-miRNA-like	 longer	 hairpin	 structures	 that	 require	 Dicer	 processing	 (Figure	 2,	upper	dashed	box).	Since	retroviral	sequences	are	stably	integrated	into	the	genome,	shRNAs	can	be	employed	to	create	stable	knockdown	cell	lines	for	the	gene	of	interest	(Sharma	&	Rao,	2009).	Disadvantages	lie,	however,	in	the	cumbersome	efforts	of	virus	production	 and	 target	 cell	 infection,	 as	 well	 as	 in	 biosafety	 considerations	 when	working	with	 lentiviruses.	Moreover,	since	genome	integration,	hairpin	transcription	and	dicer	processing	are	necessary	to	produce	functional	shRNAs,	manifestation	of	the	knockdown	can	take	several	days.	siRNAs,	on	the	other	hand,	are	delivered	into	cells	as	 21-bp	 long	 duplexes	 with	 characteristic	 3	‘	dinucleotide	 overhangs	 by	 transient	transfection	(Figure	2,	lower	dashed	box).	They	mimic	mature	miRNAs,	and	therefore	do	not	require	Dicer	cleavage.	miRNA	duplexes	consist	of	a	sense	(passenger)	and	an	antisense	 (guide)	 strand.	 Only	 the	 guide	 is	 transferred	 into	 the	 RISC,	 where	 it	functions	by	identifying	perfect	complementary	sequences	in	the	CDS	or	the	3’	UTR	of	the	intended	target	mRNA	to	induce	endonucleolytic	cleavage	by	Ago2	(Dharmacon).	Due	to	their	ease	of	use,	siRNAs	can	be	employed	for	knocking	down	multiple	genes	of	
32	 Introduction			interest	 in	 parallel,	 and	 are	 commonly	 used	 in	 loss-of-function	 screens	 where	thousands	of	samples	can	be	transfected	with	different	siRNAs	in	parallel	(Sharma	&	Rao,	2009).		
1.1.4 RNA-binding	proteins	RNA-binding	proteins	play	a	crucial	role	in	RNA	metabolism	and	function.	Throughout	their	whole	 life,	RNAs	are	decorated	with	RNA-binding	proteins	 in	 complexes	 called	ribonucleoproteins	 (RNP).	 Already	 during	 the	 transcription	 process,	 RBPs	 guide	intron-containing	 pre-mRNAs	 through	 initial	 processing	 events,	 such	 as	 splicing,	capping	and	polyadenylation.	They	are	also	 involved	in	the	nuclear	export	of	mature	transcripts,	 and	 play	 a	major	 role	 in	 quality	 control-	 and	 regulatory	mechanisms	 of	mRNA	translation,	which	are	taking	place	in	the	cytoplasm	(McKee	&	Silver,	2007).	In	this	 study,	 we	 focus	 on	 RNA-binding	 proteins	 with	 a	 role	 in	 post-transcriptional	regulation	of	protein-coding	mRNAs.		In	the	past,	protein	domains	were	characterized	which	could	confer	RNA-binding	and	subsequent	homology	searches	across	the	genome	led	to	the	identification	of	several	hundred	human	RBPs,	which	were	classified	according	to	their	RNA-binding	domains	(RBD)	 (Calabretta	 &	 Richard,	 2015).	 Recent	 approaches	 for	 a	 genome-wide	identification	of	human	RNA-binding	proteins	resulted	in	the	discovery	of	many	new	RBPs	(Baltz	et	al.,	2012;	Castello	et	al.,	2012),	leading	to	a	current	estimation	of	~700	mRNA-binding	 proteins	 being	 present	 in	 human	 cells	 (Gerstberger	 et	 al.,	 2014).	Almost	60	%	of	 these	possess	one	of	 the	 few	very	abundant	RBDs,	 such	as	 the	RNA-recognition	 motif	 (RRM),	 the	 K-homology	 (KH)	 domain,	 the	 double-stranded	 RNA-binding	 motif	 (DSRM),	 DEAD	 boxes	 and	 RNA-binding	 zinc-finger	 (ZnF)	 domains	(Gerstberger	et	al.,	2014).	However,	about	half	of	the	RBPs	discovered	by	Castello	et	al	lack	 known	RBDs,	 suggesting	 that	many	more	modes	 of	 RNA-binding	 are	 still	 to	 be	discovered	 (Castello	 et	 al.,	 2012).	 Comparison	 of	 known	 structural	 organizations	 of	several	 dozen	 well-studied	 RBPs	 led	 to	 the	 striking	 observation	 that	 RBPs	 often	possess	 multiple	 repeats	 of	 one	 or	 multiple	 RBDs,	 suggesting	 that	 one	 RBP	 might	employ	multiple	domains	 in	order	 to	 combine	multiple	 low-affinity	binding	 sites	 for	binding	the	same	or	different	target	mRNAs	(Gerstberger	et	al.,	2014).	Furthermore,	a	combination	of	different	RBPs	might	 cooperate	 in	 the	 recognition	of	one	or	multiple	target	mRNAs	(Jeltsch	&	Heissmeyer,	2016).		
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1.1.4.1 The	FMR	protein	family		The	 well-studied	 fragile	 X	 mental	 retardation	 (FMR)	 protein	 family	 employs	 both	modes	 of	 cooperativity.	 The	 three	 highly	 homologous	 family	members	 FMRP,	 FXR1	and	FXR2	each	contain	 three	classical	RBDs:	 two	 type-I	KH	domains	 in	 the	center	of	the	 protein	 and	 an	 arginine-glycine	 (RG)-rich	 region	 close	 to	 the	 C-terminus	(Winograd	&	Ceman,	2011).	Since	loss	of	FMRP	expression	or	a	single	point	mutation	in	the	second	KH	domain	can	cause	severe	mental	retardation	in	humans	(De	Boulle	et	al.,	 1993;	 Jin	 &	 Warren,	 2000),	 its	 mode	 of	 action	 in	 the	 brain	 has	 been	 studied	intensively.	 FMRP	was	 found	 to	 bind	 to	 a	 large	 number	 of	mRNAs	 expressed	 in	 the	brain	and	can	either	activate	or	suppress	translation	(Winograd	&	Ceman,	2011).	All	three	RBDs	are	involved	in	target	recognition,	with	the	KH	domains	binding	primarily	to	 the	 linear	 binding	 motives	 ACUK	 (K=	G/U)	 and	 WGGA	 (W=	U/A)	 (Ascano	 et	 al.,	2012),	while	the	RGG	box	specifically	recognizes	guanine	(G)-quadruplexes	(Vasilyev	et	al.,	2015).	The	former	are	linear	sequence	motives,	while	the	latter	are	higher-order	structures	of	guanine-rich	RNA	sequences.	In	addition	to	the	use	of	multiple	RBDs	for	RNA	 binding,	 FMR	 family	 members	 were	 observed	 to	 form	 both	 homo-	 and	heterodimers,	 with	 the	 protein/protein	 interaction	 being	 mediated	 by	 a	 coiled-coil	region	in	the	C-terminus	of	the	protein	(Winograd	&	Ceman,	2011).		
1.1.4.2 Roquin	family	proteins	Another	 example	 of	 RBPs	 is	 the	 Roquin	 protein	 family,	 consisting	 of	 Roquin-1	 and	Roquin-2.	 Roquin-1	 and	 -2	 share	 a	 common	 domain	 structure	 with	 an	 N-terminal	RING	 finger,	 the	 RNA-binding	 ROQ	 domain,	 which	 is	 embedded	 in	 a	 second	 RNA-binding	 domain	 created	 by	 amino-terminal	 HEPNN	 and	 carboxy-terminal	 HEPNC	sequences	that	come	together	to	form	the	so-called	HEPN	domain.	In	addition	Roquin	proteins	contain	a	classical	CCCH-type	zinc	finger	(ZnF)	RBD	and	a	proline-rich	region	involved	 in	 protein/protein	 interactions	 (Figure	 3)	 (Athanasopoulos	 et	 al.,	 2010;	Jeltsch	 &	 Heissmeyer,	 2016;	 Pratama	 et	 al.,	 2013).	 The	 N-terminal	 domains	 of	 both	proteins	are	highly	homologous	 (80-99	%	sequence	 similarity),	while	 the	C-terminal	domains	display	a	lower	sequence	similarity	(45-50	%)	(Pratama	et	al.,	2013).	This	is	due	to	a	differential	organization	of	the	proline-rich	region	and	the	lack	of	the	coiled-coil	region	in	Roquin-2.	Instead,	Roquin-2	possesses	a	hydrophobic	region,	which	was	initially	 suspected	 to	 be	 a	 membrane	 anchor	 (Siess	 et	 al.,	 2000).	 Since	 coiled-coil	domains	are	 frequently	 involved	 in	protein	dimerization	(Burkhard	et	al.,	2001),	 the	presence	 of	 a	 coiled-coil	 domain	 in	 Roquin-1	 might	 mediate	 its	 specific	 protein	
34	 Introduction			interactions.	 So	 far,	 however,	 no	 factor	 has	 been	 found	 to	 exclusively	 interact	 with	Roquin-1,	but	not	Roquin-2.				
	
	
Figure	3:	Roquin	proteins	possess	multiple	RBDs	and	protein-interaction	domains.		
Schematic	 representation	 of	 the	 domain	 organization	 of	 mouse	 Roquin-1	 and	 Roquin-2.	 The	 ROQ	
domain,	the	HEPN	domain	and	Zinc	finger	(ZnF)	represent	experimentally	validated	RBDs,	while	the	
RING	domain	that	confers	E3	ligase	function	and	the	C-terminal	proline-rich	(Pro-rich)	and	coiled-coil	
(CC)	 sequences	 are	 predicted	 to	 be	 important	 for	 protein/protein	 interactions.	 In	 Roquin-2,	 the	 CC	
domain	 was	 replaced	 by	 a	 hydrophobic	 region	 (HR).	 This	 scheme	 was	 adapted	 from	 (Jeltsch	 &	
Heissmeyer,	2016;	Pratama	et	al.,	2013).		
The	RNA-binding	mode	of	the	ROQ	domain	was	recently	solved	in	crystal	structures.	It	binds	with	high	affinity	to	tri-loop	and	hexa-loop	RNA	motifs	by	engaging	in	hydrogen	bonding	and	electrostatic	interactions	with	negatively	charged	phosphodiester	groups	of	the	RNA	backbone,	thereby	recognizing	its	target	sequences	in	a	structure-	and	not	sequence-dependent	manner	 (Codutti	 et	 al.,	 2015;	 Janowski	 et	 al.,	 2016;	 Schlundt	 et	al.,	 2014).	 Although	 the	 ROQ	 domain	 seems	 to	 be	 sufficient	 for	 binding	 of	 certain	motifs,	 such	 as	 a	 conserved	 tri-loop	 structure	 occurring	 in	 the	 tumor	necrosis	 factor	
(TNF)	 3’	UTR	 (Leppek	 et	 al.,	 2013),	 both	HEPN	 and	 ZnF	 domains	may	 contribute	 to	RNA	 binding	 by	 recognizing	 alternative	 cis-elements	 or	 additional	 sequences	 or	structures.	 The	HEPN	 domain	 can	 bind	 double-stranded	 RNA	 independent	 from	 the	ROQ	domain	(Srivastava	et	al.,	2015;	Tan	et	al.,	2014),	and	both	domains	were	shown	to	 be	 able	 to	 simultaneously	 bind	 to	 different	 target	mRNAs.	Moreover,	 cooperative	recognition	of	distinct	cis-elements	by	the	ROQ	domain	and	the	ZnF	has	been	proposed	to	 be	 required	 for	 high-affinity	 binding	 of	A20	mRNA	 (Murakawa	 et	 al.,	 2015).	 Like	FMRP,	Roquin-1	might	 thus	 employ	 all	 three	RNA-binding	modules	 in	 a	 cooperative	way	 for	 binding	 the	 same	 or	 different	 target	 mRNAs.	 Upon	 Roquin	 binding,	 the	respective	 target	 mRNAs	 are	 post-transcriptionally	 repressed.	 The	 mechanism	 of	Roquin-induced	 post-transcriptional	 gene	 regulation	 is	 elusive	 for	 the	 most	 part.	However,	 it	 has	 been	 shown	 that	Roquin	primarily	 induces	mRNA	deadenylation	by	
Introduction	 35	 		recruiting	the	CCR4-CAF1-NOT-deadenylation	complex	(Leppek	et	al.,	2013),	which	is	followed	 by	 mRNA	 decapping	 (Glasmacher,	 2010)	 and	 subsequent	 decapping-dependent	5’	-	3’	decay	(Chapter	1.1.1).		
1.1.4.3 Regnase	family	proteins	The	 Regnase	 (MCPIP)	 family	 of	 RNA-binding	 proteins	 consists	 of	 the	 four	 family	members	Regnase-1	to	-4.	They	share	two	highly	conserved	domains:	an	NYN	nuclease	domain	of	~170	nts	that	is	followed	by	a	CCCH-type	Zinc	finger	(Lin	et	al.,	2013).	Of	all	family	 members,	 only	 the	 function	 of	 Regnase-1	 has	 been	 investigated	 in	 greater	detail.	 Regnase-1	 has	 been	 shown	 to	 regulate	 target	 mRNA	 expression	 via	endonucleolytic	 cleavage	 (Uehata	 &	 Akira,	 2013).	 Interestingly,	 Regnase-1	 target	mRNAs	showed	a	strong	overlap	with	Roquin-1-regulated	mRNAs	(Jeltsch	et	al.,	2014;	Uehata	 et	 al.,	 2013;	 Vogel	 et	 al.,	 2013),	 and	 indeed,	 it	 was	 recently	 shown	 that	Regnase-1	 preferentially	 binds	 to	 stem-loop	 structures	 that	 resemble	 predicted	Roquin-1	 cis-elements	 (Mino	 et	 al.,	 2015).	 Since	 structural	 evidence	 for	 Regnase-1	binding	to	cis-elements	is	still	missing,	it	remains	elusive	whether	shared	recognition	of	 the	 same	 cis-elements	 by	 Roquin-1	 and	 Regnase-1	 is	 part	 of	 a	 mechanism	 that	works	 in	a	 cooperative	or	a	mutual	 exclusive	manner.	Regnase-1	 colocalized	 in	 cells	with	 the	 rough	 ER,	 and	 was	 furthermore	 detected	 in	 the	 polysomal	 fractions	 of	 a	sucrose	gradient	(Mino	et	al.,	2015),	while	Roquin-1	localized	to	P	bodies	(Glasmacher,	2010)	 and	 was	 found	 in	 the	 non-polysomal	 fractions	 (Mino	 et	 al.,	 2015).	 It	 was	consequently	 proposed	 that	 although	 recognizing	 the	 same	 set	 of	mRNAs,	 Roquin-1	and	 Regnase-1	 operated	 in	 distinct	 subcellular	 locations	 with	 Regnase-1	 targeting	actively	 translated	mRNAs,	while	Roquin-1	was	 supposed	 to	 regulate	 translationally	silenced	 mRNAs	 only	 (Mino	 et	 al.,	 2015).	 However,	 Roquin-1	 and	 Regnase-1	 have	previously	been	 shown	 to	 repress	 certain	motifs	 in	a	 cooperative	way	 (Jeltsch	et	 al.,	2014),	 suggesting	 that	 their	 function	 is	 not	 completely	 redundant	 and	 both	 can	repress	the	same	target	mRNA	independent	of	its	translation	state.	Moreover,	Roquin	was	recently	found	to	repress	the	actively	translated	Ox40	mRNA	in	T	cells	(Janowski	et	 al.,	 2016),	 indicating	 that	 the	 relationship	 of	 the	 two	 regulatory	 proteins	 is	more	complicated	than	previously	thought	and	will	require	further	investigation.		In	contrast	to	Roquin-1,	Regnase-1	does	not	seem	to	employ	deadenylation-dependent	mRNA	 decay	 for	 target	 regulation.	 Instead,	 Regnase-1	 function	 depended	 on	 its	endonuclease	activity	(Jeltsch	et	al.,	2014;	Liang	et	al.,	2010;	Mino	et	al.,	2015)	and	on	a	specific	protein/protein	interaction	with	UPF1,	an	RNA	helicase	with	a	major	role	in	
36	 Introduction			nonsense-mediated	 RNA	 decay	 (NMD)	 (Mino	 et	 al.,	 2015).	 Since	 only	 UPF-1,	 but	 no	other	 proteins	 of	 the	 NMD	 pathway	 were	 required	 for	 Regnase-1-dependent	degradation	 of	 target	mRNAs	 and	Regnase-1	 function	 furthermore	 depended	 on	 the	RNA	 helicase	 function	 of	 UPF-1,	 it	 was	 suggested	 that	 Regnase-1	 induces	 post-transcriptional	gene	regulation	of	stem-loop-containing	mRNAs	via	a	new	pathway	of	UPF-1-induced	 RNA-unwinding	 followed	 by	 Regnase-1-induced	 endonucleolytic	cleavage	(Mino	et	al.,	2015).		
1.2 The	immune	system	
Immune	 systems	 have	 evolved	 to	 protect	 organisms	 against	 harmful	 intruders.	 In	mammals,	 a	 functional	 immune	 system	 depends	 on	 the	 interplay	 of	 innate	 and	adaptive	 immunity.	 Innate	 immune	 cells,	 such	 as	 tissue-resident	 macrophages	 and	neutrophils,	recognize	common	pathogen	associated	molecular	patterns	(PAMPs)	like	bacterial	lipopolysaccharides	or	virus-specific	double-stranded	RNA	with	their	pattern	recognition	 receptors	 (PRRs)	 (Alberts	 et	 al.,	 2002).	 This	 heterogeneous	 gene	 family	includes	transmembrane	receptors	like	toll-like	receptors	(TLRs)	but	also	cytoplasmic	receptors	such	as	RIG-I-like	receptors	(RLRs)	(Kawai	&	Akira,	2009).	Following	PAMP	recognition,	pathogen	clearance	 is	mediated	by	engulfment	and	 internal	digestion	or	extracellularly	via	secretion	of	toxic	effector	molecules.	Additionally,	activated	innate	immune	 cells	 secrete	 small	 effector	 molecules	 called	 cytokines	 and	 chemokines.	Cytokines	 mediate	 communication	 with	 other	 types	 of	 immune	 cells,	 also	 of	 the	adaptive	 immune	 system,	 while	 chemokines	 are	 responsible	 for	 the	 recruitment	 of	chemokine	 receptor-bearing	 neutrophils	 and	 monocytes.	 Recruitment	 of	 large	numbers	 of	 neutrophils	 and	 macrophages	 to	 the	 site	 of	 infection	 is	 facilitated	 by	dilation	and	increased	permeability	of	the	blood	vessels	and	noticed	as	heat,	redness	and	swelling	of	the	respective	tissue,	a	process	that	is	called	inflammation	(Janeway	et	al.,	2005).		
1.2.1 The	adaptive	immune	response	in	mammals	Throughout	 evolution,	 pathogens	 have	 invented	 strategies	 to	 circumvent	 the	 innate	immune	 response	 by	 hiding	 their	 PAMPS	 from	 cells	 equipped	 with	 PRRs.	 The	development	 of	 the	 adaptive	 immune	 system	 is	 a	 late	 evolutionary	 response	 to	 this	phenomenon,	 enabling	 a	 tailor-made	 immune	 response	 to	 a	 large	 diversity	 of	pathogens	 (Alberts	 et	 al.,	 2002).	 Major	 players	 of	 the	 adaptive	 immune	 system	 are	lymphocytes	 on	 the	 cellular	 level,	 complemented	 by	 antibodies	 and	 cytokines	 as	
Introduction	 37	 		soluble	 factors.	 Lymphocytes	 arise	 from	 common	 lymphoid	 progenitor	 cells	 in	 the	bone	marrow,	which	give	rise	to	many	different	lymphocyte	populations	of	the	B	cell	or	T	cell	lineage	(Janeway,	2001).	The	primary	function	of	B	cells	is	the	production	of	antigen-specific	antibodies,	the	key	component	of	the	humoral	immune	response.	For	generation	of	high-affinity	antibodies	and	antibody	memory	B	cells	obtain	help	 from	so-called	helper	T	cells.	T	cells	develop	from	double	positive	CD4+CD8+	precursor	cells	in	the	thymus	into	single	positive	CD4+	and	CD8+	effector	T	cells.	CD8+	cytotoxic	T	cells	recognize	 peptides	 presented	 on	MHC	 class	 I	 complexes	 and	mediate	 killing	 of	 cells	that	are	transformed	or	have	been	infected	with	intracellular	pathogens,	while	CD4+	T	cells	 differentiate	 into	 distinct	 subsets	 of	 helper	 T	 cells	 upon	 activation	 in	 the	periphery.		Although	 CD8+	 T	 cells	 play	 a	 critical	 role	 in	 the	 fight	 against	 tumors	 and	 viral	infections,	I	will	concentrate	on	the	CD4+	T	cell	lineage	in	the	following	paragraphs	as	a	cellular	model	of	 this	 study.	First	of	all,	 I	will	describe	 initial	mechanisms	of	T	cell	priming	 and	 B	 cell	 activation	 and	 how	 a	 specific	 subset	 of	 helper	 T	 cells	 called	 T	follicular	 helper	 cells	 (TFH	 cells)	 contributes	 to	 the	 generation	 of	 high-affinity	antibody-producing	 B	 cells.	 I	will	 then	 elucidate	 the	 complex	 network	 of	 regulatory	mechanisms	that	direct	T	helper	cell	differentiation	and	finally	explain	the	special	role	of	costimulatory	receptors	in	TFH	cell	differentiation.		
1.2.1.1 T	cell	priming	and	activation	of	antigen-presenting	B	cells	Activation	 of	 the	 adaptive	 immune	 response	 starts	 with	 pathogen	 engulfment	 by	professional	antigen-presenting	cells	(APCs),	such	as	dendritic	cells,	macrophages	and	B	 cells,	 followed	 by	 the	 presentation	 of	 pathogen-derived	 antigenic	 peptides	 on	surface	 MHC	 class	 II	 proteins.	 Upon	 activation,	 dendritic	 cells	 migrate	 to	 the	 T	 cell	zone	 of	 secondary	 lymphoid	 organs,	 where	 the	 peptide-MHC	class	II	 complexes	 are	presented	to	naïve	CD4+	T	 lymphocytes	(Janeway	et	al.,	2005).	Approximately	1012	T	cells	are	estimated	to	be	present	in	the	human	organism,	each	carrying	a	cell	surface	receptor	called	T	cell	 receptor	 (TCR)	with	a	different	peptide	specificity	 (Goronzy	et	al.,	 2015).	 T	 cell	 receptors	 are	 randomly	 assembled	by	differential	 joining	 of	 a	 large	number	of	variable	receptor	gene	segments,	leading	to	a	combinatorial	diversity	of	up	to	 1020	 possible	 TCRs	 (Goronzy	 et	 al.,	 2015;	 Janeway	 et	 al.,	 2005).	 TCR-mediated	recognition	 of	 a	 specific	 peptide-MHC	 complex	 is	 the	 first	 signal	 to	 activate	 a	 naïve	peripheral	T	cell	and	additional	costimulatory	signals	are	required	for	full	activation.	This	 process,	 after	 which	 T	 cells	 undergo	 excessive	 proliferation	 and	 subsequent	
38	 Introduction			differentiation	 into	 designated	 subsets	 (Figure	 4,	 left-hand	 side),	 is	 called	 T	 cell	priming.			
	
Figure	4:	T	cell	priming	and	B	cell	activation.		
Schematic	representation	of	T	cell	priming	mediated	by	professional	antigen-presenting	cells	(APCs)	
in	the	T	cell	zone	of	secondary	lymphoid	organs	(left-hand	side)	and	subsequent	activation	of	antigen-
presenting	B	cells	at	 the	border	between	 the	T	 cell	and	 the	B	 cell	 zone	 (T/B	boundary)	 (right-hand	
side).	Professional	APCs	engulf	and	digest	pathogens	and	present	antigenic	peptides	on	MHC	class	 II	
molecules.	 Naïve	 T	 cells	 recognize	 the	 peptide-MHC	 complex	 with	 their	 TCR,	 which	 provides	 the	
primary	 signal	 for	 T	 cell	 activation.	 Activation-induced	 expression	 of	 B7	 on	 the	 APC	 leads	 to	
costimulatory	signals	via	CD28,	which	is	constitutively	expressed	on	naïve	T	cells.	The	combination	of	
TCR	and	CD28	signaling	induces	the	expression	of	the	inducible	T	cell	costimulators	Icos	and	Ox40	on	
the	T	cell	surface.	Icos	and	Ox40	binding	to	Icosl	and	Ox40l	on	the	APC	surface,	respectively,	completes	
the	secondary	costimulatory	signaling.	T	cell	activation	induces	proliferation	and	differentiation	into	
helper	 T	 cells	 (Th).	 These	 travel	 to	 the	 T/B	 boundary	 and	 activate	 antigen-presenting	 B	 cells	 via	
costimulatory	signals	and	secreted	cytokines	(Heissmeyer	et	al.,	2005;	Janeway	et	al.,	2005).		
Naïve	B	cells	reside	 in	 follicles	of	secondary	 lymphoid	organs,	which	are	surrounded	by	T	cell	zones	(De	Silva	&	Klein,	2015).	Similar	to	T	cells,	B	cells	recognize	antigens	via	variable	cell	surface	receptors.	Their	B	cell	receptor	(BCR)	 is	a	membrane-bound	version	 of	 the	 secreted	 antibody.	 Like	 TCRs,	 BCR-	 and	 thus	 also	 antibody-encoding	genes	are	assembled	by	genetic	rearrangement,	leading	to	a	similarly	high	diversity	of	antibodies	 and	 BCRs.	 B	 cells	 can	 function	 as	 professional	 APCs	 by	 recognizing	 their	respective	 antigen	with	 the	 BCR	 followed	 by	 antigen	 engulfment	 and	 digestion	 into	peptides,	which	are	presented	on	MHC	class	 II	molecules	on	the	B	cell	surface.	Upon	antigen	uptake,	B	 cells	 travel	 to	 the	boundary	of	 the	T	 cell	 and	 the	B	 cell	 zone	 (T/B	boundary)	in	secondary	lymphoid	organs.	Here,	they	encounter	primed	T	helper	cells,	
Introduction	 39	 		which	have	also	migrated	to	the	T/B	boundary	in	response	to	initial	activation	and	T	helper	cell	differentiation	 in	the	T	cell	zone	(Figure	4,	right-hand	side).	Peptide-MHC	complexes	displayed	on	 the	B	cell	 surface	are	 recognized	by	 the	TCR	of	 the	antigen-specific	T	helper	cell.	 Subsequent	expression	of	CD40L	on	 the	TH	cell	 surface	and	 its	interaction	with	CD40	expressed	on	the	B	cell	surface	provides	critical	costimulatory	signaling.	 T	 helper	 cells	 additionally	 secrete	 cytokines,	 such	 as	 IL-4,	 IL-5	 and	 IL-13,	which	promote	B	 cell	 proliferation	and	 their	differentiation	 into	 antibody-producing	plasma	cells	(Janeway	et	al.,	2005).		
1.2.1.2 Initiation	of	a	T	cell-dependent	antibody	response	Primed	 B	 cells	 proliferate	 and	 either	 migrate	 to	 the	 center	 of	 primary	 lymphoid	follicles	 to	 form	 germinal	 centers	 (GC)	 or	 undergo	 extrafollicular	 plasma	 cell	differentiation	 (Vinuesa	 et	 al.,	 2016).	 Germinal	 centers	 and	 the	 action	 of	 a	 special	 T	helper	cell	subset	called	follicular	helper	T	cells	(TFH	cells)	are	critical	for	mounting	a	high-affinity	antibody	response.	TFH	cells	were	discovered	in	2001	as	the	most	potent	inducers	of	antibody	production	from	B	cells	(Breitfeld	et	al.,	2000;	Kim	et	al.,	2001).	They	 express	 the	 master	 transcription	 factor	 Bcl-6,	 the	 follicular	 homing	 receptor	CXCR5,	 high	 levels	 of	 the	 costimulatory	 receptor	 Icos	 and	 the	 coinhibitory	 receptor	PD-1	and	secrete	IL-21	(Vinuesa	et	al.,	2016).		In	 the	 dark	 zone	 of	 the	 germinal	 center,	 B	 cells	 proliferate	 and	 undergo	 somatic	hypermutation	 (SHM),	 a	 process	 in	 which	 the	 specificity	 of	 the	 BCR	 is	 altered	 by	random	mutations.	B	cell	clones	carrying	mutated	BCRs	migrate	 to	 the	GC	 light	zone	for	 affinity	 selection.	 Clones	 carrying	 mutated	 BCRs	 are	 selected	 according	 to	 their	ability	to	pick	up	antigen	from	a	network	of	follicular	dendritic	cells	(De	Silva	&	Klein,	2015)	and	present	it	to	TFH	cells.	B	cell	clones	with	a	low	affinity	BCR	are	eliminated	in	this	process,	while	high-affinity	BCR	clones	receive	help	from	TFH	cells	to	migrate	back	to	 the	 dark	 zone	 to	 resume	 SHM	 (Oropallo	 &	 Cerutti,	 2014).	 The	 whole	 process	 of	multiple	 rounds	 of	 SHM	 followed	 by	 affinity	 selection	 is	 called	 affinity	 maturation.	During	affinity	maturation	IgM+	B	cells	receive	signals	 to	switch	the	constant	domain	of	their	heavy	chain	from	IgM	towards	IgG	in	a	process	called	antibody	class	switching	(McHeyzer-Williams	et	al.,	2015).	While	B	cells	undergo	affinity	maturation,	TFH	cells	develop	in	parallel	from	primed	helper	T	cells	via	an	intermediate	step	called	pre-TFH.	Pre-TFH	cells	have	upregulated	the	transcription	factor	Bcl-6,	and	express	low	levels	of	PD-1	and	Icos	(Lee	et	al.,	2011).	They	can	reside	outside	the	follicle	and	provide	help	to	B	cells	 to	 form	short-lived	extrafollicular	plasma	cells,	which	produce	 low-affinity	
40	 Introduction			antibodies	that	are	important	for	a	fast	response	against	intruding	pathogens	(Lee	et	al.,	 2011).	 Pre-TFH	 cells	 that	 enter	 the	 follicle	mature	 into	 GC	 TFH	 cells	 via	 repeated	interactions	with	B	 cells.	Upon	maturation,	GC	TFH	 cells	 provide	 cognate	B	 cells	 that	have	 undergone	 affinity	 maturation	 with	 costimulatory	 signals	 and	 IL-21,	 which	initiates	 their	differentiation	 into	antibody-producing	plasma	cells	and	memory	cells	(Vinuesa	 et	 al.,	 2016).	 GC	 plasma	 cells	 produce	 high	 amounts	 of	 high-affinity	 IgG	antibodies	that	are	capable	of	fighting	long-lasting	infections	due	to	a	long	serum	half-life	of	20	days	(Brekke	&	Sandlie,	2003),	while	long-lived	memory	B	cells	reside	in	the	secondary	follicles	with	the	option	of	differentiating	into	plasma	cells	upon	secondary	exposure	 with	 the	 same	 antigen.	 Memory	 cells	 also	 arise	 from	 activated	 TFH	 cells,	which	circulate	in	the	blood	stream	as	central	memory	TFH	cells	and	enable	a	fast	GC	formation	 upon	 secondary	 antigen	 exposure	 (Vinuesa	 et	 al.,	 2016).	 In	 response	 to	secondary	antigen	stimulation,	reactivated	class-switched	memory	B	cells	can	again	go	through	the	process	of	mutation	and	selection	in	secondary	GC	reactions	(McHeyzer-Williams	 et	 al.,	 2015).	 The	 GC	 reaction	 thus	 continuously	 improves	 the	 antibody	specificity	 both	 during	 primary	 and	 secondary	 immune	 responses,	 and	 is	 therefore	essential	for	mounting	a	high-affinity	antibody	response	and	antibody	memory.		
1.2.1.3 Lineage	determination	of	T	cell	differentiation	The	fate	of	a	naïve	CD4+	T	cell	is	mainly	determined	during	its	initial	interaction	with	the	antigen-presenting	dendritic	cell	in	the	T	cell	zone	of	secondary	lymphoid	organs	(Schmitt	&	Ueno,	2015).	Here,	a	combination	of	the	TCR	signal	strength,	costimulatory	signals	and	the	surrounding	cytokine	milieu	are	believed	to	skew	T	cell	differentiation	towards	the	specified	lineages	(Huang	&	August,	2015).	T	helper	cells	are	subdivided	into	 Th1,	 Th2,	 Th17,	 iTreg	 and	 TFH	 cells	 based	 on	 effector	 functions	 and	 secreted	cytokines.	Early	on,	cytokine	signaling	sets	the	course	for	differentiation	into	the	one	or	 the	other	subset	by	 inducing	 the	phosphorylation	and	activation	of	distinct	signal	transducer	and	activators	of	transcription	(Stat)	proteins.	These	determine	the	T	cell	fate	 by	 imposing	 specific	 gene	 expression	 programs	 leading	 to	 the	 expression	 of	 a	master	transcription	factor,	which	is	responsible	for	the	expression	of	subset-specific	effector	proteins	(Yamane	&	Paul,	2013).		
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Figure	5:	Cytokine	profiles	determine	T	helper	cell	differentiation.		
Upon	recognition	of	a	specific	peptide-MHC	complex	on	a	professional	antigen-presenting	cell	(APC),	
naive	 CD4+	 T	 cells	 proliferate	 and	 differentiate	 into	 distinct	 populations	 of	 T	 helper	 cells.	 Each	 Th	
subset	 (Th1,	 Th2,	 Th17,	 TFH	 and	 iTreg)	 is	 characterized	 by	 the	 expression	 of	 a	 unique	 master	
transcription	 factor	 (bold	 letters)	 in	 combination	 with	 a	 cytokine-activated	 signal	 transducer	 and	
activator	of	transcription	(Stat),	imposing	distinct	gene	expression	profiles.	The	resulting	expression	of	
distinct	sets	of	effector	cytokines	corresponds	to	specified	roles	in	immune	regulation.	This	scheme	was	
drawn	based	on	(Schmitt	&	Ueno,	2015;	Vinuesa	et	al.,	2016;	Yamane	&	Paul,	2013).		
T	 cell	 differentiation	 in	 response	 to	 different	 cytokine	 stimuli	 has	 been	 studied	extensively	in	the	mouse	system.	IL-12/IL12R	signaling	activates	Stat4,	which	induces	the	expression	of	IFNγ	(Park	et	al.,	2004).	IFNγ	signaling	in	turn	activates	Stat1,	which	is	responsible	for	the	induction	of	the	master	transcription	factor	Tbet	that	drives	the	characteristic	 gene	 expression	 profile	 of	 Th1	 cells	 (Afkarian	 et	 al.,	 2002).	 By	 CD40-CD40L	interaction	in	combination	with	IFNγ	secretion,	Th1	cells	are	potent	activators	of	macrophages	 and	 are	 in	 general	 responsible	 for	 regulating	 the	 immune	 response	against	 intracellular	 bacteria.	 However,	 Th1	 cells	 have	 also	 been	 found	 to	 be	associated	with	autoimmunity	(Janeway,	2001;	Yamane	&	Paul,	2013).	Helper	cells	of	the	Th2	lineage,	by	contrast,	develop	in	response	to	IL-2	and	IL-4	signaling,	resulting	in	 the	 activation	 of	 Stat5	 and	 Stat6,	 respectively	 (Maier	 et	 al.,	 2012).	 The	 lineage	
42	 Introduction			determining	transcription	factor	Gata3	induces	the	secretion	of	the	cytokines	IL-4,	IL-5	and	 IL-13,	which	are	effective	 in	 inducing	plasma	cell	differentiation	and	antibody	production	of	B	cells.	On	the	other	hand,	Th2	cells	can	be	the	driving	force	in	allergy	and	asthma	(Vinuesa	et	al.,	2016).	Th17	cells	express	the	master	transcription	factor	RORγt	 and	 are	 induced	 in	 the	 mouse	 system	 in	 response	 to	 IL-6,	 IL-21	 and	 TGF-β	stimulation	 (Schmitt	 &	 Ueno,	 2015).	 IL-6	 activates	 Stat3,	 which	 together	 with	 Icos	signaling	enables	IL-21	production	(Yamane	&	Paul,	2013).	The	main	characteristic	of	Th17	 cells	 is	 the	 secretion	 of	 the	 cytokine	 IL-17,	 along	 with	 IL-21	 and	 IL-22.	 IL-17/IL17R	 signaling	 induces	 gene	 expression	 of	 proinflammatory	 effector	molecules,	thereby	playing	an	important	role	in	the	clearance	of	extracellular	bacterial	infections	(Onishi	&	Gaffen,	2010).	Aberrant	production	of	IL-17	is	linked	to	several	autoimmune	diseases,	 such	 as	 rheumatoid	 arthritis	 and	 systemic	 lupus	 erythematosus	 (Onishi	 &	Gaffen,	 2010).	 In	 contrast	 to	 the	 differentiation	 of	 Th1,	 Th2	 and	 Th17	 cells,	 TFH	differentiation	 is	a	 two-step	process.	As	mentioned	before	(Chapter	1.2.1.2),	 initial	T	cell	 activation	 at	 the	 T/B	 boundary	 induces	 differentiation	 into	 pre-TFH	 cells,	 while	differentiation	 into	 mature	 TFH	 cells	 takes	 place	 in	 germinal	 centers	 of	 primary	lymphoid	 follicles.	 GC	 TFH	 cells	 express	 the	 subset	 determining	 transcription	 factor	Bcl-6.	By	high	expression	of	Icos	accompanied	by	the	secretion	of	IL-21	and	IL-4,	they	are	especially	potent	in	inducing	affinity	maturation	of	B	cells	for	generation	of	plasma	cells	and	memory	cells	(Marine	et	al.,	2012;	Tan	et	al.,	2014).		As	 opposed	 to	 the	 T	 cell	 subtypes	 described	 so	 far,	 regulatory	 T	 cells	 (Tregs)	 are	characterized	 by	 the	 expression	 of	 the	 subset-specifying	 transcription	 factor	 Foxp3	and	 counteract	 the	 immune	 response	 by	 inhibiting	 effector	 T	 cells	 via	 multiple	mechanisms.	These	include	the	secretion	of	immunosuppressive	cytokines	such	as	IL-10	 and	 TGF-β,	 inhibition	 via	 cell-to-cell	 contact	 e.g.	 by	 expressing	 inhibitory	 cell	surface	receptors	like	CTLA-4	and	competition	for	growth	factors	such	as	IL-2	(Sojka	et	al.,	2008).	The	main	population	of	natural	Tregs	(nTregs)	develops	 in	 the	 thymus,	while	 a	 subpopulation	 of	 induced	Tregs	 (iTregs)	 differentiate	 in	 the	 periphery	 from	naïve	CD4+	T	cells	in	response	to	stimulation	conditions	that	can	be	mimicked	in	vitro	by	IL-2	and	TGF-β	signaling	(Yamane	&	Paul,	2013).		While	Th1	and	Th2	differentiation	in	response	to	distinct	cytokine	signals	is	generally	similar	 between	 humans	 and	mice,	 stronger	 differences	 exist	 in	 Treg,	 Th17	 and	 TFH	differentiation.	 For	 instance,	 human	 naive	 T	 cells	 do	 not	 develop	 into	 Th17	 cells	 in	response	to	IL-6,	IL-21	and	TGF-β	signaling,	but	are	instead	induced	upon	stimulation	
Introduction	 43	 		with	IL-1β	and	IL-23	(Schmitt	&	Ueno,	2015).	Moreover,	human	TFH	differentiation	is	initiated	 primarily	 by	 the	 cytokine	 IL-12	 rather	 than	 by	 IL-6	 and	 IL-21.	 These	differences	 of	 human	 and	 mouse	 naïve	 T	 cells	 in	 responding	 to	 different	 cytokine	stimuli	are	caused	by	the	differential	expression	of	cytokine	receptors,	and	have	to	be	kept	in	mind	when	transferring	knowledge	from	animal	models	to	the	human	system	(Schmitt	&	Ueno,	2015).		T	 helper	 cell	 differentiation	 in	 response	 to	 distinct	 cytokine	 expression	 profiles	 is	highly	complex.	Favoring	one	lineage	differentiation	program	is	often	accompanied	by	inhibitory	 signals	 for	 reciprocally	 developing	 lineages.	 For	 example,	 Th2-promoting	IL-2/Stat5	signaling	blocks	Th17	differentiation	(Yamane	&	Paul,	2013).	In	addition	to	cytokine	 stimulation,	 Th	 cell	 differentiation	 is	 directed	 by	 the	 strength	 of	 TCR	signaling	and	costimulatory	signals	(Zhu	&	Paul,	2010).	The	 impact	of	TCR	signaling,	which	 is	 influenced	 by	 both	 antigen	 dose	 and	 TCR	 affinity,	 is	 still	 highly	 debated.	Overall,	weak	TCR	 signaling	 is	believed	 to	promote	Th2	or	TFH	differentiation,	while	intermediate	signaling	induces	Th1-	and	strong	signaling	again	induces	TFH	cells	(Tubo	&	 Jenkins,	 2014).	 Recent	 research	 has	 provided	 a	 number	 of	 examples	 of	 T	 cell	differentiation	with	a	high	degree	of	plasticity.	It	indicates	that	the	process	is	far	more	complex	 than	 previously	 anticipated	 and	 differentiation	 into	 the	 one	 or	 the	 other	lineage	is	not	as	definite	as	initially	thought.		
1.2.1.4 The	costimulatory	receptors	CD28	and	Icos	regulate	TFH	cell	
differentiation		Besides	cytokine	signaling	and	TCR	signal	strength,	T	cell	fate	decisions	are	influenced	by	 costimulatory	 signals.	 The	 development	 of	 TFH	 cells,	 which	 are	 essential	 for	 the	generation	 of	 a	 high-affinity	 antibody	 response	 and	 B	 cell	 memory	 in	 the	 germinal	center	 reaction,	 is	 critically	 influenced	 by	 the	 action	 of	 two	 Ig	 superfamily	costimulatory	receptors	CD28	and	Icos.	Icos	arose	from	gene	duplication	of	CD28,	and	both	proteins	share	39	%	amino	acid	identity	and	are	expressed	as	homodimeric	cell	surface	 proteins	 (Hutloff	 et	 al.,	 1999).	 Although	 structurally	 similar	 and	 equally	capable	of	supporting	TCR-induced	gene	expression,	T	cell	proliferation	and	cytokine	production	(Linterman	et	al.,	2009),	CD28	and	Icos	have	non-overlapping	functions	in	the	 induction	 of	 an	 antibody-dependent	 immune	 response	 and	 show	 a	compartmentalized	expression.	CD28	is	broadly	expressed	on	most	T	cell	subsets	and	found	 also	 on	 naïve	 cells,	 while	 Icos	 is	 only	 induced	 on	 the	 T	 cell	 surface	 upon	activation	(Beier	et	al.,	2000;	Gross	et	al.,	1992).	 Icos	expression	 is	 thus	restricted	to	
44	 Introduction			CD4+	effector	and	memory	T	cells	and	found	most	highly	expressed	on	TFH	cells	within	germinal	 centers	 (Akiba	 et	 al.,	 2005).	 Besides,	 a	 subset	 of	 Foxp3+	regulatory	 T	 cells	expresses	Icos	and	is	dependent	on	Icos	signaling	for	proliferation	and	function	(Yong	et	al.,	2009).	The	importance	of	CD28	and	Icos	for	mounting	a	T	cell-dependent	antibody	response	became	 apparent	 when	 studying	 knockout	mice.	 CD28-/-	 mice	 show	 impaired	 T	 cell	proliferation	after	stimulation,	a	defect	in	IL-2	production	and	impaired	antibody	class	switching	(Shahinian	et	al.,	1993).	Moreover,	germinal	centers	and	TFH	cells	are	absent	in	 these	 mice	 (Ferguson	 et	 al.,	 1996;	 Walker	 et	 al.,	 1999),	 and	 the	 numbers	 of	regulatory	 T	 cells	 are	 drastically	 reduced	 (Salomon	 et	 al.,	 2000).	 Icos-/-	 mice	phenocopy	some	of	the	CD28-/-	phenotypes	such	as	the	presence	of	smaller	and	fewer	GCs,	reduced	numbers	of	TFH	cells	and	a	deficit	in	antibody	class	switching	(McAdam	et	al.,	 2001).	 Moreover,	 reactivation	 of	 memory	 T	 cells	 is	 impaired	 in	 Icos-/-	 mice	 and	differentiated	T	cells	from	Icos-/-	mice	are	unable	to	produce	IL-2	and	IL-4	(McAdam	et	al.,	2001).	 In	CD28-/-	Icos-/-	double-deficient	mice,	antibody	production	in	response	to	T-dependent	antigens	as	well	as	viral	infection	is	more	severely	impaired	compared	to	
CD28-/-	animals,	 indicating	that	Icos	and	CD28	fulfill	redundant	but	also	diverse	roles	in	 the	 T	 cell-dependent	 antibody	 response	 (Suh	 et	 al.,	 2004).	 In	 humans,	 loss	 of	function	mutations	 in	 the	 ICOS	gene	 leading	 to	 the	 absence	 of	 ICOS	 expression	on	T	cells	have	been	identified	as	a	cause	of	common	variable	antibody	deficiency	(CVID).	Patients	have	lower	serum	levels	of	IgG	and	IgA	class	antibodies	indicating	a	defect	in	antibody	 class	 switching	 and	 are	 susceptible	 to	 recurrent	 respiratory	 and	gastrointestinal	infections	(Warnatz	et	al.,	2006).		The	burning	question	of	how	CD28	and	Icos	signaling	influence	the	development	of	a	T	cell-dependent	B	 cell	 response	was	 recently	 answered	by	 resolving	 their	 role	 in	TFH	differentiation.	Icos	ligation	leads	to	a	series	of	intracellular	signaling	events	in	T	cells,	starting	 with	 the	 recruitment	 of	 the	 p50α	 regulatory	 subunit	 of	 the	phosphatidylinositol	3-kinase	(PI3K),	which	associates	with	the	p110	catalytic	subunit	to	initiate	a	signaling	cascade	that	results	in	the	phosphorylation	and	activation	of	the	protein	kinase	Akt	(Fos	et	al.,	2008).	Akt	phosphorylates	and	thereby	 inactivates	 the	transcription	factor	Foxo1	(Stone	et	al.,	2015),	which	is	responsible	for	transcriptional	induction	of	Klf2.	Klf2	critically	determines	TFH	cell	homing.	A	 low	expression	of	 this	transcription	 factor	 is	 important	 to	 maintain	 a	 TFH	 cell-specific	 homing	 factor	repertoire	(high	expression	of	CXCR5	and	low	expression	of	CCR7,	CD62L,	PSGL-1	and	
Introduction	 45	 		S1PR1)	 and	 to	 prevent	 Klf2-induced	 expression	 of	 the	 Th1-	 and	 Th2-promoting	transcription	factors	Tbet	and	Gata3	(Weber	et	al.,	2015).	Besides,	 Icos	signaling	can	activate	 the	 alternative	 PI3K	 subunit	 p85α,	 which	 leads	 to	 protection	 from	proteasomal	 degradation	 and	 thus	 stabilization	 of	 the	 lineage-determining	transcription	 factors	Bcl-6	and	Ascl2	(Leavenworth	et	al.,	2015)	 that	are	responsible	for	upregulation	of	CXCR5	and	other	TFH	effector	molecules	such	as	PD-1,	CXCR4,	and	SAP	 (Liu	 et	 al.,	 2014).	 The	 overall	 importance	 of	 Icos-mediated	 PI3K	 signaling	 for	 a	high-affinity	antibody	response	became	clear	in	a	study	using	conditional	PI3K	p100δ	knockout	 mice.	 It	 was	 found	 here	 that	 the	 magnitude	 of	 Icos	 signaling	 via	 PI3K	determines	 the	 number	 of	 TFH	cells	 and	 consequently	 also	 the	 amount	 of	 GC	 B	 cells	(Rolf	 et	 al.,	 2010).	 In	 contrast	 to	 ICOS,	 CD28	 has	 a	 low	 affinity	 for	 the	 p110/p50α	isoform	of	PI3K,	resulting	in	a	lower	potential	of	phosphorylating	Foxo1	and	thereby	restricting	 Klf2	 expression	 (Weber	 et	 al.,	 2015).	 CD28	 is	 instead	 necessary	 for	 the	early	 events	 in	 TFH	 differentiation,	 including	 the	 upregulation	 of	 Bcl-6	 and	 CXCR5	(Weber	 et	 al.,	 2015).	 ICOS	 and	 CD28	 thus	 control	 TFH	 differentiation	 by	 acting	 in	different	 phases:	 While	 CD28	 regulates	 early	 TFH	 differentiation	 by	 upregulation	 of	Bcl-6,	Icos	is	important	for	TFH	cell	maintenance	and	homing	to	the	B	cell	zone	of	the	lymphoid	follicle	(Weber	et	al.,	2015).		
1.2.2 The	CRISPR/Cas	system:	adaptive	immunity	in	prokaryotes	For	 a	 long	 time	 it	 was	 generally	 accepted	 that	 an	 adaptive	 immune	 response	 was	restricted	 to	 higher	 eukaryotes	 simply	 because	 it	 appeared	 to	 require	 different	 cell	types.	 Therefore,	 the	 recent	 discovery	 of	 an	 RNA-based	 adaptive	 immune	 system	 in	bacteria	and	archaea	came	as	a	surprise.	Prokaryotes	protect	themselves	against	viral	re-infection	 by	 integrating	 short	 fragments	 of	 the	 foreign	 nucleic	 acids,	 called	protospacers,	into	defined	loci	of	their	own	genome.	These	loci	were	named	clustered	regularly	 interspaced	 short	palindromic	 repeats,	 or	 short	CRISPR	 (Wiedenheft	 et	 al.,	2012).	 In	 each	 CRISPR	 locus	 a	 series	 of	 identical	 DNA	 repeats	 is	 interspersed	 by	unique	spacer	sequences	derived	from	the	foreign	protospacer	motifs	(Figure	6).		
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Figure	6:	CRISPR/Cas9	genome	editing.		
Schematic	representation	of	the	CRISPR/Cas	type	II	system.	Short	sequences	derived	from	foreign	DNA	
(protospacers)	 are	 integrated	 into	 CRISPR	 loci	 in	 the	 host	 genome	 as	 spacers	 that	 are	 flanked	 by	
repetitive	 sequences	 (repeats).	 The	 locus	 also	 encodes	 tracrRNAs	 and	 the	 Cas9	 protein.	 Spacer	 and	
repetitive	 sequences	 are	 transcribed	 into	 long	 primary	 transcripts,	 which	 are	 processed	 into	 short	
crRNA	sequences	containing	one	spacer	sequence.	crRNAs	assemble	with	tracrRNA	and	a	Cas9	protein	
to	 form	 a	 functional	 gene-editing	 complex.	 This	 complex	 is	 guided	 to	 a	 specific	 site	 in	 the	 foreign	
target	 DNA	 that	 is	 complementary	 to	 the	 spacer	 sequence.	 Here,	 the	 Cas9	 protein	 induces	 double	
strand	breaks	(ds	breaks,	indicated	by	black	stars)	in	the	foreign	DNA,	which	is	subsequently	degraded	
(Wiedenheft	et	al.,	2012).	Artificial	 single	guide	RNAs	 (sgRNAs,	dashed	box)	have	been	developed	 to	
provide	 target	 recognition	and	 scaffolding	 function	of	 the	 crRNA	and	 tracrRNA,	 respectively,	 in	one	
molecule	(Jinek	et	al.,	2012).	Loaded	onto	Cas9,	sgRNAs	can	induce	ds	breaks	at	intended	genomic	loci.	
This	scheme	was	adapted	from	(Manjunath	et	al.,	2013).	
Among	 the	 three	different	 types	of	CRISPR	 systems	 that	have	been	 identified	 so	 far,	the	type	II	system	is	of	the	lowest	complexity	and	best	evaluated.	By	transcription	and	further	processing	via	endonucleolytic	cleavage,	 two	types	of	short	non-coding	RNAs	are	 generated	 from	 each	 type	 II	 CRISPR	 locus:	 a	 trans-acting	 antisense	 RNA	(tracrRNA)	 and	 a	 CRISPR-derived	 RNA	 (crRNA)	 that	 contains	 a	 unique	 spacer	
Introduction	 47	 		sequence.	 tracrRNA	 and	 crRNA	 form	 a	 complex	 with	 the	 CRISPR-associated	 (Cas)-nuclease	 9	 (Cas9),	 which	 recognizes	 protospacers	 of	 foreign	 DNA	 sequences	 by	spacer-mediated	complementary	base	pairing.	If	the	protospacer	on	the	target	DNA	is	flanked	 by	 a	 3’	protospacer	 adjacent	 motif	 (PAM),	 Cas9	 performs	 double	 strand	cleavage	 of	 the	 protospacer	 sequence,	 leading	 to	 the	 destruction	 of	 the	 pathogenic	DNA	(Wiedenheft	et	al.,	2012).		Similar	 to	 RNAi	 (Chapter	 1.1.3),	 the	 CRISPR	 system	 can	 be	 harnessed	 as	 a	biotechnological	 tool.	 A	 breakthrough	was	 achieved	when	 researchers	 succeeded	 in	combining	 features	of	 the	 crRNA	and	 the	 tracrRNA	 into	a	 single	guide	RNA	 (sgRNA)	(Figure	 6,	 dashed	 box),	which	was	 sufficient	 to	 guide	 Cas9	 to	 the	 intended	 genomic	locus	and	 induce	double	strand	breaks	(Jinek	et	al.,	2012).	These	are	repaired	either	by	 homology-directed	 repair	 (HR)	 or,	 more	 often,	 by	 error-prone	 non-homologous	end-joining	(NHEJ),	which	typically	results	in	short	stretches	of	nucleotide	insertions	or	deletions	(indels).	As	a	consequence,	the	reading	frame	is	shifted	in	2/3	of	all	cases,	and	is	likely	to	produce	transcripts	with	premature	stop-codons.	These	are	efficiently	removed	 by	 NMD.	 In	 the	 remaining	 1/3	 of	 all	 cases	 indels	 of	 DNA	 lead	 to	 mature	proteins	 with	 a	 low	 number	 of	 amino	 acid	 insertions	 or	 deletions.	 By	 contrast,	homology-directed	 repair	makes	use	of	 a	homologous	 repair	 template	and	 therefore	hardly	 introduces	 mistakes.	 One	 can	 take	 advantage	 of	 HR	 to	 produce	 tailor-made	gene	modifications	 (Zheng	et	al.,	2014)	by	 transferring	a	specifically	designed	repair	template	 along	with	 Cas9	 and	 an	 sgRNA	 into	 target	 cells.	 Simultaneous	 presence	 of	Cas9	 nuclease	 and	 sgRNA	 in	 the	 nucleus	 are	 the	 minimal	 requirements	 for	CRISPR/Cas-mediated	 genome	 editing.	 Various	 systems	 have	 been	 developed	 for	efficient	delivery	of	Cas9	into	virtually	any	type	of	target	cell.	Cas9-encoding	plasmids	can	 be	 delivered	 transiently	 by	 transfection	 (Shen	 et	 al.,	 2014)	 or	 adenoviral	transduction	(Maggio	et	al.,	2014),	but	also	stably	via	lentiviral	infection	(Shalem	et	al.,	2014).	Moreover,	 Cas9	 and	 sgRNAs	 can	 be	microinjected	 either	 as	mRNA	 or,	 in	 the	case	 of	 Cas9,	 as	 recombinant	 protein	 (Kalebic	 et	 al.,	 2016;	 Shen	 et	 al.,	 2014).	 In	combination	with	 lentivirally-	or	transiently	delivered	sgRNA-encoding	plasmids,	 the	CRISPR/Cas9	system	thus	provides	a	versatile	tool	for	the	generation	of	targeted	gene	modifications	(Shalem	et	al.,	2014;	Shen	et	al.,	2014).		
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1.3 Post-transcriptional	 gene	 regulation	 in	 the	 mammalian	
immune	system	
Immune	cells	have	to	be	able	to	quickly	adapt	their	cytokine	and	transcription	factor	profile	 in	 response	 to	 pathogen	 invasion.	 In	 mammals,	 many	 cytokine	 and	immunomodulatory	 mRNAs	 are	 thus	 prone	 to	 profound	 post-transcriptional	 gene	regulation	 and	 characterized	 by	 a	 short	mRNA	 half-life	 (Ivanov	 &	 Anderson,	 2013).	Suspension	of	 these	control	mechanisms	can	have	severe	consequences,	which	 I	will	show	exemplarily	for	two	different	post-transcriptional	regulatory	mechanisms	in	the	following	 two	 paragraphs.	 Finally,	 this	 chapter	 will	 conclude	 with	 a	 detailed	illustration	of	how	Roquin	proteins	mediate	peripheral	immune	tolerance.		
1.3.1 ARE-mediated	decay	of	cytokine	mRNAs	A	 prominent	 pathway	 of	 post-transcriptional	 gene	 regulation	 is	 AU-rich	 element	(ARE)-mediated	 decay,	 affecting	 approximately	 5	–	10	%	 of	 all	 human	 mRNAs	including	many	cytokines,	chemokines	and	other	proinflammatory	proteins	(Ivanov	&	Anderson,	2013).	It	is	conducted	by	a	large	number	of	different	ARE-binding	proteins	that	 recognize	 AREs	 in	 the	 3’	UTRs	 of	 their	 target	 mRNAs	 and	 promote	 or	 inhibit	translation	and/or	mRNA	decay	(Ivanov	&	Anderson,	2013).	A	well-studied	example	is	an	ARE	in	the	tumor	necrosis	factor	(TNF)	mRNA	(Caput	et	al.,	1986)	that	is	targeted	by	multiple	 antagonistic	 ARE-binding	 proteins	 including	 the	 ZnF	 RNA-binding	 protein	TTP,	 which	 destabilizes	 TNF	 mRNA	 (Molle	 et	 al.,	 2013).	 TNF	 is	 a	 highly	 potent	proinflammatory	 cytokine,	 which	 is	 produced	 in	 abundance	 by	 macrophages	 in	response	 to	 LPS	 stimulation	 (Zhang	 et	 al.,	 1997).	 Abrogation	 of	 TTP-mediated	regulation	of	TNF	mRNA	in	TTP-/-	mice	leads	to	excessive	TNF	production	(Carballo	et	al.,	1997)	resulting	in	spontaneous	development	of	a	complex	inflammatory	syndrome	characterized	 by	 cachexia,	 myeloid	 hyperplasia,	 dermatitis,	 arthritis	 and	 finally	autoimmunity	 including	 the	production	of	 autoantibodies	 (Taylor	et	 al.,	 1996).	Post-transcriptional	regulation	of	cytokine	mRNAs	thus	seems	to	be	a	major	mechanism	in	the	prevention	of	autoimmunity	and	inflammation.		
1.3.2 The	stem-loop	binding	proteins	Roquin-1,	Roquin-2	and	Regnase-
1	control	immunomodulatory	mRNAs	Another	mechanism	of	post-transcriptional	gene	regulation	was	recently	discovered	in	T	cells.	Here,	the	stem-loop	binding	proteins	Roquin-1,	Roquin-2	(Chapter	1.1.4.2)	and	
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TNF),	costimulatory	receptors	(Icos,	Ox40,	Ctla-4),	transcription	factors	(Irf4,	cRel)	and	transcriptional	modulators	 (Nfkbid,	Nfkbiz)	 (Jeltsch	 et	 al.,	 2014;	 Uehata	 et	 al.,	 2013;	Vogel	 et	 al.,	 2013).	 Upon	 T	 cell	 activation,	 both	 Roquin	 paralogs	 and	 Regnase-1	 are	cleaved	and	inactivated	by	the	paracaspase	Malt1,	which	results	in	the	derepression	of	their	target	mRNAs	(Jeltsch	et	al.,	2014;	Uehata	et	al.,	2013).		The	majority	 of	mRNAs	 targeted	by	Roquin-1	 and	Regnase-1	 code	 for	 proteins	with	crucial	roles	in	the	T	cell	 fate	decision.	The	cytokine	IL-6	is	a	potent	inducer	of	Th17	differentiation	(Korn	et	al.,	2008),	supported	by	Irf4	(Brustle	et	al.,	2007),	cRel	(Chen	et	al.,	2011;	Reinhard	et	al.,	2011;	Ruan	et	al.,	2011),	IκBζ	(Okamoto	et	al.,	2010)	and	IκBNS	 (Jeltsch	 et	 al.,	 2014),	which	operate	on	 the	 transcriptional	 level.	As	described	previously	 (Chapter	 1.2.1.4),	 Icos	 plays	 a	 critical	 role	 in	 TFH	 development.	 Likewise,	costimulatory	 Ox40	 signaling	 was	 found	 to	 promote	 upregulation	 of	 TFH	 effector	proteins	 on	 activated	 and	memory	 CD4+	 T	 cells	 (Jacquemin	 et	 al.,	 2015).	Moreover,	Irf4	is	not	only	essential	 for	Th17,	but	also	for	TFH	differentiation	(Bollig	et	al.,	2012;	Brustle	et	al.,	2007;	Huber	et	al.,	2008).	Roquin	and	Regnase-1	thus	primarily	regulate	mRNAs	 with	 a	 function	 in	 Th17	 and	 TFH	 differentiation,	 and	 their	 loss	 of	 function	should	 consequently	 result	 in	 a	 strong	 imbalance	 in	 T	 cell	 differentiation.	 Indeed,	mutation	of	Roquin-1	(M199R,	called	sanroque	mutation)	or	T	cell-specific	ablation	of	Roquin-1	and	its	paralog	Roquin-2	in	mice	leads	to	the	spontaneous	activation	of	CD4+	and	 CD8+	 T	 cells	 and	 an	 accumulation	 of	 TFH	 and	 Th17	 cells	 (Jeltsch	 et	 al.,	 2014;	Vinuesa	 et	 al.,	 2005;	Vogel	 et	 al.,	 2013).	 In	 addition,	 aberrant	production	of	 the	Th1	cytokine	 IFNγ	was	 observed	 in	 sanroque	mice	 (Lee	 et	 al.,	 2012).	 Strikingly,	 the	 bias	towards	 Th1,	 TFH	 and	 Th17	 cell	 differentiation	 upon	 loss	 of	 Roquin	 function	 is	connected	 to	 the	 development	 of	 severe	 autoimmunity	 and	 other	 pathologies.	 In	
sanroque	 mice,	 enhanced	 numbers	 of	 TFH	 cells	 are	 associated	 with	 spontaneous	germinal	 center	 formation	 and	 the	 production	 of	 high-affinity	 anti-nuclear	autoantibodies,	 causing	 a	 systemic	 lupus	 erythematosus	 (SLE)-like	 autoimmune	phenotype	 (Vinuesa	 et	 al.,	 2005).	 In	 Roquin-deficient	 mice,	 tissue-infiltrating	 Th17	cells	cause	 lung	pathology	(Jeltsch	et	al.,	2014).	Loss	of	Regnase-1	has	similar	severe	consequences.	 Mice	 with	 a	 T	 cell-specific	 deletion	 of	 the	 Regnase-1-encoding	 gene	
Zc3h12a	 also	display	an	autoimmune	phenotype	accompanied	by	spontaneous	T	cell	activation,	 accumulation	 of	 plasma	 cells	 and	 the	 production	 of	 anti-nuclear	autoantibodies	(Uehata	et	al.,	2013).		
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1.3.3 Roquin	proteins	mediate	peripheral	immune	tolerance	By	 restricting	 unwanted	 Th1,	 TFH	 and	 Th17	 differentiation,	 Roquin	 proteins	 thus	appear	 to	 be	 essential	 mediators	 of	 peripheral	 tolerance.	 While	 central	 tolerance	operates	 in	 the	 thymus	 to	 eliminate	 self-reactive	 B	 and	 T	 lymphocytes,	 peripheral	tolerance	 is	 a	 secondary	 fail-safe	 mechanism	 against	 autoimmunity.	 An	 important	mechanism	 in	 peripheral	 tolerance	 is	 the	 requirement	 for	 costimulation.	 Many	costimulatory	 receptors,	 such	 as	 the	 CD28	 ligands	 B7-1	 and	 B7-2,	 are	 selectively	upregulated	on	APCs	only	after	pathogen	encounter.	 In	the	absence	of	costimulation,	self-reactive	 T	 cells	 will	 become	 anergic	 upon	 activation	 (Heissmeyer	 et	 al.,	 2005).	Some	 costimulatory	 receptor	 ligands	 however,	 such	 as	 the	 Icos	 ligand	 Icosl,	 are	constitutively	 expressed	 on	 APCs.	 In	 this	 case,	 expression	 of	 the	 costimulatory	receptor,	 here	 Icos,	 has	 to	 be	 restricted	 in	 T	 cells.	 In	 addition	 to	 the	 transcriptional	program,	this	is	mediated	on	the	post-transcriptional	level	by	Roquin-1,	Roquin-2	and	Regnase-1.	In	line	with	this,	it	was	found	that	loss	of	Roquin	function	uncouples	the	T	cell-dependent	 antibody	 response	 from	 the	 requirement	 for	 CD28	 costimulation	(Linterman	et	al.,	2009).	Upregulation	of	Icos	due	to	functional	inactivation	of	Roquin	could	 revert	 the	 most	 prominent	 phenotypes	 of	 CD28-deficient	 mice,	 including	impaired	GC	formation	and	TFH	differentiation,	primary	antibody	responses	and	iTreg	development	(Linterman	et	al.,	2009).	This	was	not	the	case	when	Icos	signaling	was	abrogated	 by	 additional	 deletion	 of	 Icosl.	 By	 post-transcriptional	 regulation	 of	 Icos,	Roquin	 proteins	 therefore	 compartmentalize	 Icos	 and	 CD28	 function	 and	 prevent	autoimmunity	 by	 making	 the	 system	 dependent	 on	 CD28-mediated	 discrimination	between	 self-	 and	 foreign	 antigens	 (Linterman	 et	 al.,	 2009).	 For	 this	 reason,	upregulation	of	Icos,	together	with	other	Roquin	targets,	is	one	of	the	causative	agents	of	the	autoimmune	phenotype	of	sanroque	mice	(Yu	et	al.,	2007).  
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2 Aim	of	the	project	
Roquin-1	and	 its	paralog	Roquin-2	are	RNA-binding	proteins	with	a	crucial	 role	 in	T	cell	 differentiation.	 They	 bind	 to	 stem-loop	 structures	 in	 the	 3’	UTRs	 of	 their	 target	mRNAs,	 which	 are	 important	 mediators	 of	 Th1,	 TFH,	 and	 Th17	 differentiation,	 and	induce	 post-transcriptional	 repression.	 Mice	 where	 Roquin-1	 is	 mutated	 (sanroque	mouse	 strain)	 or	 Roquin-1	 and	 Roquin-2	 are	 missing	 in	 T	 cells	 develop	 severe	autoimmunity	 or	 show	 lung	 pathology,	 respectively.	 Although	 Roquin	 proteins	 thus	appear	to	be	highly	 important	 for	 the	maintenance	of	 immunological	 tolerance,	 their	mechanism	of	action	remains	elusive,	and	especially	their	regulators	and	cofactors	are	largely	unknown.		In	 order	 to	 solve	 this,	 the	 aim	 of	 this	 thesis	 was	 the	 development	 of	 robust	 high-throughput	 screening	 (HTS)	 approaches	 enabling	 the	 identification	 of	 unknown	cofactors	 of	 Roquin-mediated	 post-transcriptional	 gene	 regulation.	 This	 first	 of	 all	required	 the	 establishment	 of	 tailor-made	 reporter	 cell	 lines	 that	 allow	 high-throughput,	 in	 the	 best	 case	 genome-wide,	 screening.	 Once	 primary	 screening	 was	accomplished,	 hit	 validation	 started	 from	 a	 long	 list	 of	 candidate	 genes.	 A	 second	milestone	of	this	thesis	was	therefore	the	development	of	a	hit	validation	strategy	that	potently	discriminated	true	hits	from	false	positives	and	identified	the	most	promising	candidates	for	functional	validation.		The	 final	 goal	 was	 a	 detailed	 functional	 validation	 of	 a	 so	 far	 unknown	 candidate	protein	as	a	new	Roquin	cofactor.	The	first	question	 in	this	context	was	whether	the	candidate	protein	interacts	with	Roquin-1,	which	was	investigated	in	protein	binding	assays.	 Next,	 it	 was	 important	 to	 determine	 the	 cis-elements	 on	 which	 Roquin	 can	cooperate	with	its	cofactors	in	a	detailed	structure-function	analysis.		Since	 Roquin	 proteins	 play	 a	 critical	 role	 in	 T	 cells,	 it	 furthermore	 needed	 to	 be	investigated	whether	 the	 candidate	 protein	 itself	 is	 also	 active	 in	 immune	 cells,	 and	whether	 it	 acquires	 a	 special	 function	 in	 T	 cells.	 Combining	 the	 results	 from	 the	candidate	 gene	 validation	with	 the	 knowledge	 on	 potential	 cofactors	 of	 Roquin-1	 as	suggested	 by	 the	 literature	 finally	 enabled	 us	 to	 create	 a	 broader	 picture	 of	 the	assembly	of	the	mRNP	that	coordinates	Roquin	function.		
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3 Material	and	methods	
3.1 Material	
3.1.1 Mice	and	MEF	cells	Primary	immune	cells	and	mouse	embryonic	fibroblast	(MEF)	cells	used	in	this	study	were	obtained	from	wildtype	mice	unless	stated	otherwise.		
Rc3h1/2fl/fl	MEF	cells	were	generated	from	Rc3h1/2fl/fl	mice,	where	exons	4-6	of	Rc3h1	and	exon	4	of	Rc3h2	are	flanked	by	loxP	sites	(Vogel	et	al.,	2013).	To	produce		Rc3h1/2-
/-	MEF	 cells,	 Rc3h1/2fl/fl	 cells	 were	 transduced	 to	 express	 Cre	 recombinase,	 thereby	deleting	the	respective	exons.		
CAG-CARSTOP-fl	mice	express	a	signaling-inactive	form	of	the	human	coxsackie	virus	and	adenovirus	 receptor	 (CAR)	 upon	 deletion	 of	 the	 loxP-flanked	 STOP	 cassette	 by	 Cre	recombinase	 (Vogel	 et	 al.,	 2013).	 Crossing	 them	 with	 Rc3h1/2fl/fl	 mice	 and	
Gt(ROSA)26Sortm2(cre/ERT2)Brn	mice	provided	by	Dr.	Anton	Berns	(Hameyer	et	al.,	2007)	gave	rise	to	Rc3h1/2fl/fl	CAG-CARSTOP-fl	CreERT2	mice.	In	MEF	cells	generated	from	these	mice	(Rc3h1/2fl/fl	CreERT2	MEF)	the	Cre	recombinase-estrogen	receptor	fusion	protein	CreERT2	 can	 be	 activated	 in	vitro	 by	 treatment	with	 4-OH-tamoxifen,	 leading	 to	 the	disruption	 of	 the	 floxed	 exons	 of	 Rc3h1	 and	 Rc3h2,	 while	 simultaneously	 inducing	expression	of	 the	 cell	 surface	marker	CAR.	The	 single	 cell	Rc3h1/2fl/fl	Cre	ERT2	MEF	clone	used	in	this	study	was	produced	by	Desiree	Argiriu	and	shows	complete	ablation	of	Roquin-1	and	Roquin-2	protein	expression	upon	4-OH-tamoxifen	treatment.		All	mice	were	bred	on	a	C57/Bl6	background	and	housed	 in	a	 special	pathogen-free	barrier	 facility	 at	 Helmholtz	 Zentrum	 München	 in	 accordance	 with	 the	 Helmholtz	Zentrum	München	institutional,	state	and	federal	guidelines.		
3.1.2 Cell	lines	and	cell	culture	HeLa	cells	were	a	kind	gift	from	Dr.	Helmut	Holtmann.		The	origin	of	MEF	cells	with	different	genotypes	was	described	above	(Chapter	3.1.1).		Jurkat	T	cells	were	obtained	from	ThermoFisher	Scientific	(Catalog	#	R762-07).		
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MEF	cells	and	HeLa	cells	were	cultured	in	a	cell	culture	incubator	at	37	°C,	10	%	CO2	in	 DMEM	 supplemented	 with	 10	%	 fetal	 bovine	 serum	 (FBS),	 1	%	 penicillin-streptomycin	 and	 1	%	 HEPES.	 Jurkat	 T	 cells	 were	 cultured	 at	 37	 °C,	 5	%	 CO2	 in	RPMI	1640	 medium	 supplemented	 with	 10	%	fetal	 bovine	 serum,	 1	%	penicillin-streptomycin,	 1	%	HEPES,	 1	%	L-glutamine	 and	 0.1	%	β-mercaptoethanol.	 Primary	
mouse	T	cells	were	cultured	at	37	°C,	5	%	CO2	in	RPMI-1640	medium	supplemented	with	 10	%	fetal	 bovine	 serum,	 1	%	HEPES,	 1	%	penicillin-streptomycin,	 1	%	non-essential	 amino	 acids	 (NEAA),	 1	%	sodium	 pyruvate,	 1	%	vitamin	 solution,	 1	%	L-glutamine	and	0.1	%	β-mercaptoethanol	(Table	2).		
Table	2:	Cell	culture	components	
Component	 Supplier	
Dulbecco’s	Modified	Eagle	Medium	(DMEM)	 ThermoFisher	Scientific	
Fetal	bovine	serum	(FBS)	 PAN	BIOTECH	
HEPES	pH	7.4	(1	M)	 ThermoFisher	Scientific	
L-Glutamine	200	mM	 ThermoFisher	Scientific	
MEM	non-essential	amino	acids	(NEAA)	100x	 ThermoFisher	Scientific	
MEM	vitamin	solution	(100x)	 ThermoFisher	Scientific	
Penicillin-streptomycin	(10,000	U/ml)	 ThermoFisher	Scientific	
RPMI	1640,	no	glutamine	 Lonza	
Sodium	pyruvate	(100	mM)	 Lonza	
Tet-system	approved	FBS	 Clontech	Laboratories	β-mercaptoethanol	 Sigma-Aldrich		
3.1.3 Plasmids	Genes	of	 interest	were	PCR-amplified	 from	cDNA	using	gene-specific	primers	 (Table	7)	and	subsequently	cloned	into	Gateway®	entry	vectors	by	TOPO®	cloning	(Table	3).	From	 entry	 vectors,	 genes	 of	 interest	 were	 recombined	 into	 different	 Gateway®	destination	 vectors	 performing	 Gateway®	 LR	 reactions.	 Transient	 expression	destination	 vectors	 (pDest12.2,	 pLNCX2)	 were	 used	 for	 calcium	 phosphate	transfection	of	HEK293T	cells	 (Table	4),	while	retro-	(pKMV	IRES	GFP,	pMSCV-IRES-Thy1.1)	 and	 lentiviral	 (plenti	 CMV	 Hygro,	 plenti	 PGK	 Hygro,	 plentiCMVtight	 Neo)	expression	destination	vectors	were	used	to	achieve	stable	integration	of	the	gene	of	interest	by	viral	transduction	(Table	5).			
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3.1.3.1 Entry	vectors	
Table	3:	List	of	Gateway®	entry	vectors	
Vector	backbone	 Insert	
PCR8/GW	TOPO	 FBXL14	
PCR8/GW	TOPO	 ICOS	1-600	(coding	sequence,	CDS)	
PCR8/GW	TOPO	 ICOS	CDS-CDE260	
PCR8/GW	TOPO	 ICOS	1-800	
PCR8/GW	TOPO	 ICOS	1-1211		
PCR8/GW	TOPO	 ICOS	1-1811	
PCR8/GW	TOPO	 ICOS	1-2011	
PCR8/GW	TOPO	 ICOS	1-2211	Δ700-800	
PCR8/GW	TOPO	 ICOS	1-2271	
PCR8/GW	TOPO	 ICOS	1-2391	
PCR8/GW	TOPO	 ICOS	full-length	
PCR8/GW	TOPO	 ICOS	SM1	
PCR8/GW	TOPO	 ICOS	SM1	SM2	
PCR8/GW	TOPO	 ICOS	SM1	SM2R	
PCR8/GW	TOPO	 ICOS	SM1R	
PCR8/GW	TOPO	 ICOS	SM1R	SM2	
PCR8/GW	TOPO	 ICOS	SM1R	SM2R	
PCR8/GW	TOPO	 ICOS	SM2	
PCR8/GW	TOPO	 ICOS	SM2R	
PCR8/GW	TOPO	 ICOS	Δ700-800	
PCR8/GW	TOPO	 ICOS-CDS-GFP-NFκBID	3’	UTR	
PCR8/GW	TOPO	 NUFIP2	
PCR8/GW	TOPO	 Rab40c	
PCR8/GW	TOPO	 Regnase-1	
PCR8/GW	TOPO	 RNF222	
PCR8/GW	TOPO	 Roquin-1	(aa	509-1130)-GFP	
PCR8/GW	TOPO	 Roquin-1	full-length	
PCR8/GW	TOPO	 Roquin-1-mCherry	
PCR8/GW	TOPO	 Roquin-1-P2A-mCherry	
PCR8/GW	TOPO	 Roquin-1	(aa	1-509)	
PCR8/GW	TOPO	 Roquin-1	(aa	1-509)-P2A-mCherry	
PCR8/GW	TOPO	 sgRNA-resistant	NUFIP2	
PCR8/GW	TOPO	 TRIM6-TRIM34	
pENTR11	 GFP-NUFIP2	
pENTR11	 GFP-Roquin-1	full-length	
pENTR11	 HA-Cas9-GFP	
pENTR11	 siRNA#2-resistant	GFP-NUFIP2	
pENTR11		 GFP		
56	 Material	and	methods			PCR8/GW	TOPO	 vectors	with	 the	 inserts	 Roquin-1	 full-length,	 Roquin-1	 (aa	 1-509),	ICOS	 full-length,	 ICOS	 coding	 sequence,	 Roquin-1	 (aa	 509-1130)-GFP,	 ICOS	 1-1211,	ICOS	1-1811,	ICOS	1-2011,	ICOS	1-2211,	ICOS	1-2271,	ICOS	1-2391,	GFP-Roquin-1	full-length	 and	 pENTR11	 GFP-Roquin-1	 full-length	 were	 kindly	 provided	 by	 Dr.	 Elke	Glasmacher	 and	Dr.	 Katharina	 Vogel	 and	 are	 described	 in	 (Glasmacher	 et	 al.,	 2010)	and	in	(Vogel,	2012).		PCR8/GW	TOPO	 ICOS	1-2211	Δ700-800	was	provided	by	Dr.	Gitta	Heinz,	 PCR8/GW	TOPO	 ICOS	CDS-CDE260	and	 ICOS-CDS-GFP-NFκBID	3’	UTR	were	cloned	by	Dr.	Sven	Brenner	 and	 PCR8/GW	 TOPO	 ICOS	 1-800	 and	 ICOS	 Δ700-800	 were	 generated	 by	Claudia	Lohs	using	primer	sequences	listed	in	Table	7.		HA-Cas9-GFP	was	cloned	into	PE11	via	restriction	digest	of	pMJ920,	which	was	a	kind	gift	from	Dr.	Jennifer	Doudna	(Addgene	#42234)	(Jinek	et	al.,	2013).		
3.1.3.2 Transient	transfection	destination	vectors	
Table	4:	Gateway®	destination	vectors	for	transient	transfection	
Vector	backbone	 Insert	
pDest12.2	 GFP	
pDest12.2	 Roquin-1-mCherry	
pDest12.2	 Roquin-1	(aa	509-1130)-GFP	
pLNCX2	 Roquin-1-GFP	
pLNCX2	 Roquin-1	(aa	1-509)-GFP	
	pLNCX2	 Roquin-1	(aa	1-509)-GFP	 and	 Roquin-1-GFP	 were	 provided	 by	 Dr.	 Elke	Glasmacher.	All	other	transient	transfection	destination	vectors	(Table	4)	were	cloned	by	 Gateway®	 LR	 recombination	 from	 entry	 clones	 listed	 in	 Table	 3.	 pDest12.2	(ThermoFisher	 Scientific)	 contains	 a	 CMV	 promoter	 for	 transient	 expression	 and	 a	neomycin	 resistance	 gene	 as	 a	 selectable	 marker,	 while	 pLNCX2	 (Clontech)	 is	 a	retroviral	vector	that	enables	either	transient	or	stable	expression	of	a	gene	of	interest	from	the	CMV	promoter.		
3.1.3.3 Retro-	and	lentiviral	destination	vectors	Genes	of	interest	were	cloned	into	retro-	and	lentiviral	Gateway®	destination	vectors	by	LR	recombination	from	entry	vectors	listed	in	Table	3.			
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Table	5:	Retro-	and	lentiviral	Gateway®	destination	vectors	
Destination	vector		 Insert	
pKMV	IRES	GFP	 ICOS	1-600	(coding	sequence,	CDS)	
pKMV	IRES	GFP	 ICOS	CDS-CDE260	
pKMV	IRES	GFP	 ICOS	1-800	
pKMV	IRES	GFP	 ICOS	1-1211		
pKMV	IRES	GFP	 ICOS	1-1811	
pKMV	IRES	GFP	 ICOS	1-2011	
pKMV	IRES	GFP	 ICOS	1-2211		
pKMV	IRES	GFP	 ICOS	1-2211	Δ700-800	
pKMV	IRES	GFP	 ICOS	1-2271	
pKMV	IRES	GFP	 ICOS	1-2391	
pKMV	IRES	GFP	 ICOS	full-length	(FL)	
pKMV	IRES	GFP	 ICOS	SM1	
pKMV	IRES	GFP	 ICOS	SM1	SM2	
pKMV	IRES	GFP	 ICOS	SM1	SM2R	
pKMV	IRES	GFP	 ICOS	SM1R	
pKMV	IRES	GFP	 ICOS	SM1R	SM2	
pKMV	IRES	GFP	 ICOS	SM1R	SM2R	
pKMV	IRES	GFP	 ICOS	SM2	
pKMV	IRES	GFP	 ICOS	SM2R	
pKMV	IRES	GFP	 ICOS	Δ700-800	
plenti	CMV	Hygro		 HA-Cas9-GFP	
plenti	PGK	Hygro	 ICOS	1-600	(coding	sequence,	CDS)	
plenti	PGK	Hygro	 ICOS	full-length	(FL)	
plentiCMVtight	Neo	 Roquin-1-mCherry	
plentiCMVtight	Neo	 Roquin-1-P2A-mCherry	
plentiCMVtight	Neo	 Roquin-1	(aa	1-509)-P2A-mCherry	
pMSCV-IRES-Thy1.1	 FBXL14	
pMSCV-IRES-Thy1.1	 GFP	
pMSCV-IRES-Thy1.1	 GFP-NUFIP2	
pMSCV-IRES-Thy1.1	 ICOS-CDS-GFP-NFκBID	3’	UTR	
pMSCV-IRES-Thy1.1	 NUFIP2	
pMSCV-IRES-Thy1.1	 Rab40c	
pMSCV-IRES-Thy1.1	 Regnase-1	
pMSCV-IRES-Thy1.1	 RNF222	
pMSCV-IRES-Thy1.1	 Roquin-1	full-length	
pMSCV-IRES-Thy1.1	 Roquin-1	(aa	1-509)	
pMSCV-IRES-Thy1.1	 sgRNA-resistant	NUFIP2	
pMSCV-IRES-Thy1.1	 siRNA#2-resistant	GFP-NUFIP2	
pMSCV-IRES-Thy1.1	 TRIM6-TRIM34		
58	 Material	and	methods			plentiCMVtight	 Neo	 DEST	 was	 a	 kind	 gift	 from	 Dr.	 Eric	 Campeau	 (Addgene	plasmid	#26432)	and	allows	doxycycline-inducible	gene	expression	from	the	CMVtight	promoter,	while	including	a	neomycin	resistance	as	a	selectable	marker	gene.		plenti	 PGK	 Hygro	 DEST	 and	 plenti	 CMV	 Hygro	 DEST	 were	 donated	 by	 Dr.	 Eric	Campeau	(Addgene	plasmids	#19066	and	#17454)	(Campeau	et	al.,	2009)	and	serve	for	 stable	 lentiviral	expression	of	a	gene	of	 interest	 from	the	PGK	or	CMV	promoter,	respectively,	while	including	a	hygromycin	resistance	gene	as	a	selectable	marker.		pMSCV-IRES-Thy1.1	 DEST	 was	 a	 kind	 gift	 from	 Dr.	 Anjana	 Rao	 and	 allows	 stable	retroviral	 expression	 of	 a	 gene	 of	 interest	 from	 retroviral	 LTRs	 with	 bicistronic	expression	of	the	surface	marker	Thy1.1.		pKMV	IRES	GFP	allows	stable	retroviral	expression	of	a	gene	of	interest	with	an	IRES-GFP	fluorescence	reporter.		
3.1.3.4 Non-Gateway®	expression	vectors	The	 pOPINS3C	 vector	 was	 employed	 by	 Elena	 Davydova	 for	 expression	 of	recombinant	NUFIP2	(aa	255-411)	in	bacteria.		For	doxycycline-inducible	lentiviral	gene	expression	from	the	plentiCMVtight	Neo	DEST	vector	(Table	5),	cells	need	to	be	cotransduced	with	the	TET-ON	transactivator	rtTA3.	The	 rtTA3-encoding	 vector	 plenti	 CMV	 rtTA3	 Blast	 was	 a	 kind	 gift	 from	 Dr.	 Eric	Campeau	(Addgene	plasmid	#26429).		The	 genome-scale	 lentiviral	 mouse	 GeCKO	 v2	 Library	 (2	 plasmid	 system)	 was	purchased	from	Addgene	(Addgene	#1000000053)	(Sanjana	et	al.,	2014).		plentiCRISPR	 v1	 was	 a	 kind	 gift	 from	 Dr.	 Feng	 Zhang	 (Addgene,	 now	 available	 as	plentiCRISPR	v2	#52961)	(Shalem	et	al.,	2014).	plentiCRISPR	EFS	GFP	was	deposited	by	Dr.	Benjamin	Ebert	(Addgene	plasmid	#57818)	(Heckl	et	al.,	2014).		Mouse	 and	 human	 Nufip2-targeting	 sgRNAs	 were	 designed	 using	 the	 ‘optimized	CRISPR	 tool’	 (http://crispr.mit.edu)	 provided	 by	 the	 Zhang	 lab	 and	 cloned	 into	plentiCRISPR	v1	or	plentiCRISPR	EFS	GFP	by	annealing	of	oligonucleotides	with	BsmBI	overhangs	 (Table	 11)	 and	 ligation	 into	 BsmBI-digested	 vectors.	 Sequences	 for	 non-targeting	controls	(NT1,	NT2)	were	taken	from	the	mouse	GeCKO	v2	library.		
Material	and	methods	 59	 		
Table	6:	lentiCRISPR	vectors	
Vector	backbone	 Insert	 Species	
plentiCRISPR	EFS	GFP	 mNUFIP2#1	sgRNA	 Mouse	
plentiCRISPR	EFS	GFP	 mNUFIP2#2	sgRNA	 Mouse	
plentiCRISPR	EFS	GFP	 mNUFIP2#3	sgRNA	 Mouse	
plentiCRISPR	EFS	GFP	 mNUFIP2#4	sgRNA	 Mouse	
plentiCRISPR	EFS	GFP	 NT1	sgRNA	 -	
plentiCRISPR	EFS	GFP	 NT2	sgRNA	 -	
plentiCRISPR	v1	 hNUFIP2#3	sgRNA	 Human		Retrovirus	production	was	performed	with	ecotropic	(eco-pac)	or	amphotropic	(gag-pol	and	ampho-env)	packaging	vectors.		Lentivirus	 production	 was	 performed	 with	 second	 generation	 (pMD2.G	 VSVG	 and	psPAX2	)	or	third	generation	(pMD2.G	VSVG,	pRSV-Rev	and	pMDLg/pRRE)	packaging	plasmids,	 depending	 on	 the	 backbone	 of	 the	 lentiviral	 transfer	 vector	 (Chapter	3.2.3.4).		
3.1.4 Oligonucleotides	
3.1.4.1 DNA	oligonucleotides	DNA	oligonucleotides	were	purchased	from	Metabion	(Planegg,	Germany)	or	Eurofins	DNA	(Ebersberg,	Germany).		
Table	7:	Primers	for	cDNA	cloning	
Name	 Sequence	 cDNA	
CDE260	for	 CTCGAGGGAAGGCCGGGGTGTCC	 ICOS	CDS	CDE260	
CDE260	rev	 CTCGAGCTCTCAATGACCCGTAGGG	 ICOS	CDS	CDE260	
hFBXL14	for	 GTCGACCATGGAGACCCACATCTCATGC	 FBXL14	
hFBXL14	rev	 GCGGCCGCTCACCTTCTGGAGCTTCCC	 FBXL14	
hICOS_ATGfor	 ATGAAGTCAGGCCTCTGGTATTTC	 ICOS	1-800,	 ICOS	Δ700-800	
hICOS	1-700XhoIrev	 GAGACTCGAGTAAGTCAGACTCTCCGTGGTCC	 ICOS	Δ700-800	
hICOS	1-800XhoIrev	 GAGACTCGAGAGAGGACTCGGCAGTACCAAG	 ICOS	1-800	
hTRIM6_TRIM34	for	 GTCGACCATGTGCGGGTCAGAGAGGA	 TRIM6_TRIM34	
hTRIM6_TRIM34	rev	 GCGGCCGCTCAAGAGCTTGGTGGGCATAG	 TRIM6_TRIM34	
ICOS-700-end	SalI	rev	 GTCGACTACTACTGTTAAAATCTCTTTGATAAGTG	 ICOS	Δ700-800	
ICOS	XhoI	800-end	for	 CTCGAGCAAAACAAACACCCTCTTGCAAC				 ICOS	Δ700-800	
mRab40c	for	 GTCGACCATGGGCACCCAGGGCAGT	 Rab40c	
mRab40c	rev	 GCGGCCGCCTAGGAGATCTTGCAGTTGCT	 Rab40c	
mRnf222	for	 GTCGACCATGTCAGAAGGAGGAAGCAAG	 Rnf222	
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Name	 Sequence	 cDNA	
mRnf222	rev	 GCGGCCGCTCAGGCCTGCTTCCTCACCAG	 Rnf222	
Nfkbid-
UTR_fo_Sal1_Cla1	 GTCGACAAAAAAATCGATGCGGCCGCCAGTGTGATG	
ICOS	CDS	GFP	NFκBID	
UTR	
Nfkbid-UTR_re_Sfi1	 GGCCTTAATGGCCTGAGGCCAAATTGAGTTTAATT	 ICOS	CDS	GFP	NFκBID	UTR	
NotI-Linker-P2A-
mCherry	rev	 GCGGCCGCCTACTTATAAAGCTCATCCATTCC	 Roquin-1-P2A-mCherry	
NotI-Linker-P2A-
mCherry	fw	 GCGGCCGCTCAGGTTCCGGAGCCACG	 Roquin-1-P2A-mCherry	
NotI-mCherry-NotI	fw	 GCGGCCGCATGGTGAGCAAAGGCGAGG	 Roquin-1-mCherry	
NotI-mCherry-NotI	rev	 GCGGCCGCCTACTTATAAAGCTCATCCATTCC	 Roquin-1-mCherry	
Nufip2	255-411	for	 AAGTTCTGTTTCAGGGCCCGAAACAGGGACTTGAA	 NUFIP2	255-411	
Nufip2	255-411	rev	 ATGGTCTAGAAAGCTTTAAGAAGTAACAGATTTCAG	 NUFIP2	255-411	
NUFIP2	for	 GTCGACCATGGAGGAGAAGCCCGGC	 NUFIP2	
NUFIP2	rev	 GCGGCCGCTCATTGATCTGGACTATCCATGG	 NUFIP2	
Roquin-1	 DeltaPro	 rev	
2	 GCGGCCGCCTGGAATCAGTTGTGTCACTGTGC	
Roquin-1	(aa	1-509)-
P2A-mCherry	
Roquin-1DeltaPro	for	 ATGCCTGTACAAGCTCCACAATG	 Roquin-1	(aa	1-509)-P2A-mCherry	
	Primers	for	site-directed	mutagenesis	(Table	8)	were	designed	with	the	QuikChange	
Primer	Design	Tool	from	Agilents	Technologies	(http://www.genomics.agilent.com/	primerDesignProgram).		
Table	8:	Primers	for	site-directed	mutagenesis	
Name	 Sequence	 Mutation	
QC_miR101_mut_for	 TACTAGATTCAAATTACAAGTTCAGATCTGTACTGTACACATCCAGCATTAC	
ICOS	SM1	
QC_miR101_mut_rev	 GTAATGCTGGATGTGTACAGTACAGATCTGAACTTGTAATTTGAATCTAGTA	
ICOS	SM1	
QC_miR101_backmut_	
for	
CATACTAGATTCAAATTACAAGTTCAGATCTGATCTGTACACATC
CAGCATTACACATGCT	
ICOS	SM1R	
QC_miR101_backmut_	
rev	
AGCATGTGTAATGCTGGATGTGTACAGATCAGATCTGAACTTGT
AATTTGAATCTAGTATG	
ICOS	SM1R	
ICOS	SM3	fw	 CTGTTAAAATCCCCATTGACTGATAGTGTCATTCTTCCAGATTGAACAAAAC	
ICOS	SM2	
ICOS	SM3	rev	 GTTTTGTTCAATCTGGAAGAATGACACTATCAGTCAATGGGGATTTTAACAG	
ICOS	SM2	
ICOS	SM4	fw	 GCAGTCTGTTAAAATCCCCATTGACACATAGTGTCATTCTTCCAGATTGAACAAAA	
ICOS	SM2R	
ICOS	SM4	rev	 GTTTTGTTCAATCTGGAAGAATGACACTATGTGTCAATGGGGATTTTAACAGACTGC	
ICOS	SM2R	
QC_NUFIP2_rescue_for	 TTGCTGCTCACACCAGGTTTACTATCAGATGACTTCCTAAGCATA
TCACCCACAGCAGGTTTTC	
siNUFIP2#2-
res.	NUFIP2	
QC_NUFIP2_rescue_rev	 GAAAACCTGCTGTGGGTGATATGCTTAGGAAGTCATCTGATAG
TAAACCTGGTGTGAGCAGCAA	
siNUFIP2#2-
res.	NUFIP2	
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Name	 Sequence	 Mutation	
QC_sgRNAres_NUFIP2_
fw	
GTCTGCTTCAGGCTAGTGTCCACCACCTGTTGATTGCCATTGAG
GACCCTGGAA	
sgRNA#4-res.	
NUFIP2	
QC_sgRNAres_NUFIP2	
rev	
TTCCAGGGTCCTCAATGGCAATCAACAGGTGGTGGACACTAGC
CTGAAGCAGAC	
sgRNA#4-res.	
NUFIP2		Intron-spanning	 qPCR	 primers	 (Table	 9)	 were	 designed	 using	 the	 Universal	
ProbeLibrary	Assay	Design	Center	from	Roche	(https://lifescience.roche.com).		
Table	9:	Primers	for	qPCR	
Target	 Forward	primer	 Reverse	primer	 Probe	
ATP2A1	 CCGAGACAGCACTCACCAC	 GGTGAATTCCTTCTTCATTAGCTG	 42	
CERK	 TGGCACCACTGTTCACCTTA	 CCTTGGCCTGATTAGCATGT	 9	
CNOT1	 TTGGAGGACTTTCATCACAGC	 GAGCACCAGTTCCTATACCAGTC	 27	
CSTF3	 AGTGCGCACGTTGTAATCAG	 TCCGCTTTCTTCACCTTCTC	 27	
HPRT	 TCCTCCTCAGACCGCTTTT	 CCTGGTTCATCATCGCTAATC	 95	
ICOS	 GGATGCATACTTATTTGTTGGCTTA	 TGTATTCACCGTTAGGGTCGT	 47	
MARCH5	 CCGCCTCTCAGTGCTATTGT	 ACAAACCCAGCAACTTCTGTC	 60	
NUFIP2	 CGCTGAAACATGAGCAGAAA	 TCCAGCATTACCGTTTAGTTCA	 67	
PI4KA	 AAGGCCAGCTCCGTTGTAT	 TCACTGCCAGGGAGCAAT	 83	
PTBP2	 GCTCAACAAGCAAAACTAGCC	 CACAAGTTTGGAAAAATCAATCC	 40	
STAU1	 ATGGTATCGGCAAGGATGTG	 TGGTCCAACTCAGACAGCAA	 46	
STK38	 GGATTGGAAGATTTTGAGTCCTT	 TTCTTCTGAACAAGCCGTACCT	 13	
TES	 AGCGAGAAACCCCGATGT	 GCCTGGGTATACTCATTGCTG	 76	
TNRC6A	 TGGTCCACAAGCATTAAGCA	 TCCTCTTCCCAGCCAGTG	 5	
TNRC6B	 CCTGCTGGTGATAGCTGGTT	 ATGGCACTCCTGGTTGGA	 22	
TNRC6C	 ACTCACAGACATGGGCTTCC	 GCCTGATCAAGATTCATATTGTTACTC	 73	
TRUB1	 TCCGGATGTAAAAGCCTCCT	 TCCGGATGTAAAAGCCTCCT	 42	
TYW5	 CCAGAATTCTTCAAAGAGGAACA	 GACTGAAGAGTACAACACGCTTTT	 47	
YTHDC2	 TTCAGACTCCGGAACTTTTGA	 AGAAAATCAGCAATGGGACAA	 45	
YWHAZ	 CGCTAATAATGCAGTTACTGAGAGA	 TTGGAAGGCCGGTTAATTTT	 2	
ZYX	 TCCACATGAAGTGTTACAAGTGTG	 GTGTGGCACTTCCGACAGA	 38		In	 the	 CRISPR/Cas9	 screen,	 genome-integrated	 sgRNA	 sequences	were	 amplified	 by	nested	PCR.	The	first	PCR	amplifies	a	317	nt	fragment,	including	the	integrated	sgRNA	sequence.	A	second	PCR	on	the	first	PCR	product	creates	libraries	for	next	generation	sequencing	 by	 adding	 sequences	 for	 flow	 cell	 annealing,	 sequencing	 and	 indexing	primer	annealing	and	barcoding	to	produce	a	352	nt	amplicon.	Primer	sequences	for	the	first	PCR	were	taken	from	(Shalem	et	al.,	2014):		
F1:	AATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCG	 
R1:	CTTTAGTTTGTATGTCTGTTGCTATTATGTCTACTATTCTTTCC	 
62	 Material	and	methods			Primers	for	the	second	PCR	were	assembled	from	(Shalem	et	al.,	2014)	and	taking	into	account	 recommendations	 from	 Dr.	 Stefan	 Krebs,	 who	 actually	 performed	 the	 NGS	(Genzentrum,	LMU	München).	These	 included	a	variable	 length	sequence	to	 increase	library	 complexity	 (labeled	 in	 red	 in	 fw	 primers)	 and	 barcodes	 for	 multiplexing	(NEBNext	 Index	 1-12	 Primers	 for	 Illumina,	 NEB)	 (labeled	 in	 red	 in	 rev	 primers).	Primer	sequences	that	are	needed	to	amplify	the	product	of	the	first	PCR	are	shown	in	blue	(Table	10).		
Table	10:	Primers	for	the	second	CRISPR	PCR		
Primer	sequence	 Name	
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTATCTTGTGGAAA
GGACGAAACACCG	
1	fw	
CAAGCAGAAGACGGCATACGAGATACATCGGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTTCTAC
TATTCTTTCCCCTGCACTGT	
1	rev	
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTGATCTTGTGGAA
AGGACGAAACACCG	
2	fw	
CAAGCAGAAGACGGCATACGAGATTGGTCAGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTTCTAC
TATTCTTTCCCCTGCACTGT	
2	rev	
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTCTATCTTGTGGAA
AGGACGAAACACCG	
3	fw	
CAAGCAGAAGACGGCATACGAGATCACTGTGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTTCTAC
TATTCTTTCCCCTGCACTGT	
3	rev	
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTTCGATCTTGTGG
AAAGGACGAAACACCG	
4	fw	
CAAGCAGAAGACGGCATACGAGATATTGGCGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTTCTAC
TATTCTTTCCCCTGCACTGT	
4	rev	
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTAGCGTTCTAGCG
TGAAAGGACGAAACACCG	
5	fw	
CAAGCAGAAGACGGCATACGAGATGATCTGGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTTCTAC
TATTCTTTCCCCTGCACTGT	
5	rev	
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTTACTGCTCTAGCG
TGAAAGGACGAAACACCG	
6	fw	
CAAGCAGAAGACGGCATACGAGATTACAAGGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTTCTAC
TATTCTTTCCCCTGCACTGT	
6	rev		To	produce	plasmids	with	gene	editing	potential	(Table	6),	sgRNAs	were	cloned	into	lentiCRISPR	 vectors	 by	 annealing	 of	 reverse	 complementary	 oligonucleotides	 (Table	11).	CACC	and	AAAC	are	5’	overhangs	on	the	sense	and	antisense	strand,	respectively,	which	 allow	 cloning	 into	 BsmBI	 restriction	 sites.	 In	 the	 case	 that	 the	 20	nt	 sgRNA	sequence	does	not	start	with	a	guanine,	an	additional	‘G’	is	added	to	the	5’	end,	which	marks	the	transcription	start	site	downstream	of	the	U6	promoter.		
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Table	11:	Oligonucleotides	for	cloning	of	sgRNAs	into	lentiCRISPR	vectors	
Name	 Sequence	 Target	
mNUFIP2#1	for	 CACC	GCATGTTTCAGCGGCTTGGGC	 Mouse	Nufip2	
mNUFIP2#1	rev	 AAAC	GCCCAAGCCGCTGAAACATGC	 Mouse	Nufip2	
mNUFIP2#2	for	 CACC	GCGGCTCCATGCTGCAGGTAT	 Mouse	Nufip2	
mNUFIP2#2	rev	 AAAC	ATACCTGCAGCATGGAGCCGC	 Mouse	Nufip2	
mNUFIP2#3	for	 CACC	GGTGAAATAAACGGTAATGC	 Mouse	Nufip2	
mNUFIP2#3	rev	 AAAC	GCATTACCGTTTATTTCACC	 Mouse	Nufip2	
mNUFIP2#4	for	 CACC	GGCTTGTTTCTACAACTTGC	 Mouse	Nufip2	
mNUFIP2#4	rev	 AAAC	GCAAGTTGTAGAAACAAGCC	 Mouse	Nufip2	
NT1	for	 CACC	GCGAGGTATTCGGCTCCGCG	 Non-targeting		
NT1	rev	 AAAC	CGCGGAGCCGAATACCTCGC	 Non-targeting	
NT2	for	 CACC	GCCGAGAGGCGTAAGCGCGA	 Non-targeting	
NT2	rev	 AAAC	TCGCGCTTACGCCTCTCGGC	 Non-targeting	
hNUFIP2#3	for	 CACC	GTACCTGCAGCATGGAGCCGA	 Human	NUFIP2	
hNUFIP2#3	rev	 AAAC	TCGGCTCCATGCTGCAGGTAC	 Human	NUFIP2		
3.1.4.2 siRNA	duplexes	siGENOME	siRNA	duplexes	were	ordered	 from	GE	Healthcare	Dharmacon,	Lafayette,	CO,	USA	(Table	12).		
Table	12:	siRNA	duplexes	
Name	 Sequence	 Catalog#	 Species	
siATP2A1#1	 GAAAGUCCAUGUCUGUCUA	 D-006113-01	 Human	
siATP2A1#2	 GCAAGAUGUUUAUCAUUGA	 D-006113-02	 Human	
siATP2A1#3	 CCAAAGGUGUCUAUGAGAA	 D-006113-03	 Human	
siATP2A1#4	 GCACCGAGAUUGGGAAGAU	 D-006113-04	 Human	
siCERK#1	 GAUCAUCGCCGUUGAGGAA	 D-004061-01	 Human	
siCERK#2	 CAACGGACUGCGUGUGUUA	 D-004061-02	 Human	
siCERK#3	 CCACUGACAUCAUCGUUAC	 D-004061-03	 Human	
siCERK#4	 CAAGGCAAGCGGAUAUAUG	 D-004061-04	 Human	
siCNOT1#1	 AUAAGUGGCUCACAGAUAA	 D-015369-01	 Human	
siCNOT1#2	 CAAGUUAGCACUAUGGUAA	 D-015369-02	 Human	
siCNOT1#3	 GAGUGUGCGUUGCUGAUUA	 D-015369-03	 Human	
siCNOT1#4	 GCAAUAUAAUCGUGCAGUU	 D-015369-04	 Human	
siCSTF3#1	 CUGAGUAUGUCCCAGAGAA	 D-011247-21	 Human	
siCSTF3#2	 CUAUAGACAAAGCACGGAA	 D-011247-22	 Human	
siCSTF3#3	 GAAACUGUACAUUGAAGCA	 D-011247-23	 Human	
siCSTF3#4	 GCGGAAAAGAAAUUAGAAG	 D-011247-24	 Human	
siMARCH5#1	 UCAAACAGCAGCAAUAUUU	 D-007001-01	 Human	
siMARCH5#2	 GGACAGCUGUGACUUAUGG	 D-007001-02	 Human	
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Name	 Sequence	 Catalog#	 Species	
siMARCH5#3	 GUAAAUUGAUGUUCAGUAG	 D-007001-03	 Human	
siMARCH5#4	 GACAGAAGUUGCUGGGUUU	 D-007001-04	 Human	
siNUFIP2#1	 GUAGAUAAGUCUGAUACUA	 D-021280-01	 Human	
siNUFIP2#2	 CGGAAAAGCUCAGAUAGUA	 D-021280-03	 Human	
siNUFIP2#3	 GGUCAGCCACUGCUAACUA	 D-021280-04	 Human	
siNUFIP2#4	 AGGAAAGCUAGGCGCAAUA	 D-021280-17	 Human	
siPTBP2#1	 GAGAGGAUCUGACGAACUA	 D-021323-01	 Human	
siPTBP2#2	 GAAAGACAGCGCUCUAAUA	 D-021323-02	 Human	
siPTBP2#3	 UAAGAAACCUGGAUCCAAA	 D-021323-03	 Human	
siPTBP2#4	 GGAAGCAGCUAUUACUAUG	 D-021323-04	 Human	
siSTAU1#1	 AAACGGAACUUGCCUGUGA	 D-011894-01	 Human	
siSTAU1#2	 GAACGAAUUUGUAUCUCUU	 D-011894-02	 Human	
siSTAU1#3	 GCAAUUUAAUGGCAAAGGA	 D-011894-03	 Human	
siSTAU1#4	 CACGGUAACUGCCAUGAUA	 D-011894-04	 Human	
siTES#1	 CGAAAGGGCUGGCUAUGAU	 D-013026-01	 Human	
siTES#2	 GUUAUGAUAUUGACGAAUC	 D-013026-02	 Human	
siTES#3	 CGGGUGACCUAUAACAAUU	 D-013026-03	 Human	
siTES#4	 CCUGCUAUGUGAAGAAUCA	 D-013026-04	 Human	
siTNRC6A#1	 GAAAUGCUCUGGUCCGCUA	 D-014107-01	 Human	
siTNRC6A#2	 GCCUAAAUAUUGGUGAUUA	 D-014107-02	 Human	
siTNRC6A#3	 GAUCUGCUGUUAAGGUGUU	 D-014107-03	 Human	
siTNRC6A#4	 GAACAAUGGACUUGCCCUA	 D-014107-04	 Human	
siTRUB1#1	 GAAAGCUACUGAUACACUA	 D-016391-01	 Human	
siTRUB1#2	 CAGAAUGGACCAAGAGGAA	 D-016391-03	 Human	
siTRUB1#3	 CUGAAUCGGUUGAAGGAGA	 D-016391-04	 Human	
siTRUB1#4	 GAAGAGAGGUGAAGUCGUA	 D-016391-17	 Human	
siTYW5#1	 GGUGAUGUAUUAUUCAUUC	 D-016468-01	 Human	
siTYW5#2	 GGACUUCUAUGCACGACGA	 D-016468-02	 Human	
siTYW5#3	 CGAGAUGCCCAGUAUUUAU	 D-016468-03	 Human	
siTYW5#4	 CCGAGUUACCAGAGGAAUA	 D-016468-04	 Human	
siYTHDC2#1	 GCAAAUAGAUACCUAACUG	 D-014220-01	 Human	
siYTHDC2#1	 CAGCAUAGUUUACUUGGUA	 D-014220-02	 Human	
siYTHDC2#1	 GCAGGCAUGUAUCCUAAUU	 D-014220-03	 Human	
siYTHDC2#1	 GGACUAGGAGGAGUAUUUA	 D-014220-04	 Human	
siZYX#1	 GACAAGAACUUCCACAUGA	 D-016734-01	 Human	
siZYX#2	 GAAUGUGGCUGUCAACGAA	 D-016734-02	 Human	
siZYX#3	 GACCAAGAAUGAUCCUUUC	 D-016734-03	 Human	
siZYX#4	 GGUGAGCAGUAUUGAUUUG	 D-016734-04	 Human	
Nufip2	siRNA	pool	:				#1	 UAAGACCGAUACCAUAGCA	 M-063890-01	 Mouse	
	#2	 UAACAAGUAGUUCAGGCUA	 M-063890-01	 Mouse	
#3	 GGAUAUACCACUCCUAAAA	 M-063890-01	 Mouse	
#4	 AGGAAAGCUAGGCGCAAUA	 M-063890-01	 Mouse	
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Name	 Sequence	 Catalog#	 Species	
Non-targeting	siRNA	#1	 UAGCGACUAAACACAUCAA	 D-001210-01	 Mouse	
Non-targeting	siRNA	#2	 UAAGGCUAUGAAGAGAUAC	 D-001210-02	 Mouse	
Rc3h1	siRNA	pool:						#1	 GUACGGUAGUGCAUGGAUU	
GAACAUGACUCCCAGAUAG	
UCUCAUAUGCAGUCUAUUA	
GAAUUUGAACCGACUAAGA	
	
M-044230-01	 Mouse	
#2	 M-044230-01	 Mouse	
#3	 M-044230-01	 Mouse	
#4	 M-044230-01	 Mouse		
3.1.5 Artificially	synthesized	DNA	sequences	A	mammalian	 codon-optimized	 sequence	 encoding	 an	 SGSG-linker	 followed	by	P2A-mCherry	(798	nts)	was	synthesized	by	Entechelon	GmbH	(now	Eurofins	Genomics).		ICOS-GFP	CDS	was	synthesized	by	GeneArt	Gene	Synthesis	(ThermoFisher	Scientific).		
3.1.6 cDNA	clones	For	cloning	of	NUFIP2,	FBXL14,	TRIM6-TRIM34,	Rab40c	and	RNF222	full-length	cDNA	sequences,	 IMAGE	 cDNA	 clones	 were	 ordered	 from	 Source	 BioScience	 LifeSciences	(Nottingham)	(Table	13).		
Table	13:	IMAGE	cDNA	clones	
Name	 Image	#	 Code	 Species	
FBXL14	 IMAGE:5205284	 RATp970D0949D	 Human	
LOC643904	(RNF222)	 IMAGE:100016331	 OCACo5052D077D	 Mouse	
NUFIP2	 IMAGE:40128910	 IRCMp5012G0838D	 Human	
Rab40c	 IMAGE:5364768	 IRAVp968G0665D	 Mouse	
TRIM6-TRIM34	 IMAGE:9021590	 IRCBp5005G2410Q	 Human		
3.1.7 Antibodies	and	fluorescent	dyes	Antibodies	 employed	 for	 flow	 cytometry	 (FC),	 tissue	 culture	 (TC),	immunofluorescence	 (IF),	 immunoblotting	 (IB)	 or	 immunoprecipitation	 (IP)	 and	fluorescent	dyes	used	for	fluorescent	cell	barcoding	(FCB)	are	listed	in	Table	14.					
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Table	14:	Antibodies	and	fluorescent	dyes	
Name	 Conjugation	 Dilution	 Supplier	 Applica
tion	
Alexa	Fluor®	488	Carboxylic	
Acid,	Succinimidyl	Ester,	
Mixed	Isomers	
	 5	mg/ml	
stock		
Life	Technologies	 FCB	
Anti-Ago	(Pan,	11G1)	 -	 1:10	 In-house	production	 IB	
Anti-CD3	(145-2C11)	 -		 2.5	μg/ml	 In-house	production	 TC	
Anti-Mouse	Cd4	(Rm4-5)	 APC	 1:200	 eBioscience	 FC	
Anti-CD8	 eFluor450	 1:200	 eBioscience	 FC	
Anti-CD28	(37N)		 -	 0.25	μg/ml	 In-house	production	 TC	
Anti-Mouse	Cd45r	(B220)		 PeCy7	 1:200	 eBioscience	 FC	
Anti-Cd90.1	(Thy1.1)	 PerCP	 1:5000	 eBioscience	 FC	
Anti-Cd90.1	(Thy1.1)	 PE	 1:5000	 eBioscience	 FC	
Anti-CD125		 -	 1:200	 eBioscience	 FC	
Anti-CD278	(Human	ICOS)	
Clone	ISA-3	
Biotin	 1:400	 eBioscience	 FC	
Anti-FMRP	 -	 1:1000	 Cell	Signaling	Technologies	 IB	
Anti-GAPDH	 -	 1:10,000	 Calbiochem	 IB	
Anti	G3BP1	 -	 1:100	 Santa	Cruz	Biotechnology	 IF	
Anti-GFP	 -	 1:1000	 ThermoFisher	Scientific	 IB	
Anti-HA	(12CA5)	 -	 1:10	 In-house	production	 IB	
Anti-IL4	(11B11)	 -	 10	μg/ml	 In-house	production	 TC	
Anti-IκBNS		 -	 1:5000	 In-house	production	 IB	
Anti-Mouse	IgG	 HRP	 1:3000	 Cell	Signaling	Technologies	 IB	
Anti-NUFIP2	 -	 1:1000	 BETHYL	Laboratories	 IB	
Anti-Rabbit	IgG	 HRP	 1:3000	 Cell	Signaling	Technologies	 IB	
Anti-Rat	IgG	 HRP	 1:3000	 Cell	Signaling	Technologies	 IB	
Anti-Renase-1	(15D11)	 -	 1:10	 In-house	production	 IB	
Anti-Roquin-1	 -	 1:500	 BETHYL	Laboratories	 IB	
Anti-Roquin-1	(Q4-2)	 -	 1:10	 In-house	production	 IP	
Anti-Roquin-1/-2	(3F12)	 -	 1:10	 In-house	production	 FC,	IB	
Anti-Tubulin	 -	 1:2000	 Santa	Cruz	Technologies	 IB	
Pacific	 Blue™	 Succinimidyl	
Ester	
	 5	mg/ml	
stock		
Life	Technologies	 FCB	
Streptavidin	 Allophycocyanin	 1:600	 eBioscience	 FC	
3.1.8 Cytokines	Recombinant	 cytokines	 were	 used	 for	 stimulation	 of	 primary	 mouse	 CD4+	 T	 cells	(Table	15).			
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Table	15:	Cytokines	
Name	 Species	 Dilution	 Supplier	 Application	
IL-2	 human	 20	U/ml	 Novartis	 TC	
IL-12	 mouse	 10	ng/ml	 BD	Biosciences	 TC		
3.1.9 Chemicals,	enzymes	and	kits	
Table	16:	Chemicals	
Compound	 Supplier	
2-Propanol	 Merck	
2log	DNA	ladder	 New	England	Biolabs	
Acrylamide	4K	solution	 AppliChem	
AmershamTM	ECLTM	Prime	 GE	Healthcare	
Ammonium	persulfate	(APS)	 Serva	
Ampicillin	 Roche	
Bio-rad	protein	assay	(Bradford	assay)	 Bio-rad	
Biozym	LE	agarose	 Biozym	
Blasticidin	S	HCl	(10	mg/ml)	 ThermoFisher	Scientific	
Boric	acid	 Calbiochem	
Bovine	serum	albumin	(BSA)	 Carl	Roth	
Calcium	chloride	 Sigma-Aldrich	
Chloroform	 Sigma-Aldrich	
Chloroquine	diphosphate	salt	 Sigma-Aldrich	
DEPC	 Carl	Roth	
Dimethyl	sulfoxide	 Sigma-Aldrich	
Dithiothreitol	(DTT)	 AppliChem	
dNTP	set	 ThermoFisher	Scientific	
Doxycycline	 AppliChem	
Dynabeads®	MyOne™	Tosylactivated	 ThermoFisher	Scientific	
Dynabeads®	Protein	G	for	immunoprecipitation	 ThermoFisher	Scientific	
Ethanol	 Merck	Millipore	
Ethidium	bromide	(0.07%)	 AppliChem	
Ethylendiamin-tetraessigsäure	Dinatriumsalz	
Dihydrat	 Carl	Roth	
Formaldehyde	solution	36.5-38	%	 Sigma-Aldrich	
Geneticin®	selective	antibiotic	(G418)	50	mg/ml	 ThermoFisher	Scientific	
GlycoBlueTM	coprecipitant	 Ambion	
HiPerFect®	transfection	reagent	 Qiagen	
Hygromycin	B	 ThermoFisher	Scientific	
Ionomycin,	free	acid,	Streptomyces	conglobatus	 Merck	Millipore	
Kanamycin	 Carl	Roth	
Methanol	 Merck	Millipore	
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Compound	 Supplier	
Nonfat	dry	milk	powder	 AppliChem	
Nonident	P40	 Sigma-Aldrich	
Phorbol-12-myristate-13-acetate	(PMA)		 Merck	Millipore	
Polybrene	 Sigma-Aldrich	
Protease	inhibitor	tablets,	cOmpleteTM	Mini	EDTA-
free	 Roche	diagnostics	
Protein	Marker	VI	(10	-	245)	prestained	 AppliChem		
Saponin	GPR	RECTAPUR®	 VWR	
Sodium	dodecylsulfate,	pellets	 Serva	Electrophoresis	
Spectinomycin	 AppliChem	
4-OH-tamoxifen	 Sigma-Aldrich	
TEMED	 AppliChem	
TRI	reagent®	solution	 Ambion	
Trypsin-EDTA ThermoFisher	Scientific	
Tween	20	 AppliChem		
Table	17:	Enzymes	
Enzyme	 Supplier	
BsmBI	 New	England	Biolabs	
FastAPTM	thermosensitive	alkaline	phosphatase	 ThermoFisher	Scientific	
Gateway®	LR	Clonase®	II	enzyme	mix	 ThermoFisher	Scientific	
Herculase	II	Fusion	DNA	polymerase	 Agilent	Technologies	
NotI-HF®	 New	England	Biolabs	
Proteinase	K	 Roche	
SalI-HF®	 New	England	Biolabs	
T4	DNA	ligase	 New	England	Biolabs	
T4	polynucleotide	kinase	 New	England	Biolabs	
T4	RNA	ligase	 New	England	Biolabs	
Taq	DNA	polymerase	 ThermoFisher	Scientific	
Vent®	polymerase	 New	England	Biolabs	
XhoI	 New	England	Biolabs		
Table	18:	Kits	
Kits	 Supplier	
DNeasy®	Blood	&	Tissue	Kit	 QIAGEN	
EasySep™	Mouse	CD4+	T	Cell	Isolation	Kit	 Stemcell	Technologies	
Gateway®	LR	Clonase®	II	enzyme	mix	 ThermoFisher	Scientific	
LightCycler®	480	Probes	Master	
Universal	probe	library	
Roche	
NucleoBond®	Xtra	Maxi	 MACHEREY-NAGEL	
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Kits	 Supplier	
OneStep	RT-PCR	Kit	 QIAGEN	
pCR™8/GW/TOPO®	TA	Cloning®	Kit	 ThermoFisher	Scientific	
pGEM®-T	Easy	Vector	System	 Promega	
PureYield™	Plasmid	Miniprep	System	 Promega	
QIAquick®	Gel	Extraction	Kit	 QIAGEN	
QIAquick®	PCR	Purification	Kit	 QIAGEN	
QuantiTect®	Reverse	Transcription	Kit	 QIAGEN	
Qubit®	dsDNA	BR	Assay	Kit	 ThermoFisher	Scientific	
QuikChange®	II	XL	Site-Directed	Mutagenesis	Kit	 Agilent	Technologies	
RNeasy®	Mini	Kit	 QIAGEN		
3.1.10 Buffers	
Table	19:	Buffers	
Buffer	name	 Composition	
Blotting	buffer	 25	mM	Tris	
192	mM	glycine	
20	%	methanol	
ECL	solution	1	
	
	
	
ECL	solution	2	
100	mM	Tris-HCl	pH	8.8	
1.25	mM	Luminol	
200	nM	p-Coumaric-acid	
	
3	%	H2O2	
FACS	staining	buffer	 PBS		
2	%	FCS	
2	mM	EDTA	
HBS	(2x)	 274	mM	NaCl	
10	mM	KCl	
1.4	mM	Na2HPO4,	pH	7.0	
Laemmli	SDS	sample	buffer	(4x)	 200	mM	Tris-HCl,	pH	6.8	
8	%	SDS	
40	%	gycerol	
0.1 %	bromophenol	blue	
10	%	β-mercaptoethanol	
Lysis	buffer	 20	mM	Tris-HCl	pH	7.5	
150	mM	NaCl	
0.25	%	NP-40	
1.5	mM	MgCl2	
PBS	 137	mM	NaCl	
10	mM	Na2HPO4,	pH	7.4	
2.7	mM	KCl	
Saponin	buffer	 PBS	
0.5	%	saponin	
1	%	BSA	
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Buffer	name	 Composition	
SDS	PAGE	buffer	 25	mM	Tris	
250	mM	glycine	
0.1	%	SDS	
TAC	lysis	buffer	 13	mM	Tris	
140	mM	NaH4Cl,	pH	7.2	
TE		 10	mM	Tris-HCl	pH	7.5	
1	mM	EDTA	pH	8	
TBE	(1x)	 89	mM	Tris-borate	
2	mM	EDTA,	pH	8	
TBS	 10	mM	Tris-HCl	pH	8	
150	mM	NaCl	
TBST	 10	mM	Tris-HCl	pH	8	
150	mM	NaCl	
0.05	%	Tween-20		
Table	20:	Consumables	
Name	 Supplier	
1.5	ml,	2	ml	centrifuge	tubes	 Eppendorf		
15	ml,	50	ml	tubes	 Falcon	
96-well	reaction	plate	(qPCR)	 4titude 
Cell	culture	plates	 Thermo	Scientific	
Cell	scraper	 Sarstedt	
Clear	seal	foils	for	qPCR	 4titude	
Cryotubes	 Thermo	Scientific	
Cuvettes		 Brand	
Disposable	pipetting	reservoirs	 VWR	
Filter	paper	Whatman,	3	mm VWR	
Gloves	 ShieldSkinTM	orange	Nitril	
Immobilon®	Nitrocellulose	membrane		 Merck	
Pipette	tips Sorenson		
Surgical	disposable	scalpels	 Braun 
X-ray	films	 Agfa	health	Care	
3.1.11 Instruments	
Table	21:	Instruments	
Instrument	Name	 Supplier	
Agarose	gel	chambers		 Peqlab	
Bacterial	incubator		
	
Brutschrank	BINDER	BF	53	(Binder	Labortechnik)		
Innova	4400	incubator	shaker	(New	Brunswick	
Scientific	GmbH)		
Balances	
	
KERN	ABJ-220-4M	(Kern	und	Söhne	GmbH)		
KERN	EW	220-3NM	(Kern	und	Söhne	GmbH)		
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Instrument	Name	 Supplier	
BD	FACS	AriaIII	cellsSorter	 BD	Biosciences		
BD	LSRFortessa	cell	analyzer		 BD	Biosciences		
Benchtop	working	rack	1.5	ml	 Stratagene	
Cell	freezing	container	 CoolCell®	(Biocision)	
Blotting	chamber		 Bio-Rad		
Centrifuges	and	rotors		
	
Beckman	Coulter	Avanti-J-26XP	(Beckman	
Coulter);	JA-10	Rotor,	Fixed	Angle	(Beckman	
Coulter)		
	
Allegra®X-12R	Centrifuge	(Beckman	Coulter);	
Rotor	SX	4750	(Beckman	Coulter)		
	
Eppendorf	Centrifuge	5810R	(Eppendorf);	Rotor	
A-4-62	and	F-34-6-38		
Confocal	microscope	 Leica	TCS	SP5	
CO2	incubator		
	
Forma	Direct	Heat	CO2	Incubator	HEPA	Class	100	
(Thermo	Electron	Corporation)		
Gel	documentation	system	 Quantum	ST4	(Vilber)	
High-throughout	sampler	 BD	Biosciences		
Ice	machine		 Scotsman	AF	200	(Scotsman	Icesystem)		
Magnet	stirrer		 RCT	basic	safety	control	(IKA)		
Microscope		 Axiovert	40C	(Zeiss)		
Microwave		 Bosch		
Neubauer	improved	hemocytometer	 Marienfeld	
pH	meter		 pH-Meter	inoLab®	pH	720	(W	TW)		
Pipettor		 Pipetboy	acu	(IBS)		
Power	supplies	
Stromgeber	EC105	(Thermo	Electron	Corporation)		
Power	Pac200	(Bio-Rad)		
Sterile-working	bench		 BDK,	Luft	und	Reinraumtechnik		
Spectrophotometer	 NanoDropTM	1000	Spectrophotometer	(ThermoFisher	Scientific)	
Table	centrifuge		
Centrifuge	5415D	(Eppendorf)		
Centrifuge	5417R	(Eppendorf)		
Thermocycler	
DNA	Engine	48/48	Dual	Alpha	Unit	(Bio-Rad)		
Light	Cycler	480II	(Roche)		
Thermo	mixer		 Thermomixer	comfort	(Eppendorf)		
Vacuum	pump	 Diaphgragm	Vacuum	Pump	MZ	2C	(Vacuubrand)	
Vertical	electrophoresis	chamber	
	
Bio-Rad		
Eppendorf	BioPhotometers	(Eppendorf)		
Vortex	MS2	mini	shaker	 IKA		
Waterbath	 WB7	(Memmert)		
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3.1.12 Software		
Table	22:	Software	
Name	 Application	
Adobe	Illustrator	CS5	 Image	processing	
Adobe	Photoshop	CS5	 Image	processing	
ApE	 Analysis	of	DNA	sequences	
Endnote	X7	 Literature	organization	
FlowJo	3	 Flow	cytometry	data	analysis	
GraphPad	Prism	 Graphs,	statistics	
Light	Cycler	480	software	release	1.5.1	 qPCR	data	analysis	
Microsoft	Office	for	Mac	2011	 Writing	in	Word,	data	analysis	in	Excel	
3.2 Methods	
3.2.1 Cloning	of	cDNA	and	amplification	of	DNA	plasmids		
3.2.1.1 Polymerase	chain	reaction	and	TOPO	cloning	DNA	 fragments	 were	 amplified	 in	 standard	 polymerase	 chain	 reactions	 (PCR)	 with	gene-specific	 3’	and	 5’	flanking	 oligonucleotides	 (primers)	 (Table	 7).	 The	 set	 up	 of	 a	standard	 PCR	 reaction	 is	 shown	 in	 Table	 23,	 left.	 A	 mixture	 of	 Taq-	 and	 Vent®-polymerase	was	employed	for	DNA	amplification	in	order	to	combine	critical	features,	such	as	3’	adenine	overhangs	and	proofreading	activity.	Cycling	conditions	are	shown	in	Table	23,	right.	The	annealing	temperature	 is	adjusted	according	to	the	calculated	melting	temperature	(Tm)	of	the	primers.	For	TOPO®	cloning,	a	final	step	for	5	min	at	72°C	is	added	to	ensure	the	synthesis	of	3’	adenosine	overhangs.		
Table	23:	PCR	composition	and	cycling	conditions	
Amount	 Reagent	
0.3	μl	 Taq	polymerase	
0.2	μl	 Vent	Polymerase	
2.5	μl	 10x	reaction	buffer	
1	μl	 MgCl2	(50	mM)	
0.5	μl	 dNTP	10	mM	each	
0.5	μl	 Forward	primer	(10	pM)	
0.5	μl	 Reverse	primer	(10	pM)	
20	ng	 Template	cDNA	
Up	to	25	μl	 H2O		
Step Temp Duration
Activation 95°C 2 min
Denaturation 95°C 15 sec
Annealing
Elongation
~Tm - 5°C 30 sec
72°C 1 min/kb cDNA
32x
Material	and	methods	 73	 		Following	PCR	amplification,	DNA	was	separated	on	0.8	%	agarose	gels	containing	1	droplet	 of	 0.07	%	 ethidium	 bromide	 solution	 per	 75	ml	 gel	 in	 TBE	 buffer	 at	 100	 –	120	V.	The	PCR	product	 of	 the	desired	 size	was	 excised	under	254	nm	UV	 light	 and	purified	 using	 the	 QIAquick®	 Gel	 Extraction	 Kit	 (Qiagen)	 according	 to	 the manufacturer’s	instructions.	 After	gel	elution,	PCR	products	were	subcloned	into	linearized	TOPO®	vectors,	which	possess	3’	thymine	overhangs	and	covalently	linked	topoisomerase	enzymes.		
3.2.1.2 Bacterial	culture	and	plasmid	preparation	Plasmids	were	 propagated	 in	 chemically	 competent	E. coli DH5α	 bacteria	 (in-house	production).	 50	 μl	 of	 bacterial	 suspension	 were	 transformed	 with	 ~100	 ng	 of	 the	desired	plasmid	by	heat	shock	transformation	(20	min	on	ice,	30	s	42°C,	2	min	on	ice).	Subsequently,	 250	 μl	 glucose-containing	 SOC	 medium	 was	 added	 and	 cells	 were	shaken	 at	 600	 rpm,	 37	°C	 for	 1	h	 in	 a	 Thermo	 mixer.	 50	 -	 200	 μl	 of	 the	 amplified	suspension	was	spread	onto	LB-agar	plates	containing	 the	respective	antibiotics	and	incubated	 in	 a	 bacterial	 incubator	 for	 18	 h	 at	 37	 °C.	 5	 ml	 bacterial	 cultures	 („mini	cultures“)	 were	 inoculated	 from	 single	 colonies	 and	 subjected	 to	 plasmid	 isolation	with	PureYield™	Plasmid	Miniprep	kit	according	 to	 the	manufacturer’s	protocol.	300	ml	 cultures	 (“maxi	 cultures”)	were	 inoculated	 from	mini	 cultures,	 and	 plasmid	DNA	was	 isolated	with	 the	NucleoBond®	Xtra	Maxi	kit	 (Macherey	Nagel)	according	 to	 the	manufacturer’s	 instructions. LB	media	and	LB	agar	were	prepared	with	LB	medium	powder	 (SERVA),	 supplemented	 with	 ampicillin	 (100	 μg/ml),	 spectinomycin	 (50	μg/ml),	 kanamycin	 (30	 μg/ml)	 or	 chloramphenicol	 (170	 μg/ml)	 depending	 on	 the	plasmid-encoded	antibiotic	resistance	gene.		
3.2.1.3 Restriction	enzyme	digestion	and	ligation	of	DNA	fragments		Enzymatic	digestion	of	plasmid	DNA	was	performed	in	30	μl	reactions	containing	2	μg	of	plasmid	DNA,	3	μl	of	the	appropriate	10x	buffer,	and	0.2	μl	of	the	desired	restriction	enzyme(s).	 Digestion	 was	 performed	 for	 1.5	h	 at	 the	 appropriate	 temperature.	Restriction	digest	products	were	separated	by	agarose	gel	electrophoresis	and	eluted	from	the	gel	as	described	above	(Chapter	3.2.1.3).		For	 the	 ligation	of	digested	DNA	 fragments	 into	 the	desired	vector	backbones,	20	μl	ligation	 reactions	were	 set	up	 including	2	μl	10x	T4	DNA	 ligase	buffer,	 1	μl	T4	DNA	ligase,	3	-	5	μl	(~300	ng)	of	purified	insert	DNA,	1	–	2	μl	(~100	ng)	of purified	vector	
74	 Material	and	methods			DNA	 and	 H20.	 Ligation	 was	 performed	 overnight	 at	 16	°C.	 Ligation	 reactions	 were	heat-inactivated	for	10	min	at	65	°C,	and	6	μl	of	each	reaction	were	used	for	bacterial	transformation.		
3.2.1.4 Site-directed	mutagenesis	Targeted	mutations	were	 introduced	 into	plasmid	DNA	using	 the	QuikChange®	 II	XL	Site-Directed	 Mutagenesis	 Kit	 according	 to	 the	 manufacturer’s	 instructions.	 Primer	sequences	are	listed	in	Table	8.		
3.2.2 Extraction	of	RNA	and	qPCR	
3.2.2.1 Isolation	of	RNA	TRI	 reagent®	 (Ambion)	was	employed	 for	 isolation	of	RNA	 from	varying	amounts	of	cells.	 Cells	 were	 centrifuged	 at	 300	x	g	 for	 5	min	 and	 the	 resulting	 cell	 pellet	 was	resuspended	 in	 1	 ml	 TRI	 reagent®	 and	 lysed	 for	 5	 min	 at	 room	 temperature	 (RT).	Lysed	 reactions	 were	 either	 stored	 at	 -80	 °C,	 or	 subjected	 to	 instant	 RNA	 isolation	according	 to	 the	 manufacturer’s	 protocol. The	 resulting RNA	 concentration	 was	determined	spectrophotometrically	using	the	NanoDrop	device.	In	the	case	of	phenol	contaminations,	samples	were	subjected	to	additional	purification	using	the	RNeasy®	Mini	Kit	according	to	the	manufacturer’s	instructions.		
3.2.2.2 Reverse	transcription	RNA	was	reverse	 transcribed	 into	cDNA	with	 the	QuantiTect®	Reverse	Transcription	Kit,	according	to	the	manufacturer’s	instructions.	The	resulting	cDNA	was	diluted	with	H2O	to	100	μl	and	stored	at	–20	°C.	 
3.2.2.3 Quantitative	PCR	Following	reverse	transcription,	quantitative	PCR	assays	(qPCR)	were	run	on	a	Light	Cycler	480II	machine	using	the	Roche	Universal	Probe	Library.	Primers	and	universal	probes	are	listed	in	Table	9.	Relative	gene	expression	was	determined	with	the	Light	Cycler	 480	 SW	 1.5.1	 software,	 and	 normalized	 to	 the	 expression	 of	 a	 housekeeping	gene	(YWHAZ	or	Hprt).		
Material	and	methods	 75	 		
3.2.3 Cell	culture	
3.2.3.1 Cultivation	of	cell	lines	Cells	were	cultured	in	the	appropriate	medium	as	described	in	chapter	3.1.2	and	split	every	 2	 -	 3	 days	 when	 reaching	 confluency.	 For	 storage,	 at	 least	 3	x	106	 cells	 were	centrifuged,	resuspended	in	1.8	ml	cell	freezing	medium	(10	%	DMSO,	90	%	FCS)	and	transferred	 into	 cryotubes.	 Multiple	 cell	 aliquots	 were	 subsequently	 frozen	 in	 a	CoolCell®	 Cell	 Freezing	Container	 cooling	 down	 at	 a	 rate	 of	 -1	 °C/min.	After	 a	 short	period	at	-80	°C,	cells	were	transferred	to	a	liquid	nitrogen	tank	for	long-term	storage.		
3.2.3.2 Isolation	of	genomic	DNA	Genomic	DNA	(gDNA)	was	isolated	from	3.5	–	5	x	106	MEF	cells	with	the	DNeasy	Blood	&	 Tissue	 Kit	 according	 to	 the	manufacturer’s	 protocol	 and	 resolved	 in	 200	 -	 800	 μl	H2O.	The	 resulting	 gDNA	concentration	was	determined	with	 the	Qubit®	dsDNA	BR	Assay	Kit,	according	to	the	manufacturer’s	instructions.		
3.2.3.3 Preparation	and	stimulation	of	primary	mouse	CD4+		T	cells	Cell	suspensions	were	generated	from	spleen	and	lymph	nodes	obtained	from	C57/Bl6	mice	by	mashing	the	organs	through	a	150	μm	mesh.	Splenocytes	were	centrifuged	for	5	min,	300	x	g	at	4	°C	and	the	cell	pellet	was	resuspended	in	3	ml	TAC	lysis	buffer.	TAC	lysis	 was	 performed	 for	 5	 min	 at	 RT,	 resulting	 in	 erythrocyte	 lysis.	 The	 remaining	leucocytes	were	filtered	and	combined	with	the	cell	suspension	obtained	from	lymph	nodes	for	T	cell	purification.	CD4+	T	cells	were	isolated	by	depletion	of	all	non-CD4+	T	cells	 using	 the	 EasySep™	Mouse	 CD4+	 T	 Cell	 negative	 selection	 kit,	 according	 to	 the	manufacturer’s	 instructions.	 Purified	 CD4+	 T	 cells	 were	 stimulated	 on	 goat-anti-hamster	 coated	plates	with	 anti-CD3	 and	 anti-CD28	 antibodies	 and	 skewed	 towards	Th1	differentiation	in	RPMI	complete	medium	(Chapter	3.1.2)	by	addition	of	IL-12	and	anti-IL-4.	Following	48	h	of	activation,	Th1	cells	were	amplified	in	the	presence	of	IL-2.		
3.2.3.4 Retro-	and	lentivirus	production		Retro-	and	 lentiviral	supernatants	were	produced	by	calcium-phosphate	transfection	of	 HEK293T	 cells	 with	 the	 retro-	 or	 lentiviral	 expression	 plasmid	 and	 the	corresponding	 packaging	 vectors	 (Chapter	 3.1.3.3).	 8-14	x	106	 HEK293T	 cells	 were	seeded	onto	14	cm	plates	18	h	prior	 to	 transfection.	Starting	transfection,	cells	were	incubated	 with	 fresh	 DMEM	 medium	 containing	 25	μM	 chloroquine	 for	 1	h.	
76	 Material	and	methods			Meanwhile,	 transfection	mixes	were	prepared	by	dropwise	 addition	of	 the	DNA	mix	(Table	24)	to	the	same	amount	(1250	μl)	of	2x	HBS	buffer,	while	constantly	vortexing.	Transfection	mixes	were	incubated	at	37	°C	for	20	min	and	finally	added	to	the	cells.	The	medium	was	 replaced	 8-10	h	 later.	 After	 48	h,	 the	 virus-containing	 supernatant	was	harvested,	filtered	(0.45	μm)	and	frozen	at	-80	°C	or	directly	used	for	transduction	of	recipient	cells.		
	
Table	24:	Composition	of	the	DNA	mix	for	calcium-phosphate	transfection.	
Lentivirus	
2nd	generation	vector	
Lentivirus	
3rd	generation	vector	
Retrovirus	
ecotropic	
Retrovirus	
amphotropic	
25	µg	transfer	vector	 21	μg	transfer	vector	 50	μg	transfer	vector	 50	μg	transfer	vector	
12.5	μg	pspax2	 14	μg	pMDLg/pRRE	 5	μg	Ecopac	 5	μg	env	
12.5	μg	pMD2.VSVG	 7	μg	pMD2.VSVG	 	 5	μg	gag/pol	
	 7	μg	pRSV-Rev	 	 	
125	μl	CaCl2	(2.5	M)	 125	μl	CaCl2	(2.5	M)	 125	μl	CaCl2	(2.5	M)	 125	μl	CaCl2	(2.5	M)	
add	H2O	to	1250	μl	
	
	In	addition	to	the	transfer	plasmid	encoding	the	gene	of	interest,	lentivirus	production	requires	the	genes	gag,	pol,	rev	and	env.	Second	generation	lentiviral	transfer	vectors	additionally	require	 the	 tat	protein,	which	 is	encoded	on	 the	vector	pspax2	 together	with	gag,	pol,	and	rev.	 Second	generation	 lentivirus	production	 is	 therefore	achieved	with	 pspax2	 in	 addition	 to	 pMD2.VSVG	 encoding	 env.	 Third	 generation-lentiviral	vector	backbones	are	tat-independent,	and	therefore	only	require	gag,	pol,	rev	and	env.	For	 safety	 reasons,	 the	 gag,	 pol	 and	 rev	 genes	 have	 been	 split	 onto	 two	 vectors:	pMDLg/pRRE	encodes	gag	and	pol	and	pRSV-Rev	delivers	rev.		
3.2.3.5 Virus	transduction	MEF	 or	 HeLa	 cells	 were	 transduced	 with	 lenti-	 or	 retroviral	 supernatants	 by	 spin-infection.	Therefore,	100,000	cells	were	plated	onto	each	well	of	a	six-well	plate	18	h	prior	 to	 transduction.	 The	 medium	 was	 replaced	 by	 the	 desired	 amount	 of	 viral	supernatant	 (100	μl	 to	2.5	ml),	and	 filled	up	 to	a	 total	of	5	ml	using	 the	appropriate	medium.	 Infection	 was	 performed	 by	 centrifugation	 for	 2	h	 at	 32	 °C,	 300	x	g	 in	 the	presence	 of	 8	μg/ml	 polybrene.	 8	 –	 10	h	 after	 transduction,	 the	 supernatant	 was	replaced	by	fresh	medium.		
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3.2.3.6 Lentiviral	doxycycline-inducible	overexpression	system	A	 lentiviral	 tet-ON	 expression	 system	was	 employed	 to	 achieve	 stable,	 doxycycline-inducible	 overexpression	 of	 genes	 of	 interest.	 cDNAs	 were	 ligated	 into	 the	plentiCMVtight	 Neo	 Dest	 vector	 downstream	 of	 the	 CMVtight	 promoter	 by	 LR	recombination	 (Chapter	 3.1.3.3)	 The	 CMVtight	 promoter	 consists	 of	 a	 tet-response	element	 (TRE)	 that	 is	 located	 upstream	 of	 a	minimal	 CMV	 promoter	 (Gossen	 et	 al.,	1995).	The	minimal	CMV	promoter	by	itself	cannot	induce	transgene	expression	and	is	consequently	silent	in	the	absence	of	TRE	activation.	It	is	therefore	required	to	either	sequentially	or	to	cotranduce	cells	with	a	second	plasmid,	encoding	the	transactivator	rtTA3.	rtTA3	is	inactive	in	the	absence	of	the	tetracycline	derivative	doxycycline,	and	activated	 upon	 doxycycline	 binding.	 An	 activation-induced	 conformational	 change	allows	 binding	 to	 the	 TRE	 and	 a	 subsequent	 activation	 of	 the	 CMVtight	 promoter,	leading	to	inducible	overexpression	of	the	gene	of	interest	(Figure	7).		
	
	
Figure	7:	Tet-ON	inducible	gene	expression	system.		
The	 CMVtight	 promoter	 upstream	 of	 the	 gene	 of	 interest	 consists	 of	 a	 tet-response	 element	 (TRE)	 of	
seven	 identical	 sequence	repeats	 followed	by	a	minimal	CMV	promoter	(CMVmin).	When	activated	by	
doxycycline	(dox),	the	transactivator	rtTA3	can	bind	to	the	TRE	and	induce	gene	expression.		
Cells	were	transduced	with	CMVtight	Neo	+gene	of	interest	and	rtTA3	Blast	lentiviruses	on	two	consecutive	days	by	spin-infection	as	described	in	chapter	3.2.3.5.	Starting	48	h	after	 the	 second	 transduction,	 cells	 were	 cultured	 in	 medium	 supplemented	 with	500	μg/ml	Geneticin	(Neomycin)	and	2.85	μg/ml	Blasticitin	S	HCl	for	7	days	to	select	for	stably	infected	cells.	
3.2.3.7 siRNA	transfection	of	HeLa	cells	
Reverse transfection of HeLa cells with siGENOME siRNAs (Table	12) was performed 
with the lipid-based HiPerFect transfection reagent according to the manufacturer’s 
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instructions. The original 96-well reverse transfection protocol was scaled up to a 24-
well format to allow simultaneous generation of samples for qPCR and flow cytometry. The	 HiPerFect	 transfection	 reagent	 was	 pre-diluted	 32-fold	 in	 Opti-MEM	 serum-reduced	medium.	125	μl	of	the	pre-diluted	transfection	reagent	were	pipetted	into	one	well	of	a	24-well	plate,	followed	by	the	addition	of	6	μl	of	a	2	μM	siRNA	stock.	Samples	were	incubated	for	10	min	to	allow	the	formation	of	siRNA-lipid	complexes,	followed	by	the	addition	of	25,000	HeLa	cells	in	475	μl	of	complete	DMEM	medium.	Plates	were	incubated	 for	 48	h	 and	 subsequently	 the	 medium	 was	 replaced	 by	 fresh	 medium	containing	1	μg/ml	doxycycline.	After	18	h,	 ICOS	 surface	 staining	was	 carried	out	 as	described	in	chapter	3.2.7.1.	
3.2.4 Confocal	microscopy	HEK293T	 cells	were	 transfected	with	 pDest12.2	 GFP-Nufip2	 and	 pDest12.2	 Roquin-mCherry	by	 calcium-phosphate	 transfection	as	described	 in	 chapter	3.2.3.4.	 200,000	cells	 were	 seeded	 onto	 glass	 cover	 slips	 and	 incubated	 overnight	 at	 37	 °C	 to	 allow	adherence.	 Before	 staining,	 cells	 were	 subjected	 to	 oxidative	 stress	 with	 0.5	mM	sodium	arsenite	 for	1	h	 at	 37	 °C	or	 left	 untreated.	Next,	 cells	were	 rinsed	once	with	PBS,	and	fixed	in	2	%	formaldehyde	for	10	min.	After	washing	twice	with	PBS	+	0.5	%	Triton	 and	 twice	 with	 plain	 PBS,	 primary	 antibody	 staining	 with	 anti-G3bp1	 was	performed	 for	 1	h	 at	 RT.	 After	 washing,	 the	 secondary	 antibody	 staining	 was	performed	with	 anti-mouse	 Cy5	 for	 45	min.	 All	washing	 and	 incubation	 steps	were	performed	 at	 room	 temperature.	 Images	 of	 mCherry,	 GFP	 and	 Cy5	 signals	 were	captured	 with	 a	 Leica	 TCS	 SP5	 confocal	 microscope,	 and	 analyzed	 with	 the	 Leica	confocal	LAS	AF	software.		
3.2.5 Expression	and	purification	of	recombinant	proteins	Expression	 and	 purification	 of	 recombinant	 Roquin	 and	 NUFIP2	 proteins	 was	performed	 by	 Elena	 Davydova	 from	 Prof.	 Dr.	 Dierk	 Niessing’s	 group.	 The	 Roquin	fragment	(amino	acids	2-441),	which	was	inserted	into	pETM11,	was	expressed	as	an	N-terminal	His6-fusion	protein	in	E.coli	BL21(DE3)Star.	The	cells	were	grown	at	37	°C	in	 LB	 medium	 with	 50	μg/mL	 kanamycin,	 34	μg/mL	 chloramphenicol	 and	 100	μM	ZnCl2.	After	reaching	an	OD600	of	0.9,	the	cell	cultures	were	induced	by	adding	0.5	mM	IPTG	and	overnight	growing	conditions	changed	 to	20	°C.	Afterwards,	 the	cells	were	harvested,	 resuspended	 in	 lysis	 buffer	 (500	mM	NaCl,	 2	mM	DTT,	 15	mM	 imidazole,	1	mg/mL	 lysozyme,	 10	μg/mL	 DNase	 I,	 protease	 inhibitors,	 50	mM	 Tris,	 pH	 8)	 and	
Material	and	methods	 79	 		sonicated	at	4	°C.	After	centrifugation,	the	cleared	lysates	were	applied	to	a	HisTrap	FF	column	 (GE	 Healthcare)	 and	 subsequently	 size	 exclusion	 chromatography	 was	performed	 using	 a	 HighLoad	 16/60	 Superdex	 200	 column	 (Amersham	 Pharmacia	Biosciences)	in	buffer	containing	500	mM	NaCl,	2	mM	DTT,	20	mM	Tris,	pH	7.0.		The	 NUFIP2	 fragment	 (amino	 acids	 255-411)	 was	 inserted	 into	 the	 pOPINS3C	 and	expressed	 as	 N-terminal	 His6-SUMO-fusion	 protein	 in	 E.coli	 BL21(DE3)pRIL.	 Cells	were	 grown	 at	 37	°C	 in	 LB	 medium	 with	 100	μg/mL	 ampicillin	 and	 34	μg/mL	chloramphenicol.	At	OD600	=	0.7,	the	cell	cultures	were	induced	by	adding	0.5	mM	IPTG	and	overnight	growing	conditions	changed	to	20	°C.	Next,	the	cells	were	harvested	and	resuspended	in	lysis	buffer	(500	mM	NaCl,	20	mM	imidazole,	0.1	%	Tween,	10	μg/mL	DNase	 I,	 protease	 inhibitors,	 50	mM	 HEPES,	 pH	7.5)	 and	 sonicated	 at	 4	°C.	 After	centrifugation,	 the	 cleared	 lysates	 were	 applied	 to	 a	 HisTrap	 FF	 column	 (GE	Healthcare).	 The	His6-SUMO	 tag	was	 cut	 off	 by	 applying	 the	 PreScission	 Protease	 at	4	°C	 overnight	 and	 then	 removed	 using	 a	 HisTrap	 FF	 column	 (GE	 Healthcare).	 The	protein,	 which	 did	 not	 bind	 to	 the	 HisTrap	 FF	 column,	 was	 concentrated	 and	 gel	filtrated	using	a	Superdex	75	10/300	GL	column	(Amersham	Pharmacia	Biosciences)	in	200	mM	NaCl	and	50	mM	HEPES	pH	7.5.		
3.2.6 Surface	plasmon	resonance	Surface	 plasmon	 resonance	 experiments	 were	 performed	 by	 Elena	 Davydova	 from	Prof.	Dr.	Dierk	Niessing’s	group.	A	BIACORE	3000	instrument	(Biacore	Inc.)	was	used	to	 perform	 Roquin-NUFIP2	 binding	 experiments.	 Roquin	 (amino	 acids	 2-441)	 was	immobilized	 to	 the	 CM5	 sensor	 chip	 with	 amine	 coupling	 (Biacore	 Inc.)	 at	 a	concentration	of	50	μg/ml	in	10	mM	Na-phosphate	buffer	pH	5.7.	NUFIP2	(amino	acids	255-411)	 was	 injected	 onto	 the	 sensor	 chip	 using	 the	 concentrations	 0.063	μМ,	0.125	μM,	 0.25	μM,	 0.5	μM,	 1	μM,	 2	μM	 and	 4	μM	 at	 30	μL/min	 at	 20	 °C	 in	 running	buffer	 (150	mM	 NaCl,	 0.05%	 Tween20,	 10	mM	 HEPES).	 The	 experiment	 was	performed	 three	 times	 and	 the	 injection	 of	 0.5	μМ	 NUFIP2	 was	 performed	 twice	within	each	experiment.	The	equilibrium	dissociation	constant	KD	was	calculated	from	steady-state	measurements	using	the	BIAevaluation	program	(Biacore	Inc.).	
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3.2.7 Flow	cytometry	
3.2.7.1 Surface	staining	For	 staining	 of	 ICOS	 on	 adherent	 cells	 (MEF,	 HeLa),	 cells	 were	 trypsinized	 and	 cell	suspensions	 were	 incubated	 with	 biotinylated	 anti-human	 ICOS	 antibody	 in	 FACS	staining	 buffer.	 Antibody	 staining	 was	 performed	 for	 20	 min	 at	 4	°C.	 Cells	 were	washed	 once,	 and	 subsequently	 incubated	 with	 Streptavidin-Allophycocyanin	 in	 a	second	staining	 step.	After	washing	 twice,	 sample	 readouts	were	acquired	on	a	 flow	cytometer.		
3.2.7.2 Intracellular	staining	For	 intracellular	 staining	 of	 Roquin-1/-2,	 MEF	 cells	 were	 trypsinized	 and	 cell	suspensions	 were	 fixed	 with	 2	%	 formaldehyde	 for	 20	 min	 at	 room	 temperature.	Following	 fixation,	 cells	 were	 permeabilized	 by	 washing	 in	 saponin	 buffer.	 Primary	antibody	staining	was	performed	with	anti-Roquin	3F12	 for	1	h	at	RT,	 followed	by	a	staining	 with	 the	 secondary	 antibody	 anti-mouse	 Alexa647.	 After	 washing	 twice,	sample	readouts	were	acquired	on	a	flow	cytometer.		
3.2.8 Coimmunoprecipitation	and	immunoblotting	For	GFP-immunoprecipitation,	a	polyclonal	anti-GFP	antibody	was	coupled	to	protein	G	 dynabeads,	 whereas	 pulldown	 of	 endogenous	 Roquin-1/2	 from	 MEF	 cells	 was	performed	 with	 anti-Roquin-1/2	 (Q4-2)-coupled	 tosylactivated	 MyOne	 Dynabeads.	Antibody	 coupling	was	 performed	 according	 to	 the	manufacturer’s	 instructions.	 For	preparation	 of	 the	 protein	 lysates,	 MEF	 or	 HEK293T	 cells	 growing	 on	 large	 tissue	culture	 plates	 were	 rinsed	 once	 with	 cold	 PBS,	 detached	 with	 cell	 scrapers	 and	centrifuged	 (300	 x	 g,	 5	min,	 4	 °C).	 Cell	 pellets	were	 shock	 frozen	 in	 liquid	 nitrogen,	thawed	and	resuspended	in	varying	amounts	of	 lysis	buffer	depending	on	the	size	of	the	cell	pellet	(Table	19).	Lysis	was	performed	for	20	min	on	ice,	followed	by	clearance	of	 the	 lysate	 via	 centrifugation	 (10,000	x	g,	 4	°C,	 10	min).	 The	 protein	 concentration	was	 determined	with	 the	Bio	Rad	protein	 assay	 (Bradford	 assay).	 Antibody-coupled	beads	were	subsequently	 incubated	with	2	mg	of	protein	 lysate	 for	4	h	at	4	°C	 in	the	presence	or	absence	of	RNAse.	After	washing	three	times	with	 lysis	buffer	 the	beads	were	 resuspended	 in	 Laemmli	 SDS	 sample	 buffer	 and	 boiled	 for	 5	min	 at	 95	°C	 for	protein	elution.	The	supernatant	was	subjected	to	immunoblotting.		
Material	and	methods	 81	 		For	 immunoblotting,	 protein	 lysates	 were	 generated	 as	 described	 above.	 After	determination	 of	 the	 protein	 concentration,	 the	 desired	 amount	 of	 lysate	 (usually	50	μg	 protein/	slot	 for	 detection	 of	 endogenous	 proteins)	was	 diluted	with	H2O	 and	Laemmli	SDS	sample	buffer	and	samples	were	subsequently	boiled	for	5	min	at	95	°C.	Denatured	samples	were	loaded	into	the	slots	of	an	SDS-polyacrylamide	gel	consisting	of	an	upper	stacking	gel	and	a	lower	running	gel	(Table	25).	Gels	with	an	acrylamide	content	of	10	%	were	used	for	detection	of	smaller	proteins,	such	as	Nufip2	(75	kDa),	while	 8	%	 gels	 were	 employed	 for	 detection	 of	 larger	 proteins,	 such	 as	 Roquin	(130	kDa).	The	 stacking	 gel	 serves	 to	 line	up	 the	proteins	 in	 the	 samples,	which	 are	subsequently	separated	according	to	size	in	the	running	gel.	A	prestained	protein	size	marker	was	used	as	 a	 reference.	Electrophoresis	was	performed	at	50	V	 for	20	min,	followed	by	120	V	for	1.5	h.	Separated	proteins	were	blotted	onto	methanol-activated	PVDF	membranes	at	40	V	overnight	in	a	wet	gel	blotting	chamber	filled	with	blotting	buffer.	After	blotting,	membranes	were	blocked	in	TBS	+	5	%	milk	for	two	hours	at	RT.	After	a	10	min	washing	step	with	TBST,	primary	antibody	dilutions	in	TBST	+	1	%	milk	or	 5	%		were	 applied	 for	 incubation	 overnight	 at	 4	 °C.	 Afterwards	membranes	were	washed	 three	 times	 with	 TBST	 +	 1	%	 milk,	 and	 incubated	 with	 HRP-conjugated	secondary	antibody	dilutions	for	1	h	at	RT.	Following	three	more	washing	steps	with	TBST	+1	%	milk,	TBST	and	TBS,	blots	were	developed	with	self-made	ECL	solution.		
Table	25:	Composition	of	SDS	PAGE	gels	
Stacking	gel	 Separating	gel	(8%	or	10%)	
5%	Polyacrylamide	
125	mM	Tris-HCl	pH	6.8	
0.1 %	SDS	
0.1 %	APS	
0.1 %	TEMED	
up	to	5	ml	with	H2O	
8	%	or	10	%	Polyacrylamide		
375	mM	Tris-HCl	pH	8.8	
0.2 %	SDS	
0.2 %	APS	
0.06	%	TEMED		
up	to	10	ml	with	H2O		
3.2.9 High-throughput	siRNA	screen	
3.2.9.1 siRNA	Transfection	High-throughput	siRNA	screening	in	HeLa	cells	was	performed	by	reverse	transfection	of	siRNAs	 in	96-wells	similar	 to	 the	protocol	described	 in	chapter	3.2.3.7	 for	 the	24-well	 format.	 The	 high-throughput	 transfection	 protocol	 included	 transfection	 in	duplicates	 and	 automated	 delivery	 of	 the	 siRNA	 reagents	 and	 the	 cells.	 40	μl	 of	 the	pre-diluted	HiPerFect	transfection	reagent	was	dispensed	manually	into	each	well	of	a	
82	 Material	and	methods			96-well	 U-bottom	 plate	 (plate	 A)	 using	 a	 multichannel	 pipette.	 8	μl	 of	 1	mM	 siRNA	library	stocks	and	32	μl	of	H2O	were	subsequently	added	by	a	robot,	and	after	mixing,	the	robot	dispensed	half	of	the	solution	(40	μl)	into	a	replicate	plate	(plate	B).	8	μl	of	1	mM	control	siRNAs	in	32	μl	H2O	(siRoquin,	siCtrl)	had	been	added	manually	before	addition	of	the	library	stocks.	Following	an	incubation	time	of	10	min	to	allow	complex	formation,	4,000	HeLa	cells	were	added	in	160	μl	of	complete	DMEM	medium	to	each	well.	 Plates	were	 incubated	 for	 48	h	 and	 subsequently	 the	medium	was	 replaced	by	fresh	medium	containing	1	μg/ml	doxycycline.	After	18	h	 the	cells	were	subjected	 to	fluorescent	cell	barcoding	and	antibody	staining.		
3.2.9.2 Fluorescent	cell	surface	barcoding	and	ICOS	staining	Before	ICOS	staining,	cells	were	subjected	to	fluorescent	cell	barcoding,	which	allows	multiplexing	of	different	samples	for	combined	antibody	staining	and	data	acquisition	(Krutzik	 et	 al.,	 2011;	 Krutzik	 &	 Nolan,	 2006).	 Fluorescent	 cell	 barcoding	 was	 in	principal	performed	as	described	in	(Krutzik	et	al.,	2011),	however,	the	protocol	was	adapted	 to	 label	 cell	 surface	 proteins	 only.	 HeLa	 cells	 were	washed	 once	with	 PBS,	trypsinized	 and	 transferred	 to	 U-bottom	 96-well	 plates.	 Washing	 steps	 were	 now	carried	out	by	resuspension,	centrifugation	at	400	x	g	and	4	°C	for	5	min	followed	by	aspiration	of	 the	supernatant	with	a	vacuum	pump	containing	an	8-channel	adaptor.	Cells	were	washed	 once	with	 PBS,	while	 dilutions	 of	 the	 amine-reactive	 fluorescent	dyes	 Pacific	 blue	 Succinimidyl	 Ester	 and	 Alexa	 Fluor	 488	 Succinimidyl	 Ester	 were	simultaneously	 prepared	 from	 5	mg/ml	 stock	 solutions	 in	 PBS.	 Four	 different	barcoding	 solutions	 were	 generated	 by	 employing	 both	 dyes	 in	 either	 a	 low	(0.2	μg/ml)	or	a	high	(4	μg/ml)	concentration.	Cell	pellets	of	each	96-well	plate	were	resuspended	in	50	μl	of	one	of	 the	 four	distinct	barcoding	solutions,	and	plates	were	sealed,	 vortexed	 and	 incubated	 at	 4	 °C	 for	 30	 min.	 After	 washing	 twice	 with	 FACS	buffer,	 four	plates	with	differential	barcoding	signatures	were	pooled	 into	one.	After	spinning	for	5	min	at	400	x	g,	4°C,	cells	were	resuspended	in	50	μl	of	the	biotinylated	anti-ICOS	 antibody	 dilution	 in	 FACS	 buffer.	 Antibody	 staining	was	 performed	 for	 20	min	 at	 4	 °C.	 After	 washing	 once	 with	 PBS,	 cells	 were	 stained	 with	 a	 dilution	 of	Stretavidin-Allophycocyanin.	After	a	final	washing	step,	cells	were	resuspended	in	100	μl	 FACS	 buffer	 and	 analyzed	 on	 a	 LSRII	 Fortessa	 flow	 cytometer	with	 the	 help	 of	 a	high-throughput	sampler.		
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3.2.10 Pooled	CRISPR/Cas9	screen	A	 pooled	 CRISPR/Cas9	 screen	was	 performed	 to	 identify	 genes	 that	 are	 involved	 in	Roquin-induced	cell	death	(Figure	39).		
3.2.10.1 Library	amplification	The	 mouse	 Gecko	 v2	 library	 is	 delivered	 as	 two	 half-libraries	 (A	 and	 B),	 each	containing	one	half	of	the	sgRNAs	targeting	genes	and	miRNAs.	Library	amplification	was	 performed	 as	 described	 in	 the	 data	 sheet	 provided	 by	 Addgene.	 In	 brief,	 four	aliquots	of	 electrocompetent	bacteria	were	electroporated	with	100	ng	of	 the	Gecko	library	 each.	 All	 batches	 were	 pooled,	 and	 plated	 onto	 two	 24.5	cm2	 agar	 plates	containing	ampicillin.	Cells	were	grown	at	32°C	for	14	h.	All	colonies	were	scraped	off	the	plate	with	a	cell	scraper,	and	plasmid	DNA	was	prepared	from	the	total	amount	of	bacteria	using	the	maxiprep	kit	(Chapter	3.2.1.2).		
3.2.10.2 Lentivirus	production	and	virus	transduction	Lentiviral	 particles	 were	 produced	 as	 described	 for	 second-generation	 lentiviral	vectors	in	chapter	3.2.3.4.	One	plate	of	HEK293T	cells	each	was	transfected	with	25	μg	of	library	A	and	B	together	with	the	corresponding	packaging	plasmids.	The	lentiviral	supernatant	was	 harvested	 as	 described	 in	 chapter	 3.2.3.4,	 frozen	 and	directly	 used	for	transduction.	Virus	titration	was	performed	as	described	in	(Shalem	et	al.,	2014).	Transduction	was	performed	via	 spin	 infection	as	described	 in	 chapter	3.2.3.5.	After	spinning,	 the	medium	was	 replaced	 by	 fresh	medium,	 and	 cells	 were	 incubated	 for	20	h	at	37	°C.	After	 trypsinizing	and	pooling	of	all	cells,	5	x	107		cells	were	 frozen	 for	isolation	 of	 genomic	 DNA	 as	 described	 in	 chapter	 3.2.3.2.	 The	 remaining	 cells	were	cultured	 in	 the	presence	of	2	μg/ml	puromycin	 for	seven	days.	Following	puromycin	selection,	maintenance	of	5	x	106	cells	was	sufficient	to	maintain	the	complexity	of	the	library.	Cells	were	passaged	every	other	day	 for	 the	duration	of	 the	experiment,	and	5	x	106		cells		were	harvested	for	genomic	DNA	on	the	indicated	days	(Figure	40A).		
3.2.10.3 Amplification	of	sgRNA	sequences	from	genomic	DNA	Following	isolation	of	genomic	DNA	as	described	in	chapter	3.2.3.2,	integrated	sgRNA	sequences	were	amplified	 in	a	 two-step	PCR	reaction	using	Herculase	 II	Fusion	DNA	polymerase.	 For	 the	 first	 PCR,	 the	 required	 amount	 of	 input	 genomic	 DNA	 was	calculated	 in	 order	 to	 achieve	 300-fold	 coverage	 over	 the	 GECKO	 library,	 which	resulted	in	280	µg	DNA	per	sample	(assuming	7	pg	of	genomic	DNA	per	cell).	For	each	
84	 Material	and	methods			sample,	 a	 PCR	master	mix	 (Table	 26)	was	 prepared	 to	 contain	 the	 280	µg	 template	DNA.	The	master	mix	was	distributed	to	28	wells	of	a	96-well	plate	(100	μl/well)	and	run	on	a	Lightcycler	(cycling	conditions:	2	min	at	95	°C,	18	x	(20	s	at	95	°C,	45	s	at	61	°C,	30	s	at	72	°C),	72	°C	for	3	min).		
Table	26:	Master	mix	for	the	first	CRISPR/Cas9	PCR	
Amount	 Reagent	
560	μl	 5x	buffer	
28	μl	 dNTP	10mM	each	
70	μl	 Forward	primer	(10	μM)	
70	μl	 Reverse	primer	(10	μM)	
28	μl	 Herculase	
280	μg	 Genomic	DNA	
Up	to	2800	μl	 H2O	
	Following	 amplification,	 the	 reactions	 of	 all	 28	 wells	 were	 pooled	 and	 5	μl	 of	 the	pooled	amplicons	were	amplified	in	a	single	100	μl	reaction	using	the	primers	of	the	second	CRISPR/Cas9	PCR	(Table	10)	(2	min	at	95	°C,	24	x	(20	s	at	95	°C,	45	s	at	60	°C,	30	 s	 at	 72	 °C),	 72	 °C	 for	 3	 min).	 The	 resulting	 PCR	 products	 were	 gel-purified	 as	described	in	chapter	3.2.1.3	and	subjected	to	next-generation	sequencing	(NGS),	which	was	performed	by	Dr.	Stefan	Krebs	in	the	laboratory	of	Dr.	Helmut	Blum,	Gene	Center	Munich.					
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4 Results	
4.1 Targeted	 siRNA	 screen	 for	 cofactors	 of	 Roquin-1	 in	 post-
transcriptional	gene	regulation	
Roquin	 family	 proteins	 (Chapter	 1.1.4.2)	 bind	 to	 stem-loop	 structures	 in	 the	3’	untranslated	 region	 (3’	UTR)	 of	 their	 target	 mRNAs	 and	 inhibit	 gene	 expression	(Jeltsch	 &	 Heissmeyer,	 2016).	 However,	 the	 mechanism,	 which	 is	 employed	 by	 the	highly	 homologous	 proteins	 Roquin-1	 and	 Roquin-2	 to	 induce	 post-transcriptional	gene	regulation,	is	still	elusive.	Roquin-1	was	initially	shown	to	interact	with	the	RNA	helicase	Rck	(also	known	as	Ddx6)	and	the	enhancer	of	mRNA	decapping	Edc4	(also	known	 as	 Hedls	 or	 Ge-1),	 supporting	 a	model	 in	 which	 Roquin-1	 inhibits	 its	 target	mRNA	 expression	 through	 decapping	 and	 subsequent	 5’	 to	 3’	 degradation	(Glasmacher	et	al.,	2010).	More	recent	studies	primarily	found	interactions	of	mouse	and	human	ROQUIN-1	with	 subunits	of	 the	CCR4-CAF1-NOT	deadenylation	complex,	in	 particular	 with	 the	 scaffolding	 subunit	 CNOT1	 and	 the	 deadenylases	 CNOT7	 and	CNOT8	(Leppek	et	al.,	2013;	Murakawa	et	al.,	2015).	Therefore,	in	Roquin-1-mediated	mRNA	 degradation	 deadenylation	 may	 precede	 decapping.	 Additionally,	 it	 was	demonstrated	that	Roquin-1	can	cooperate	with	the	endonuclease	Regnase-1	(Chapter	1.1.4.3)	 on	 the	 3’	 terminal	 260	 nucleotides	 (nts)	 of	 the	TNF	 3’	UTR	 to	 induce	 post-transcriptional	 repression	 (Jeltsch	 et	 al.,	 2014).	 Obviously,	 Roquin-1-mediated	repression	 of	 its	 target	 mRNAs	 is	 highly	 complex	 and	 our	 understanding	 of	 the	underlying	 principles	 is	 still	 sketchy	 at	 best.	 Consequently,	 crucial	 cofactors	 and	collaborating	RNA-binding	proteins	(RBPs)	are	likely	missing	in	current	models.		The	inducible	T	cell	co-stimulator	ICOS	(Chapter	1.2.1.4)	was	the	first	identified	mRNA	targeted	by	Roquin-1	(Vinuesa	et	al.,	2005).	Its	long	3’	UTR	of	~2000	nucleotides	(nts)	would	 allow	 for	 a	 multitude	 of	 cooperative	 interactions	 with	 different	 post-transcriptional	 regulators,	 such	 as	miRNAs	 and	 RBPs,	 but	 only	miR-101-,	miR-146-,	Regnase-1-	 and	 Roquin-1-mediated	 repression	 have	 been	 described	 thus	 far	(Glasmacher,	 2010;	 Jeltsch	 et	 al.,	 2014;	 Srivastava	 et	 al.,	 2015;	 Yu	 et	 al.,	 2007).	 In	sanroque	mice,	where	Roquin-1	function	is	impaired	due	to	a	single	point	mutation,	all	T	cells	show	enhanced	Icos	expression	(Vinuesa	et	al.,	2005)	and	dysregulated	Icos	can	take	over	CD28	functions	in	initiating	T	cell	help	(Linterman	et	al.,	2009).	Uncoupling	of	 the	 T	 cell-dependent	 antibody	 response	 from	 the	 requirement	 for	 CD28	
86	 Results			costimulation	to	discriminate	between	foreign	and	self	is	thought	to	contribute	to	the	development	of	 the	 severe	autoimmune	phenotype	of	sanroque	mice	 (Chapter	1.3.3)	(Linterman	 et	 al.,	 2009).	 Insights	 into	 the	 principles	 of	 post-transcriptional	 ICOS	regulation	 would	 consequently	 be	 of	 considerable	 interest	 and	 may	 also	 be	transferred	 to	 other	 transcripts	 targeted	 by	 Roquin-1.	 On	 the	 basis	 of	 these	considerations,	we	decided	to	perform	a	high-throughput	RNAi	screen	for	cofactors	of	Roquin-1-mediated	ICOS	regulation.	
4.1.1 Generating	a	reporter	cell	line		I	started	out	to	produce	a	reporter	cell	line,	which	would	enable	the	quantification	of	post-transcriptional	regulation	of	ICOS	by	Roquin-1	with	flow	cytometry.	Recently,	up	to	 20-fold	 downregulation	 of	 exogenously	 expressed	 ICOS	 surface	 protein	 was	observed	 in	 response	 to	 retroviral	 overexpression	 of	 Roquin-1	 in	mouse	 embryonic	fibroblast	 (MEF)	cells	 (Glasmacher	et	al.,	2010).	Therefore,	 I	decided	 to	also	use	 this	system	 for	 the	 development	 of	my	 reporter	 cell	 line.	 I	 adopted	 the	 flow	 cytometric	readout	of	 ICOS	surface	expression	after	antibody	staining.	Avoiding	cell	 toxicity	due	to	 constitutive	 Roquin-1-IRES-Thy1.1	 expression,	 I	 decided	 to	 generate	 a	 clonal	 cell	line	with	stable	ICOS-	and	inducible	Roquin-1	overexpression.	To	circumvent	the	need	for	intracellular	FACS	staining,	Roquin-1	was	cloned	in	frame	with	 the	 fluorescence	 marker	 mCherry.	 The	 two	 genes	 were	 separated	 by	 the	sequence	 of	 a	 self-cleaving	 peptide	 from	 porcine	 teschovirus-1	 (P2A),	which	 causes	defined	 stopping	 and	 reinitiation	 events	of	 the	 ribosome	during	 translation,	 thereby	allowing	the	expression	of	stoichiometric	amounts	of	two	separate	proteins	from	one	mRNA	 (Figure	 8A)	 (Kim	 et	 al.,	 2011).	 A	 fusion	 construct	 lacking	 the	 P2A	 peptide	(Roquin-1-mCherry)	 was	 cloned	 as	 a	 control.	 The	 lentiviral	 tet-on	 system	 (Chapter	3.2.3.6)	 was	 used	 to	 achieve	 doxycycline-inducible	 gene	 expression.	 Specifically,	wildtype	 MEF	 cells	 were	 transduced	 with	 the	 transactivator	 rtTA3	 and	 a	 second	lentivirus	encoding	Roquin-1-P2A-mCherry	or	Roquin-1-mCherry	expressed	from	the	doxycycline-inducible	CMVtight	promoter.	After	24	h	of	doxycycline	treatment,	Roquin-1	 expression	 levels	 were	 analyzed	 by	 immunoblotting	 (Figure	 8B)	 showing	 strong	induction	 after	 doxycycline	 treatment.	 Comparing	 cells	 transduced	 with	 Roquin-1-P2A-mCherry	versus	Roquin-1-mCherry	revealed	that	only	a	small	amount	of	protein	from	 the	 Roquin-1-P2A-mCherry	 construct	 was	 not	 separated	 (Figure	 8B),	 second	lane,	highest	band),	leading	to	the	expression	of	relatively	small	amounts	of	a	Roquin-1-mCherry	fusion	protein.		
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Figure	8:	Evaluation	of	dox-inducible	overexpression	of	Roquin-1-P2A-mCherry.	
(A)	Schematic	representation	of	Roquin-1-P2A-mCherry	and	Roquin-1-mCherry	expression	constructs.	
In	the	upper	construct,	Roquin-1	and	mCherry	are	separated	by	a	7-amino	acid	linker	and	a	porcine	
techovirus-1	2A	(P2A)	peptide	of	19	amino	acids	(aa).	The	C-terminus	of	the	2A	peptide	is	“cleaved”	by	
ribosome	skipping,	resulting	in	the	separation	of	the	proteins	Roquin-1	and	mCherry.	The	linker	and	
the	N-terminal	18	amino	acids	of	the	2A	peptide	stay	attached	to	the	C-terminus	of	Roquin-1,	while	a	
single	proline	residue	of	P2A	is	added	to	the	N-terminus	of	mCherry.	The	lower	construct	(Roquin-1-
mCherry)	results	in	the	generation	of	a	Roquin-1-mCherry	fusion	protein.	(B)	Immunoblot	analysis	of	
Roquin-1	expression	 in	whole	cell	 lysates	 from	wt	MEF	cells	 transduced	 lentivirally	with	doxycycline	
(dox)-inducible	 Roquin-1-P2A-mCherry	 or	 Roquin-1-mCherry.	 Cells	were	 cultured	 in	 the	 presence	 of	
dox	for	24	h	or	left	untreated	as	indicated.	(C)	Flow	cytometric	analysis	of	intracellular	Roquin-1-	and	
mCherry	 expression	 in	 a	 clonal	Rc3h1/2-/-	 cell	 line	with	 dox-inducible	 Roquin-1-P2A-mCherry.	 Cells	
were	cultured	in	the	presence	of	dox	for	24	h	(+dox)	or	left	untreated	(-dox).	Intracellular	Roquin	was	
stained	with	an	antibody	recognizing	Roquin-1	and	Roquin-2.		
In	 order	 to	 achieve	maximal	 changes	 of	Roquin-1	 levels	 after	 doxycycline-induction,	we	 used	Rc3h1/2-/-	 MEF	 cells,	 in	 which	 the	 genes	 encoding	 Roquin-1	 and	 Roquin-2	(Rc3h1	 and	 Rc3h2,	 respectively)	 were	 deleted.	 These	 cells	 were	 transduced	 with	doxycycline-inducible	Roquin-1-P2A-mCherry,	and	single	clones	were	generated.	Flow	cytometric	 analysis	 of	 the	 clone	 with	 highest	 induction	 revealed	 a	 full	 correlation	between	 intracellular	 Roquin-1	 and	 mCherry	 expression,	 validating	 the	 use	 of	mCherry	 as	 a	 fluorescent	marker	 for	Roquin-1	overexpression	 for	 the	 course	of	 this	study	(Figure	8C).		After	 establishing	 the	 inducible	Roquin-1	overexpression	 system,	 the	 reporter,	 ICOS,	was	stably	integrated	into	the	genome	of	the	cells	via	lentiviral	transduction.	In	order	
88	 Results			to	find	physiologic	cofactors	with	an	impact	on	Roquin-1-mediated	mRNA	repression	of	 ICOS,	 the	 protein	 coding	 sequence	 (CDS)	 and	 the	 whole	 ~2	kb	 3’	untranslated	region	 (3’	UTR)	 of	 ICOS	 mRNA	were	 used	 as	 a	 reporter.	 Another	 step	 of	 single	 cell	cloning	eventually	resulted	 in	 the	successful	generation	of	a	reporter	cell	 line,	which	was	 suitable	 for	 the	 intended	 screening	 experiment.	 This	 cell	 line	 showed	 high	expression	of	ICOS	in	the	absence	of	Roquin	(Figure	9A,	cells	in	black),	but	enabled	a	strong	downregulation	of	ICOS	surface	expression	in	response	to	doxycycline-induced	overexpression	 of	 Roquin-1	 (Figure	 9A,	 cells	 in	 red).	 Supporting	 specificity	 of	 this	assay,	there	was	no	repression	of	the	CDS	of	ICOS	without	the	3’	UTR	after	Roquin-1-induction,	and	similarly	the	ICOS	 full-length	mRNA	was	not	regulated	by	a	truncated,	inactive	version	of	Roquin-1,	(Roquin-1	aa	1-509)	(Glasmacher,	2010)	(Figure	9B,	C).		
	
	
Figure	9:	 Validation	 of	 the	 reporter	 system	 for	Roquin-1-mediated	post-transcriptional	 gene	
regulation.	
(A)	Flow	cytometric	analysis	of	ICOS	and	mCherry	expression	in	a	clone	of	Rc3h1/2-/-	MEF	cells	that	
were	 lentivirally	 transduced	with	 doxycycline	 (dox)-inducible	 Roquin-1-P2A-mCherry	 and	 ICOS	 full-
length	 (ICOS	 FL).	 Cells	 were	 treated	 with	 dox	 for	 24	h	 (+dox)	 or	 left	 untreated	 (-dox).	 (B)	 Flow	
cytometric	analysis	of	ICOS	and	mCherry	expression	of	MEF	cell	clones	that	were	transduced	with	dox-
inducible	 Roquin-1-P2A-mCherry	 or	 Roquin-1	(aa	1-509)-P2A-mCherry	 constructs	 and	 superinfected	
with	 vectors	 encoding	 only	 the	 coding	 sequence	 of	 ICOS	 mRNA	 (CDS)	 or	 ICOS	 CDS	 followed	 by	 its	
3’	UTR	(full-length,	FL),	 respectively.	Cells	were	 treated	with	dox	 for	24	h	 (+dox)	or	 left	untreated	(-
dox).		
4.1.2 Characterization	 of	 Roquin-1-induced	 post-transcriptional	
regulation	of	ICOS	The	 newly	 established	Rc3h1/2-/-	MEF	 reporter	 cell	 line	 for	 Roquin-dependent	 ICOS	repression	 (Figure	 9A)	 was	 characterized	 in	 a	 time	 course	 of	 ICOS	 regulation	 after	doxycycline-induction	of	Roquin-1	(Figure	10).		
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Figure	10:	Time	course	of	Roquin-1-dependent	ICOS	regulation.	
(A)	Immunoblot	analysis	of	Roquin-1	expression	in	whole	cell	lysates	from	Rc3h1/2-/-	MEF	cells	with	
doxycycline-inducible	 Roquin-1-P2A-mCherry	 and	 stable	 ICOS	 expression.	 Cells	 were	 treated	 with	
doxycycline	 (dox)	 for	 the	 indicated	 times.	 (B)	 Quantified	 protein	 and	 mRNA	 expression	 of	 ICOS	 in	Rc3h1/2-/-	MEF	cells	with	dox-inducible	Roquin-1-P2A-mCherry	and	stable	ICOS	expression.	Cells	were	
treated	with	dox	for	the	indicated	times.	Mean	Fluorescence	Intensity	(MFI)	of	ICOS	surface	expression	
was	quantified	by	flow	cytometry	and	ICOS	mRNA	expression	was	measured	by	qPCR	relative	to	Hprt.		
Roquin-1	 overexpression	 was	 detectable	 in	 immunoblots	 as	 early	 as	 4	h	 after	doxycycline-induction	 (Figure	 10A).	 At	 that	 time	 ICOS	 mRNA	 was	 also	 maximally	repressed,	 while	 full	 regulation	 of	 ICOS	 surface	 expression	 did	 not	 occur	 until	 15	h	after	doxycycline	treatment	(Figure	10B).	Interestingly,	Rc3h1/2-/-	MEF	cells	showed	a	high	 downregulation	 of	 ICOS	 expression	 on	 the	 protein	 level	 (30-fold),	 while	 ICOS	mRNA	was	only	2-fold	reduced.	This	finding	suggests	that	mRNA	decay	is	not	the	only	mechanism	 by	 which	 Roquin-1	 controls	 ICOS	 expression.	 These	 data	 would	 be	consistent	with	 Roquin-1	mediating	mRNA	 decay	 early	 on,	 and,	 in	 addition,	 causing	translational	 inhibition	 at	 later	 time	 points.	 Starting	 from	 these	 findings	 another	project	 in	our	 lab	is	currently	 investigating	Roquin-mediated	translational	 inhibition,	which	 is	 not	 addressed	 further	 in	 this	 study.	 As	 maximal	 downregulation	 of	 ICOS	surface	expression	 required	at	>	15	h	of	doxycycline	 stimulation	 (Figure	10),	18	h	of	doxycycline	treatment	was	chosen	for	read	out	during	the	following	pilot	experiments	and	the	actual	screen.	
4.1.3 Pilot	experiments	to	prepare	the	screen	After	 successful	 generation	 and	 characterization	 of	 the	 reporter	 system,	 pilot	experiments	 were	 run	 in	 order	 to	 prepare	 for	 the	 high-throughput	 screen.	 In	 this	chapter,	 I	will	 first	describe	how	assay	robustness	was	assessed	by	calculating	the	Z’	
90	 Results			factor.	This	was	 first	performed	 in	a	24-well	 format	without	 siRNAs	and	 then	 in	 the	96-well	 screening	 format	 with	 positive	 and	 negative	 control	 siRNAs.	 Finally,	fluorescent	 cell	 barcoding	was	 incorporated	 into	 the	 screening	protocol	 to	minimize	consumable	costs	on	the	one	hand	and	sample	handling	and	data	acquisition	time	on	the	other.		
4.1.3.1 Calculation	of	the	Z’	factor	The	 Rc3h1/2-/-	 MEF	 reporter	 cells	 showed	 strong	 downregulation	 of	 ICOS	 surface	proteins	 in	 response	 to	 doxycycline-induced	 Roquin-1	 expression,	 however,	 it	 was	unclear	whether	it	would	be	possible	to	achieve	high	siRNA	knockdown	efficiencies	in	MEF	cells.	As	 this	was	already	proven	 for	HeLa	cells,	which	are	widely	used	 in	RNAi	screens	(Badertscher	et	al.,	2015;	Henderson	&	Azorsa,	2013;	Simpson	et	al.,	2012),	a	second	reporter	cell	 line	was	also	set	up	in	HeLa	cells	using	the	same	system	of	dox-inducible	Roquin-1-P2A-mCherry	and	stable	ICOS	expression	as	described	in	chapter	4.1.1.	 In	order	to	choose	one	of	the	two	reporter	cell	 lines,	Z’	 factors	were	calculated	for	both.	The	Z	factor	assesses	the	quality	of	a	high-throughput	screening	assay,	taking	both	the	dynamic	range	and	the	data	variation	into	account,	which	are	calculated	from	mean	and	standard	deviation	of	sample	versus	control	data	(Figure	11).	The	Z’	factor	is	 usually	 calculated	 during	 the	 pre-screening	 pilot	 experiments	 with	 multiple	measurements	 of	 a	 known	 positive	 control	 versus	 a	 negative	 control	 (Zhang	 et	 al.,	1999).			
	
Figure	 11:	 Schematic	 representation	 of	 data	 variation	 and	 dynamic	 range	 of	 a	 high-
throughput	screen	(adapted	from	(Zhang	et	al.,	1999)).	
This	 graphic	 illustrates	 normally	 distributed	 sample	 and	 control	 data	 of	 a	 high-throughput	 screen.	
The	dynamic	range	is	defined	as	the	difference	between	the	mean	of	sample	data	(μs)	and	the	mean	of	
the	 control	 data	 (μc).	 The	 standard	 deviation	 (SD)	 of	 sample	 (σs)	 and	 control	 data	 (σc)	 defines	 the	
variation	of	 the	assay.	 In	normally	distributed	populations,	95	%	of	 the	data	points	 lie	within	3	SDs	
from	the	mean.		
Results	 91	 		The	 equation	 for	 calculating	 the	 Z	 factor	 is	 shown	 in	 Figure	 11.	 For	 low	 standard	deviations	(SDs)	of	positive	(σs)	and	negative	controls	(σc),	the	numerator	approaches	0	and	in	consequence	Z	approaches	1.	Likewise,	a	high	difference	between	the	means	of	 positive	 and	 negative	 controls	 will	 drive	 the	 denominator	 towards	 infinity;	therefore	Z	will	again	approach	1.	Thus,	the	ideal	assay	with	no	SD	or	an	infinitely	high	difference	 between	 positive	 and	 negative	 controls	 would	 have	 a	 Z	 factor	 of	 1.	 In	practice,	assays	with	a	Z	factor	between	0.5	and	1	are	considered	excellent	and	show	a	good	separation	between	positive	and	negative	controls	(Zhang	et	al.,	1999).		In	 our	 screen,	 doxycycline-inducible	 Roquin-1-P2A-mCherry	 overexpression	 causes	post-transcriptional	repression	of	stably	expressed	ICOS,	which	will	be	inhibited	after	knockdown	of	a	Roquin-1	cofactor.	Hits	are	therefore	characterized	by	increased	ICOS	expression,	and	the	maximal	signal	is	expected	to	reach	the	level	of	ICOS	expression	in	the	 absence	 of	 Roquin-1,	 which	 can	 be	 mimicked	 by	 non-induced	 reporter	 cells.	 In	contrast,	 doxycycline-induced	 samples	 with	 fully	 downregulated	 ICOS	 surface	expression	 represent	 the	 minimal	 screening	 signal.	 To	 calculate	 the	 Z’	 factors	 of	Roquin-1-mediated	 ICOS	 repression	 in	Rc3h1/2-/-	 MEF	 and	 HeLa	 reporter	 cell	 lines,	the	 dynamic	 range	 and	 data	 variation	 of	 untreated	 versus	 doxycycline-treated	 cells	were	analyzed	in	a	24-well	format.		The	MEF	cell	line	showed	higher	expression	of	mCherry	and	stronger	downregulation	of	 ICOS	 than	 the	 HeLa	 cell	 line	 (Figure	 12A).	 Immunoblot	 analysis	 confirmed	 the	absence	of	endogenous	Roquin-1	and	 -2	 in	Rc3h1/2-/-	MEF	cells	without	doxycycline	and	a	higher	overexpression	of	Roquin-1	in	response	to	doxycycline	treatment	than	in	HeLa	 cells,	where	 endogenous	 Rc3h1	 and	 -2	were	 present	 in	 untreated	 cells	 due	 to	their	wildtype	background	(Figure	12B).	Both	cell	lines	showed	only	small	amounts	of	the	"uncleaved"	Roquin-1-mCherry	fusion	protein.	Calculating	the	mean	and	standard	deviation	of	12	treated	and	12	untreated	samples,	MEF	cells	showed	a	larger	screening	window	 (30-fold	 difference	 between	 μs	 and	 μc),	 but	 also	 a	 much	 higher	 variance	between	equally	treated	samples	(Figure	12C).	For	HeLa	cells,	 the	screening	window	was	smaller,	with	a	3-fold	difference	between	μs	and	μc,	but	due	to	the	lower	variation	this	assay	proved	to	be	more	robust	and	with	a	Z	score	of	0.65	better	suitable	for	high-throughput	screening.	The	HeLa	cell	 line	was	therefore	chosen	as	a	reporter	cell	 line	for	the	RNAi	screen.		
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Figure	12:	Calculation	of	the	Z’	factor	in	induced	versus	non-induced	Rc3h1/2-/-	MEF	and	HeLa	
reporter	cell	lines.	
(A)	Representative	 flow	cytometric	analysis	of	 ICOS	and	mCherry	expression	 in	Rc3h1/2-/-	MEF	and	
HeLa	 reporter	 cells	 with	 stable	 ICOS	 and	 doxycycline	 (dox)-inducible	 Roquin-1-P2A-mCherry	
expression.	 Cells	 were	 induced	 with	 dox	 for	 18	h	 (+dox)	 or	 left	 untreated	 (-dox).	 (B)	 Immunoblot	
analysis	of	Rc3h1	and	-2	expression	in	whole	cell	lysates	from	Rc3h1/2-/-	MEF	and	HeLa	reporter	cells.	
Cells	were	 induced	with	dox	 for	18	h	 (+dox)	or	 left	untreated	 (-dox).	(C)	Quantified	 ICOS	expression	
from	 24	 wells	 of	 MEF	 or	 HeLa	 reporter	 cells	 that	 were	 treated	 with	 dox	 for	 18	h	 (+dox)	 or	 left	
untreated	 (-dox).	 ICOS	mean	 fluorescence	 intensity	 (MFI)	 was	 determined	 by	 flow	 cytometry.	 Solid	
lines	show	the	means	of	positive	(-dox,	μs)	and	negative	control	(+dox,	μc)	data,	dashed	lines	display	
3	SDs	from	the	mean	of	each	data	set.		
After	 choosing	 the	 desired	 reporter	 cell	 line,	 the	 next	 important	 step	 was	 the	development	 of	 a	 robust	 high-throughput	 RNAi	 screening	 protocol.	 Therefore,	 a	procedure	 was	 established	 to	 include	 siRNA	 transfection	 and	 doxycycline-induced	expression	of	Roquin-1	after	48	h,	in	order	to	provide	enough	time	for	the	knockdown	to	become	effective	in	HeLa	reporter	cells	(Figure	13A).	ICOS	surface	expression	was	then	 analyzed	 18	h	 after	 Roquin-1-induction,	 in	 a	 96-well	 format	 and	 using	 a	 flow	cytometer	in	combination	with	a	high-throughput	sampler.	In	this	set	up	the	reporter	cell	 line	 was	 routinely	 transfected	 with	 siGENOME	 siRNA	 pools.	 In	 each	 pool	 four	
Results	 93	 		different	 siRNAs	 target	 the	 same	 gene.	 In	 each	 well	 of	 a	 96-well	 plate,	 one	 pool	 of	siRNAs	 leads	 to	 the	 knockdown	 of	 the	 expression	 of	 a	 different	 candidate	 gene.	 To	investigate	whether	a	robust	Z	factor	could	be	reached	in	the	96-well	screening	format	and	 with	 siRNA	 transfection,	 2	x	36	 wells	 with	 reporter	 cells	 were	 treated	 with	Roquin-1-targeting	 (siRoquin-1)	 or	 non-targeting	 siRNAs	 (siCtrl)	 as	 positive	 and	negative	 controls,	 respectively.	 Knockdown	 of	 Roquin-1	 resulted	 repeatedly	 and	uniformly	in	an	effective	derepression	of	ICOS,	while	its	expression	was	unaffected	by	non-targeting	control	siRNAs.	The	protocol	above	was	optimized	until	a	Z’	factor	of	0.7	was	reached	to	make	it	highly	suitable	for	high-throughput	screening	(Figure	13B).		
	
Figure	 13:	 Calculation	 of	 the	 Z’	 factor	 after	 siRNA	 knockdown	 of	 Roquin-1	 in	 HeLa	 reporter	
cells.	
(A)	Schematic	representation	of	the	screen	workflow.	HeLa	reporter	cells	were	transfected	with	siRNA	
pools	 targeting	 different	 genes	 in	 each	 well	 of	 a	 96-well	 plate.	 48	h	 after	 transfection,	 Roquin-1	
overexpression	 was	 induced	 with	 doxycycline	 (dox).	 After	 18	h,	 ICOS	 and	mCherry	 expression	 were	
quantified	by	 flow	cytometry.	(B)	Distribution	of	 ICOS	expression	 in	HeLa	reporter	 cells	after	 siRNA	
transfection.	 HeLa	 reporter	 cells	 were	 transfected	 with	 Roquin-1-targeting	 siGENOME	 siRNA	 pools	
(siRoquin-1)	 or	a	non-targeting	 control	 siRNA	 (siCtrl)	 in	a	96-well	 plate	as	described	 in	 (A).	 The	Z’	
factor	was	calculated	from	mean	and	SDs	of	positive	(siRoquin-1)	and	negative	(siCtrl)	control	data.	
Solid	 lines	 show	 the	means	 of	 positive	 (siRoquin-1)	 and	 negative	 control	 (siCtrl)	 data,	 dashed	 lines	
indicate	three	SDs	from	the	mean	of	each	data	set.		
4.1.3.2 Establishing	fluorescent	cell	surface	barcoding	In	order	to	enhance	the	screening	throughput,	I	established	fluorescent	cell	barcoding	as	a	 technique	of	multiplexing	different	samples	 for	combined	antibody	staining	and	data	 acquisition.	 First	 described	 in	 2006,	 fluorescent	 cell	 barcoding	 employs	chemically	activated	fluorescent	dyes	for	labeling	of	amino	acid	side	chains	of	cellular	proteins.	 Incubation	with	 different	 concentrations	 of	 the	 fluorescent	 barcoding	 dyes	
94	 Results			results	 in	a	unique	 fluorescence	signature	of	each	 individual	sample.	After	combined	data	acquisition,	samples	can	be	deconvoluted	based	on	their	fluorescence	fingerprint	(Krutzik	 et	 al.,	 2011;	 Krutzik	 &	 Nolan,	 2006)	 (Figure	 14A).	 Eventually	 four	 distinct	barcoding	 signatures	 were	 created	 by	 combination	 of	 two	 fluorescent	 dyes	 in	 two	different	 concentrations.	Alexa	Fluor	488	and	Pacific	blue	were	 chosen	as	barcoding	dyes	 in	 order	 to	 minimize	 spillover	 into	 the	 mCherry	 or	 ICOS	 (Allophycocyanin)	channel	of	the	flow	cytometer.		0	
	
Figure	 14:	 Fluorescent	 cell	 surface	 barcoding	 allows	 multiplexing	 of	 different	 samples	 for	
antibody	staining	and	data	acquisition.	
(A)	 Schematic	 representation	 of	 the	 transfection,	 barcoding	 and	 data	 acquisition	 workflow.	 (B)	
Deconvolution	of	barcoded	samples.	Samples	from	(A)	were	first	deconvoluted	based	on	their	Pacific	
blue	 (PB)	 fluorescence	 intensity	 into	 high	 (PBhi)	 and	 low	(PBlo)-expressing	 cells.	 Second,	 Alexa	 fluor	
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488	high	 (AF488hi)	 and	 low	(AF488lo)-expressing	 cells	were	 separated,	 leading	 to	 the	deconvolution	
into	the	four	original	samples.	ICOS	and	mCherry	expression	was	plotted	for	each	sample.		
At	 this	 point	 all	 requirements	 had	 been	 met	 to	 perform	 a	 high-throughput	 RNAi	screen.		
4.1.4 Arrayed	RNAi	screening	RNAi	screening	was	performed	at	 the	Functional	Genomics	Center	of	La	Jolla	Institute	
for	 Allergy	 and	 Immunology	 (LJI)	 under	 the	 supervision	 of	 Dr.	 Sonia	 Sharma	 and	 in	collaboration	with	Dr.	Anjana	Rao’s	lab.	Prior	to	using	an	expensive	customized	siRNA	library,	we	wanted	to	test	our	assay	in	the	high-throughput	RNAi	screening	mode.	We	therefore	 started	 by	 screening	 six	 arrayed	 Dharmacon	 siGENOME	 subset	 libraries	(GPCR,	 Ion	 Channels,	 Proteases,	 Phosphatases,	 Kinases	 and	 Ubiquitin	 Conjugation)	that	 were	 instantly	 available	 at	 the	 Functional	 Genomics	 Center.	 Screening	 these	protein	subset	libraries	also	had	a	second	purpose:	Since	possible	cofactors	of	Roquin-1-mediated	 ICOS	 regulation	 are	 not	 necessarily	 restricted	 to	 RNA-binding	 proteins,	interesting	hits	might	also	arise	from	one	of	these	subset	libraries.		After	conclusion	of	the	protein	subset	screens,	we	set	our	focus	on	the	identification	of	targets	involved	in	known	steps	of	ICOS	post-transcriptional	regulation:	RNA	binding,	localization	 into	 P	 bodies	 or	 stress	 granules,	 and	 finally	 mRNA	 decay.	 Therefore,	 a	cherry-picked,	customized	siRNA	library	was	assembled	of	~1500	candidates.	This	list	comprised:		
• All	RBPs	bound	to	polyadenylated	mRNA	in	HeLa	cells	(Castello	et	al.,	2012)	as	well	 as	 all	 proteins	 that	 were	 annotated	 as	 “RNA-binding”	 in	 gene	 ontology	(www.geneontology.org)	
• Factors	 that	 are	 involved	 in	 P	 body	 and	 stress	 granule	 assembly	 (Ohn	 et	 al.,	2008)	
• Proteins	 involved	 in	 deadenylation-	 and	 decapping-dependent	 mRNA	 decay	(Braun	et	al.,	2012;	Chen	&	Shyu,	2011;	Cooke	et	al.,	2010)	
4.1.4.1 Screening	of	arrayed	subset	libraries	ICOS	 regulation	 in	 HeLa	 cells	 transfected	 with	 siRNA	 pools	 targeting	 the	 protein	families	 of	 GPCR,	 ion	 channels,	 phosphatases,	 proteases,	 kinases	 and	 the	 ubiquitin	conjugation	 system	 was	 assessed	 with	 the	 96-well	 screening	 protocol	 including	barcoding	 as	 described	 before	 (Figure	 13A,	 Figure	 14A).	 After	 data	 deconvolution,	
96	 Results			average	 ICOS	 mean	 fluorescence	 intensity	 (MFI)	 of	 each	 duplicate	 sample	 was	normalized	into	a	Z	score	using	the	following	equation:		
𝑍 = 𝐼𝐶𝑂𝑆 𝑀𝐹𝐼!"#$%& −  𝐼𝐶𝑂𝑆 𝑀𝐹𝐼!"#$% !"#$!%#  𝑆𝐷 𝑝𝑙𝑎𝑡𝑒 	Ranked	Z	scores	were	plotted	for	each	subset	library	(Figure	15),	and	every	data	point	with	a	Z	score	>	2	was	considered	a	hit.	Hit	rates	lay	constantly	between	5	and	6.5	%,	with	 the	 subset	 of	 phosphatases	 showing	 the	 lowest	 hit	 rate.	 Strikingly,	 positive	 Z	scores	reached	 from	zero	up	 to	a	maximum	of	16,	while	negative	Z	scores	never	 fell	below	 -2	 in	 any	 of	 the	 protein	 subset	 screens	 (Figure	 15).	 This	 is	 explained	 by	 the	nature	of	the	reporter	cell	line:	The	HeLa	cell	line	is	characterized	by	a	rather	low	level	of	 ICOS	 overexpression,	 which	 is	 completely	 reduced	 to	 background	 levels	 after	doxycycline-induced	Roquin	overexpression	(Figure	12).	Our	assay	did	thus	not	allow	the	 identification	of	Roquin	antagonists,	which	 is	 an	aspect	 that	was	not	part	of	 this	research	project.		
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Figure	15:	Screening	of	six	siGENOME	arrayed	subset	libraries.	
Normalized	data	from	screening	six	subset	libraries.	HeLa	reporter	cells	were	transfected	with	siRNA	
pools	 targeting	 all	members	 of	 each	 subset	 library	 in	 duplicates.	 48	h	 after	 transfection,	 Roquin-1-
overexpression	 was	 induced	 with	 doxycycline	 for	 18	h.	 Cells	 were	 harvested,	 barcoded	 and	 4	 wells	
were	combined	into	one	for	ICOS	staining	and	data	acquisition.	After	deconvolution,	average	ICOS	MFI	
of	each	sample	was	normalized	into	a	Z	score	with	the	plate	mean	and	SD.	Ranked	Z	scores	are	shown	
for	each	library.	Each	data	point	with	an	average	Z	score	>	2	was	considered	a	hit,	and	hit	rates	are	
indicated	in	red	as	percentages.	Candidates	that	were	chosen	for	further	validation	are	labeled	in	red.		
Since	Roquin-1	 is	 a	putative	E3	ubiquitin	 ligase	 and	 contains	 a	RING	 finger	 at	 its	N-terminus	(Vinuesa	et	al.,	2005),	candidates	from	the	ubiquitin	conjugation	subset	were	initially	chosen	for	further	validation.		
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4.1.4.2 Overexpression	of	individual	candidates	of	the	ubiquitin	conjugation	
system	in	MEF	reporter	cell	lines	Of	the	28	candidates	that	scored	positively	in	the	primary	screen	of	proteins	involved	in	 ubiquitin	 conjugation,	 seven	 showed	 reduced	 mCherry	 expression	 (>	25	%)	 as	compared	 to	 siCtrl.	 This	 indicates	 off-target	 effects	 on	 Roquin-1-P2A-mCherry	overexpression	and	the	respective	candidates	were	excluded	from	further	analysis.		In	 contrast,	 four	 promising	 candidates	 showed	 unaffected	 mCherry	 and	 strongly	increased	 ICOS	 expression	 after	 siRNA	 knockdown	 (Figure	 16A,	 red	 versus	 black	populations)	 and	 thus	 were	 chosen	 for	 further	 validation.	 Since	 the	 knockdown	 of	FBXL14,	 RAB40C,	 TRIM6-TRIM34	 and	 RNF222	 caused	 a	 derepression	 of	 ICOS,	 we	reasoned	that	their	overexpression	should	reciprocally	lead	to	lower	ICOS	expression.	The	 reporter	 system	of	 our	 screen	 is	 based	on	 the	 system	published	by	Glasmacher	and	 colleagues	 (Glasmacher	 et	 al.,	 2010),	 and	 likewise	 employs	 mouse	 Roquin	 in	combination	 with	 human	 ICOS.	 Since	 we	 have	 thus	 far	 not	 observed	 any	 species-specific	differences	using	mouse	or	human	proteins,	the	pathway	of	Roquin-mediated	ICOS	 repression	 seems	 to	 be	 generally	 conserved	 between	 the	 two	 species.	 For	overexpression	of	potential	Roquin	cofactors	we	therefore	employed	human	or	mouse	cDNA	clones	whichever	was	available.	The	mouse	or	human	cDNAs	were	cloned	into	a	retroviral	 expression	 vector,	 which	 contained	 the	 surface	 marker	 Thy1.1.	 The	candidate	 proteins	were	 subsequently	 overexpressed	 in	Rc3h1/2-/-	 or	wildtype	MEF	cells	 with	 inducible	 Roquin-1-P2A-mCherry	 that	 stably	 expressed	 ICOS,	 in	 order	 to	assess	 whether	 overexpression	 of	 the	 candidate	 itself,	 or	 only	 in	 combination	 with	overexpressed	Roquin-1,	can	repress	ICOS	expression.	In	Rc3h1/2-/-	MEF	cells,	none	of	the	 candidates	 and	 only	 Roquin-1	 overexpression	 led	 to	 downregulation	 of	 ICOS	expression	in	cells	that	were	positive	for	the	infection	marker	Thy1.1	(Figure	16B).	In	wildtype	 MEF	 cells	 with	 doxycycline-induced	 Roquin-1	 overexpression,	 ICOS	 levels	were	 already	 strongly	 reduced	 in	 non-infected	 Thy1.1-	 cells,	 and	 were	 not	 further	repressed	by	additional	retroviral	overexpression	of	Roquin-1	(Thy1.1+	cells)	(Figure	16C	upper	panel).	Again,	none	of	 the	candidates	 further	downregulated	 ICOS	 (Figure	16C	lower	panel).		
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Figure	 16:	 Validation	 of	 four	 candidates	 from	 the	 ubiquitin	 conjugation	 system	 by	
overexpression.	
(A)	 Flow	cytometric	analysis	 of	 ICOS	and	mCherry	 expression	 in	doxycycline-induced	HeLa	 reporter	
cells	 after	 siRNA	 knockdown	 of	 FBXL14,	 RAB40C,	 RNF222	 or	 TRIM6-TRIM34	 (red	 population)	
compared	 to	 a	 non-targeting	 siRNA	 (black	 population).	 (B)	 Flow	 cytometric	 analysis	 of	 ICOS	 and	
Thy1.1	expression	in	Rc3h1/2-/-	MEF	cells	upon	overexpression	of	FBXL14,	Rab40C,	Rnf222	or	TRIM6-
TRIM34.	Thy1.1	was	used	as	a	marker	for	retroviral	transduction	with	the	overexpression	constructs.	
(C)	Overexpression	of	 candidates	was	performed	as	 in	(B).	 Instead	of	Rc3h1/2-/-	MEF	cells,	wt	MEF	
cells	with	doxycycline-induced	overexpression	of	Roquin-1	were	used	in	order	to	assess	the	impact	of	
candidate	overexpression	in	the	presence	of	Roquin-1.		 	
100	 Results			Due	 to	 failure	 of	 the	 candidates	 to	 repress	 ICOS	 upon	 overexpression	 in	 our	 initial	validation	approach,	the	analysis	was	not	further	pursued.	Instead,	we	proceeded	with	the	customized	RNAi	screen.		
4.1.4.3 Screening	of	RBPs,	P	body-,	stress	granule-	and	mRNA	decay-factors	Screening	of	the	customized	siRNA	library	targeting	RBPs,	P	body-,	stress	granule-	and	mRNA	decay-factors	arrived	at	a	hit	rate	of	5.5	%,	similar	to	the	smaller	protein	subset	screens	performed	previously	(Figure	17).	 In	 the	resulting	 list	of	candidates,	already	established	 Roquin-1	 interacting	 proteins	 were	 identified	 by	 eye	 and	 additional	literature	searches	were	aimed	to	select	for	further	interesting	hits.	Two	well-known	candidates	 that	 are	 part	 of	 the	 mRNA	 decapping-	 and	 deadenylation	 pathways,	 the	enhancer	of	decapping	EDC4	and	the	scaffolding	subunit	of	the	deadenylation	complex	CNOT1,	 scored	 positively,	 thereby	 confirming	 that	 the	 screen	 was	 able	 to	 identify	candidates	 in	 the	 pathway	 of	 Roquin-mediated	 post-transcriptional	 gene	 regulation	(Glasmacher	 et	 al.,	 2010;	 Leppek	 et	 al.,	 2013).	 Yet,	 the	 RNAse	 REGNASE-1,	 the	 only	RBP	that	has	been	described	as	a	cofactor	of	Roquin-1	in	the	literature	so	far	(Jeltsch	et	al.,	2014)	was	not	identified.		
	
Figure	17:	Screening	of	a	customized	siRNA	library	targeting	RBPs	and	factors	of	mRNA	decay.	
Normalized	 screen	data	of	 the	 customized	 siRNA	 library	 for	Roquin-1	cofactors.	HeLa	reporter	 cells	
were	transfected	with	siRNA	pools	in	duplicates.	48	h	after	transfection,	Roquin-1-overexpression	was	
induced	with	doxycycline	for	18	h.	Cells	were	harvested,	barcoded	and	four	wells	were	combined	into	
one	for	ICOS	staining	and	data	acquisition.	After	deconvolution,	average	ICOS	MFI	of	each	sample	was	
normalized	 into	a	 Z	 score	based	on	plate	mean	and	SD.	Ranked	Z	 scores	are	 shown	 for	 each	 siRNA	
pool.	Each	data	point	with	an	average	Z	score	>	2	was	considered	a	hit.	Known	cofactors	of	Roquin-1	
are	indicated	in	red.		
Results	 101	 		Regnase-1	was	recently	shown	to	be	indispensable	for	Roquin-1-mediated	repression	of	 a	minimal	 response	 element	 from	TNF,	 the	most	 3’	 260	nts	 of	 its	 3’	UTR	 (termed	CDE260)	 (Figure	 18A).	 Moreover,	 Regnase-1	 overexpression	 in	 MEF	 cells	downregulated	 ICOS	 suggesting	 a	 cooperation	 of	 both	 proteins	 also	 on	 this	 3'UTR	(Jeltsch	et	al.,	2014).		
4.1.5 Regnase-1	 is	 dispensable	 for	 Roquin-1-mediated	 regulation	 of	
ICOS	We	 investigated	 whether	 Regnase-1	 is	 similarly	 important	 for	 Roquin-1-mediated	repression	of	 ICOS	 as	 it	 is	 for	TNF	mRNA.	Specifically,	Rc3h1/2-/-	MEF	cells	 and	MEF	cells,	which	are	deficient	 for	Regnase-1	(Zc3h12a-/-	MEF	cells),	were	transduced	with	reporter	constructs	consisting	of	the	ICOS	CDS	followed	by	either	the	TNF	CDE260	or	the	 complete	 3’	UTR	 of	 ICOS	 (Figure	 18A	 and	 B)	 as	 used	 in	 the	 RNAi	 screen.	Subsequently,	 the	 cells	 were	 superinfected	 with	 retroviruses	 encoding	 Roquin-1	 or	Regnase-1.	Reporter	expression	was	measured	using	flow	cytometry.	The	ICOS	mean	fluorescence	intensity	(MFI)	was	normalized	to	the	MFI	of	the	uninfected	control	cells	(Figure	 18C).	 Regnase-1-mediated	 regulation	 of	 the	 CDE260	 reporter	 was	 almost	completely	abolished	 in	Rc3h1/2-/-	MEF	cells,	while	reconstitution	with	Roquin-1	 led	to	a	10-fold	repression	of	reporter	expression	(Figure	18C).	Vice	versa,	overexpressed	Roquin-1	was	unable	 to	 repress	 the	CDE260	 reporter	 in	 the	 absence	of	 endogenous	Regnase-1	in	Zc3h12a-/-	MEF	cells,	while	reconstitution	with	Regnase-1	led	to	a	rescue	of	 reporter	 regulation.	 Thus,	 overexpressed	 Regnase-1	 and	 Roquin-1	 require	endogenous	amounts	of	each	other	for	the	repression	of	the	CDE260	reporter	from	the	
TNF	3’	UTR.			
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Figure	18:	Analysis	of	post-transcriptional	regulation	of	the	TNF	CDE260	or	full-length	ICOS	by	
Roquin-1	and	Regnase-1.	
(A)	Schematic	representation	of	the	TNF	mRNA.	The	CDE260	reporter	element	comprises	the	most	3’	
260	nts	of	the	TNF	3’	UTR,	including	the	constitutive	decay	element	(CDE)	stem-loop	that	is	recognized	
by	 Roquin-1.	 (B)	 Schematic	 representation	 of	 ICOS	 mRNA	 used	 as	 a	 reporter	 in	 the	 RNAi	 screen	
including	 the	 ~2	 kb	 long	 3’	UTR.	 (C)	Rc3h1/2-/-	 or	Zc3h12a-/-	 MEF	 cells	 were	 transduced	with	 the	CDE260	 or	 ICOS	 3’	UTR	 reporters	 that	were	 cloned	downstream	of	 the	CDS	of	 ICOS.	 The	 cells	were	
superinfected	with	Roquin-1	or	Regnase-1	encoding	retroviruses	and	ICOS	expression	was	analyzed	by	
flow	cytometry	after	48	h.	ICOS	MFI	of	each	sample	was	normalized	to	the	average	of	the	uninfected	
control.	This	data	set	was	provided	by	Dr.	Sven	Brenner.		
Analyzing	 the	3’	UTR	of	 ICOS	 on	 the	other	hand	showed	 that	 the	respective	 reporter	could	 be	 repressed	 by	 Regnase-1	 in	 Rc3h1/2-/-	 MEF	 cells	 to	 at	 least	 twofold.	 Most	importantly	however,	Roquin-1	was	 able	 to	 strongly	 repress	 ICOS	 in	Zc3h12a-/-	MEF	cells	 in	 the	 absence	 of	 Regnase-1,	 indicating	 that	 Roquin-1	 and	 Regnase-1	 can	 also	work	 independently	 of	 each	 other	 on	 certain	 target	 transcripts,	 such	 as	 ICOS.	 This	result	 clearly	 demonstrates	 that	 Regnase-1	 is	 unlikely	 to	 be	 an	 essential	 cofactor	 of	Roquin-1	 under	 the	 conditions	 used	 in	 the	 screen	 and	 hence	 cannot	 be	 expected	among	the	candidate	genes	of	the	target	list.	
4.1.6 Establishment	of	a	target	list	of	candidate	genes		29	 candidates	 arising	 from	 the	 primary	 customized	 screen	 (Figure	 17)	 with	 a	 Z	score	>	2	and	with	an	mCherry	expression	that	was	not	more	than	threefold	reduced	as	compared	to	the	non-targeting	control	are	listed	in	Table	27.	Within	each	group	of	genes	(indicated	by	different	shades	of	gray)	candidates	were	ranked	according	to	the	
Results	 103	 		increase	 in	 ICOS	 expression	 (ICOS	MFI)	 that	was	 observed	 upon	 siRNA	 knockdown.	Known	 regulators	 (CNOT1,	 EDC4)	 as	 well	 as	 positive	 (Rc3h1)	 and	 negative	 (Ctrl)	controls	were	included	as	references.		
Table	27:	Ranked	candidate	list	of	the	customized	siRNA	screen.		
	
	
Gene	name	 Gene	ID	 Gene	subset	 ICOS	MFI	
YTHDC2	 64848	 RNA-binding	protein	 275	
TRUB1	 142940	 RNA-binding	protein	 228	
STAU1	 6780	 RNA-binding	protein	 182.5	
TES	 26136	 RNA-binding	protein	 167.5	
SF1	 7536	 RNA-binding	protein	 166	
ZC3H10	 84872	 RNA-binding	protein	 160	
GTF2E2	 2961	 RNA-binding	protein	 159	
NUFIP2	 57532	 RNA-binding	protein	 157.5	
RPGR	 6103	 RNA-binding	protein	 154.8	
TNRC6A	 27327	 RNA-binding	protein	 154.5	
PTBP2	 58155	 RNA-binding	protein	 149	
ZYX	 7791	 RNA-binding	protein	 125	
DYNC1H1	 1778	 RNA-binding	protein	 113.5	
WDR6	 11180	 RNA-binding	protein	 110	
SARS	 6301	 RNA-binding	protein	 103.65	
CSTF3	 1479	 RNA-binding	protein	 216.5	
GTF2H3	 2967	 RNA-binding	protein	 173	
C2orf60	 129450	 RNA-binding	protein	 166.5	
SNRPN	 6638	 RNA-binding	protein	 164.5	
DHFR	 1719	 RNA-binding	protein	 129	
HEXIM2	 124790	 RNA-binding	protein	 127	
SF4	 57794	 RNA-binding	protein	 118.5	
DDX11	 1663	 RNA-binding	protein	 97.2	
AGL	 178	 P	body	formation	 99.2	
ATP2A1	 487	 Stress	granule	formation	 291	
C9ORF115	 138428	 Stress	granule	formation	 136.5	
PLAUR	 5329	 Stress	granule	formation	 127	
SFRS2B	 10929	 Stress	granule	formation	 117	
EIF3S7	 8664	 Stress	granule	formation	 106.6	
Roquin-1	 	 Positive	control	 279.5	
CNOT1	 23019	 Validated	cofactor	 136.5	
EDC4	 23644	 Validated	cofactor	 108	
Ctrl	 -	 Non-targeting	control	 38.1	
104	 Results			23	proteins	were	derived	from	the	subset	of	RNA-binding	proteins,	whereas	only	one	P	 body	 factor	 and	 five	 stress	 granule	 factors	 made	 it	 into	 the	 list	 of	 new	 potential	cofactors	of	Roquin-1-mediated	ICOS	repression.		
4.1.7 Deconvolution	of	siRNA	pools	identifies	false	positive	hits	For	 further	 validation	 14	 RNA-binding	 candidates	with	 a	 high	 derepression	 of	 ICOS	were	 chosen	 from	 Table	 27.	 As	 already	 performed	 for	 candidates	 arising	 from	 the	ubiquitin	 conjugation	screen	 (Chapter	4.1.4.2),	our	primary	validation	approach	was	cloning	 and	 overexpression	 of	 the	 selected	 candidates	 in	 an	 ICOS	 reporter	 cell	 line,	expecting	 further	 downregulation	 of	 ICOS	 after	 candidate	 overexpression.	 12	 RBP	candidates	were	successfully	cloned	and	overexpressed	in	the	exact	HeLa	reporter	cell	line	 of	 the	 screen.	However,	 as	 observed	 before	 (Figure	 16),	 none	 of	 the	 candidates	could	downregulate	ICOS	(Appendix	I).	This	approach	was	consequently	dropped	for	multiple	 reasons.	 First	 of	 all,	 although	 Thy1.1	 was	 used	 as	 a	 marker	 for	 retroviral	infection,	this	does	not	guarantee	that	the	candidate	protein	is	likewise	expressed	and	functional.	For	confirmation,	one	would	have	 to	establish	 immunoblotting	assays	 for	each	 single	 candidate,	 which	 is	 both	 expensive	 and	 time-consuming.	 Furthermore,	even	if	candidate	overexpression	was	successfully	accomplished,	 it	 is	not	guaranteed	that	increased	levels	of	Roquin	cofactors	will	 lead	to	further	downregulation	of	ICOS.	When	 a	 candidate	 protein	 is	 highly	 expressed	 at	 endogenous	 levels,	 Roquin	 might	already	be	saturated	with	 this	cofactor,	 so	 that	 its	overexpression	would	not	 further	contribute	 to	 ICOS	repression.	Overall,	 since	cloning	of	multiple	candidates	demands	high	 efforts,	 but	 the	 outcome	 of	 overexpression	 is	 rather	 uncertain,	 this	 method	appeared	to	be	not	particularly	suited	for	validation	of	primary	screen	candidates.		Since	overexpression	experiments	had	been	unsuccessful,	I	decided	to	rather	validate	candidates	 by	 deconvoluting	 all	 siRNA	 pools	 and	 compare	 phenotypic	 effects	 with	knockdown	 efficiencies	 for	 the	 individual	 siRNAs.	 This	 approach	 allows	 to	discriminate	between	genuine	hits	 and	 false	positive	 results,	 since	 sequence-specific	off-target	effects	are	often	caused	by	one	 individual	 siRNA	 in	 the	pool,	which	can	be	identified	by	a	low	knockdown	efficiency	of	the	target	mRNA	in	combination	with	an	inexplicably	 strong	 phenotypic	 effect.	 The	 known	 cofactor	 CNOT1	 was	 included	 to	serve	as	an	internal	positive	control.		For	CNOT1	a	clear	correlation	between	knockdown	efficiency	and	derepression	of	the	ICOS	 reporter	was	 observed.	 Each	 single	 siRNA	 of	 the	 pool	 led	 to	 a	 derepression	 of	
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ICOS,	and	the	decrease	of	CNOT1	mRNA	correlated	inversely	with	ICOS	levels	(Figure	19).	This	confirmed	that	CNOT1	was	indeed	a	positive	control	in	the	screen.		
	
Figure	 19:	 Deconvolution	 of	 the	 CNOT1	 siRNA	 pool	 confirms	 its	 role	 as	 an	 internal	 positive	
control	of	the	siRNA	screen.	
(A)	Flow	cytometric	analysis	of	ICOS	and	mCherry	expression	in	HeLa	reporter	cells	after	doxycycline-
induction	of	Roquin-1.	Cells	were	treated	with	the	CNOT1-targeting	siGENOME	siRNA	pool	used	in	the	
screen	or	the	four	individual	siRNAs	as	indicated	(red	population).	For	comparison,	cells	treated	with	
a	non-targeting	control	siRNA	are	shown	in	black.	(B)	Quantified	ICOS	MFI	shown	in	(A).	Expression	
was	normalized	to	the	average	of	the	non-targeting	control,	which	was	set	to	1.	(C)	qPCR	analysis	of	CNOT1	mRNA	 expression	 in	 cells	 from	 (A).	 Expression	was	 calculated	 relative	 to	 the	 housekeeping	
gene	YWHAZ	and	normalized	to	the	average	of	the	non-targeting	control.	Shown	is	one	representative	
of	 three	 independent	 experiments	 (A)	 or	 mean	 and	 standard	 deviation	 of	 three	 independent	
experiments	(B,	C).	Statistical	significance	in	(B)	was	calculated	with	one-way	Anova	Kruskal-Wallis	
test	followed	by	Dunn’s	multiple	comparisons	test	(**p<0.01).		
Of	the	remaining	13	candidates,	surprisingly,	12	did	not	pass	this	primary	validation	step.	Regularly,	 one	 single	 siRNA	was	 identified	 to	dominate	 the	performance	of	 the	siRNA	pool,	which	potentially	 reflects	 the	 result	of	 an	off-target	effect	 (Appendix	 II).	For	 five	 candidates,	 two	out	of	 four	 individual	 siRNAs	were	phenotypically	effective,	but	 their	 knockdown	 efficiency	 did	 not	 correlate	 well	 with	 the	 effect	 on	 ICOS	expression	 (Appendix	 III).	 One	 representative	 of	 this	 group	 was	 the	 mammalian	TNRC6A,	 also	 known	 as	GW182.	 The	mammalian	TNRC6A	 and	 its	 paralogs	TNRC6B	
106	 Results			and	 TNRC6C	 play	 an	 important	 role	 in	 miRNA-induced	 gene	 repression	 (Chapter	1.1.3).	 They	 are	 recruited	 to	 target	 mRNAs	 to	 induce	 translational	 inhibition	 and	deadenylation-dependent	mRNA	decay	(Chapter	1.1.1)(Lazzaretti	et	al.,	2009).	It	was	recently	reported	that	Roquin-1	directly	 interacts	with	the	RISC	component	Ago2	on	the	mouse	Icos	3’	UTR	(Srivastava	et	al.,	2015),	proposing	that	Roquin-1	might	induce	deadenylation-dependent	 mRNA	 decay	 via	 the	 miRNA	 pathway	 of	 gene	 silencing.	These	findings	make	TNRC6A	an	attractive	potential	cofactor	of	Roquin-1,	warranting	further	investigations.		HeLa	 reporter	 cells	 were	 treated	 either	 with	 the	 TNRC6A-targeting	 pool	 of	 four	siRNAs	or	with	each	 individual	siRNA	prior	 to	 induction	of	Roquin-1-overexpression	(Figure	 20A).	 Flow	 cytometric	 analysis	 of	 ICOS	 and	 mCherry	 expression	 clearly	showed	 that	 the	 derepression	 of	 ICOS	 in	 response	 to	 TNRC6A	 knockdown	with	 the	siRNA	 pool	was	mediated	 by	 two	 individual	 siRNAs,	 siTNRC6A#2	 and	 siTNRC6A#3,	with	 #3	 causing	 the	 strongest	 increase	 in	 ICOS	 levels	 (Figure	 20A,	 B).	 However,	mCherry	expression,	which	was	only	slightly	reduced	after	knockdown	with	the	siRNA	pool,	 was	 strongly	 reduced	 in	 response	 to	 treatment	 with	 siRNA#3,	 indicating	decreased	expression	of	Roquin-1-P2A-mCherry.	This	effect	was	obviously	masked	in	the	 pool	 by	 the	 two	other,	 non-responsive	 siRNAs.	 qPCR	 analysis	 of	 TNRC6A	mRNA	expression	 revealed	 a	 strong	 knockdown	 of	 TNRC6A	 expression	 with	 siRNA#2	 and	siRNA#4,	 while	 the	 functionally	 most	 effective	 siRNA#3	 showed	 no	 reduction	 of	mRNA	expression	at	all	(Figure	20C).	Since	TNRC6A,	-B	and	–C	are	closely	related,	we	wondered	whether	the	strong	phenotypic	effect	of	siTNRC6A#3	could	be	explained	by	an	off-target	knockdown	of	TNRC6B	and	TNRC6C.	This	has	been	observed	before	for	the	septin	protein	family	(Sharma	et	al.,	2013).	Before	examining	off-target	effects	of	TNRC6A-targeting	siRNAs	on	other	family	members,	the	expression	levels	of	TNRC6A,	TNRC6B	and	TNRC6C	were	determined	in	HeLa	cells	(Figure	20D).	TNRC6A	was	most	prominently	expressed,	 followed	by	TNRC6B.	Since	TNRC6C	showed	a	10-fold	 lower	expression	 as	 compared	 to	 its	 family	 members,	 we	 evaluated	 off-target	 effects	 of	TNRC6A	knockdown	on	TNRC6B	only.	Of	note,	none	of	the	TNRC6A-targeting	siRNAs	caused	a	decrease	in	TNRC6B	expression.	In	line	with	this,	sequence	alignment	of	the	TNRC6A-targeting	 siRNAs	 showed	 frequent	 seed-sequence	 matching,	 but	 no	 full	complementarity	of	any	individual	TNRC6A-targeting	siRNA	with	TNRC6B	mRNA.	This	experiment	 clearly	 indicates	 that	 TNRC6A-targeting	 siRNAs	 are	 well	 designed	 and	cause	 no	 off-target	 knockdown	 of	 the	 paralog	 TNRC6B.	 Since	 the	 results	 of	 siRNA	deconvolution	were	inconclusive	at	best,	TNRC6A	was	not	evaluated	any	further.		
Results	 107	 		
	
Figure	20:	Deconvolution	of	siRNA	pools	identifies	TNRC6A	as	a	false	positive	hit.	
(A)	Flow	cytometric	analysis	of	ICOS	and	mCherry	expression	in	HeLa	reporter	cells	after	doxycycline-
induction	of	Roquin-1.	Cells	were	treated	with	the	TNRC6A-targeting	siRNA	pool	used	in	the	screen	or	
the	 four	 individual	 siRNAs	as	 indicated	 (red	population).	 Cells	 treated	with	 a	 non-targeting	 control	
siRNA	are	shown	 in	black.	(B)	Quantified	 ICOS	MFI	shown	 in	(A).	Expression	was	normalized	 to	 the	
average	 of	 the	 non-targeting	 control,	 which	 was	 set	 to	 1.	 (C)	 qPCR	 analysis	 of	 TNRC6A	 mRNA	
expression	in	cells	from	(A).	Expression	was	calculated	relative	to	the	housekeeping	gene	YWHAZ	and	
normalized	to	the	average	of	the	non-targeting	control.	(D)	qPCR	analysis	of	TNRC6A,	TNRC6B	and	TNRC6C	mRNA	expression	in	wt	HeLa	cells.	mRNA	expression	relative	to	YWHAZ	was	calculated	with	
the	ΔΔCt	method	using	the	primer	efficiencies	determined	with	standard	curves.	(E)	qPCR	analysis	of	TNRC6B	 mRNA	 expression	 in	 cells	 from	 (A).	 Error	 bars	 show	 standard	 deviation	 of	 two	 (B,	 C)	
independent	experiments	or	two	technical	replicates	(D,	E).	
108	 Results			Apart	from	CNOT1,	flawless	results	for	four	individual	siRNAs	were	only	obtained	for	one	more	candidate:	the	NUFIP2	protein.	Similar	to	CNOT1,	most	individual	NUFIP2-targeting	 siRNAs	 caused	 strongly	 derepressed	 ICOS,	 except	 for	 siRNA#3,	 which	however	also	showed	the	lowest	knockdown	efficiency	(Figure	21).		
	
	
Figure	21:	Deconvolution	of	 the	NUFIP2	siRNA	pool	shows	a	strong	correlation	between	ICOS	
derepression	and	knockdown	of	NUFIP2	mRNA.		
(A)	Flow	cytometric	analysis	of	ICOS	and	mCherry	expression	in	HeLa	reporter	cells	after	doxycycline-
induction	of	Roquin-1.	Cells	were	treated	with	the	NUFIP2-targeting	siGENOME	siRNA	pool	used	in	the	
screen	or	the	four	individual	siRNAs	as	indicated	(red	population).	For	comparison,	cells	treated	with	
a	non-targeting	control	siRNA	are	shown	in	black.	(B)	Quantified	ICOS	MFI	shown	in	(A).	Expression	
was	normalized	to	the	average	of	the	non-targeting	control,	which	was	set	to	1.	(C)	qPCR	analysis	of	NUFIP2	mRNA	expression	 in	 cells	 from	 (A).	 Expression	was	 calculated	 relative	 to	 the	housekeeping	
gene	YWHAZ	and	normalized	to	the	average	of	the	non-targeting	control.	Shown	is	one	representative	
of	 three	 independent	 experiments	 (A)	 or	 mean	 and	 standard	 deviation	 of	 three	 independent	
experiments	(B,	C).	Statistical	significance	in	(B)	was	calculated	with	one-way	Anova	Kruskal-Wallis	
test	followed	by	Dunn’s	multiple	comparisons	test	(**p<0.01).		
ICOS	derepression	caused	by	knockdown	of	NUFIP2	with	 the	siRNA	pool	was	highly	significant	and	even	outperformed	the	effect	of	CNOT1	(Figure	22A).	The	knockdown	efficiency	 of	 the	 NUFIP2	 siRNA	 pool	 was	 close	 to	 90	%	 on	 the	 mRNA	 level	 (Figure	22B).	For	validation	of	NUFIP2	protein	knockdown,	a	NUFIP2	 immunoblotting	assay	was	 established	 using	 a	 commercially	 available	 polyclonal	 anti-NUFIP2	 antibody.	
Results	 109	 		Immunoblotting	confirmed	the	decrease	of	protein	expression	in	agreement	with	the	qPCR	analysis	(Figure	22C).		
	
	
Figure	22:	Knockdown	of	NUFIP2	leads	to	a	strong	derepression	of	ICOS.	
(A)	 Quantified	 mean	 fluorescence	 intensity	 (MFI)	 of	 ICOS	 expression	 after	 siRNA	 knockdown	 of	
NUFIP2	and	CNOT1	in	HeLa	reporter	cells.	Cells	were	treated	with	siGENOME	siRNA	pools,	and	ICOS	
expression	was	determined	by	flow	cytometry.	(B)	qPCR	analysis	of	NUFIP2	mRNA	expression	in	HeLa	
reporter	 cells	 after	 treatment	 with	 the	 siGENOME	 NUFIP2	 siRNA	 pool.	 Expression	 relative	 to	 the	
housekeeping	gene	YWHAZ	was	normalized	to	the	non-targeting	control	(C)	Immunoblot	analysis	of	
NUFIP2	expression	in	HeLa	reporter	cells	upon	NUFIP2	knockdown.	Error	bars	represent	mean	and	SD	
of	 three	 (A)	 and	 two	 (B)	 independent	 experiments.	 In	 (C)	 one	 representative	 of	 two	 independent	
experiments	 is	 shown.	 Statistical	 significance	 in	 (A)	 was	 calculated	 with	 one-way	 Anova	 Kruskal-
Wallis	test	followed	by	Dunn’s	multiple	comparisons	test	(*p<0.05).		
Overall,	 siRNA	 deconvolution	 allowed	 the	 discrimination	 between	 true	 hits	 and	 off-target	 effects	 and	 identified	 NUFIP2	 as	 the	 sole	 remaining	 RNA-binding	 candidate	from	 our	 customized	 RNAi	 screen.	 For	 validation	 of	 candidates	 from	 one	 of	 the	 six	protein	 subset	 screens	 performed	 before,	 siRNA	 deconvolution	 should	 therefore	 be	the	method	 of	 choice.	 Employing	 it	 on	 selective	 candidates	 arising	 from	 the	 protein	kinase	 screen	 identified	 two	 kinases,	 PI4KA	 and	 STK38,	 for	which	 a	 strong	 positive	correlation	 between	 knockdown	 efficiency	 and	 the	 phenotypic	 effect	 is	 seen	 with	multiple	 individual	siRNAs	(Appendix	 IV).	This	confirms	that	siRNA	deconvolution	 is	the	 best	 way	 of	 identifying	 promising	 candidates	 for	 follow-up	 validation.	 NUFIP2	from	 the	 RBP	 subset	was	 subsequently	 chosen	 for	 functional	 validation.	 The	 strong	
ICOS	derepression	after	NUFIP2	knockdown	and	the	fact	that	 it	 is	an	RNA-binding	of	unknown	 function	 with	 only	 three	 references	 in	 the	 literature	 made	 it	 a	 perfect	candidate	for	further	exploration.		
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4.1.8 Functional	validation	of	NUFIP2	as	a	cofactor	of	Roquin		
4.1.8.1 Rescue	through	expression	of	siRNA-resistant	NUFIP2		In	order	to	unambiguously	prove	that	the	strong	derepression	of	ICOS	 in	response	to	
NUFIP2	 knockdown	 in	HeLa	cells	was	 indeed	caused	by	a	 loss	of	NUFIP2	 function,	a	NUFIP2	expression	construct	was	designed	to	contain	six	silent	mutations	rendering	it	immune	to	siRNA	(siNUFIP2#2)	targeting	(Figure	23).		
	
	
Figure	23:	Generation	of	NUFIP2-targeting	siRNA#2	resistant	NUFIP2	cDNA.	
Schematic	 representation	 of	 the	 target	 sites	 of	 NUFIP2-targeting	 siRNAs	 #1-4	 (blue)	 in	 the	 coding	
sequence	 (CDS)	 of	NUFIP2	 mRNA.	 Six	 silent	 mutations	 (red)	 were	 inserted	 into	 the	 NUFIP2	 cDNA	
sequence	 to	 create	an	 siRNA#2-resistant	 (si.-res.)	NUFIP2	overexpression	 construct.	The	amino	acid	
(aa)	sequence	was	not	altered	(shown	in	grey).		
HeLa	 reporter	 cells	 with	 stable	 ICOS-	 and	 doxycycline-inducible	 Roquin-1-P2A-mCherry	 expression	 were	 retrovirally	 transduced	 to	 express	 siNUFIP2#2-resistant	GFP-NUFIP2	 or	 GFP	 as	 a	 control.	 Immunoblot	 analysis	 of	 NUFIP2	 levels	 confirmed	overexpression	of	GFP-NUFIP2	as	well	as	the	presence	of	endogenous	NUFIP2	(Figure	24A).	 GFP-	 or	 GFP-NUFIP2-overexpressing	 cells	 were	 subsequently	 treated	 with	siNUFIP2#2,	 siNUFIP2#4	 or	 non-targeting	 control	 siRNAs,	 and	 ICOS	 and	 GFP	expression	 were	 measured	 by	 flow	 cytometry	 after	 doxycycline-induced	 Roquin-1	overexpression.	 ICOS	 expression	 was	 analyzed	 after	 gating	 on	 populations	 of	 low,	intermediate	 and	 high	 GFP	 expression	 for	 each	 sample	 (Figure	 24B).	 ICOS	MFI’s	 of	siNUFIP2-treated	samples	were	normalized	to	the	MFI’s	of	samples	treated	with	non-targeting	controls	(Figure	24C,	D).	A	4-fold	increase	of	ICOS	expression	was	observed	after	NUFIP2	knockdown	with	siRNA#2,	which	was	rescued	by	the	overexpression	of	siRNA#2-resistant	GFP-NUFIP2	(Figure	24C).		
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Figure	24:	Overexpression	of	siRNA-resistant	NUFIP2	rescues	ICOS	repression.	
(A)	 Immunoblot	 analysis	 of	 NUFIP2	 expression	 in	 whole	 cell	 lysates	 from	 HeLa	 cells	 retrovirally	
transduced	 to	 express	 siNUFIP2#2-resistant	 NUFIP2	 or	 GFP.	 Analysis	 was	 performed	 using	 bulk	
populations	 prior	 to	 siRNA	 knockdown.	 (B)	 Flow	 cytometric	 analysis	 of	 GFP	 expression	 in	 HeLa	
reporter	 cells	 with	 stable	 ICOS	 and	 doxycycline-inducible	 Roquin-1-P2A-mCherry	 expression	 after	
retroviral	overexpression	of	 siNUFIP2#2-resistant	GFP-NUFIP2	or	GFP.	Gates	 for	GFP-high	 (GFPhi),	 -
intermediate	(GFPint)	or	-low	(GFPlo)	expressing	cells	are	indicated.	(C)	Quantified	ICOS	expression	of	
siNUFIP2#2	targeted	GFPlo,	GFPint	and	GFPhi	populations	 from	(B).	 ICOS	MFI	of	each	GFP-expressing	
population	of	NUFIP2-siRNA#2	 treated	cells	was	normalized	 to	 ICOS	MFI	 in	 the	 same	population	of	
cells	treated	with	a	non-targeting	control	(siCtrl),	which	was	set	to	1.	(D)	Quantified	ICOS	expression	
of	 siNUFIP2#4	 targeted	 GFPlo	 and	 GFPmed	 populations	 from	 (B).	 ICOS	 MFI	 of	 each	 GFP-expressing	
population	of	NUFIP2-siRNA#4	 treated	cells	was	normalized	 to	 ICOS	MFI	 in	 the	 same	population	of	
cells	treated	with	a	non-targeting	control	(siCtrl),	which	was	set	to	1.	(B)	shows	one	representative	of	
three	independent	experiments,	(C)	and	(D)	show	mean	and	standard	deviation	of	three	independent	
experiments.	 Statistical	 significance	 in	 (C)	 was	 calculated	 with	 one-way	 Anova	 Kruskal-Wallis	 test	
followed	by	Dunn’s	multiple	comparisons	test	(*p<0.05).		
112	 Results			The	rescue	effect	occurred	in	a	concentration-dependent	manner.	In	the	cells	with	the	strongest	 GFP-NUFIP2	 expression,	 ICOS	 expression	 almost	 reached	 the	 level	 of	 the	non-targeting	 control,	 indicating	 that	 Roquin-1-dependent	 post-transcriptional	regulation	 of	 ICOS	 was	 completely	 restored.	 Overexpression	 of	 GFP	 alone	 did	 not	rescue	ICOS	regulation,	even	at	high	expression	 levels.	When	NUFI2	knockdown	was	performed	 with	 siRNA#4	 instead	 of	 siRNA#2,	 overexpressed	 siNUFIP2#2-resistant	GFP-NUFIP2	 was	 obviously	 silenced,	 resulting	 in	 a	 loss	 of	 GFPhi-expressing	 cells	(Figure	24B,	upper	right).	Quantification	of	ICOS	expression	in	the	remaining	GFP-low	and	 -intermediate	 expressing	 populations	 showed	 no	 impact	 of	 GFP-NUFIP2	 on	derepressed	ICOS	levels	(Figure	24D)	neither	did	GFP	in	the	cells	transduced	with	the	GFP-control.		
4.1.8.2 Rescue	of	Roquin-1-mediated	ICOS	repression	in	Nufip2-/-	MEF	cells	As	 a	 final	 proof	 that	 loss	 of	 Nufip2	 leads	 to	 inhibition	 of	 ICOS	 repression,	 the	CRISPR/Cas9	 gene	 editing	 system	 was	 employed	 to	 generate	 a	 pool	 of	 Nufip2	knockout	cells.	The	CRISPR/Cas9	system	makes	use	of	single	guide	RNAs	(sgRNAs)	to	direct	the	endonuclease	Cas9	to	a	genomic	 locus	of	 interest,	where	 it	 induces	double	strand	 breaks	 (Chapter	 1.2.2).	 These	 are	 usually	 repaired	 by	 non-homologous	 end-joining	(NHEJ),	an	error-prone	mechanism	that	often	causes	untemplated	insertions	or	deletions	(indels)	of	nucleotides	and	consequently	the	disruption	of	the	reading	frame	of	 the	 target	 gene	 (Jinek	 et	 al.,	 2013).	 It	 is	 thus	 a	 useful	 tool	 to	 generate	 Nufip2-deficient	MEF	cells.		Four	 different	 sgRNAs	were	 designed	 to	 target	 the	 second	 exon	 of	 the	Nufip2	 gene	locus.	Along	with	 two	non-targeting	 sgRNAs,	 the	 four	Nufip2-targeting	 sgRNAs	were	cloned	into	the	lentiCRISPR	vector,	which	additionally	contains	an	open	reading	frame	to	 express	 a	 humanized,	 nuclear	 localization	 signal	 (NLS)-bearing	 Cas9	 gene.	 The	knockout	efficiency	of	each	sgRNA	was	first	tested	in	wildtype	MEF	cells	(Figure	25A).	All	 sgRNAs	 caused	 a	 reduction	 in	 Nufip2	 protein	 expression	 as	 analyzed	 by	immunoblot	 analysis,	 with	 sgRNA#4	 causing	 the	 most	 efficient	 knockout	 of	 Nufip2	expression	(Figure	25A).	Figure	25B	shows	the	targeting	strategy	of	sgRNA#4.		In	 a	 second	 step	 Rc3h1/2fl/fl	 Cre	 ERT2	MEF	 cells,	 a	 cell	 line	 in	 which	 endogenous	Roquin-1	and	-2	can	be	deleted	by	4-OH-tamoxifen-induced	nuclear	translocation	of	a	Cre	 recombinase,	 were	 lentivirally	 transduced	 to	 transcribe	 the	 mouse	 Nufip2-targeting	sgRNA#4	and	Cas9.	Disruption	of	the	Nufip2	coding	sequence	resulted	in	an	
Results	 113	 		approximately	70-80	%	reduction	of	Nufip2	protein	levels	in	the	bulk	cell	populations,	as	 judged	 by	 immunoblotting	 (Figure	 25C).	 It	 should	 be	 mentioned	 here	 that	 the	results	 of	 Nufip2	 knockdown	 (Figure	 22C)	 and	 -knockout	 (Figure	 25C)	may	 appear	similar	while	 they	are	not.	 siRNA-mediated	knockdowns	usually	 reduce	 the	 levels	of	the	 targeted	 protein	 in	 all	 cells	 similarly.	 This	 may	 not	 be	 sufficient	 to	 detect	 the	anticipated	 phenotype,	 because	 the	 cellular	mechanism	 of	 interest	 might	 also	 work	with	 decreased	 protein	 levels.	 However,	 if	 the	 knockdown	was	 sufficient	 to	 cause	 a	phenotypic	 effect,	 this	 should	 equally	 affect	 all	 cells	 in	 the	pool.	 In	 contrast,	 sgRNAs	either	lead	to	double	strand	breaks	or	do	not.	This	means	that	in	the	cells	in	which	the	sgRNA	was	effective	to	generate	a	knockout,	the	anticipated	phenotype	can	definitely	be	observed	if	present,	but	wildtype	cells	in	the	bulk	population	may	mask	the	effect.	
	
	
Figure	25:	Generating	Nufip2	knockout	MEF	cells	using	the	CRISPR/Cas9	system.	
(A)	 Immunoblot	 analysis	 of	 Nufip2	 expression	 in	 whole	 cell	 lysates	 from	 wildtype	 MEF	 cells	 after	
transduction	with	lentiCRISPR-encoded	Cas9	nuclease	and	different	Nufip2-targeting	sgRNAs	or	non-
targeting	controls	(NT1,	NT2).	Whole	cell	lysates	were	prepared	10	days	after	transduction	to	provide	
time	 for	 the	 gene	 editing	process	 to	 take	place.	 (B)	 Schematic	 representation	 of	mNufip2	 sgRNA#4	
targeting	its	complementary	genomic	sequence	in	the	second	exon	of	Nufip2.	Cas9	nuclease	binds	the	
sgRNA	and	subsequently	cleaves	both	strands	of	the	genomic	DNA,	leading	to	NHEJ,	indels	and	finally	
gene	inactivation	(Mali	et	al.,	2013).	Exons	are	depicted	as	grey	boxes,	whereas	introns	are	indicated	
by	black	lines.	(C)	Immunoblot	analysis	of	Nufip2	expression	in	whole	cell	lysates	from	Rc3h1/2fl/fl	Cre	ERT2	MEF	cells	that	were	transduced	with	lentiCRISPR	mNufip2	sgRNA#4	or	left	untransduced.		
In	 order	 to	 perform	 rescue	 experiments	 with	 this	 pool	 of	 Nufip2	 knockout	 cells,	 I	cloned	 an	 sgRNA-resistant	 NUFIP2	 cDNA.	 Since	 the	 lentiCRISPR	 vector	 sequence	stably	 integrates	 into	 host	 genomes,	 the	 cell	 pool	 will	 maintain	 sgRNA-	 and	 Cas9	expression	 throughout	 the	 whole	 experiment,	 thereby	 cleaving	 any	 Nufip2	 DNA	sequence	 that	 resembles	 the	 genomic	 target	 sequence.	 To	 circumvent	 this	 problem,	
114	 Results			the	human	NUFIP2	cDNA	was	used	as	a	basis	for	the	rescue	construct,	since	it	already	contains	natural	mismatches	to	the	mouse	genomic	sequence.	Further	silent	mutations	were	 introduced	 as	 depicted	 in	 Figure	 26A	 to	 render	 the	 site	 immune	 against	sgRNA#4/Cas9	recognition.		
	
	
Figure	26:	Rescue	of	Roquin-1-mediated	ICOS	repression	in	Nufip2	knockout	cells.		
(A)	 Schematic	 representation	 of	 mouse	 Nufip2-sgRNA#4-resistant	 human	 NUFIP2	 cDNA	 sequence.	
Several	mutations	were	introduced	in	order	to	prevent	base	pairing	with	sgRNA#4	and	to	protect	the	
human	cDNA	sequence	from	Cas9	cleavage.	Differences	to	the	wildtype	sequence	are	shown	in	orange.	
(B)	 Immunoblot	analysis	of	Nufip2	and	Roquin-1	expression	 in	Rc3h1/2fl/fl	Cre	ERT2	MEF	 cells	 that	
were	 first	 transduced	with	 lentiCRISPR	mNufip2	 sgRNA#4	 to	knock	out	Nufip2	expression	and	 then	
superinfected	with	different	amounts	of	sgRNA#4-resistant	NUFIP2	cDNA	or	an	empty	control	vector.	
Cells	were	 subsequently	 treated	with	4-OH-tamoxifen	 (+4-OH-TAM)	 for	6	days	 to	delete	endogenous	
Roquin-1	 and	 -2	 expression	 or	 left	 untreated	 (-4-OH-TAM).	 (C)	 Flow	 cytometric	 analysis	 of	 ICOS	
expression	in	cells	from	(B).		
Results	 115	 		Bulk	 Rc3h1/2fl/fl	Cre	 ERT2	MEF	 cells	 transduced	 with	 lentiCRISPR	 mNufip2#4	 as	 in	Figure	25C	were	transduced	with	the	complete	sequence	of	ICOS	mRNA	as	a	reporter.	Once	stable	ICOS	expression	was	achieved,	cells	were	superinfected	with	a	retroviral	vector	encoding	the	sgRNA#4-resistant	NUFIP2	or	an	empty	control	vector.	Cells	from	each	 transduction	were	 split	 into	 two	pools,	 and	were	 either	 left	 untreated	 or	were	treated	with	4-OH-tamoxifen	to	induce	deletion	of	Rc3h1	and	-2.	Immunoblot	analysis	confirmed	 deletion	 of	 Roquin-1	 and	 -2	 in	 response	 to	 4-OH-tamoxifen,	 as	 well	 as	overexpression	of	NUFIP2	(Figure	26B).	Flow	cytometric	analysis	of	 ICOS	expression	in	 untreated	 cells	 showed	 a	 clear	 downshift	 of	 ICOS	 expression	 in	 response	 to	overexpression	of	 increasing	amounts	of	NUFIP2,	which	was	not	 seen	 for	 the	empty	vector	 control	 (Figure	 26C).	 In	 cells	were	Roquin-1	 and	 -2	were	 deleted	with	 4-OH-tamoxifen,	rescue	of	Nufip2	expression	by	overexpression	of	sgRNA-resistant	NUFIP2	cDNA	 did	 not	 enhance	 post-transcriptional	 regulation	 of	 ICOS.	 These	 findings	 show	that	the	effect	of	Nufip2	is	dependent	on	the	presence	of	Roquin-1,	indicating	that	it	is	a	 true	 cofactor	 of	 Roquin-1	 and	 not	 a	 regulator	 of	 ICOS	 that	 works	 independent	 of	Roquin-1	 function.	The	question	whether	the	 inhibitory	effect	of	endogenous	Roquin	on	 ICOS	 is	 similarly	dependent	on	Nufip2	 could	not	be	 solved	 in	 this	 experiment.	 In	Nufip2	knockout	cells	without	the	rescue	construct	(Figure	26C	blue	curves)	ICOS	was	clearly	 upregulated	 in	 4-OH-tamoxifen-treated	 cells	 compared	 to	 untreated	 cells,	indicating	that	endogenous	Roquin	might	still	be	able	to	repress	ICOS	in	the	absence	of	Nufip2.	 The	 Nufip2	 knockout	 cell	 pool	 did,	 however,	 also	 contain	 cells	 where	 the	CRISPR/Cas9	deletion	of	Nufip2	was	not	effective,	as	observed	by	detection	of	residual	Nufip2	 in	protein	 lysates	 (Figure	25C),	which	might	be	responsible	 for	Roquin	being	still	able	to	regulate	ICOS	here.	To	solve	this,	we	will	use	the	pool	to	generate	a	clonal	cell	 line	 where	 both	 Nufip2	 alleles	 were	 deleted	 and	 repeat	 the	 experiment	 under	complete	knockout	conditions.		The	downshifts	of	 ICOS	expression	upon	re-expression	of	Nufip2	 that	were	achieved	with	 the	CRISPR/Cas9	 system	were	 considerably	 smaller	 than	observed	 in	 the	RNAi	rescue	 approach.	 In	 addition	 to	 the	 dependency	 of	 the	 repression	 on	 endogenous	instead	 of	 overexpressed	 Roquin,	 this	might	 as	well	 be	 caused	 by	 those	 cells	 in	 the	pool	 where	 Nufip2	 was	 not	 deleted,	 and	 repetition	 of	 the	 experiment	 in	 a	 Nufip2	knockout	clone	might	result	in	a	stronger	signal.	Still,	these	findings	confirmed	Nufip2	as	 a	 Roquin	 cofactor	 because	 the	 rescue	 effect	 could	 also	 be	 achieved	 in	 a	 different	species	 (mouse)	 and	 with	 a	 different	 method	 for	 Nufip2	 depletion	 (CRISPR/Cas9	knockout	versus	siRNA	knockdown).	
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4.1.9 Characterization	of	the	Roquin-1/Nufip2	interaction	Knowing	that	Nufip2	was	important	for	Roquin-1-mediated	repression	of	ICOS	mRNA,	we	 set	 out	 to	 explore	 its	 function	 in	 this	 pathway	 in	more	detail.	Nufip2	 is	 a	 hardly	investigated	 protein,	 with	 only	 few	 references	 in	 the	 literature.	 It	 was	 identified	 in	2003	 in	 a	 screening	 approach	 for	 interactors	 of	 the	 RNA-binding	 protein	 FMRP	(Chapter	1.1.4.1),	whose	 loss	causes	a	severe	mental	retardation	syndrome	(Bardoni	et	 al.,	 2003).	As	 an	unknown	protein	 that	 interacted	 specifically	with	FMRP,	but	not	with	 the	 highly	 homologous	 family	 members	 FXR1	 and	 FXR2,	 and	 furthermore	displayed	the	characteristic	nuclear-/cytoplasmic	expression	pattern	of	FMRP,	 it	was	termed	Nuclear	FMRP	Interaction	Partner	(NUFIP2).		RNA-binding	 ability	 was	 attributed	 to	 NUFIP2	 due	 to	 its	 capability	 of	 binding	polyadenylated	 RNA	 and	 its	 detection	 in	 polysomal	 fractions	 of	 sucrose	 gradients,	which	 indicated	 an	 association	 with	 mRNA	 in	 polyribosomal	 ribonucleoprotein	complexes	 (Bardoni	 et	 al.,	 2003).	 However,	 no	 RNA-binding	 domain	 or	 any	 other	known	 functional	 protein	 domain	 was	 predicted	 from	 the	 primary	 amino	 acid	sequence	 of	 NUFIP2	 so	 far.	 Using	 the	 DisEMBL	 server	 (http://dis.embl.de)	 the	prediction	for	NUFIP2	showed	that	large	areas	of	the	protein	have	a	high	probability	of	being	intrinsically	disordered	(personal	communication	with	Prof.	Dr.	Dierk	Niessing),	which	 is	 probably	 why	 no	 stable	 protein	 domains	 were	 identified	 so	 far.	 Our	knowledge	 about	 the	 domain	 organization	 of	 NUFIP2	 thus	 consists	 of	 an	 annotated	histidine-rich	 region	 in	 the	N-terminus	and	a	 serine-rich	 region	 in	 the	middle	of	 the	protein	(www.uniprot.org).	Additionally,	the	interaction	with	FMRP	has	been	mapped	to	amino	acid	255-411	of	NUFIP2	(Figure	27)	(Bardoni	et	al.,	2003).		
	
	
Figure	27:	Domain	organization	of	NUFIP2.		
The	domain	organization	of	NUFIP2	is	mostly	unknown	except	for	a	histidine-rich	(his-rich)	region	in	
the	N-terminal	part	and	a	serine-rich	region	(ser-rich)	in	the	middle	of	the	protein.	The	amino	acids	
255-411	of	NUFIP2	have	been	demonstrated	to	be	crucial	in	its	interaction	with	FMRP	(Bardoni	et	al.,	
2003;	Ramos	et	al.,	2006).		
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4.1.9.1 Investigating	protein/protein	interactions	of	Roquin-1	and	Nufip2	We	 wanted	 to	 find	 out	 whether	 or	 not	 Nufip2	 binds	 Roquin-1.	 For	 this	 purpose,	NUFIP2	 and	 GFP-Roquin-1	 were	 overexpressed	 in	 HEK293T	 cells.	 In	 these	experiments,	 NUFIP2	 could	 be	 co-immunoprecipitated	 with	 GFP-Roquin-1	 from	 cell	lysates	 using	 anti-GFP	 antibodies	 (Figure	 28A).	 The	 interaction	was	 not	 sensitive	 to	RNase	 treatment,	 indicating	 an	 RNA-independent	 protein/protein	 interaction.	 Yet,	although	 unlikely,	 it	 cannot	 be	 excluded	 that	 both	 proteins	 recognize	 the	 same	 cis-element	of	one	mRNA	or	 two	different	cis-elements	 in	 close	proximity	 to	each	other	that	may	protect	this	short	stretch	of	RNA	from	RNase	activity.		In	order	to	find	out	which	domain	in	Roquin-1	mediates	the	interaction	with	NUFIP2,	HEK293T	 cells	 were	 transfected	 with	 NUFIP2	 and	 GFP-tagged	 Roquin-1	 constructs	that	were	either	Roquin-1	 full-length	 (FL),	 an	N-terminal	 (aa	1-509)	or	 a	C-terminal	(aa	509-1130)	 fragment	of	Roquin-1	(Figure	28B).	 Interestingly,	only	 the	N-terminal	part	of	Roquin-1	was	able	to	pull-down	NUFIP2	(Figure	28C).	It	can	thus	be	concluded	that	the	interaction	between	Roquin-1	and	Nufip2	is	mediated	by	the	RING	finger,	the	ROQ/HEPN	 domain	 or	 the	 Zinc	 finger	 of	 Roquin-1.	 So	 far	 only	 the	 binding	 of	 the	enhancer	of	mRNA	decapping	4	(Edc4)	has	been	mapped	to	the	N-terminus	of	Roquin-1	(Glasmacher	et	al.,	2010).			
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Figure	28:	NUFIP2	and	Roquin-1	interact	in	an	RNase-independent	manner.		
(A)	 HEK293T	 cells	 overexpressing	 GFP-Roquin-1	 and	 human	 NUFIP2	 were	 lysed	 and	 the	 Roquin-1	
fusion	protein	was	immunoprecipitated	using	polyclonal	anti-GFP	antibodies.	Immunoblot	analysis	of	
NUFIP2	and	Roquin-1	after	anti-GFP	immunoprecipitation	(IP)	is	shown.	Samples	were	treated	during	
immunoprecipitation	 with	 or	 without	 RNase	 as	 indicated.	 Efficient	 degradation	 of	 rRNA	 by	 RNase	
treatment	was	 confirmed	 by	 Ethidium	 bromide	 staining	 of	 RNA	 extracts	 from	 IP	 supernatants.	 (B)	
Schematic	representation	of	mouse	Roquin-1	protein	domains.	Roquin-1	contains	a	RING	finger	with	
putative	 E3	 ubiquitin	 ligase	 activity,	 the	 RNA-binding	 ROQ	 domain	 embedded	 in	 an	 amino-	 and	 a	
carboxy-terminal		part	of	a	HEPN	domain,	a	CCCH-type	Zinc	finger	(ZnF)	with	potential	RNA-binding	
activity,	and	the	proline-rich	(pro-rich)	and	coiled-coil	(CC)	regions	at	the	C-terminus,	which	may	be	
involved	 in	 the	 protein/protein	 interactions	 with	 CCR4-NOT	 complexes	 (Schlundt	 et	 al.,	 2016).	 (C)	
Immunoblot	analysis	of	NUFIP2	and	GFP	expression	after	immunoprecipitation	of	protein	lysates	with	
polyclonal	 anti-GFP	 from	HEK293T	 cells	 overexpressing	human	NUFIP2	and	GFP-Roquin-1	FL,	GFP-
Roquin-1-N-term	 (aa	 1-509)	 or	 GFP-Roquin-1-C-term	 (aa	 509-1130).	 One	 representative	 of	 three	
independent	experiments	is	shown	in	(A)	and	(C).		
A	single	point	mutation	in	the	ROQ	domain	of	Roquin-1	(M199R)	is	responsible	for	the	severe	 autoimmune	 phenotype	 of	 the	 sanroque	 mouse,	 which	 is	 caused	 by	derepression	of	several	Roquin-1	target	mRNAs	in	response	to	Roquin-1	dysfunction	
Results	 119	 		(Vinuesa	 et	 al.,	 2005).	 Although	 this	 mutation	 is	 located	 in	 the	 RNA-binding	 ROQ-domain,	it	does	neither	disrupt	the	structure	of	the	RNA-binding	domain	nor	interfere	with	RNA-binding	(Srivastava	et	al.,	2015).	It	also	does	not	seem	to	play	a	major	role	in	selecting	 RNA	 binders	 (Janowski	 et	 al.,	 2016).	 It	 can	 therefore	 be	 assumed	 that	 the	
sanroque	mutation	abolishes	an	unknown	protein/protein	interaction	that	is	essential	for	 Roquin-1	 function.	 To	 find	 out	 whether	 this	 unknown	 factor	 might	 be	 Nufip2,	endogenous	Roquin-1	was	precipitated	from	MEF	cell	extracts	in	which	Roquin-1	and	-2	 were	 present	 (wt),	 deleted	 (Rc3h1/2-/-)	 or	 Roquin-1	 was	 carrying	 the	 sanroque	mutation	 (Rc3h1san/san)	 by	 Aicha	 Jeridi	 in	 our	 lab	 (Figure	 29).	 Immunoprecipitated	Roquin-1	 protein	 was	 strongly	 enriched	 over	 input	 levels	 in	 wildtype	 and	
Rc3h1/2san/san	MEF	 cells,	 while	 no	 Roquin-1	 was	 detected	 in	 Rc3h1/2-/-	MEF	 cells,	which	served	as	negative	control.	Co-immunoprecipitated	Nufip2	levels	derived	from	wildtype	 and	 Rc3h1/2san/san	 lysates	were	 also	 similarly	 enriched	 over	 input	 levels.	Although	 the	antibody	was	able	 to	equally	well	 immunoprecipitate	Roquin-1	and	 -2,	the	 co-immunoprecipitated	 amount	 of	 Nufip2	 was	 unchanged	 when	 comparing	extracts	of	wildtype	or	sanroque	MEF	cells.	This		suggested	that	the	sanroque	mutation	did	not	abolish	Roquin-1	interaction.	Strikingly,	Roquin-1	and	Nufip2	showed	almost	the	 same	 enrichment	 over	 input,	 indicating	 that	 most	 Roquin-1	 protein	 that	 was	pulled	down	was	bound	to	Nufip2.	
	
	 	
Figure	29:	Co-immunoprecipitation	of	endogenous	Roquin-1	or	Roquin-1san	with	Nufip2.		
Immunoblot	 analysis	 of	 Nufip2	 and	 Roquin-1	 expression	 after	 immunoprecipitation	 of	 endogenous	
Roquin-1	 from	 wt	 MEF	 cells,	 Rc3h1/2-/-	 MEF	 cells	 and	 Rc3h1san/san	 MEF	 cells.	 This	
immunoprecipitation	 was	 performed	 by	 Aicha	 Jeridi	 using	 a	monoclonal	 pan-Roquin-1/2	 antibody.	
One	representative	of	three	independent	experiments	is	shown	here.		
To	 address	 whether	 the	 observed	 interaction	 between	 Nufip2	 and	 the	 Roquin-1-N-terminus	was	direct,	 recombinant	proteins	were	produced	 in	bacteria	 as	N-terminal	His6-SUMO-fusion	proteins,	purified	by	HisTrapTM	and	size	exclusion	chromatography	(Chapter	3.2.5)	and	tested	in	in-vitro	binding	assays	by	Elena	Davydova	from	Prof.	Dr.	Dierk	 Niessing’s	 group.	 An	 N-terminal	 fragment	 (aa	 2-441)	 of	mouse	 Roquin-1	was	
120	 Results			purified	first,	while	an	internal	protein	fragment	(aa	255-411)	was	chosen	for	Nufip2.	Successful	 expression	 of	 Nufip2	 (aa	 255-411)	 has	 already	 been	 reported	 in	 the	literature,	where	it	was	stable	enough	for	use	in	protein	binding	assays	(Ramos	et	al.,	2006).		A	direct	interaction	between	mouse	Roquin-1	(aa	2-441)	and	human	NUFIP2	(aa	255-411)	was	 demonstrated	 in	 surface	 plasmon	 resonance	 (SPR)	 experiments.	 Roquin-1	was	 coupled	 to	 the	 sensor	 chip	 of	 a	 Biacore	 SPR	 system,	 followed	 by	 injection	 of	different	 concentrations	 of	 NUFIP2.	 Direct	 binding	 of	 NUFIP2	 to	 Roquin-1	 caused	changes	 in	 the	 refractivity	 of	 the	 sensor	 chip	 surface,	 which	 was	 measured	 as	resonance	units	by	the	SPR	instrument.		
	
	
Figure	30:	Binary	interaction	of	NUFIP2	and	Roquin-1	fragments.		
	(A,	B)	 Surface	 plasmon	 resonance	 study	 of	 the	 binding	 of	 NUFIP2	 (aa	 255-411)	 to	 immobilized	
Roquin-1	(aa	2-441).	(A)	Biacore	sensograms	recording	the	binding	of	NUFIP2	(aa	255-441)	injected	
at	 twofold	 serial	 dilutions	 ranging	 from	 4-0.063	 μM	 to	 Roquin-1	 (aa	 2-441).	 After	 the	 highest	
concentration,	 the	 0.5	 μM	 sample	 dilution	 was	 re-injected	 in	 order	 to	 ensure	 that	 the	 increase	 in	
resonance	 units	 (RUs)	was	 caused	 by	 increasing	 concentrations	 of	 NUFIP2	 and	 not	 by	 background	
signals	adding	up	after	 each	 concentration.	 (B)	 Steady	 state	affinity	analysis	of	 the	binding	 level	 in	
RUs	against	the	Nufip2	(aa	255-411)	protein	concentration.	One	representative	of	three	independent	
experiments	 are	 shown	 in	 both	 (A)	 and	 (B).	 The	 Kd	 was	 calculated	 from	 mean	 and	 SD	 of	 three	
independent	experiments.	This	experiment	was	performed	and	analyzed	by	Elena	Davydova.		
The	 Biacore	 sensogram	 clearly	 showed	 a	 concentration-dependent	 increase	 in	resonance	units	in	response	to	injection	of	NUFIP2	(aa	255-411)	(Figure	30A).	Steady	state	affinity	analysis	depicted	the	binding	level	 in	resonance	units	that	is	reached	at	equilibrium	 (saturation	 points	 of	 the	 curves	 in	 Figure	 30A)	 for	 each	 NUFIP2	concentration.	 The	 dissociation	 constant	 Kd	 of	 the	 Roquin-1-NUFIP2	 complex	 at	equilibrium	is	defined	as	the	NUFIP2	concentration	where	half	of	the	NUFIP2	protein	
Results	 121	 		is	engaged	in	a	complex	with	Roquin-1.	As	deduced	from	the	steady	state	affinity	plot	a	Kd	of	182	nM	was	calculated	indicating	a	strong,	direct	interaction	between	Roquin-1	2-441	and	NUFIP2	(aa	255-411).			
4.1.9.2 Subcellular	localization	of	Nufip2	Having	learnt	that	Roquin-1	and	NUFIP2	directly	interact,	we	asked	whether	they	also	colocalized	within	cells.	Nufip2	has	originally	been	described	as	a	protein	that	shuttles	to	nucleo-cytoplasmic	localizations	in	different	phases	of	the	cell	cycle	(Bardoni	et	al.,	2003).	In	the	cytoplasm,	NUFIP2	was	described	to	localize	diffusely,	without	showing	colocalization	 with	 RCK	 in	 P	 bodies	 (Chapter	 1.1.2)	 (Bish	 et	 al.,	 2015).	 However,	NUFIP2	was	 observed	 to	 localize	 to	 stress	 granules	 in	 response	 to	 arsenite-induced	oxidative	 stress	 (Bish	 et	 al.,	 2015).	 Roquin-1	 also	 localizes	 to	 stress	 granules	 upon	arsenite	treatment	(Glasmacher	et	al.,	2010;	Vinuesa	et	al.,	2005;	Yu	et	al.,	2007).	We	therefore	addressed	whether	Nufip2	and	Roquin-1	colocalize	in	stress	granules	when	cells	are	exposed	to	oxidative	stress.		
	
	
Figure	31:	NUFIP2	and	Roquin-1	colocalize	in	stress	granules	upon	arsenite	treatment.		
(A)	 Confocal	 microscopy	 of	 the	 localization	 of	 GFP-NUFIP2	 (green)	 in	 HEK293T	 cells	 upon	
overexpression	of	GFP-NUFIP2	without	arsenite	treatment	(no	stress).	(B)	Confocal	microscopy	of	the	
localization	 of	 GFP-NUFIP2	 (green),	 G3BP1	 (light	 blue)	 and	 Roquin-1-mCherry	 (pink)	 in	 HEK293T	
cells	upon	overexpression	of	GFP-NUFIP2	and	Roquin-1-mCherry	after	arsenite-induced	 stress.	 Since	
the	Roquin-1/Nufip2	 interaction	was	mapped	 to	 the	N-terminus	of	Roquin-1,	 a	C-terminal	 fusion	of	
the	fluorescent	reporter	mCherry	was	used	here	in	order	to	prevent	disturbance	of	the	interaction	with	
N-terminally	GFP-tagged	NUFIP2.		
122	 Results			First,	I	reconfirmed	the	findings	by	Bish	et	al.,	2015,	that	overexpressed	GFP-NUFIP2	showed	a	diffuse,	primarily	cytoplasmic	 localization	 in	HEK293T	cells	 in	the	absence	of	 stress	 (Figure	 31A).	 Upon	 arsenite	 treatment,	 almost	 all	 GFP-NUFIP2	 signal	relocated	 to	 stress	 granules,	 where	 it	 colocalized	 with	 overexpressed	 Roquin-1-mCherry	protein	(Figure	31B).		Both	Roquin-1	and	Nufip2	have	been	reported	to	possess	amino	acid	stretches	with	a	higher	frequency	of	glutamine	and	asparagine	residues	(Bish	et	al.,	2015;	Glasmacher	et	 al.,	 2010).	 These	 so-called	 Q/N	 rich	 regions,	 originally	 discovered	 as	 protein	aggregation	sequences	of	prion	proteins,	were	found	to	be	involved	in	the	assembly	of	stress	granules	(Chapter	1.1.2)	(Gilks	et	al.,	2004).	Nufip2	and	Roquin-1	might	thus	be	important	 mediators	 of	 the	 cellular	 stress	 response	 by	 binding	 to	 translationally	arrested	 mRNAs	 and	 inducing	 stress	 granule	 assembly	 via	 their	 Q/N	 rich	 protein	aggregation	domains.		Nufip2	 has	 been	 described	 as	 a	 cell-cycle	 dependent	 nucleo-cytoplasmic	 shuttle	protein,	 showing	 high	 nuclear	 localization	 in	 G1,	 both	 cytoplasmic	 and	 nuclear	localization	in	S	and	predominantly	cytoplasmic	localization	in	the	G2/M	phase	of	the	cell	cycle	(Bardoni	et	al.,	2003).	These	studies	were	performed	in	NIH3T3	fibroblasts	and	 fibroblast-like	 COS	 cells	with	 endogenous	Nufip2.	However,	we	 did	 not	 observe	significant	nuclear	expression	of	overexpressed	GFP-NUFIP2	in	HEK293T	cells	during	our	 confocal	 microscopy	 experiments,	 a	 finding	 which	 was	 supported	 by	 a	 recent	publication	showing	a	predominantly	cytoplasmic	expression	of	endogenous	NUFIP2	in	HEK293T	cells	(Bish	et	al.,	2015).		
4.1.10 Expression	of	Nufip2	in	immune	cells	Since	 the	 functional	 role	 of	 Nufip2	 is	mostly	 unclear,	we	wondered	whether	Nufip2	expression	 was	 ubiquitous,	 similar	 to	 that	 of	 Roquin-1,	 or	 restricted	 to	 certain	 cell	types,	 which	 might	 provide	 important	 clues	 with	 respect	 to	 its	 function.	 Publicly	available	gene	expression	data	(www.biogps.org,	www.immgen.org)	pointed	towards	a	constant	mRNA	expression	over	a	wide	range	of	different	tissues	and	cells	types.	In	order	to	assess	whether	this	was	indeed	also	the	case	for	Nufip2	protein,	we	evaluated	Nufip2	expression	in	different	cell	types	using	immunoblots.	Due	to	its	low	sensitivity,	the	commercially	available	polyclonal	antibody	proved	unsuitable.	Therefore,	a	high-affinity	monoclonal	 antibody	was	 generated	 against	 recombinant	NUFIP2	 protein	 in	collaboration	 with	 the	 in-house	 monoclonal	 antibody	 service	 facility	 (Dr.	 Elisabeth	
Results	 123	 		Kremmer/Dr.	 Regina	 Feederle).	 Rats	 were	 immunized	 with	 recombinant	 human	NUFIP2	protein	and	splenocytes	from	these	rats	were	fused	with	a	myeloma	cell	line.	After	 clonal	 expansion	 of	 antibody-secreting	 cells,	 several	 dozens	 of	 supernatants	were	screened.	We	selected	one	hybridoma	supernatant	showing	the	highest	signal	for	endogenous	mouse	and	human	Nufip2	for	future	applications.	This	antibody	appeared	to	 bind	 to	 an	 epitope	 near	 the	 N-terminus	 of	 Nufip2	 (between	 aa	 1-255),	 and	specifically	recognized	Nufip2	with	a	molecular	weight	of	75	kDa.	Specific	recognition	was	 confirmed	 in	 immunoblotting	 experiments	 with	 different	 Nufip2-knockout	 and	overexpression	cell	lines	(Appendix	V).		
4.1.10.1 Analysis	of	Nufip2	protein	expression	in	different	mouse	tissues	The	 newly	 established	 monoclonal	 Nufip2	 antibody	 was	 employed	 for	 immunoblot	analysis	 of	 Nufip2	 expression	 in	 lysates	 from	 different	 mouse	 organs	 (Figure	 32A).	Nufip2	 expression	 peaked	 in	 the	 brain,	 which	 is	 in	 agreement	 with	 the	 literature	where	 Nufip2	was	 shown	 to	 be	 highly	 expressed	 in	 neurons	 (Bardoni	 et	 al.,	 2003).	Apart	 from	 the	 brain,	 Nufip2	 was	 more	 abundant	 in	 lymphoid	 tissues,	 with	 a	 high	expression	 in	 the	 thymus	 but	 also	 in	 the	 lung,	 and	 intermediate	 levels	 found	 in	 the	spleen	and	in	lymph	nodes.	These	results	indicate	that,	apart	from	its	known	role	as	an	interactor	 of	 FMRP	 in	 the	 brain,	 Nufip2	 potentially	 carries	 out	 specific	 functions	 in	immune	cells.		
	
	
Figure	32:	Nufip2	is	strongly	expressed	in	the	brain	and	in	lymphoid	tissues.		
(A)	 Immunoblot	 analysis	 of	 Nufip2	 protein	 expression	 in	 different	 mouse	 tissues	 with	 GAPDH	 as	 a	
loading	control.	(B)	Immunoblot	analysis	of	Roquin-1	and	Nufip2	expression	in	sorted	B	and	T	cells.		
In	order	to	determine	which	types	of	immune	cells	showed	the	highest	expression	of	Nufip2,	 whole	 cell	 lysates	 from	 FACS-sorted	 mouse	 B	 cells,	 CD8+	 T	 cells	 and	 CD4+	CD25-	(non-regulatory	T	cells)	T	cells	were	analyzed	for	Nufip2	expression.	Similar	to	Roquin-1,	Nufip2	showed	a	high	expression	 in	B	cells	and	CD4+	T	cells,	with	a	 lower	expression	in	CD8+	T	cells	(Figure	32B).		
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4.1.10.2 Correlating	expression	levels	of	ICOS,	Roquin-1	and	potential	Roquin-
1	cofactors	in	a	time	course	of	T	cell	activation	We	focused	on	CD4+	T	cells	 to	study	the	control	of	Nufip2	expression	 in	more	detail.	Upon	 activation	 of	 CD4+	 T	 cells,	 Roquin-1	 is	 cleaved	 into	 its	 inactive	 form	 by	 the	paracaspase	 Malt1	 (Jeltsch	 et	 al.,	 2014).	 We	 therefore	 wondered	 how	 Nufip2	expression	levels	would	develop	in	the	course	of	T	cell	activation	and	differentiation	in	comparison	 to	 Roquin-1	 itself	 and	 other	 known	 and	 potential	 Roquin-1	 cofactors.	Therefore,	 the	 expression	 levels	 of	 Nufip2,	 Fmrp,	 Fxr1,	 Ago	 1-4,	 Regnase-1	 and	Roquin-1	were	analyzed	in	a	time	course	of	T	cell	activation	and	IL-2	culture,	followed	by	 restimulation	 with	 anti-CD3/CD28	 antibodies	 and	 secondary	 IL-2	 culture	 and	correlated	with	their	common	target	Icos	(Figure	33A).		Stimulation	 of	 naïve	 T	 cells	with	 anti-CD3/CD28	 antibodies	 induces	Malt1-mediated	cleavage	of	Roquin-1	as	early	as	three	hours	after	stimulation	(Jeltsch	et	al.,	2014).	In	line	with	this,	we	observed	an	accumulation	of	the	cleavage	product	(50	-	60	kDa)	on	the	first	day	after	T	cell	activation	(d1)	(Figure	33B).	During	IL-2	culture,	the	cleavage	product	 as	 well	 as	 full-length	 Roquin-1	 became	 less	 abundant,	 indicating	 that	 both	post-transcriptional	 cleavage	 and	 transcriptional	 induction	 of	 Roquin-1	 decreased	over	 time.	After	 restimulation	on	day	7,	 expression	of	both	 full-length	Roquin-1	and	the	cleavage	product	was	strongly	induced	and	their	expression	remained	constant	for	two	days,	before	declining	again	(Figure	33B).	Strikingly,	Nufip2	was	strongly	induced	24	h	after	stimulation	of	naive	T	cells	with	anti-CD3/CD28	(d1)	(Figure	33B).	Nufip2	expression	stayed	maximal	for	3	days	and	then	constantly	declined	from	day	4	till	day	7.	A	similar	expression	pattern	was	observed	after	restimulation.	
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Figure	33:	Correlating	Icos	levels	with	the	expression	of	different	trans-acting	factors.		
(A)	Schematic	representation	of	the	performed	time	course	of	T	cell	activation.	Primary	mouse	CD4+	T	
cells	were	stimulated	with	anti-CD3	and	anti-CD28	antibodies	under	Th1	differentiating	conditions	for	
48	h,	and	then	cultured	in	IL2-containing	medium	for	five	days.	After	restimulation	with	anti-CD3	and	
anti-CD28	antibodies,	cells	were	rested	in	IL-2	medium	for	another	four	days.	Cells	for	flow	cytometry	
and	 immunoblotting	 experiments	 were	 harvested	 daily.	 (B)	 Immunoblot	 analysis	 of	 Roquin-1,	
Regnase-1,	Nufip2,	Fxr1,	Ago	and	Fmrp	expression	 levels	 in	whole	cell	 lysates	derived	 from	the	 time	
course	of	T	cell	activation	as	described	in	(A).	(C)	Flow	cytometric	analysis	of	Icos	surface	expression	
on	 mouse	 CD4+	 T	 cells	 during	 the	 time	 course	 described	 in	 (A).	 (D)	 Quantified	 mean	 fluorescence	
intensity	(MFI)	of	ICOS	expression	in	(C).		
126	 Results			The	RNAse	Regnase-1	can	work	in	concert	with	Roquin-1	in	the	regulation	of	certain	mRNA	targets	and	is	equally	subject	to	Malt1-induced	cleavage	after	T	cell	activation	(Uehata	et	al.,	2013).	In	line	with	this,	expression	of	full-length	Regnase-1	was	low	on	day	 1	 and	 day	 2	 after	 T	 cell	 activation	 and	was	 restored	 between	 day	 2	 and	 day	 3	(Figure	33B).	This	was	 similarly	observed	after	T	 cell	 restimulation	on	day	7.	 Fmrp,	which	 was	 included	 in	 this	 experiment	 due	 to	 its	 function	 as	 a	 direct	 interaction	partner	of	Nufip2	(Bardoni	et	al.,	2003;	Ramos	et	al.,	2006),	was	induced	upon	T	cell	activation	similar	to	Nufip2.	However,	there	appeared	to	be	a	time	delay,	resulting	in	Fmrp	 expression	 peaks	 occurring	 3	-	4	 days	 after	 T	 cell	 activation.	 Fmrp	 can	 form	homodimers,	but	also	heterodimers	with	its	family	member	Fxr1	(Dolzhanskaya	et	al.,	2006).	Fxr1	was,	however,	induced	early	upon	T	cell	activation,	thereby	mimicking	the	expression	pattern	of	Nufip2	(Figure	33B).	Finally,	Ago	proteins	were	investigated	due	to	 a	 potential	 collaboration	 of	 Roquin-1	 with	 the	 miRNA	 pathway,	 which	 has	 been	proposed	 for	 certain	Roquin-1	 targets	 (Pratama	et	al.,	2015;	Srivastava	et	al.,	2015).	Ago	 1-4	 were	 detected	 with	 a	 pan-Ago	 antibody	 and	 showed	 a	 time-delayed	downregulation	 upon	 T	 cell	 activation	 (Figure	 33B).	 This	 is	 in	 concert	 with	 the	literature,	where	a	strong	downregulation	of	Ago	proteins	between	24	h	and	48	h	after	T	 cell	 activation	 accompanied	 by	 a	 general	 reduction	 of	 overall	 miRNA	 expression	were	 observed	 in	 a	 similar	 time	 course	 (Bronevetsky	 et	 al.,	 2013).	 In	 their	experiments,	 loss	 of	 Ago2	 was	 found	 to	 be	 mediated	 by	 ubiquitin-dependent	proteasomal	 degradation	 of	 Ago2	 proteins.	 Although	 the	 first	 part	 of	 our	 T	 cell	activation	time	course	confirmed	a	loss	of	Ago	expression	upon	T	cell	activation,	this	was	not	 the	case	after	T	cell	 restimulation	on	day	7.	How	Ago	proteins	behave	upon	secondary	T	cell	stimulation	has,	however,	never	been	investigated	before,	and	might	thus	be	different	from	initial	priming.		While	 Roquin-1	 and	 Regnase-1	 were	 cleaved	 and	 inactivated	 upon	 anti-CD3/CD28	stimulation,	 their	 target	 Icos	was	strongly	 induced	on	the	T	cell	surface	between	the	first	 and	 second	 day	 after	 T	 cell	 activation	 (Figure	 33C,	D).	 It	 remained	 at	 its	 upper	limit	 for	 two	days	and	suddenly	declined	between	 the	second	and	 the	 third	day	and	then	 stayed	 low	 until	 restimulation.	 After	 restimulation	 of	 resting	 T	 cells	 on	 the	seventh	 day,	 high	 ICOS	 levels	 were	 reached	 again	 for	 48	h,	 followed	 by	 a	 slower	decline	 between	 day	 10	 and	 day	 12.	 How	 the	 observed	 expression	 pattern	 of	 Icos	during	 T	 cell	 activation,	 resting	 and	 restimulation	 might	 relate	 to	 the	 differential	expression	patterns	of	Roquin-1	and	its	cofactors	will	be	discussed	later	in	this	work	(Chapter	5.3.3).	
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4.1.11 Analysis	of	cis-elements	in	the	human	ICOS	3’	UTR	Roquin-1	 directly	 binds	 to	 stem-loops	 in	 the	 3’	UTR	 of	 ICOS	mRNA	 (Schlundt	 et	 al.,	2014;	Srivastava	et	 al.,	 2015)	and	 in	 turn	Nufip2	directly	binds	Roquin-1,	which	has	been	clearly	demonstrated	during	the	work	of	this	thesis.	Knockdown	and	knockout	of	Nufip2	 in	 combination	 with	 the	 respective	 rescue	 experiments	 showed	 that	 this	protein	 is	 a	 player	 in	 Roquin-1-dependent	 ICOS	 repression.	 Although	 Nufip2	 was	initially	 chosen	 as	 a	 candidate	 for	 the	 Roquin-1	 cofactor	 screen	 because	 of	 its	annotation	as	an	RNA-binding	protein,	it	is	still	elusive	whether	it	binds	to	ICOS	mRNA	in	addition	to	its	interaction	with	Roquin-1.	To	answer	that	question,	a	first	step	would	be	to	find	out	if	Nufip2	and	Roquin-1	bind	to	the	same	cis-elements	of	the	ICOS	3’	UTR.	Unfortunately,	a	complete	list	of	the	sites	and	motifs	bound	by	Roquin-1	in	this	3'	UTR	does	not	exist.	Therefore,	in	the	last	part	of	this	study,	we	performed	a	comprehensive	mutation	analysis	of	the	human	ICOS	3’	UTR	sequence	to	find	the	sites	with	the	highest	impact	on	ICOS	repression.			
4.1.11.1 Identification	of	the	main	regulatory	regions	of	human	ICOS	mRNA	Several	 Roquin-1	 cis-elements	 have	 been	 described	 in	 the	 literature	 for	 the	 human	
ICOS	3’	UTR	(Figure	34A).	The	first	to	be	identified	was	a	target	sequence	of	miR-101,	close	 to	 the	 3’	end	 of	 ICOS	 mRNA.	 Inversion	 of	 two	 nucleotides	 in	 the	 sequence	targeted	by	miR-101	caused	 impaired	Roquin-1-dependent	post-transcriptional	gene	regulation	 in	 reporter	 assays	 (Yu	 et	 al.,	 2007).	 A	 potential	 direct	 binding	 site	 for	Roquin-1	on	ICOS	mRNA	was	subsequently	mapped	immediately	upstream	of	the	miR-101	 target	 site	 (Athanasopoulos	 et	 al.,	 2010).	 Next,	 the	 ICOS	 constitutive	 decay	element	(CDE)	close	to	the	3’	end	was	inferred	from	the	TNF	CDE	sequence	(Leppek	et	al.,	2013).	Finally,	Glasmacher	et	al.	could	demonstrate	(Glasmacher	et	al.,	2010)	in	gel	shift	assays	 that	Roquin-1	strongly	binds	 to	a	region	close	 to	 the	coding	sequence	of	human	ICOS	mRNA	(nt	700-800).	Within	this	region	a	stem-loop	of	high	similarity	to	the	 previously	 described	 CDE	 was	 identified	 as	 the	 crucial	 cis-acting	 element	 and	called	‘CDE-like’	(Schlundt	et	al.,	2014).	While	several	binding	sites	of	Roquin-1	in	the	
ICOS	3’	UTR	have	been	described	thus	far,	the	functional	impact	of	these	elements	has	not	been	analyzed	systematically.		For	 a	 comprehensive	 investigation	 of	 Roquin-1	 cis-elements	 in	 the	 ICOS	 3’	UTR,	 I	employed	 a	 set	 of	 3’	UTR	 deletion	 constructs,	 which	were	 fused	 to	 the	 ICOS	 coding	sequence	as	a	reporter.	Those	constructs	were	evaluated	in	two	different	cell	lines.	On	the	one	hand,	Rc3h1/2-/-	MEF	cells	with	doxycycline-inducible	expression	of	Roquin-1-
128	 Results			P2A-mCherry	 allowed	 the	 quantification	 of	 reporter	 expression	 in	 the	 presence	 and	absence	 of	 high	 amounts	 of	 Roquin-1.	 Advantages	 of	 this	 system	 lie	 in	 the	 high	dynamic	range,	since	overexpressed	Roquin-1	can	cause	up	to	20-fold	downregulation	of	 ICOS	 expression	 (Chapter	 4.1.1).	 However,	 the	 high	 expression	 of	 a	 protein	 may	potentially	lead	to	unphysiologic	regulation.	Therefore,	Rc3h1/2fl/fl	Cre	ERT2	MEF	cells	were	 employed	 as	 a	 second	 cell	 line,	 where	 changes	 in	 reporter	 expression	 in	response	 to	 the	 presence	 or	 absence	 of	 endogenous	 Roquin-1	 and	 Roquin-2	 can	 be	monitored.	However,	in	this	kind	of	experiment	the	dynamic	range	is	much	reduced	as	compared	 to	 overexpression.	 In	 a	 best-case	 scenario	 the	 results	 obtained	 from	both	approaches	support	the	same	conclusion(s).	It	has	been	shown	previously	that	serial	shortening	of	the	human	ICOS	UTR	from	the	3’	end	 leads	 to	 a	 stepwise	 decrease	 in	 the	 degree	 of	 regulation	 by	 overexpressed	Roquin-1	 (Glasmacher	 et	 al.,	 2010).	 We	 could	 confirm	 this	 finding	 with	 our	doxycycline-inducible	 Roquin-1	 overexpression	 system	 (Figure	 34B).	 The	 1-2271	construct	still	exhibited	full	regulation,	but	regulation	strongly	decreased	with	further	shortening	 of	 the	 mRNA	 (Figure	 34B).	 Testing	 the	 same	 deletion	 constructs	 in	 the	presence	 or	 absence	 of	 endogenous	 Roquin-1	 arrived	 at	 different	 results.	 Now	repression	 was	 either	 on	 or	 off,	 with	 no	 intermediate	 phenotype	 (Figure	 33C).	However,	similar	to	the	first	"boundary"	in	overexpression,	loss	of	regulation	occurred	when	the	3’	UTR	constructs	were	2011	nts	or	shorter,	while	constructs	of	2271	nts	or	longer	were	fully	repressed.			
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Figure	34:	Identification	of	Roquin-1	cis-elements	present	in	the	3’	UTR	of	human	ICOS	mRNA.		
(A)	 Schematic	 representation	 of	 known	 and	 suspected	 cis-elements	 in	 the	 human	 ICOS	 3’	UTR.	 (B)	
Reporter	 regulation	 of	 gradually	 shortened	 ICOS	 3’	UTR	 fragments	 in	 response	 to	 overexpressed	
Roquin-1	 in	 Rc3h1/2	-/-MEF	 cells	+	doxycycline	(dox)-inducible	 Roquin-1-P2A-mCherry.	 ICOS	
expression	of	reporter	constructs	consisting	of	ICOS	CDS	fused	to	different	fragments	of	ICOS	3’	UTR	as	
indicated	 was	 measured	 by	 flow	 cytometry	 in	 cells	 with	 and	 without	 induction	 of	 Roquin-1	
overexpression	with	dox	for	18	h.	Fold	regulation	was	quantified	by	dividing	(ICOS	MFI	-dox)/	(ICOS	
MFI	+dox)	and	normalized	to	the	regulation	of	ICOS	CDS,	which	was	set	to	1.	(C)	Reporter	regulation	
of	 gradually	 shortened	 ICOS	 3’	UTR	 fragments	 in	 response	 to	 deletion	 of	 endogenous	 Roquin-1	 in	Rc3h1/2fl/fl	 CreERT2	 MEF	 cells.	 Fold	 regulation	 was	 determined	 by	 dividing	 (ICOS	 MFI	 –4-OH-
TAM)/(ICOS	MFI	+4-OH-TAM)	and	normalized	to	the	regulation	of	ICOS	CDS,	which	was	set	to	1.	(D)	
Reporter	 regulation	 of	 ICOS	 3’	UTR	 deletion	 constructs	 in	 response	 to	 overexpressed	 Roquin-1	 in	Rc3h1/2-/-	 MEF	 cells	 +dox-inducible	 Roquin-1-P2A-mCherry.	 Fold	 regulation	 was	 calculated	 as	
described	 in	 (A).	 Constructs	missing	 the	miR-101	TS	are	 labeled	 in	orange	and	 lack	of	 the	CDE-like	
element	is	indicated	in	blue.	(E)	Reporter	regulation	of	ICOS	3’	UTR	deletion	constructs	in	response	to	
deletion	of	endogenous	Roquin-1	in	Rc3h1/2fl/fl	Cre	ERT2	MEF	cells.	Fold	regulation	was	calculated	as	
described	in	(B).	Error	bars	indicate	mean	and	SD	of	two	independent	experiments	for	(A)	to	(C).	 In	
(D),	 mean	 and	 SD	 are	 calculated	 from	 two	 or	 three	 independent	 experiments	 depending	 on	 the	
construct.		
130	 Results			Considering	these	results	in	the	context	of	the	three	described	cis-elements,	there	was	a	 strong	 indication	 towards	 an	 important	 cis-element	 being	 present	 between	nucleotide	2011	and	2271,	the	region	where	the	miR-101	target	site	had	been	mapped	(Yu	et	al.,	2007).	Noteworthy,	the	1-2391	and	the	1-2271	constructs,	both	lacking	the	
ICOS	 CDE	 at	 the	 very	 3’	 end	 of	 the	 3’	 UTR,	 showed	 unimpaired	 regulation	 in	 the	context	 of	 Roquin-1	 overexpression	 (Schlundt	 et	 al.,	 2014)	 and	 after	 deletion	 of	endogenous	Roquin-1.	Therefore,	in	the	biological	context	and	under	the	conditions	of	these	 experiments	 the	 canonical	 CDE	 in	 the	 ICOS	 3’	 UTR	 is	 not	 a	major	 cis-element.	This	 finding	 is	particularly	surprising	since	 the	 isolated	CDE	sequence	was	shown	to	induce	Roquin-1-mediated	mRNA	decay	in	vitro	(Leppek	et	al.,	2013).	Yet,	Stöcklin	and	colleagues	 never	 deleted	 or	 mutated	 the	 CDE	 in	 the	 context	 of	 the	 full-length	 ICOS	3’	UTR.	 Moreover,	 while	 I	 determined	 post-transcriptional	 gene	 regulation	 by	quantifying	ICOS	protein	expression	as	a	final	output	of	mRNA	stability	and	translation	efficiency,	Stöcklin	and	colleagues	solely	investigated	mRNA	decay,	thereby	excluding	other	 post-transcriptional	 mechanisms	 that	 can	 influence	 the	 output,	 such	 as	translational	inhibition.	The	discrepancy	between	the	results	of	their	and	my	analysis	of	the	importance	of	the	CDE	highlights	the	different	outcomes	that	can	result	from	the	application	of	different	methods	for	studying	cis-elements,	and	underlines	the	need	for	a	comprehensive	analysis	of	ICOS	cis-elements	in	their	native	context.		The	 impact	 of	 the	 remaining	 two	 cis-elements	 was	 investigated	 more	 precisely	through	the	additional	 trimming	of	 the	existing	deletion	constructs.	 In	 the	context	of	Roquin-1	 overexpression	 the	 deletion	 of	 the	 CDE-like	 stem-loop	 region	 (Δ700-800)	surprisingly	 did	 not	 interfere	 with	 Roquin-1-dependent	 regulation,	 although	 the	isolated	 sequence	 was	 previously	 reported	 to	 be	 bound	 by	 Roquin-1	 in	 vitro	(Glasmacher	et	al.,	2010;	Schlundt	et	al.,	2014)	(Figure	33D).	 In	contrast,	a	construct	ending	 directly	 5’	 of	 the	 miR-101	 target	 site	 (1-2211)	 showed	 already	 impaired	repression,	which	was	even	more	compromised	upon	additional	deletion	of	the	CDE-like	stem-loop	region	(1-2211	Δ700-800).	This	result	suggests	that	both	cis-elements	work	 redundantly,	 with	 the	miR-101	 target	 sequence	 playing	 a	 dominant	 role.	 This	was	 confirmed	 by	 studies	 relying	 on	 endogenous	 Roquin-1	 levels	 (Figure	 33E).	Repression	 of	 a	 construct	 lacking	 the	 CDE-like	 element	 (Δ700-800)	 was	 partially	impaired,	 and	 additional	 deletion	 of	 the	 miR-101	 target	 site	 completely	 abolished	regulation.	However,	no	contributive	effect	could	be	seen	for	additional	deletion	of	the	CDE-like	element	 in	 the	shorter	compared	to	 the	 full-length	construct.	This	might	be	
Results	 131	 		explained	by	 the	 small	dynamic	 range	of	 the	assay	 (on/off	 type),	which	possibly	did	not	allow	for	the	detection	of	intermediate	states.		
4.1.11.2 A	new	stem-loop	structure	in	the	miR-101	target	site	is	a	putative	cis-
element	targeted	by	Roquin-1	miR-101	was	 initially	 described	 as	 the	 cis-element-recognizing	 trans-acting	 factor	 in	Roquin-1-dependent	 post-transcriptional	 gene	 regulation	 of	 ICOS	 mRNA	 (Yu	 et	 al.,	2007).	 Since	 Roquin-1	 binding	 sites	 were	 mapped	 immediately	 upstream	 of	 the	predicted	 miR-101	 target	 site,	 it	 has	 been	 proposed	 that	 Roquin-1	 binding	 enables	miR-101	 targeting	 by	 changing	 the	 secondary	 structure	 of	 ICOS	 3’	UTR	(Athanasopoulos	 et	 al.,	 2010).	 However,	 the	 contribution	 of	 miR-101	 to	 Roquin-1-mediated	post-transcriptional	repression	is	still	controversial,	since	it	was	shown	later	that	overexpression	of	Roquin-1-induced	 ICOS	regulation	 independent	of	 the	miRNA	pathway	(Glasmacher	et	al.,	2010).	Instead,	Roquin-1	itself	was	demonstrated	to	be	an	RNA-binding	protein	(Athanasopoulos	et	al.,	2010;	Glasmacher	et	al.,	2010),	and	as	a	
trans-acting	 factor	 it	 recognizes	 specific	 tri-loop	 and	 hexa-loop	 or	 U-rich	 hairpin	structures	with	different	loop	sizes	(Codutti	et	al.,	2015;	Janowski	et	al.,	2016;	Leppek	et	al.,	2013;	Murakawa	et	al.,	2015;	Schlundt	et	al.,	2014;	Tan	et	al.,	2014).	Therefore,	we	asked	whether	a	secondary	structure	was	buried	within	the	sequence	predicted	to	be	 recognized	 by	 miR-101	 and	 regulated	 by	 Roquin-1.	 In	 the	 group	 of	 Dr.	 Jörg	Hackermüller	 and	 Dr.	 Kristin	 Reiche,	 Anne	 Hoffmann	 generated	 a	 model	 of	 the	secondary	 structure	of	 the	 ICOS	 3’	UTR.	 She	used	 the	LocARNA	 software	 (Will	 et	 al.,	2012;	Will	et	al.,	2007),	which	employs	structure-based	alignments	of	sequences	from	different	species	to	identify	evolutionary	conserved	structured	motifs.	This	algorithm	first	 calculates	 for	 each	 nucleotide	 the	 probability	 for	 base	 pairing	 with	 other	nucleotides	within	 the	 same	RNA	molecule	 (i.e.	 the	probability	 to	 form	a	 structure),	then	aligns	multiple	sequences	based	on	sequence	and	structure,	and	finally	predicts	the	secondary	structure	of	the	alignment	(Hoffmann,	2015).	The	consensus	secondary	structure	was	predicted	for	the	3’	UTR	of	ICOS	 in	the	context	of	its	preceding	protein	coding	sequence	(CDS)	to	ensure	proper	folding	of	the	most	5’	part	of	the	3’	UTR	and	the	 sequence	 around	 the	 stop	 codon.	 Since	 the	 CDE	 had	 no	 impact	 on	 Roquin-1-dependent	regulation	of	ICOS	mRNA	in	the	experiments	presented	above,	we	focused	on	the	miR-101	target	site	and	the	CDE-like	stem-loop	in	the	5’	end	of	the	3’	UTR.	As	suspected,	 a	 highly	 conserved	 tri-loop	 structure	 was	 identified	 in	 the	 region	 of	 the	miR-101	 target	 sequence	 (Figure	 35A,	 B).	 For	 the	 CDE-like	 stem-loop,	 the	 locARNA	
132	 Results			sequence	alignment	predicted	the	same	structure	as	previously	published	(Schlundt	et	al.,	2014).	However,	as	compared	to	 the	stem-loop	buried	within	 the	miR-101	target	site,	the	degree	of	structural	conservation	of	this	sequence	was	less	evident.		
	
	
Figure	35:	Multiple	sequence	and	structure	alignments	for	the	CDE-like	stem-loop	and	the	miR-
101	target	site	stem-loop.		
(A)	 LocARNA	multiple	 sequence	 and	 structure	 alignment	 of	 the	 CDE-like	 stem-loop	 and	 the	 newly	
identified	 stem-loop	 in	 the	 region	 targeted	by	miR-101	of	human	 ICOS	mRNA.	Structural	alignment	
was	performed	with	 ICOS	 coding	 sequence	and	 the	 complete	3’	UTR	 sequences	 from	24	 species.	The	
color	 code	 indicates	 the	 degree	 of	 secondary	 structure	 conservation	 across	 species.	 Compensatory	
mutations	 (types	 of	 pairs)	 are	 indicated	 by	 different	 colors,	while	 the	 number	 of	 incompatible	 base	
pairs	is	reflected	in	the	saturation.	Saturated	colors	indicate	a	low	number	of	incompatible	base	pairs	
and	thus	high	structural	conservation.	Opposing	brackets	indicate	base	pairing	nucleotides,	while	dots	
represent	 flexible	 loops.	 (B)	 Schematic	 representation	 of	 the	 CDE-like	 stem-loop	 and	 the	 miR-101	
target	 site	 stem-loop	 secondary	 structures	 as	 identified	 in	 (A)	 and	 their	 relative	 position	 on	 ICOS	
mRNA.	LocARNA	sequence	alignment	was	performed	by	Anne	Hoffmann.		
After	 modeling	 of	 the	 secondary	 structure,	 we	 set	 out	 to	 validate	 the	 predicted	structure	 elements	 by	 functional	 assays.	 Interestingly,	 the	 mutations	 that	 were	formerly	 introduced	 by	 Prof.	 Carola	 Vinuesa’s	 group	 (Yu	 et	 al.,	 2007)	 to	mutate	 the	
Results	 133	 		region	that	is	targeted	by	the	seed	sequence	of	miR-101	overlapped	with	the	position	of	the	closing	base	pair	and	the	next	base	pair	in	the	upper	stem	of	the	predicted	stem-loop	(SM1	in	Figure	36).	It	is	thus	possible	that	the	mutations,	which	were	previously	thought	to	ablate	miR-101	binding,	actually	destroyed	a	stem-loop	structure	located	at	the	very	same	position.	
	
	
Figure	 36:	 Two	 stem-loop	 structures	 contribute	 to	 Roquin-1-dependent	 regulation	 of	 ICOS	
mRNA.		
(A)	Schematic	representation	of	 the	miR-101	target	 site	 stem-loop	structure	and	the	CDE-like	stem-
loop	together	with	stem-loop	mutants	affecting	the	closing	base	pair	and	the	upper	stem	(SM1,	SM2)	
and	 stem-restoring	 mutants	 (SM1R,	 SM2R).	 Mutated	 nucleotides	 are	 labeled	 in	 red.	 (B)	 Flow	
cytometric	 analysis	 of	 ICOS	 wt	 and	 ICOS	 SM1	 SM2	 expression	 in	 Rc3h1/2-/-	 MEF	 cells	 with	
doxycycline	(dox)-inducible	Roquin-1-P2A-mCherry	overexpression	+/-dox.	Cells	were	transduced	with	
reporter	constructs	of	ICOS	CDS	and	the	wt	3’	UTR	or	a	3’	UTR	carrying	the	SM1	and	SM2	stem-loop	
mutation.	 (C)	Quantified	 ICOS	 regulation	of	 ICOS	 stem-loop	mutation	 constructs	 in	Rc3h1/2-/-	MEF	
cells	 with	 dox-inducible	 Roquin-1-P2A-mCherry	 overexpression.	 Fold	 regulation	 was	 quantified	 by	
dividing	(ICOS	MFI	-dox)/	(ICOS	MFI	+dox)	and	normalized	to	the	regulation	of	ICOS	wt,	which	was	set	
to	1.	(B)	 shows	 representative	examples	of	 two	 independent	experiments,	while	mean	and	 standard	
deviation	from	two	independent	experiments	are	shown	in	(C).		
To	find	out	 if	 the	cis-element	at	 this	position	conveys	 function	through	its	secondary	stem-loop	structure,	we	introduced	the	SM1	mutation	(similar	to	(Yu	et	al.,	2007))	or	a	reverse	mutation	that	restored	the	stem	by	additional	mutation	of	 the	opposite	base	
134	 Results			pairs	 (SM1R)	 into	 ICOS	 mRNA	 (Figure	 36A).	 Since	 our	 previous	 experiments	 had	indicated	a	cooperation	between	a	cis-element	located	at	the	miR-101	TS	and	the	CDE-like	 stem-loop	 structure	 in	 the	 5’	 end	 of	 the	 3’	 UTR,	 we	 also	 designed	 a	 mutation	destroying	the	closing	base	pair	and	the	upper	stem	of	the	CDE-like	stem-loop	(SM2)	as	well	 as	 a	 reverse	mutation	 that	 restored	 the	 stem-loop	 structure	 (SM2R)	 (Figure	36A).		ICOS	reporter	mRNAs	with	the	different	stem-loop	mutations	were	overexpressed	 in	
Rc3h1/2-/-	 MEF	 cells	 with	 doxycycline-inducible	 Roquin-1-P2A-mCherry,	 and	 ICOS	expression	was	analyzed	in	the	presence	and	absence	of	Roquin-1.	Mutating	the	miR-101	 TS	 stem-loop	 alone	 had	 a	 mild	 effect	 on	 ICOS	 repression,	 which	 however	 was	restored	by	the	reverse	mutation	SM1R.	In	good	accordance	with	our	previous	results	(Figure	36	D	and	E)	the	SM2	mutation	by	itself	had	no	impact	on	ICOS	regulation.	 In	the	 double	mutant	 SM1	 SM2,	 where	 both	 the	miR-101	 TS	 stem-loop	 as	 well	 as	 the	CDE-like	 stem-loop	 were	 disrupted,	 ICOS	 downregulation	 in	 response	 to	 Roquin-1	overexpression	 was	 considerably	 impaired	 (Figure	 36B),	 leading	 to	 about	 half	 of	repression	observed	for	the	ICOS	wildtype	3'	UTR	(Figure	36C).	Most	importantly,	this	effect	 could	 be	 fully	 restored	 with	 the	 reverse	 mutations	 SM1R	 SM2R.	 The	 results	support	a	model	in	which	RNA-binding	factors	bind	to	the	two	investigated	stem-loop	structures	 and	 act	 cooperatively	 in	 ICOS	 repression.	 Based	 on	 our	 mutagenesis	 we	propose	that	the	conserved	stem-loop	structure	and	not	the	miR-101	target	sequence	is	 the	 actual	 cis-element	 that	 contributes	 to	 ICOS	 repression	 in	 the	 context	 of	 the	mapped	region	(nt	2011-2271)	(Athanasopoulos	et	al.,	2010).	 To	sum	up,	a	comprehensive	analysis	of	Roquin-1	cis-elements	 in	the	3’	UTR	of	 ICOS	revealed	exciting	new	insights.	The	CDE	at	 the	very	end	of	 the	ICOS	3’	UTR,	which	 is	considered	 the	bona	 fide	Roquin-1	 target	 sequence,	 appeared	 to	be	of	no	 regulatory	impact	in	the	context	of	the	whole	ICOS	mRNA	sequence	in	the	fibroblast	cells	that	we	analyzed.	 Instead,	 a	 close-by	 region	 (nt	 2011-2271)	 that	 was	 initially	 described	 as	being	 targeted	 by	 Roquin-1	 via	 a	 miR-101	 target	 sequence	 emerged	 as	 the	 most	important	cis-element.	Advanced	structure	predictions	led	to	the	surprising	discovery	of	 a	 so	 far	 overlooked	 but	 highly	 conserved	 stem-loop	 structure	 in	 the	 same	 region	that	 was	 previously	 assumed	 to	 be	 a	 miR-101	 target	 site.	 The	 findings	 presented	above	 provide	 a	 start	 point	 for	 future	 experiments	 that	 shall	 dissect	 the	 structural	aspects	 for	 the	 cooperation	 on	 the	 RNA	 and	 elucidate	 the	 individual	 and	 combined	contributions	of	Roquin-1	and	Nufip2	to	the	post-transcriptional	regulation	of	ICOS.	 	
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4.2 Genome-wide	 CRISPR/Cas9	 screen	 for	 cofactors	 of	
Roquin-1-induced	cell	death																																																
Initially,	 it	was	 unclear	whether	 or	 not	 a	 promising	 candidate	would	 arise	 from	 the	Roquin-1	cofactor	screen	central	 to	 the	 first	part	of	 this	study	(Chapter	4.1.1).	While	preparing	 the	 reporter	 cell	 lines	 for	 the	 screen,	 I	made	 a	 striking	 observation:	 Cells	seemed	 to	 suffer	 in	 response	 to	 long-term	 doxycycline-induced	 overexpression	 of	Roquin-1-P2A-mCherry,	such	 that	all	cells	were	dying	 from	a	not	yet	defined	type	of	cell	death	upon	>	48	h	of	doxycycline	stimulation.	Since	this	function	of	Roquin-1	was	completely	new	to	the	field,	we	wanted	to	shed	light	on	it	by	exploring	which	cellular	factors	 were	 critically	 involved	 in	 the	 pathway	 of	 Roquin-1-induced	 cell	 death.	 We	therefore	 decided	 to	 employ	 one	 of	 the	 new	 publicly	 available	 CRISPR/Cas9	 gene	knockout	libraries	(Koike-Yusa	et	al.,	2013;	Shalem	et	al.,	2014;	Wang	et	al.,	2014)	and	performed	a	genome-wide	pooled	positive	selection	screen	for	cofactors	of	Roquin-1-induced	cell	death.	This	screen	was	performed	parallel	to	the	functional	validation	of	Nufip2	(Chapter	4.1.8-4.1.10),	which	had	emerged	as	a	promising	candidate	from	the	Roquin-1	cofactor	screen.		
4.2.1 Overexpression	of	Roquin-1	induces	cell	death	The	observed	cell	death	in	response	to	Roquin-1	overexpression	could	either	be	linked	to	 a	 specific	 function	 of	 Roquin-1,	 or	 arise	 from	 general	 toxicity	 of	 the	 high	overexpression	 levels	 reached	 with	 the	 lentiviral	 doxycycline-inducible	 expression	system.	To	discriminate	between	the	two	possibilities,	we	compared	cell	survival	upon	overexpression	of	Roquin-1	 full-length	 and	 the	N-terminal	 fragment	Roquin-1	(aa	1-509),	 which	 lacks	 Roquin-1	 effector	 functions	 (Glasmacher	 et	 al.,	 2010).	 MEF	 cell	clones	 overexpressing	 Roquin-1-P2A-mCherry	 or	 Roquin-1	(aa	 1-509)-P2A-mCherry	to	equal	levels	upon	doxycycline	treatment	were	chosen	for	a	time	course	experiment	(Figure	37A).	Already	after	48	h	of	doxycycline	treatment	the	percentage	of	living	cells	was	 considerably	 reduced	 when	 Roquin-1	 full-length	 (FL)	 was	 expressed,	 whereas	Roquin-1	(aa	1-509)–overexpressing	 cells	 showed	similar	 frequencies	of	 live	 cells	 as	non-induced	 control	 cells	 (Figure	 37B).	 Counting	 viable	 cells	 in	 a	 time	 course	 of	doxycycline	 treatment	 revealed	 normal	 exponential	 cell	 growth	 for	 cells	 expressing	the	 truncated	 Roquin-1	(aa	 1-	509),	 while	 cells	 overexpressing	 full-length	 Roquin-1	were	dying	(Figure	37C).		
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Figure	37:	 Long-term	overexpression	of	 full-length	Roquin-1	 in	MEF	 cells	 interferes	with	 cell	
survival	.		
(A)	 Flow	 cytometric	 analysis	 of	 mCherry	 expression	 in	 MEF	 cells	 overexpressing	 doxycycline	(dox)-
inducible	Roquin-1-P2A-mCherry	 (FL)	 or	Roquin-1	(aa	1-509)-P2A-mCherry.	 Cells	were	 treated	with	
dox	for	48	h	or	left	untreated	(control).	(B)	Percentage	of	living	cells	as	determined	by	flow	cytometric	
analysis	 of	 size	 (FSC)	 and	 granularity	 (SSC)	 of	 cells	 in	 (A).	 (C)	 Growth	 curves	 of	 MEF	 cells	
overexpressing	dox-inducible	Roquin-1-P2A-mCherry	(FL)	or	Roquin-1	(aa	1-509)-P2A-mCherry.	Cells	
were	counted	24	h	and	48	h	after	dox-addition.		
Thus,	 the	 observed	 cell	 death	 phenotype	 upon	 overexpression	 of	 Roquin-1	 was	specific	 to	Roquin-1	 function	and	required	 the	C-terminal	part	of	Roquin-1	 (proline-rich	 region,	 coiled-coil)	 in	 addition	 to	 the	 N-terminal	 part,	 which	 contains	 motifs	involved	in	RNA-binding	(ROQ	domain,	Zn	finger)	and	putative	ubiquitination	function	(RING	finger).		
4.2.2 Genome-wide	CRISPR/Cas9	screen	To	 identify	 the	 signaling	 pathways	 involved	 in	 Roquin-1-mediated	 cell	 death,	which	might	ultimately	guide	us	towards	a	yet	unidentified	form	of	cell	death,	we	made	use	of	a	genome-wide	pooled	CRISPR/Cas9	knockout	 library.	The	CRISPR/Cas9	genome-editing	 technology	 (Chapter	 1.2.2)	 opened	 up	 a	 new	 dimension	 in	 loss-of-function	screening	by	providing	easily	accessible	tools	for	rapid	and	inexpensive	generation	of	targeted	 gene	 knockouts.	 Researchers	 recently	 employed	 this	 technology	 to	 create	pooled	 sgRNA	 libraries	 capable	 of	 inactivating	 every	 single	 gene	 of	 the	 mouse	 or	human	genome	on	the	DNA	level	(Koike-Yusa	et	al.,	2013;	Shalem	et	al.,	2014;	Wang	et	
Results	 137	 		al.,	 2014).	 In	 contrast	 to	 arrayed	 RNAi	 screening	 where	 RNAi	 reagents	 targeting	different	genes	are	delivered	 into	 separate	wells	of	a	96-	or	384-well	plate	 (Chapter	4.1),	pooled	CRISPR/Cas9	screening	involves	the	delivery	of	genome-covering	sgRNA	pools	with	multiple	perturbations	per	gene	simultaneously	to	a	large	number	of	cells.	Following	 positive	 or	 negative	 selection	 for	 a	 desired	 phenotype,	 the	 responsible	sgRNA	 sequences	 are	 identified	 by	 deep	 sequencing	 (Chapter	 3.2.10)	 (Sims	 et	 al.,	2011).	 A	 positive	 selection	 screen	 aims	 at	 the	 identification	 of	 sgRNAs	 that	 are	enriched	in	the	pool	after	selection,	 thereby	identifying	genes	that	were	essential	 for	the	selected	phenotype,	while	a	negative	selection	screen	identifies	sgRNAs	that	were	inhibitory	for	the	selected	phenotype	and	are	thus	underrepresented	in	the	final	pool.	Being	interested	in	sgRNAs	that	enabled	cells	to	survive	Roquin-1-overexpression	due	to	 specific	 inactivation	 of	 Roquin-1	 cofactors,	 we	 performed	 a	 positive	 selection	screen.	 Two	 different	 mouse	 Genome-scale	 CRISPR/Cas9	 Knockout	 (GeCKO)	 Gecko	libraries	provided	by	the	 lab	of	Dr.	Feng	Zhang	(MIT,	Boston,	USA)	were	available	at	Addgene:	a	one	vector	system,	where	sgRNAs	and	Cas9	nuclease	are	encoded	on	one	vector,	and	a	two-vector	system,	where	Cas9	is	provided	from	a	separate	vector.	Since	higher	 virus	 titers	 can	 be	 reached	without	 Cas9	 being	 present	 on	 the	 library	 vector	(Sanjana	et	al.,	2014),	we	decided	to	use	the	two-vector	system.	The	first	step	of	our	screen	workflow	thus	involved	the	generation	of	a	reporter	cell	 line	with	stable	Cas9	expression.		
4.2.2.1 Producing	a	stable	Cas9-GFP-expressing	reporter	cell	line	First,	the	MEF	cell	clone	with	doxycycline-inducible	overexpression	of	Roquin-1-P2A-mCherry	used	 for	pre-screening	experiments	 in	 chapter	4.2.1	was	 stably	 transduced	with	 Cas9-GFP	 (Figure	 38A).	 After	 a	 second	 round	 of	 single	 cell	 cloning,	 the	 clone	showing	the	highest	expression	of	HA-tagged	Cas9-GFP	(Figure	38B,	C)	was	chosen	as	a	reporter	cell	line	(clone	8).		
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Figure	38:	Producing	a	stable	Cas9-GFP-expressing	reporter	cell	line.		
(A)	Flow	cytometric	analysis	of	GFP	expression	of	doxycycline	(dox)-inducible	Roquin-1-P2A-mCherry-
expressing	MEF	cells	upon	 stable	 transduction	with	Cas9-GFP.	Cells	were	 transduced	with	Cas9-GFP	
expressing	 lentivirus	(bulk)	or	 left	untransduced	(control).	(B)	 Immunoblot	analysis	of	HA-Cas9-GFP	
expression	on	whole	cell	extracts	from	single	cell	clones	of	Cas9-GFP	expressing	bulk	cells	in	(A).	HA-
Cas9-GFP	 expression	 is	 shown	 in	 comparison	 to	 untransduced	 control	 cells.	 (C)	 Flow	 cytometric	
analysis	 of	 GFP	 expression	 of	 single	 cell	 clones	 in	 (B).	 GFP	 expression	 is	 shown	 in	 comparison	 to	
untransduced	control	cells	(grey).		
4.2.2.2 Primary	CRISPR/Cas9	screen	and	data	analysis	Once	 pre-screening	 preparations	 including	 establishment	 of	 the	 reporter	 cell	 line,	puromycin	 titration,	 lentiviral	 library	 production	 and	 -titration	 were	 completed	(Chapter	3.2.10),	the	genome-wide	CRISPR/Cas9	screen	was	initiated	(Figure	39).			
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Figure	39:	Positive	selection	CRISPR/Cas9	screen.		
Schematic	representation	of	the	screen	workflow.	Stable	Cas9-GFP	expressing	MEF	reporter	cells	with	
doxycycline	(dox)-inducible	Roquin-1-P2A-mCherry	expression	were	transduced	with	the	two	plasmid	
system	Mouse	GeCKO	v2	Library	(Addgene).	The	library	contains	130,209	sgRNA	sequences	cloned	into	
the	 lentiGuide	 vector.	 20,611	 genes	 of	 the	 mouse	 genome	 are	 targeted	 with	 6	 sgRNAs	 each,	 1175	
miRNAs	are	targeted	by	4	sgRNAs	each,	and	1000	non-targeting	controls	were	included.	Reporter	cells	
were	infected	at	a	low	MOI	to	ensure	single	copy	sgRNA	integration,	and	infected	cells	were	selected	
with	puromycin.	Upon	expression	of	Cas9	and	sgRNA,	double	strand	breaks	were	created	at	the	sgRNA	
target	sites,	 leading	to	disruption	of	a	different	protein-coding	gene	 in	each	cell.	After	seven	days	of	
selection,	one	pool	of	knockout	cells	was	treated	with	dox	to	induce	Roquin-1-mediated	cell	death	and	
a	second	pool	of	knockout	cells	 is	 left	untreated.	Cells	 that	survived	due	to	deletion	of	a	gene	that	 is	
indispensable	 for	Roquin-1-induced	 cell	 death	were	proliferating	and	 thereby	amplifying	 the	 sgRNA	
sequence,	 which	 was	 lentivirally,	 integrated	 into	 the	 genome.	 Isolation	 of	 genomic	 DNA	 and	 deep	
sequencing	 of	 sgRNA	 integration	 sites	 revealed	 which	 sgRNA,	 i.e.	 deletion	 of	 which	 gene	 was	
responsible	for	the	rescue	phenotype.		
The	 screen	 and	 all	 follow-up	 experiments	were	 performed	 in	 collaboration	with	Dr.	Kai	 Höfig.	 To	 ensure	 single	 copy	 sgRNA	 integration,	 we	 aimed	 at	 a	 multiplicity	 of	infection	(MOI)	of	0.3,	meaning	that	each	cell	was	infected	on	average	with	0.3	viruses.	According	to	the	Poisson	distribution,	only	3	%	of	cells	are	predicted	to	contain	more	
140	 Results			than	one	 lentiviral	 integration	at	MOI	0.3,	while	74	%	of	cells	contain	no	 integration.	1.8	x	108	reporter	cells	were	 infected	with	 the	 lentiviral	 library	 to	ensure	 full	 library	coverage	with	300	infected	cells	per	sgRNA.	5.0	x	107	cells	were	harvested	for	genomic	DNA	 (gDNA)	 extraction	 24	h	 after	 infection	 for	 evaluation	 of	 the	 initial	 library	complexity	and	coverage.	After	elimination	of	uninfected	cells	by	puromycin	selection,	maintenance	of	a	pool	of	5.0	x	107	cells	was	sufficient	to	ensure	the	initial	complexity	of	the	library.	The	timeline	of	the	screening	procedure	is	shown	in	Figure	40A.		
	
	
Figure	40:	Genome-wide	CRISPR/Cas9	screen	for	mediators	of	Roquin-1-induced	cell	death.		
(A)	Schematic	representation	of	the	screen	workflow.	On	d0,	9.0	x	107	reporter	cells	were	seeded	into	
30	12-well	plates	with	250,000	cells	per	well.	24	h	 later,	cells	were	 transduced	with	 the	 lentiCRISPR	
library	 at	MOI	 0.3.	 Starting	 30	h	 after	 transduction,	 cells	were	 cultured	 in	 the	 presence	 of	 2	μg/ml	
puromycin.	After	7	days	of	puromycin	 selection,	 cells	were	 split	 into	 two	cultures	and	5.0	x	107	 cells	
each	were	treated	with	1	μg/ml	doxycycline	(dox)	to	induce	Roquin-1	overexpression	(+dox)	or	were	
left	untreated	(-dox).	Dox	treatment	was	continued	for	14	days.	Genomic	DNA	was	 isolated	from	5.0	
x	107	cells	 (d2,	d9)	or	3.5	x	107	cells	 (d23+dox,	d23-dox)	on	the	 indicated	days.	(B)	Growth	curves	of	
dox-treated	 (+dox)	 and	 untreated	 cells	 (-dox)	 from	 the	 CRISPR	 screen	 versus	 dox-treated	
untransduced	 reporter	 cells	 (untransduced	 control).	 The	 CRSPR/Cas9	 screen	 was	 performed	 in	
collaboration	with	Dr.	Kai	Höfig.		
Following	doxycycline	treatment	of	half	of	the	cell	pool	on	day	9,	cells	started	dying	in	response	to	overexpression	of	Roquin-1	as	expected	(Figure	40B),	while	the	untreated	
Results	 141	 		half	 showed	 normal	 exponential	 cell	 growth.	 The	 cell	 number	 of	 the	 doxycycline-treated	 sample	declined	drastically	 (>	1	log-level)	until	day	6	of	 treatment,	however,	starting	from	day	8,	surviving	cells	started	to	grow	out,	reaching	normal	exponential	growth	on	day	10.	Cell	survival	was	clearly	caused	as	a	consequence	of	infection	with	the	CRISPR	library,	since	untransduced	control	reporter	cells	did	neither	start	to	grow	eight	days	after	Roquin-1	overexpression	was	induced,	nor	at	later	time	points	(Figure	40B).	Genomic	DNA	was	extracted	from	the	cell	pool	on	d2	and	d9	before	doxycycline	stimulation	and	 from	the	untreated	sample	on	d23	 in	order	 to	assess	how	the	 initial	library	complexity	changed	over	time	without	selective	pressure	(Chapter	3.2.3.2).	On	the	 other	 hand,	 gDNA	 extracted	 from	 the	 doxycycline-surviving	 cell	 pool	 on	 d23	contained	 the	 information	 which	 sgRNAs	 were	 responsible	 for	 the	 rescue	 from	Roquin-1-induced	 cell	 death.	 Integrated	 sgRNA	 sequences	 were	 amplified	 from	genomic	DNA	in	a	two-step	PCR	reaction	as	described	in	chapter	3.2.10	and	final	PCR	products	were	 subjected	 to	NGS	 in	 the	 laboratory	 of	 Dr.	 Helmut	 Blum,	 Gene	 Center	Munich.		Analysis	of	deep	sequencing	data	was	performed	by	Dr.	Dirk	Repsilber	and	Dr.	Brynjar	Bjarnason,	 Örebro	 Universitet,	 Sweden.	 Evaluation	 of	 raw	 counts	 for	 each	 sgRNA	confirmed	 a	 fairly	 even	 distribution	 of	 the	 library	 in	 the	 sample	 taken	 24	h	 after	infection	(d2)	(Figure	41,	upper	left).	At	this	time	point,	98.5	%	of	all	sgRNA	sequences	were	 identified	 in	 the	 genomes	 of	 the	 MEF	 cell	 pool,	 indicating	 that	 the	 library	amplification,	 virus	 production	 and	 MEF	 infection	 had	 maintained	 the	 original	complexity	of	 the	 library.	Uniform	sgRNA	distribution	hardly	changed	over	7	days	of	puromycin	selection	(d8)	(Figure	41,	upper	right).	At	the	end	of	the	screen	on	day	23,	in	the	sample	that	was	not	treated	with	doxycycline	(d23-dox)	some	sgRNA	sequences	were	 overrepresented	 up	 to	 12-fold,	 while	 others	 were	 depleted	 (Figure	 41,	 lower	left).	This	was	expected,	since	cells	carrying	sgRNAs	that	negatively	affect	cell	survival	are	outgrown	by	those	where	the	sgRNA	has	no	effect	or	even	a	positive	influence	on	cell	 proliferation.	 This	 sample	 served	 as	 a	 very	 good	 negative	 control,	 because	 it	allowed	us	to	differentiate	between	Roquin-1-specific	candidates	and	factors	that	have	a	 general	 function	 in	 cell	 death	 or	 related	 pathways.	 After	 doxycycline-induced	Roquin-1	overexpression	(d23+dox)	some	sgRNA	sequences	were	massively	enriched	(up	to	2000-fold),	but	most	had	disappeared	completely	(Figure	41,	lower	right).	This	indicates	a	successful	outcome	of	our	positive	selection	screen.		
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Figure	41:	Raw	counts	of	individual	sgRNA	sequences.		
Raw	counts	of	concatenated	sgRNA	sequences	as	obtained	by	deep	sequencing	of	final	PCR	products.	
Obtained	 sequences	were	 demultiplexed,	 trimmed	 and	 aligned	 to	 the	 concatenated	 sequences	 of	 all	
~130,000	sgRNAs	by	Dr.	Dirk	Repsilber.		
4.2.2.3 Identification	of	candidates	using	MAGeCK	Dirk	 Repsilber	 and	 Brynjar	 Bjarnason	 employed	Model-	 based	 Analysis	 of	 Genome-wide	CRISPR/Cas9	Knockout	(MAGeCK)	in	order	to	identify	those	genes	where	sgRNA-mediated	 gene	 knockout	 induced	 survival	 of	 Roquin-1-overexpression	 (Li	 et	 al.,	2014a).	The	MAGeCK	algorithm	consists	of	four	steps:	First,	sgRNA	read	counts	in	each	sample	 are	 median-normalized	 in	 order	 to	 correct	 for	 differences	 in	 sequencing	depths	between	different	samples.	Next,	sgRNAs	are	ranked	according	to	the	number	of	read	counts.	sgRNAs	that	are	not	 involved	 in	the	rescue	phenotype	should	show	a	uniform	 distribution	 across	 treated	 and	 untreated	 samples.	 sgRNAs,	 however,	 that	rank	 significantly	 higher	 in	 the	 treated	 than	 in	 control	 samples,	 are	 prioritized.	Significance	 is	 calculated	 with	 the	 mean	 variance	 model,	 i.e.	 considering	 mean	 and	variance	 of	 sgRNA	 read	 counts	 over	 several	 replicate	 samples.	 Finally,	 the	 list	 of	significantly	enriched	sgRNAs	is	assembled	and	genes	are	ranked	based	on	how	many	
Results	 143	 		sgRNAs	 targeting	 the	 same	 gene	 are	 significantly	 enriched	 (Li	 et	 al.,	 2014a).	 In	 our	screen,	 MAGeCK	 analysis	 resulted	 in	 the	 identification	 of	 31	 protein-coding	 genes	where	multiple	 of	 the	 six	 gene-targeting	 sgRNAs	 from	 the	 library	were	 significantly	enriched	in	the	doxycycline-surviving	cell	pool	as	compared	to	the	untreated	cell	pool	at	 the	 end	 of	 the	 screen	 (d23)	 (Table	 28).	 Although	 1,175	 miRNAs	 were	 likewise	targeted	by	4	sgRNAs	each,	none	was	found	enriched	in	the	doxycycline-surviving	cell	pool.		
Table	 28:	 Ranked	 list	 of	 candidates	 resulting	 from	MAGeCK	 analysis	 comparing	 the	 sample	
d23-dox	with	sample	d23+dox.		
Rank	 Gene	name	 q-value	 Fold	change	 Rank	 Gene	name	 q-value	 Fold	change	
1	 Rc3h1	 4.42E-10	 2,697.6	 17	 Extl1	 3.38E-02	 73.4	
2	 Med24	 4.42E-10	 2,151.0	 18	 Cxxc1	 9.54E-02	 69.1	
3	 Med25	 2.18E-12	 1,478.7	 19	 Ext1	 4.22E-04	 65.8	
4	 Med17	 5.83E-05	 1,342.7	 20	 Usp7	 2.27E-04	 59.8	
5	 Med16	 1.52E-02	 1,255.2	 21	 Trim29	 3.90E-02	 51.2	
6	 Med26	 4.22E-04	 885.9	 22	 Cacybp	 5.98E-02	 50.2	
7	 Rc3h2	 1.76E-02	 470.8	 23	 B3galt6	 3.22E-04	 44.3	
8	 Kmt2b/Wbp7	 3.48E-03	 440.2	 24	 Pcbp1	 8.71E-02	 26.7	
9	 Rhoh	 8.75E-02	 344.0	 25	 Nxf1	 8.44E-03	 23.0	
10	 Snw1	 2.50E-02	 198.6	 26	 Rbm33	 4.87E-02	 17.5	
11	 Ext2	 5.73E-02	 162.5	 27	 Trim28	 3.48E-03	 15.2	
12	 Extl3	 1.08E-06	 123.5	 28	 Kpna6	 1.93E-05	 10.3	
13	 Slc35b2	 5.21E-05	 98.7	 29	 Tada2b	 2.51E-03	 10.3	
14	 Kmt2a/	Mll1	 3.65E-03	 92.3	 30	 Phip	 2.27E-04	 5.1	
15	 Usp8	 5.16E-02	 92.3	 31	 Leprel2	 5.98E-02	 2.7	
16	 Cacul1	 1.51E-04	 85.3	 	 	 	 		The	fold	change	indicates	the	extent	of	enrichment	in	the	doxycycline-treated	sample	and	 determines	 the	 rank,	while	 the	 q-value	 shows	 the	 significance.	 Identification	 of	Rc3h1	 as	 the	 top	 gene	 necessary	 for	 Roquin-1-induced	 cell	 death	 (>	 2000-fold	enriched)	 was	 an	 expected	 positive	 control,	 since	 targeting	 sgRNAs	 will	 prevent	overexpression	 of	 Roquin-1-P2A-mCherry,	 thereby	 providing	 the	 cell	 with	 the	opportunity	to	circumvent	Roquin-1-induced	cell	death.	To	help	classify	the	remaining	candidates,	the	STRING	protein	interaction	database	was	consulted	in	order	to	identify	known	 and	 predicted	 protein-interactions	 among	 the	 candidates	 (http://string-db.org).	 Five	 clusters	 of	 protein	 interactions	 were	 discovered.	 Ubiquitin-specific	peptidase	7	(Usp7)	and	Usp8	are	deubiquitinating	enzymes	involved	in	the	removal	of	 ubiquitin	 residues	 from	 proteins	 that	 were	 previously	 transferred	 by	 E3	 protein	ligases	 (Komander	 et	 al.,	 2009).	 Since	 Roquin-1,	 Roquin-2,	 Trim28	 and	 Trim29	 all	
144	 Results			possess	 predicted	 or	 proven	 E3	 ligase	 function	 (Vinuesa	 et	 al.,	 2005),	 this	 group	 of	genes	 is	 highly	 interesting	 and	 may	 represent	 a	 network	 of	ubiquitination/deubiquitination	 events	 to	 promote	 Roquin-1-mediated	 cell	 death	signaling.	Another	striking	protein-interaction	cluster	comprised	several	members	of	the	 heparan	 sulfate	 synthesis	 pathway.	 Four	 of	 five	 members	 of	 the	 Exostosin	protein	 family	 (Ext1,	Ext2,	Extl3,	Extl1)	were	 found	among	 the	screen	candidates,	as	well	 as	 two	 other	 proteins	 (Slc35b2,	 B3galt6)	 that	 are	 involved	 in	 protein	glycosylation.	 Other	 interactions	 suggested	 by	 STRING	 involved	 the	 nuclear	
import/export	 pathway	 (Kpna6/Nxf1),	 a	 cluster	 involved	 in	histone	 methylation	(Cxxc1,	 Mll1,	 Wbp7)	 and	 interactions	 between	 subunits	 of	 the	mediator	 complex	(Med16,	Med17,	Med24,	Med25,	Med26).		
	
Figure	 42:	 Clustering	 of	 screen	 candidates	 according	 to	 known	 and	 predicted	 protein	
interactions.		
The	 list	 of	 screen	 candidates	 was	 evaluated	 using	 the	 STRING	 protein	 interaction	 database	
(http://string-db.org).	 Predicted	 protein	 interactions	 are	 based	 on	 coexpression	 (black	 lines),	
experimental	protein-interaction	data	(pink),	occurrence	in	databases	(turquoise),	homology	(purple)	
or	text	mining	(green).		
Results	 145	 		In	addition	to	Rc3h1,	five	subunits	of	the	mediator	complex	were	the	highest-scoring	candidates	in	the	screen.	The	large	mediator	complex	consists	of	26	core	proteins	and	is	 recruited	 to	 DNA	 by	 transcription	 factors	 to	 induce	 polymerase-II-dependent	transcription	of	protein-coding	genes	(Allen	&	Taatjes,	2015).	Thus,	we	had	a	sneaking	suspicion	 that	 transcription	of	Roquin-1-P2A-mCherry	 rather	 than	effector	 functions	associated	with	 Roquin-1	 overexpression	 seemed	 to	 be	 affected	 by	 the	 knockout	 of	these	 candidate	 genes.	 This	 could	 also	 be	 true	 for	 other	 candidates	 with	 known	transcription	 promoting	 functions,	 such	 as	 histone	 methyltransferases.	 In	 order	 to	discriminate	 between	 true	Roquin-1	 effector	 proteins	 and	 transcriptional	 regulators	required	 to	 express	 Roquin-1,	 we	 decided	 to	 repeat	 the	 screen	 with	 an	 additional	sorting	step	for	mCherry	expression	at	the	end,	which	would	allow	us	to	focus	only	on	those	cells	with	intact	Roquin-1-P2A-mCherry	overexpression.		
4.2.2.4 Secondary	CRISPR/Cas9	screen		For	the	cell	sorting	approach,	frozen	cell	aliquots	of	library-transduced	reporter	cells	after	 puromycin	 selection	 (d8)	 from	 the	 first	 CRISPR/Cas9	 screen	were	 thawed	 and	treated	 with	 doxycycline	 or	 left	 untreated.	 Cells	 were	 cultured	 in	 the	 presence	 of	doxycycline	for	18	instead	of	14	days	in	order	to	reach	to	the	cell	number	required	for	cell	 sorting	 and	 downstream	 processing.	 14.5	%	 of	 doxycycline-treated	 cells	 were	mCherry+	on	day	18	of	doxycycline	treatment	as	compared	to	uninduced	control	cells,	indicating	that	indeed	a	large	number	of	sgRNAs	in	this	pool	interfered	with	Roquin-1-P2A-mCherry	overexpression.	Alternatively,	cells	may	have	adapted	to	counteract	the	strong	 overexpression,	 or	 both.	 Next,	 cells	 were	 sorted	 using	 a	 BD	 FACSAria	 cell	sorting	machine	to	separate	mCherry+	from	mCherry-	cells	(Figure	43).	The	purity	of	the	 cell	 populations	was	 >	99	%	 for	mCherry-	cells,	 but	 only	 67	%	 for	 the	mCherry+	population.	This	 result	might	be	due	 to	 the	 tendency	of	MEF	 cells	 to	 adhere	 to	 each	other,	 or	 due	 to	 a	 loss	 of	 the	 mCherry	 fluorescence	 signal	 due	 to	 photobleaching	(Shaner	et	al.,	2005).		
146	 Results			
	
Figure	43:	Sorting	of	mCherry+	cells	from	the	Roquin-1-overexpression-surviving	cell	pool.		
Flow	cytometric	analysis	of	mCherry	expression	in	reporter	MEF	cells	of	our	secondary	CRISPR/Cas9	
screen,	 after	 18	 days	 of	 doxycycline	 treatment.	 Cells	 were	 sorted	 into	 mCherry+	 and	 mCherry-	
populations	using	uninduced	cells	as	a	negative	reference.		
After	 PCR-amplification	 of	 the	 integrated	 sgRNA	 sequences	 from	 genomic	 DNA	obtained	 from	 both	 cell	 populations,	 high-throughput	 sequencing	 and	 data	 analysis	were	 performed.	 In	 the	 analysis,	 Dirk	 Repsilber	 focused	 on	 the	 31	 candidates	identified	in	the	first	screen,	and	asked	whether	these	hits	were	significantly	enriched	in	the	genomes	of	mCherry+	cells	as	compared	to	mCherry-	cells	and	vice	versa.	From	normalized	 sgRNA	 sequence	 counts	 the	 fold	 changes	 were	 calculated	 for	 each	candidate	(Table	29).	A	fold	change	<	1	means	that	more	sgRNA	counts	were	observed	in	mCherry-	 cells	 than	 in	mCherry+	cells,	 while	 a	 fold	 change	 >	1	 points	 towards	 an	enrichment	 in	 mCherry+	 cells.	 Additionally,	 false	 discovery	 rates	 (FDR)	 for	 sgRNA	enrichment	 were	 calculated,	 with	 a	 FDR	<	0.05	 indicating	 significant	 enrichment	(shown	in	red	in	Table	29).		
The	 most	 prominent	 result	 of	 our	 secondary	 CRISPR/Cas9	 screen	 was	 that	 sgRNA	sequences	 targeting	 mediator	 complex	 proteins	 were	 strongly	 and	 significantly	enriched	 in	 the	mCherry-	 sample.	Since	 the	mediator	complex	 functions	as	a	general	transcriptional	 co-activator,	 it	might	be	concluded	 that	 sgRNA-mediated	knockout	of	some	 of	 its	 components	 represses	 overexpression	 of	 Roquin-1-P2A-mCherry.	Surprisingly,	 Rc3h1	was	 not	 found	 enriched	 in	mCherry-	 samples.	 This	might	mean	that	 in	 addition	 to	 overexpressed	 Roquin-1,	 which	 is	 coexpressed	 with	 mCherry,	 a	certain	amount	of	endogenous	Roquin-1	may	be	required	to	induce	cell	death.			
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Table	29:	MAGeCK	analysis	of	candidate	enrichment	in	mCherry+	and	mCherry-	cells.		
Gene	name	 Fold	change	 FDR	mCherry-	 FDR	mCherry+	
Med24	 0.35	 6.07E-06	 1.00E+00	
Med25	 0.35	 6.07E-06	 1.00E+00	
Med17	 0.14	 3.45E-04	 7.40E-01	
Med16	 0.18	 1.19E-03	 7.40E-01	
Med26	 0.36	 1.03E-02	 1.00E+00	
Rc3h1	 4.14	 1.00E+00	 1.22E-01	
Rc3h2	 5.78	 1.00E+00	 3.65E-01	
Usp8	 2.41	 1.00E+00	 1.00E+00	
Usp7	 3.11	 1.00E+00	 6.95E-01	
Trim29	 0.41	 3.83E-02	 1.00E+00	
Cacybp	 62.16	 1.00E+00	 1.47E-03	
Trim28	 0.90	 6.97E-01	 1.00E+00	
Ext2	 22.76	 1.00E+00	 4.77E-02	
Extl3	 6.58	 1.00E+00	 2.49E-02	
Ext1	 51.79	 1.00E+00	 5.89E-03	
Extl1	 10.63	 1.00E+00	 6.73E-01	
Slc35b2	 16.76	 1.00E+00	 2.19E-03	
B3galt6	 3.45	 1.00E+00	 1.57E-02	
Kmt2b	 2.05	 1.00E+00	 1.00E+00	
Kmt2a	 2.98	 1.00E+00	 6.86E-01	
Nxf1	 5.07	 1.00E+00	 1.43E-01	
Kpna6	 102.92	 1.00E+00	 6.07E-06	
Rbm33	 3.40	 1.00E+00	 6.73E-01	
Tada2b	 3.26	 1.00E+00	 1.43E-01	
Phip	 2.12	 7.91E-01	 1.00E+00	
Cacul1	 128.31	 1.00E+00	 6.07E-06		
Despite	 the	surprising	result	 for	Roquin-1-targeting	sgRNAs,	 this	approach	served	to	successfully	weed	 out	 factors	 that	 generally	 interfere	with	 transcription	 such	 as	 the	mediator	complex	and	increased	our	confidence	in	the	remaining	candidates.		
4.2.2.5 Identification	of	promising	candidates	Of	the	eight	candidates	that	were	significantly	enriched	in	mCherry+	cells,	five	turned	out	to	be	highly	interesting	due	to	their	function	in	a	shared	pathway.	Ext1,	Ext2	and	Extl3	belong	to	the	Exostosin	protein	family.	Moreover,	the	family	member	Extl1	was	identified	 in	 the	 primary	 screen	 and	 also	 enriched	 in	 mCherry+	 cells,	 though	 not	significantly.	 Together	 with	 the	 similarly	 enriched	 candidates	 Slc35b2	 and	 B3galt6,	EXT	family	proteins	are	involved	in	the	biosynthesis	of	heparan	sulfate	proteoglycans	(Duncan	et	al.,	2001).	Heparan	sulfates	are	negatively	charged	oligosaccharide	chains	
148	 Results			that	are	covalently	linked	to	selective	serine	residues	on	core	proteins	via	the	action	of	EXT	 glycosyl	 transferases.	 The	 resulting	 heparan	 sulfate	 proteoglycans	 are	transported	to	the	outer	surface	of	the	cell,	where	they	mediate	cell	migration	and	cell-to-cell	contact	(Simon	Davis	&	Parish,	2013).	Looking	at	the	normalized	counts	of	each	individual	sgRNA	in	mCherry+	versus	mCherry-	cells,	 it	was	obvious	that	for	all	 three	Ext	family	members	as	well	as	for	Slc35b2	and	B3galt6,	three	or	even	four	individual	sgRNAs	 were	 identified	 by	 deep	 sequencing,	 and	 most	 importantly,	 all	 of	 them	occurred	prevalently	in	mCherry+	cells	(Figure	44).		
	
	
Figure	 44:	 sgRNA	 sequence	 representation	 in	mCherry+	 and	mCherry-	 cells	 for	 candidates	 of	
the	heparan	sulfate	biosynthesis	pathway.		
Normalized	sgRNA	sequence	counts	derived	from	genomes	of	mCherry+	and	mCherry-	cell	populations	
shown	 for	 six	 candidates	 involved	 in	 heparan	 sulfate	 synthesis.	 Colors	 represent	 different	 sgRNAs	
targeting	the	same	gene.	Each	candidate	gene	was	targeted	by	six	sgRNAs,	but	sgRNA	sequences	that	
were	 neither	 present	 in	 mCherry+	 nor	 in	 mCherry-	 samples	 were	 not	 depicted.	 This	 data	 set	 was	
provided	by	Dr.	Dirk	Repsilber.		
Even	 for	 Extl1,	where	 enrichment	 in	mCherry+	 cells	was	 not	 significant,	 one	 sgRNA	showed	 a	 strong	 overrepresentation	 in	 mCherry+	 cells.	 Discovery	 of	 several	 critical	players	 of	 one	 pathway,	which	 are	 represented	 by	multiple	 sgRNAs	 per	 gene,	 is	 the	ideal	outcome	of	a	genome-wide	screen.	It	now	remains	to	be	solved	how	the	heparan	sulfate	 proteoglycan	 synthesis	 pathway	 is	 linked	 to	 Roquin-1-induced	 cell	 death.	Interestingly,	EXT	family	proteins	have	been	described	as	tumor	suppressor	genes	in	the	literature	(Busse-Wicher	et	al.,	2014).	Mutations	of	either	EXT1	or	EXT2,	but	not	of	their	 paralogs	 EXTL1,	 EXTL2	 or	 EXTL3,	 lead	 to	 the	 hereditary	 multiple	
Results	 149	 		osteochondromas	(HMO)	disease	in	humans,	which	is	characterized	by	the	formation	of	multiple	bone	tumors	(Jennes	et	al.,	2009).	How	exactly	EXT1	and	EXT2	elicit	their	role	as	tumor	suppressors	is	still	unknown.	Their	loss	might	prevent	the	generation	of	certain	 proteoglycan(s)	 that	 restrict	 aberrant	 cell	 growth,	 which	 might	 equally	 be	responsible	for	Roquin-1-induced	cell	death.	Identifying	these	unknown	factors	will	be	a	 central	 aim	 of	 future	 studies.	 Other	 interesting	 candidates	 that	 emerged	 from	 the	screen	were	proteins	linked	to	the	E3	ligase	function	of	Roquin-1.	Rc3h2,	encoding	the	Roquin	paralog	Roquin-2,	was	>	400-fold	increased	in	the	primary	screen	and	showed	a	 strong,	 but	 non-significant	 enrichment	 in	 mCherry+	 cells,	 represented	 by	 two	sgRNAs	(Figure	45).	Roquin-1	and	Roquin-2	might	function	as	heterodimers	here,	as	it	is	 often	 observed	 among	 members	 of	 RBP	 families	 (e.g.	 the	 FMR	 family	 chapter	1.1.4.1).	 Alternatively,	 Roquin-2	might	 act	 as	 an	 E3	 ligase	 downstream	 of	 Roquin-1,	ubiquitinating	 the	 apoptosis-signal	 regulating	 kinase	 1	 (ASK-1)	 (Maruyama	 et	 al.,	2014).	 Other	 highly	 interesting,	 ubiquitination-related	 candidates	 were	 Cacybp,	 a	bridging	 factor	 of	 calcium-dependent	 ubiquitination,	 and	 the	 deubiquitinases	 Usp7	and	Usp8.	These	candidates	will	be	central	to	the	discussion	(Chapter	5.2).		
	
	
Figure	 45:	 sgRNA	 sequence	 representation	 in	mCherry+	 and	mCherry-	 cells	 for	 candidates	 of	
the	ubiquitin	conjugation	and	deubiquitination	pathway.		
Normalized	sgRNA	counts	derived	from	genomes	of	mCherry+	and	mCherry-	cell	populations	shown	for	
six	 candidates	 involved	 in	 ubiquitination/deubiquitination	 of	 proteins.	 Colors	 represent	 different	
sgRNAs	 targeting	 the	 same	 gene.	 Each	 candidate	 gene	 was	 targeted	 by	 six	 sgRNAs,	 but	 sgRNA	
sequences	that	were	neither	present	in	mCherry+	nor	in	mCherry-	samples	were	not	depicted.	This	data	
set	was	provided	by	Dr.	Dirk	Repsilber.		
150	 Results			To	 conclude,	 our	 genome-wide	 CRISPR/Cas9	 screen	 led	 to	 the	 identification	 of	promising	 candidates	 with	 a	 possible	 role	 in	 Roquin-1-induced	 cell	 death.	 Further	evaluation	 of	 target	 proteins	 involved	 in	 ubiquitin	 conjugation	 will	 likely	 reveal	exciting	 new	 insights	 into	 Roquin-1’s	 putative	 role	 as	 an	 E3	 ligase.	 Finding	 several	essential	 members	 of	 the	 heparan	 sulfate	 synthesis	 pathway	 among	 our	 top	candidates	 enormously	 strengthened	 our	 confidence	 in	 the	 performance	 of	 the	CRISPR/Cas9	 technology	 as	 applied	 in	 this	 whole-genome	 screening	 approach.	 As	unexpected	 as	 it	 was	 to	 uncover	 a	 potential	 role	 for	 heparan	 sulfates	 in	 Roquin-1-mediated	 cell	 death,	 it	 bears	 the	 potential	 to	 cast	 light	 on	 a	 Roquin-1	 function	 that	until	now	is	entirely	unknown.			
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5 Discussion	
In	 this	 research	 project,	 two	 different	 high-throughput	 screening	 technologies	were	applied	in	order	to	identify	cofactors	of	Roquin-1-mediated	post-transcriptional	gene	regulation.	In	a	targeted	siRNA	screen,	we	screened	for	cofactors	of	Roquin-1	in	post-transcriptional	repression	of	 the	 inducible	T	cell	costimulator	 ICOS,	while	a	genome-wide	 CRISPR/Cas9	 screen	 aimed	 at	 the	 discovery	 of	 gene	 products	 required	 for	Roquin-1-induced	 cell	 death.	 In	 this	 discussion,	 I	 will	 first	 compare	 the	accomplishment	and	results	of	both	screening	approaches,	emphasizing	the	particular	challenges	faced	within	each	screen.	After	developing	hit	validation	strategies	for	both	screening	approaches,	I	will	then	focus	on	the	uncharacterized	protein	Nufip2,	which	arose	 as	 a	 promising	 candidate	 from	 the	 RNAi	 screen.	 Based	 on	 the	 functional	validation	of	Nufip2	as	 a	 cofactor	of	Roquin-1	 that	was	part	 of	 this	 research	work,	 I	will	 discuss	 the	 burning	 question	 for	 the	 function	 of	 Nufip2	 in	 Roquin-1-mediated	post-transcriptional	gene	regulation,	and	how	this	can	be	solved	experimentally.		
5.1 Accomplishment	 and	 data	 analysis	 of	 two	 high-
throughput	screens	
5.1.1 Targeted	 siRNA	 screen	 for	 cofactors	 of	 Roquin-1-mediated	 ICOS	
regulation	When	this	research	project	was	started,	loss-of	function	screening	in	mammalian	cells	was	 restricted	 to	 the	 RNA-interference	 technology	 (Chapter	 1.1.3).	 In	 collaboration	with	the	Functional	Genomics	Center	at	La	Jolla	Institute	for	Allergy	and	Immunology,	we	decided	to	set	up	an	arrayed	reporter-based	siRNA	screen	for	Roquin-1	function.	I	generated	 a	 HeLa	 reporter	 cell	 line	 where	 downregulation	 of	 an	 ICOS	 reporter	 in	response	 to	 doxycycline-inducible	 Roquin-1-P2A-mCherry	 overexpression	 was	quantified	 in	 a	 flow	 cytometric	 assay.	 The	 suitability	 of	 the	 cell	 line	 for	 high-throughput	screening	was	confirmed	 in	pilot	assays	without	siRNAs	(Figure	12)	and	after	 transfection	 with	 control	 siRNAs	 (Figure	 13).	 To	 increase	 the	 screening	throughput,	I	established	fluorescent	cell	barcoding	with	a	2x2	barcoding	matrix	that	was	capable	of	enhancing	the	screening	throughput	4-fold	(Figure	14).	However,	due	to	 the	complexity	of	 the	screening	assay	we	were	unable	 to	perform	a	genome-scale	screen,	and	decided	for	a	targeted	screen	instead.	We	thus	screened	six	preassembled	protein	 subset	 libraries	 (Figure	 15)	 and	 a	 customized	 siRNA	 library	 of	 RBPs,	 stress	
152	 Discussion			granule-,	 P	 body-	 and	mRNA	decay	 factors	 (Figure	17).	 Screening	 of	 the	 customized	siRNA	 library	 resulted	 in	 the	 assembly	 of	 a	 primary	 target	 list	 of	 candidate	 genes	(Table	27).	This	list	included	several,	but	not	all	proteins	being	referred	to	as	Roquin-1	cofactors	in	the	literature.	Two	validated	cofactors	of	Roquin-1,	the	enhancer	of	mRNA	decapping	Edc4	(Glasmacher,	2010)	and	the	scaffolding	subunit	of	the	Ccr4-Caf1-Not	deadenylation	 complex	 Cnot1	 (Leppek	 et	 al.,	 2013;	 Murakawa	 et	 al.,	 2015)	 were	identified	 in	 the	screen.	However,	 considering	 the	 fact	 that	both	proteins	are	part	of	large	multi-protein	complexes,	(Figure	1)	one	would	have	expected	to	find	more	than	just	 one	 representative	 protein	 of	 each	 complex.	 Next	 to	 Edc4,	 an	 interaction	 with	Roquin-1	has	been	 shown	 for	 the	RNA	helicase	Rck,	which	 is	 also	part	of	 the	mRNA	decapping	complex	(Glasmacher	et	al.,	2010).	Moreover,	Roquin-1	has	been	reported	to	 be	 co-immunoprecipitated	 with	 several	 more	 proteins	 of	 the	 Ccr4-Caf1-Not	complex	 including	 the	 catalytic	 subunits	 Cnot7	 and	 Cnot8	 (Leppek	 et	 al.,	 2013;	Murakawa	 et	 al.,	 2015).	 The	 nonappearance	 of	 Edc4,	 Rck,	 Cnot7	 and	 Cnot8	 in	 the	target	 list	can	have	multiple	reasons.	First	of	all,	knockdown	of	one	protein	might	be	compensated	by	a	paralog.	In	line	with	this,	 it	has	been	shown	that	the	deadenylases	Cnot7	and	Cnot8	can	largely	compensate	for	each	other’s	function	(Aslam	et	al.,	2009).	Furthermore,	the	impact	of	certain	cofactors	might	be	target-specific,	as	in	the	case	of	Regnase-1.	 Regnase-1	 was	 shown	 to	 be	 indispensable	 for	 Roquin-1-mediated	repression	of	 the	CDE260	minimal	response	element	 from	the	TNF	mRNA	(Jeltsch	et	al.,	2014),	and	was	therefore	expected	to	be	likewise	required	for	Roquin-1	dependent	
ICOS	regulation.	However,	our	overexpression	analysis	of	Roquin-1	and	Regnase-1	in	knockout	 MEF	 cells	 revealed	 that	 both	 proteins	 could	 work	 independently	 of	 each	other	 on	 ICOS	 (Figure	 18),	which	 explains	why	Regnase-1	was	missing	 in	 the	 target	list.	The	last,	most	prominent	reason	for	the	lack	of	certain	known	cofactors	in	the	list	of	candidate	genes	may	be	insufficient	protein	knockdown.	siRNAs	interfere	with	their	target	gene	expression	at	the	transcript	level,	leading	to	incomplete	gene	knockdown	since	some	transcripts	naturally	escape	the	silencing	mechanism	(Chapter	1.1.3).	This	characteristic	of	RNAi-based	screening	approaches	 is	responsible	 for	a	 large	number	of	false	negatives	in	primary	hit	lists	(Booker	et	al.,	2011).		Besides	false	negatives,	the	identification	of	false	positives	is	a	major	challenge	when	analyzing	RNAi	screening	data.	Screening	the	six	preassembled	siRNA	libraries	as	well	as	the	customized	siRNA	library	arrived	at	hit	rates	of	approximately	5	to	7	%	(Figure	15).	Whether	 this	 is	 high	 or	 low	 compared	 to	 other	 siRNA	 screens	 is	 hard	 to	 judge,	since	 the	 definition	 of	 a	 hit	 is	 different	 for	 individual	 researchers.	 Primary	 hit	 rates	
Discussion	 153	 		range	from	2	–	3	%	up	to	17	%,	depending	on	the	chosen	threshold	(Said	et	al.,	2014).	While	the	threshold	of	genome-wide	screens	is	often	set	to	Z	>	3	due	to	limited	follow-up	capacities	(Sharma	&	Rao,	2009),	targeted	screens	start	with	a	much	lower	number	of	siRNAs	to	be	screened	and	can	thus	afford	to	include	all	candidates	with	Z	>	2.	Since	the	 former	 option	 bears	 the	 risk	 of	 false	 negatives,	 we	 decided	 to	 use	 Z	>	2	 as	 the	cutoff,	thus	taking	higher	rates	of	false	positives	into	account.		For	validation,	I	deconvoluted	the	siRNA	pools	to	determine	phenotypic	effect	as	well	as	the	knockdown	efficiency	for	each	individual	siRNA.	To	our	big	surprise,	only	two	of	14	 candidates	 passed	 this	 first	 step	 of	 validation	 (Figure	 19,	Figure	 21,	 Appendix	 II,	Appendix	III).	Interestingly,	the	fact	that	false	positive	candidates	dominate	hit	lists	of	primary	 RNAi	 screens	 has	 been	 more	 and	 more	 acknowledged	 (personal	communication	at	the	screening	conference	“Discovery	on	Target”,	Boston,	September	2015).	Already	 a	 decade	 ago,	 it	 has	 been	described	 that	 siRNAs	 can	 cause	 off-target	knockdowns,	 which	 is	 thought	 to	 be	 due	 to	 miRNA-like	 repression	 of	 mRNAs	 that	harbor	 seed-region	 complementarity	 (Birmingham	 et	 al.,	 2006).	 In	 principle,	 19-nt-long	siRNAs	are	carefully	designed	to	show	perfect	and	exclusive	complementarity	to	one	RNA	of	the	whole	transcriptome,	but	nonetheless,	their	5’	ends	can	mimic	the	6	-	8	nt	long	seed	regions	of	endogenous	miRNAs,	resulting	in	hundreds	of	potential	target	sites	 bearing	 seed-region	 complementary.	 Recently,	 researchers	 realized	 the	magnitude	of	 this	phenomenon	and	 its	 impact	on	RNAi	 screens	(Marine	et	al.,	2012;	Sudbery	 et	 al.,	 2010).	Marine	 and	 colleagues	 performed	 a	Wnt/β-catenin-Luc	 siRNA	screen	using	a	 library	 in	which	one	gene	 is	 targeted	by	multiple	 individual	duplexes.	Disturbingly,	 they	 saw	 almost	 no	 correlation	 between	 the	 results	 of	 different	 siRNA	duplexes	 targeting	 the	 same	gene,	but	a	 stronger	 correlation	 for	 individual	duplexes	sharing	the	same	seed	sequence	but	designed	to	target	different	genes	(Marine	et	al.,	2012).	 In	 their	 screen,	 the	 seed	 sequence	 appeared	 to	 be	 the	 main	 determinant	 of	siRNA	performance.	This	led	to	the	conclusion	that	primary	hit	lists	are	dominated	by	false-positives,	resulting	from	seed-based	off-target	effects	(Marine	et	al.,	2012).	Based	on	 this	 finding	 it	 appears	 logical	 that	 of	 14	 RNA-binding	 proteins	 identified	 in	 my	primary	screen	only	two	emerged	as	true	cofactors	of	Roquin-1.		Several	improvements	in	the	set-up	of	an	RNAi	screen	can	help	to	avoid	false	positives,	some	 of	which	 had	 already	 been	 considered	 in	 our	 approach.	 First	 of	 all,	 a	 gain-of-function	screen	was	favored	over	a	loss-of-function	screen.	When	looking	for	the	loss	of	 a	 certain	 phenotype,	 false	 positives	 can	 arise	 from	 all	 proteins	 with	 functions	 in	
154	 Discussion			general	 cellular	 processes,	 such	 as	 cell	 viability,	 transcription	 or	 translation.	 Such	proteins	can	inhibit	reporter	expression	regardless	of	the	pathway	that	is	supposed	to	be	 screened.	 Moreover,	 upon	 advice	 of	 Dr.	 Sonia	 Sharma	 from	 the	 Functional	Genomics	Center	at	La	Jolla	Institute	for	Allergy	and	Immunology,	we	administered	the	siRNA	pools	at	a	low	concentration	(20	nM	total),	which	limits	off-target	effects	due	to	low	individual	siRNA	concentrations.	However,	since	our	primary	hit	list	still	included	≈85	%	 false	 positive	 candidates,	 I	 propose	 these	 additional	 changes	 to	 reduce	 this	number	in	future	screening	assays:		
• Use	of	second-generation	siRNA	libraries	such	as	Dharmacon	ON-TARGETplus	instead	 of	 siGENOME.	 siRNA	 duplexes	 consist	 of	 a	 sense	 and	 an	 antisense	strand,	whereby	only	the	antisense	strand	is	intended	to	be	incorporated	into	the	 RISC	 complex	 for	 cleavage	 of	 perfectly	 complementary	 target	 sequences	(Chapter	 1.1.3).	 Off-target	 effects	 can,	 however,	 arise	 from	 unwanted	 RISC	loading	 of	 the	 sense	 strand	 (Schwarz	 et	 al.,	 2003).	 In	 the	 ON-TARGETplus	library,	 chemical	 modifications	 of	 the	 siRNA	 duplexes	 bias	 strand	 loading	towards	the	antisense	strand	(Dharmacon;	Vaish	et	al.,	2011).	Moreover,	seed	sequences	 from	 known	 mammalian	 microRNAs	 are	 avoided	 in	 second	generation	siRNA	libraries	(Dharmacon).		
• Take	 all	 positively	 scoring	 candidates	 arising	 from	 a	 primary	 screen	 with	siRNA	 pools	 into	 a	 secondary	 screen	 with	 a	 custom-arrayed	 library	 of	 4	-	6	individual	duplexes	per	gene.		
• Designing	“C9-11	controls”	for	all	hits	arising	from	the	secondary	screen.	Here,	bases	9-11	of	the	siRNA	duplex	are	exchanged	by	their	complementary	bases,	thereby	 prohibiting	 endonucleolytic	 cleavage	 of	 the	 perfectly	 complementary	target	 mRNA,	 while	 seed-based	 off-target	 knockdowns	 are	 unimpaired.	 For	true	candidates,	exchanging	bases	9-11	should	abrogate	the	phenotypic	effect,	while	its	persistence	indicates	a	false	positive	candidate	(Buehler	et	al.,	2012a).		
• For	 large	 data	 sets	 screened	with	 individual	 duplexes,	 two	 different	 publicly	available	 software	 tools,	 Genome-wide	 Enrichment	 for	 Seed	 Sequence	match	(GESS)	(Sigoillot	et	al.,	2012)	and	Haystack	(Buehler	et	al.,	2012b),	can	help	to	identify	seed	sequence-caused	off-target	effects	of	primary	screen	data	prior	to	candidate	validation.		
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5.1.2 CRISPR/Cas9	screen	for	cofactors	of	Roquin-1-induced	cell	death	While	the	targeted	siRNA	screen	was	ongoing,	pooled	lentiviral	CRISPR/Cas9	libraries	(Chapter	 1.2.2)	 were	 developed	 as	 an	 alternative	 to	 RNAi	 based	 screens.	 Here,	genome-covering	single	guide	RNAs	(sgRNAs)	are	delivered	simultaneously	to	a	large	cell	pool	together	with	the	Cas9	nuclease,	and	initiate	targeted	gene	knockouts	(Koike-Yusa	et	al.,	2013;	Shalem	et	al.,	2014;	Wang	et	al.,	2014;	Zhou	et	al.,	2014).	By	targeting	the	 genomic	 loci	 rather	 than	 the	 transcript	 level,	 the	 CRISPR/Cas9	 technology	overcomes	one	of	the	big	challenges	of	RNAi:	the	incomplete	gene	knockdown	leading	to	 a	 high	 frequency	 of	 false	 negatives	 in	 a	 screen.	 Due	 to	 the	 advantages	 that	 this	system	offers,	we	decided	 to	 employ	 a	CRISPR/Cas9	 rather	 than	an	RNAi	 screen	 for	our	second	screening	approach	searching	for	cofactors	of	Roquin-1-induced	cell	death.		I	 found	 out	 that	 Roquin-1-induced	 cell	 death	 was	 elicited	 when	 a	 reporter	 cell	 line	with	 doxycycline-inducible	 Roquin-1-P2A-mCherry	was	 stimulated	with	 doxycycline	for	 >24	h	 (Figure	 37).	 This	 aspect	was	 not	 part	 of	 the	 first	 screen,	where	 a	 shorter	doxycycline	treatment	(18	h)	was	employed	that	was	insufficient	to	induce	cell	death.	As	 the	 readout	 of	 our	 screen	 was	 cell	 death,	 no	 Z’	 factors	 needed	 to	 be	 calculated	beforehand.	 Instead,	 the	 most	 important	 pre-experiment	 was	 the	 titration	 of	 the	lentiviral	library	to	ensure	single	copy	integration	of	the	sgRNA	cassette	into	each	cell	(Chapter	3.2.10.2).	When	starting	the	screen,	multiple	pooled	 lentiviral	CRISPR/Cas9	libraries	 were	 available	 at	 Addgene.	 Having	 a	 MEF	 reporter	 cell	 line	 at	 hand,	 we	decided	 to	 employ	 the	 mouse	 GeCKO	 v2.0	 library	 designed	 by	 the	 lab	 of	 Dr.	 Feng	Zhang	 (MIT,	 Boston,	 USA).	 The	 mouse	 GeCKO	 library	 contains	 ≈130,000	 individual	sgRNA	 lentiviral	 plasmids,	with	 6	 sgRNAs	 targeting	 each	 of	 the	 20,611	 genes	 of	 the	mouse	genome	(Sanjana	et	al.,	2014).	24	h	after	transduction	of	reporter	cells	with	the	CRISPR/Cas9	 library,	 deep	 sequencing	 of	 reporter	 cells	 revealed	 that	 >	98	%	 of	sgRNAs	 were	 represented	 in	 the	 cell	 pool	 in	 more	 or	 less	 similar	 frequencies,	indicating	 successful	 library	 propagation	 and	 almost	 unbiased	 transduction	 of	 the	MEF	cell	line	(Figure	41).	This	analysis	required	bioinformatics	assistance,	which	is	a	major	drawback	of	pooled	screening.	After	culturing	library-infected	cells	for	14	days	with	or	without	doxycycline	(+/-dox),	deep	sequencing	and	subsequent	statistical	data	analysis	 revealed	 which	 sgRNAs	 were	 selectively	 enriched	 in	 the	 cells	 that	 had	survived	Roquin-1	overexpression	(+dox)	compared	to	those	that	were	left	untreated	(-dox)	(Table	28).		
156	 Discussion			Since	no	screening	results	have	been	published	 for	 the	mouse	Gecko	 library	yet,	our	findings	 can	 only	 be	 compared	 to	 screening	 data	 obtained	 with	 different	 CRISPR	libraries.	The	first	Gecko	library	expressed	both	Cas9	and	the	sgRNA	from	one	vector	to	 target	 ≈18,000	 genes	 of	 the	 human	 genome	 containing	 3	-	4	 sgRNAs	 per	 gene	(Shalem	 et	 al.,	 2014).	 This	 library	 was	 successfully	 applied	 in	 a	 protein	 kinase	inhibitor	 screen	 and	 led	 to	 the	 identification	 of	 several	 known,	 but	 also	 unknown	factors	that	conferred	inhibitor	resistance.	However,	sgRNA	cleavage	efficiencies	and	off-target	hits	were	not	addressed	in	this	publication.	The	CRISPR	library	designed	by	Eric	 Lander’s	 group,	 by	 contrast,	 was	 evaluated	 in	 more	 detail.	 When	 screening	 a	haploid	cell	line	for	essential	factors	of	the	DNA	mismatch	repair	(MMR)	pathway,	the	20	most	abundant	 sgRNAs	were	directed	against	 the	 four	known	components	of	 the	MMR	pathway,	while	only	few	other	sgRNAs	scored	positively	(Wang	et	al.,	2014).	In	combination	with	a	low	number	of	off-target	effects	found	for	the	investigated	sgRNAs,	this	result	suggested	that	 in	contrast	to	RNAi,	CRISPR	screens	are	characterized	by	a	low	 false	 discovery	 rate.	 For	 the	 identified	 candidates,	 at	 least	 4	 out	 of	 10	 sgRNAs	scored	positively,	 indicating	 that	 for	 some	 candidates	up	 to	50	%	of	 sgRNAs	worked	efficiently.	This	 is	 in	good	accordance	with	 the	results	of	our	CRISPR	screen.	For	 the	only	 known	 positive	 control	 Roquin-1	 itself	 as	 well	 as	 candidates	 of	 the	 ubiquitin	conjugation	and	the	glycosylation	pathway	(Figure	44,	Figure	45),	 two	to	 four	out	of	the	 six	 provided	 sgRNAs	 were	 represented	 in	 the	 final	 cell	 pool.	 The	 mouse	 Gecko	library	has	only	been	available	for	two	years,	and	the	six	sgRNAs	targeting	each	gene	were	 randomly	 distributed	 over	 3	-	4	 coding	 exons	 (Sanjana	 et	 al.,	 2014).	 It	 can	therefore	 be	 anticipated	 that	 with	 increasing	 knowledge	 on	 sgRNA	 performance,	better	 design	 of	 CRISPR/Cas9	 libraries	 with	 higher	 cleavage	 efficiencies	 will	 be	possible	in	the	future.	However,	the	outcome	of	our	screen,	identifying	Roquin-1	as	the	top	 candidate	 as	well	 as	 complete	 networks	 of	 proteins,	 demonstrates	 that	 usage	 of	early	CRISPR/Cas9	libraries	can	as	well	lead	to	a	successful	result.		
5.1.3 Comparison	of	both	screening	approaches	Comparing	both	screening	approaches	(Table	30),	 the	arrayed	siRNA	screen	was	the	method	of	 choice	 for	a	 reporter-based	screen	 to	 investigate	Roquin-1-	 induced	post-transcriptional	 gene	 regulation.	 Pooled	 screening	 would	 have	 required	 repeated	sorting	 steps	 for	 cells	 with	 the	 desired	 reporter	 expression,	 which	 is	 both	 time-consuming	 and	 expensive	 and	 therefore	 disadvantageous.	 A	 pooled	 CRISPR/Cas9	screen	was,	however,	chosen	to	investigate	Roquin-1-induced	cell	death,	since	positive	
Discussion	 157	 		selection	 could	 easily	 be	 achieved	 by	 application	 of	 doxycycline	 in	 this	 case.	 The	arrayed	siRNA	screen	included	processing	hundreds	of	plates,	thereby	restricting	the	assay	to	a	targeted	screen.	By	contrast,	all	genes	of	the	mouse	genome	were	targeted	in	 the	 CRISPR/Cas9	 screen.	 This	 higher	 depth	 of	 information	 did,	 however,	 require	bioinformatics	and	statistical	data	analysis	 for	the	CRISPR	screen,	while	results	were	instantly	 available	 in	 the	 RNAi	 screen.	 One	 of	 the	 major	 differences	 between	 both	screening	approaches	is	the	method	of	target	gene	inactivation.	While	siRNAs	achieve	transient	and	 incomplete	gene	knockdown	by	 targeting	 the	mRNA,	 sgRNAs	cause	an	irreversible	knockout	of	 the	gene	of	 interest,	 leading	 to	complete	ablation	of	protein	expression.	 The	 CRISPR/Cas9	 system	 might	 thus	 overcome	 the	 challenge	 of	accumulating	false	negatives	resulting	from	insufficient	protein	knockdown,	which	is	a	big	issue	in	siRNA	screens.		
Table	30:	Comparison	of	high-throughput	screening	methods.		
Type	of	screen	 siRNA	 CRISPR/Cas9	
Screening	format	 arrayed	 pooled	
Delivery	method	 transfection	 lentiviral	
Genome-scale	 (+)	 ++	
Loss	of	gene	expression	 transient	knockdown	 knockout	
Reporter-based		screen	 ++	 (+)	
Positive	selection	screen	 (+)	 ++	
Ease	of	data	analysis	 ++	 (+)	
Off-target	effects	 +++	 (+)	
Primary	validation	 deconvolution	of	siRNA	pools	 -	
	
	On	the	other	hand,	gene	knockout	can	lead	to	another	kind	of	false	negatives.	Recently,	the	 CRISPR/Cas9	 technology	 was	 employed	 in	 order	 to	 identify	 the	 whole	 set	 of	essential	 human	 genes	 in	 a	 whole-genome	 negative	 selection	 screen	 (Wang	 et	 al.,	2015).	 Essential	 genes,	 represented	 by	 sgRNAs	 that	 were	 depleted	 in	 the	 final	population	of	cells	after	14	population	doublings,	made	up	9.2%	of	the	entire	genome.	These	 would	 consequently	 never	 be	 identified	 in	 a	 CRISPR/Cas9	 positive	 selection	screen,	 and	 are	 likely	 to	 be	 missing	 in	 our	 target	 list.	 When	 performing	 a	 positive	selection	screen	expecting	essential	genes	in	the	target	 list,	RNAi	rather	than	CRISPR	might	 thus	 be	 the	 method	 of	 choice.	 False	 positives	 arising	 from	 siRNA	 off-target	effects	were	prevailing	in	the	primary	hit	list	arising	from	our	RNAi	screen.	Separating	true	hits	from	false	positives	emerged	as	a	major	challenge	in	RNAi	screening,	and	was	addressed	 by	 deconvolution	 of	 siRNA	 pools	 in	 this	 research	 work.	 Although	 this	
158	 Discussion			technique	 readily	 identified	 false	 positives,	 it	 is	 expensive	 and	 cumbersome.	 This	primary	 validation	 was	 unnecessary	 in	 the	 CRISPR/Cas9	 screen.	 Each	 gene	 was	targeted	by	6	 individual	 sgRNAs	 in	 the	pool,	 and	only	 those	genes	where	more	 than	one	individual	sgRNA	was	enriched	in	the	doxycycline-surviving	cell	pool	as	identified	by	statistical	analysis	were	considered	as	candidates.		Overall,	 both	 screening	 approaches	 have	 advantages	 and	 disadvantages	 and	 the	appropriate	 technique	 has	 to	 be	 selected	 carefully	 with	 respect	 to	 the	 biological	question.	For	a	reporter-based	screen,	RNAi	is	the	method	of	choice,	while	a	positive	selection	screen	can	highly	benefit	from	the	CRISPR/Cas9	technology.		
5.2 Candidates	 arising	 from	 the	 CRISPR	 screen:	 Towards	 a	
pathway	of	Roquin-1-induced	cell	death?	
A	 total	 of	 30	 candidate	 proteins	 arose	 from	 our	 primary	 screen	 for	 cofactors	 of	Roquin-1-induced	 cell	 death	 (Table	 28),	 comprising	 whole	 networks	 of	 proteins	involved	 in	 protein	 deubiquitination,	 the	 heparan	 sulfate	 synthesis	 pathway,	nucleocytoplasmic	 transport,	 histone	 methylation	 and	 the	 mediator	 complex.	However,	a	network	of	proteins	involved	in	one	of	the	common	pathways	of	cell	death	was	missing,	and	also	individual	candidates	did	not	help	to	shed	light	on	the	question	why	cells	were	dying	in	response	to	Roquin-1	overexpression.	In	the	following,	I	will	therefore	discuss	which	forms	of	cell	death	are	possible	considering	the	morphological	changes	 that	 occur	 during	 Roquin-1-induced	 cell	 death,	 and	 how	 they	 can	 be	confirmed	experimentally.		
5.2.1 Possible	cell	death	pathways	and	their	validation	After	 inducing	 Roquin-1	 overexpression,	 MEF	 cells	 changed	 their	 morphology,	transforming	from	large	plasmacytoid	and	adherent	cells	into	smaller,	more	elongated	and	barely	attached	cells,	which	were	rounding	up,	detaching	and	finally	fragmenting	in	solution	(Figure	46).	This	process	was	strikingly	accompanied	by	the	conversion	of	small,	irregularly	shaped	black	structures	into	larger,	light	round	vesicular	structures,	which	accumulated	in	the	cytoplasm	over	time.		
Discussion	 159	 		
	
Figure	46:	Morphological	changes	of	MEF	cells	undergoing	Roquin-1-induced	cell	death.		
Phase-contrast	 images	 of	 cells	 overexpressing	 doxycycline	 (dox)-inducible	 Roquin-1-P2A-mcherry	
were	captured	under	a	Zeiss	microscope	using	a	20x	magnification	objective.	Cells	were	treated	with	
doxycycline	for	48	h	(+dox)	of	left	untreated	(-dox).		
Determining	the	responsible	cell	death	pathway,	the	first	question	is	whether	it	is	an	active	(regulated)	or	a	passive	form	of	cell	death.	While	regulated	cell	death	is	actively	induced	by	certain	signaling	pathways	and	requires	energy,	passive	cell	death	occurs	upon	 extracellular	 stress	 and	 results	 in	 uncontrolled	 cell	 rupture	 called	 necrosis	(Labbé	 &	 Saleh,	 2011).	 Roquin-1-induced	 cell	 death	 specifically	 occurred	 after	overexpression	of	 full-length	Roquin-1	and	required	 the	C-terminal	part	of	Roquin-1	(proline-rich	region,	coiled-coil)	in	addition	to	the	N-terminal	part	(Figure	37).	It	can	thus	be	 assumed	 that	Roquin-1	overexpression	elicits	 a	 regulated	 form	of	 cell	 death	involving	specific	signaling	pathways	rather	than	inducing	unspecific	cell	stress	due	to	high	 protein	 overexpression.	 Five	 different	 pathways	 of	 regulated	 cell	 death	 are	discriminated	 in	 the	 literature:	 Apoptosis,	 necroptosis,	 autophagy,	 pyroptosis	 and	ferroptosis.	Their	morphological	characteristics	are	compared	in	Table	31.	Apoptosis	is	 the	 most	 prominent	 cell	 death	 pathway	 (Nikoletopoulou	 et	 al.,	 2013).	 It	 can	 be	induced	 intrinsically	 by	 intracellular	 stress	 signals,	 or	 extrinsically	 in	 response	 to	stimulation	of	cell	surface	death	receptors	(Duprez	et	al.,	2009).	Both	pathways	lead	to	the	activation	of	caspases,	the	central	players	of	apoptosis,	which	are	responsible	for	DNA	 fragmentation.	 In	 the	 course	 of	 apoptosis,	 cells	 are	 rounding	 up,	 while	 large	vacuoles	 form	 in	 the	 cytoplasm.	 Apoptotic	 cells	 can	 be	 identified	 by	 characteristic	morphological	changes	such	as	shrinkage	of	nuclei	and	membrane	blebbing,	the	latter	of	which	should	be	easily	detectable	by	light	microscopy	as	round	structures	emerging	from	 the	 plasma	 membrane	 that	 are	 finally	 released	 into	 the	 extracellular	 space	(Schwarzer	 et	 al.,	 2014).	 These	 were	 clearly	 absent	 in	 cells	 dying	 from	 Roquin-1	overexpression	 (Figure	 46),	 thereby	 decreasing	 the	 likelihood	 that	 Roquin-1-overexpressing	cells	underwent	apoptosis.		
160	 Discussion			Another	option	is	necroptosis,	a	programmed	form	of	necrotic	cell	death.	Necroptosis	is	 induced	 by	 death	 receptor	 signaling,	 and	 crucially	 depends	 on	 activation	 of	 the	kinase	 RIP-1,	which	 forms	 a	 pro-necrotic	 protein	 complex	with	 RIP-3	 that	 activates	downstream	effector	proteins.	Morphologically,	necroptotic	cells	can	be	recognized	by	cytoplasmic	 and	 organelle	 swelling,	 which	 is	 noticeable	 by	 cells	 growing	 in	 size.	Finally,	the	cell	membrane	is	ruptured	and	the	cytoplasmic	content	is	released	into	the	extracellular	space	(Duprez	et	al.,	2009).	Since	cells	undergoing	Roquin-1-dependent	cell	death	did	not	grow	 in	size	and	 finally	 “explode”,	but	rather	shrunk	and	rounded	up,	necroptosis	is	unlikely	to	be	the	mechanism	searched	for.	The	same	holds	true	for	pyroptosis,	which	displays	similar	morphological	characteristics.	Pyroptosis	works	via	activation	of	caspase-1,	which	 initiates	DNA	fragmentation	by	other	caspases	as	well	as	 nuclear	 condensation	 as	 observed	 in	 apoptosis	 (Fernandes-Alnemri	 et	 al.,	 2007).	This	 is	 followed	 by	 the	 formation	 of	 pores	 in	 the	 plasma	membrane,	 leading	 to	 cell	swelling	and	membrane	rupture	similar	to	necrosis	(Duprez	et	al.,	2009).		
Considering	 the	 prominent	 accumulation	 of	 vesicular	 structures	 in	 cells	 dying	 from	Roquin-1	overexpression	(Figure	46),	I	find	it	likely	that	autophagy	is	involved	in	the	pathway	 of	 Roquin-1-induced	 cell	 death.	 Autophagy	 is	 a	 cell-intrinsic	 recycling	pathway,	where	cellular	components	are	engulfed	by	specialized	cytoplasmic	vesicles	called	autophagosomes	and	 finally	digested	after	 fusion	with	 lysosomes	 (Jiang	et	 al.,	2011).	 Although	 autophagy	 is	 generally	 believed	 to	 support	 cell	 survival,	 massive	autophagic	activity	can	induce	programmed	cell	death	leading	to	“self-engulfment”	of	a	 dying	 cell	 by	 autophagosomes	 (Fernandes-Alnemri	 et	 al.,	 2007).	 Autophagy	 is	negatively	regulated	by	the	serine/threonine	kinase	mTOR,	and	consequently	initiated	by	mTOR	 inhibition	 e.g.	 in	 response	 to	 starvation	 (Fullgrabe	 et	 al.,	 2014).	The	ULK–Atg13–FIP200	 protein	 complex	 is	 activated	 in	 turn,	 and	 initiates	 the	 formation	 of	autophagosomes	 (Jung	 et	 al.,	 2009).	 Vesicle	 nucleation	 requires	 the	 activation	 of	 a	phosphatidylinositol	3-kinase	(PI3K)	complex	for	generation	of	phosphatidylinositol-3-phosphate	 (Fullgrabe	 et	 al.,	 2014).	 The	 following	 step	 of	 vesicle	 elongation	 is	mediated	 by	 two	 ubiquitin-like	 conjugation	 systems.	 In	 this	 context,	 conjugation	 of	LC3	(LC3-I)	with	phosphatidylethanolamine	(PE)	to	LC3-PE	(also-called	LC3-II),	which	stays	attached	to	the	autophagic	membrane,	is	a	characteristic	marker	of	autophagy.		
Roquin-1-induced	 cell	 death	 also	 shows	 some	 morphological	 characteristics	 of	ferroptosis.	 Ferroptosis	 was	 identified	 in	 2012	 as	 a	 new	 form	 of	 non-apoptotic	 cell	death	being	unaffected	by	inhibitors	of	apoptosis,	necrosis,	necroptosis	and	autophagy	
Discussion	 161	 		(Dixon	 et	 al.,	 2012).	 Moreover,	 it	 showed	 prominently	 different	 morphological	characteristics,	 such	 as	 mitochondrial	 condensation	 and	 rupture	 of	 the	 outer	mitochondrial	membrane.	 The	 execution	 of	 ferroptosis	was	 found	 to	 depend	 on	 the	iron	 metabolisms,	 with	 an	 accumulation	 of	 reactive	 oxygen	 species.	 Inhibitors	 and	inducers	of	ferroptosis	have	readily	been	identified,	however,	 it	 is	still	unclear	which	factors	 control	 ferroptosis	 cell-intrinsically.	 Cells	 undergoing	 ferroptosis	were	 found	to	round	up	and	detach,	which	is	also	a	characteristic	of	Roquin-1-induced	cell	death	(Xie	et	al.,	2016).	This	is,	however,	also	observed	during	apoptosis.	The	comparison	of	characteristic	 morphological	 features	 of	 the	 different	 kinds	 of	 cell	 death	 is	summarized	in	Table	31.		
Table	 31:	 Comparison	 of	 morphological	 features	 of	 different	 types	 of	 regulated	 cell	 death	
(adapted	from	(Xie	et	al.,	2016)).		
Type	of	
cell	death	
Apoptosis	 Necroptosis	 Autophagy	 Ferroptosis	 Pyroptosis	
Cell	
membrane	
Plasma	
membrane	
blebbing	
Rupture	of	the	
plasma	
membrane	
No	changes	 No	changes	 Rupture	of	the	
plasma	
membrane	
Cytoplasm	 Reduction	of	
cellular	
volume,	
rounding	up	
Cytoplasmic	
swelling,	swelling	
of	organelles	
Accumulation	
of	cytoplasmic	
vacuoles	
Condensation	of	
mitochondria,	
outer	
mitochondrial	
membrane	
rupture,	
rounding	up	
Cytoplasmic	
swelling,	
swelling	of	
organelles	
Nucleus	 Nuclear	
shrinkage	and	
fragmentation
,	chromatin	
condensation	
Intermediate	
chromatin	
condensation	
Lack	of	
chromatin	
condensation	
No	changes	 Nuclear	
shrinkage	and	
fragmentation
,	chromatin	
condensation	
	In	 future	experiments,	we	will	 first	 test	whether	autophagy	 is	 involved	 in	Roquin-1-induced	 cell	 death.	 The	 standard	 assay	 demonstrating	 autophagy	 is	 the	 detection	 of	enhanced	 LC3-II,	 the	 lipidated	 form	 of	 LC3-I,	 in	 immunoblotting	 assays.	 This	experiment	 is	 often	 carried	 out	 in	 the	 presence	 and	 absence	 of	 Bafilomycin	 A1,	 an	inhibitor	 of	 the	 autophagosomal-lysosomal	 fusion	 (Gammoh	et	 al.,	 2012;	 Jiang	 et	 al.,	2011).	Since	LC3-II	 is	degraded	 in	 lysosomes	 in	 the	course	of	autophagy,	autophagic	cells	should	accumulate	LC3-II	upon	Bafilomycin	A1	treatment	when	exhibiting	the	full	autophagy	pathway	 including	 the	 formation	of	an	autolysosome.	The	 functionality	of	autolysosomes	can	be	proven	by	determining	the	expression	of	p62.	P62	is	subject	to	strong	degradation	in	autolysosomes,	and	should	consequently	be	reduced	in	protein	lysates	of	 autophagic	 cells	 (Gammoh	et	 al.,	 2012;	 Jiang	et	 al.,	 2011).	All	 three	assays	
162	 Discussion			can	be	performed	easily	by	preparing	protein	extracts	 from	doxycycline-treated	and	untreated	MEF	reporter	cells.	Employing	the	mTOR	inhibitor	rapamycin	as	a	positive	control,	 these	 three	 immunoblotting	 assays	 will	 finally	 clarify	 whether	 or	 not	autophagy	 is	a	 central	aspect	of	Roquin-1-induced	cell	death.	A	 final	proof	would	be	provided	if	Roquin-1-induced	cell	death	was	suspended	upon	application	of	autophagy	inhibitors,	such	as	the	PI3K	inhibitor	3-Methyladenine	(Seglen	&	Gordon,	1982).		
If	autophagic	cell	death	is	not	involved,	assays	for	detection	of	the	other	types	of	cell	death	will	follow.	The	multitude	of	different	methods	existing	to	discriminate	different	cell	 death	 pathways	 are	 summarized	 and	 compared	 in	 (Galluzzi	 et	 al.,	 2009).	 In	general,	a	combination	of	different	approaches	should	be	employed	to	unambiguously prove	a	certain	type	of	cell	death.	The	Nomenclature	Committee	on	Cell	Death	(NCCD)	has	recently	released	recommendations	on	the	classification	of	cell	death	(Galluzzi	et	al.,	2012),	which	might	provide	help	in	the	matter	of	choosing	the	right	assays.		
For	a	 final	diagnosis	of	Roquin-1-induced	cell	death,	 it	would	be	beneficial	 to	obtain	electron	 microscopy	 images	 of	 dying	 cells	 in	 collaboration	 with	 an	 experienced	research	group.	This	would	enable	the	visualization	of	morphological	changes	that	are	too	 small	 to	 be	 seen	 by	 light	 microscopy,	 such	 as	 plasma	 membrane	 rupture,	mitochondrial	changes	as	occurring	during	ferroptosis	or	chromatin	condensation	and	nuclear	 shrinkage,	 which	 are	 hallmarks	 of	 apoptosis	 and	 pyroptosis	 (Galluzzi	 et	 al.,	2009).		
5.2.2 Ubiquitin	conjugation	as	a	potential	pathway	linked	to	Roquin-1	
effector	functions	A	 total	 of	 30	 candidate	 proteins	 arose	 from	 our	 primary	 screen	 for	 cofactors	 of	Roquin-1-induced	 cell	 death	 (Table	28).	 Surprisingly,	 this	 primary	 candidate	 list	 did	not	 contain	 any	 central	 players	 of	 common	 cell	 death	 pathways.	 To	 narrow	 the	candidate	list	down	to	downstream	effector	proteins	of	Roquin-1,	we	first	of	all	aimed	at	eliminating	all	sgRNAs	that	interfered	with	Roquin-1-P2A-mCherry	overexpression.	A	 secondary	 screen	was	 therefore	 performed	with	 an	 additional	 sorting	 step	 at	 the	end	of	the	cell	culture,	separating	mCherry+	from	mCherry-	cells	using	flow	cytometry.	In	 future	 hit	 validation	 experiments,	we	will	 concentrate	 on	 candidate	 genes,	which	were	 targeted	 by	 sgRNAs	 that	 did	 not	 have	 a	 negative	 impact	 on	 Roquin-1-P2A-mCherry	 expression	 (Table	 29).	 This	 final	 list	 of	 proteins	 whose	 sgRNAs	 were	enriched	in	mCherry+	cells	was	dominated	by	six	proteins	of	the	ubiquitin	conjugation	
Discussion	 163	 		system	 (Figure	 44,	Figure	 45).	 Even	without	 knowing	 how	Roquin-1	 overexpression	induces	cell	death,	this	suggests	that	Roquin-1-induced	cell	death	might	be	connected	to	 its	as	yet	barely	 investigated	 function	as	an	E3	ubiquitin	 ligase.	Yet,	 contradicting	evidence	 is	 provided	 by	 my	 initial	 finding	 that	 the	 truncated	 Roquin-1	 (aa	 1-509)	protein	containing	the	RING	finger	and	hence	the	putative	E3	ligase	function	is	unable	to	induce	cell	death	(Figure	37).	However,	since	protein/protein	interaction	domains	are	contained	in	the	C-terminal	part	of	the	Roquin-1	protein,	it	might	be	possible	that	in	addition	to	an	E3	ligase	function	Roquin-1	is	required	to	interact	with	other	factors	(e.	 g.	 Roquin-2)	 in	 order	 to	 induce	 cell	 death.	 To	 clarify	 whether	 the	 RING	 finger	domain	 is	 required	 to	 induce	 Roquin-1-mediated	 cell	 death,	 we	 will	 generate	 a	reporter	 cell	 line	 with	 doxycycline-inducible	 overexpression	 of	 Roquin-1	 where	 the	structure	of	the	RING	finger	is	destroyed	by	point	mutations.	If	this	mutant	is,	similar	to	Roquin-1	(aa	1-509),	unable	to	induce	cell	death,	this	would	be	a	final	proof	that	the	RING	domain	in	combination	with	the	C-terminal	part	of	Roquin-1	mediates	Roquin-1-induced	cell	death.		Among	 the	 final	 candidates	 whose	 cellular	 function	 is	 related	 to	 protein	ubiquitination,	 the	 deubiquitination	 (DUB)	 enzyme	 Usp7	 is	 especially	 interesting.	Usp7	is	strongly	expressed	in	regulatory	T	cells	and	was	found	to	be	associated	with	the	 transcription	 factor	 Foxp3	 in	 the	 nucleus	 of	 Tregs.	 Here,	 Usp7	 stabilizes	 Foxp3	expression	 through	 deubiquitination	 and	 protection	 from	 proteasomal	 degradation.	Therefore,	 Usp7	 strongly	 contributes	 to	 the	 maintenance	 of	 the	 Treg-specific	transcription	program	(van	Loosdregt	et	al.,	2013)	and	consequently	to	immunological	tolerance.	 It	 thus	 complements	 the	 action	 of	 Roquin-1,	 which	 confers	 peripheral	tolerance	by	restricting	aberrant	Th1,	TFH	and	Th17	differentiation.		Interestingly,	Usp7	can	be	a	mediator	of	cell	death	by	deubiquitination	of	p53.	P53	is	a	transcription	factor	that	is	induced	upon	cellular	stress	signals	such	as	DNA	damage	or	starvation	and	a	potent	initiator	of	cell-cycle	arrest	and	apoptosis	(Chen,	2016).	Usp7	can	 stabilize	 both	 p53	 and	 the	 ubiquitin	 ligase	 Mdm2,	 which	 induces	 proteasomal	degradation	of	p53	(Sheng	et	al.,	2006).	 In	normal	cycling	cells,	Mdm2	is	 its	primary	target,	and	Usp7	thus	restricts	p53	levels	(Vucic	et	al.,	2011).	In	line	with	this,	loss	of	Usp7	 has	 been	 reported	 to	 result	 in	 enhanced	 p53	 expression	 and	 thus	 increased	apoptosis	 (Fan	 et	 al.,	 2013;	Kon	 et	 al.,	 2010).	Overexpression	 of	Roquin-1,	 however,	might	 bias	 Usp7	 towards	 deubiquitination	 of	 p53,	 resulting	 in	 high	 p53	 expression	levels	and	cell	death.	Whether	enhanced	p53	expression	is	responsible	for	Roquin-1-
164	 Discussion			induced	 cell	 death	 shall	 be	 easily	 evaluated	 by	 p53	 immunoblotting	 of	 doxycycline-treated	versus	untreated	reporter	cells.	Another	possible	function	of	Usp7	in	Roquin-1-induced	 cell	 death	 is	 direct	 interaction	 and	 stabilization	 of	 Roquin-1.	 DUBs	 are	commonly	 found	 associated	 with	 E3	 ubiquitin	 ligases	 to	 protect	 them	 from	autoubiquitination	 and	 thus	 proteasomal	 degradation	 (Wilkinson,	 2009).	 Following	the	steps	of	the	original	publication	describing	such	a	relationship	for	Usp7	and	Mdm2	(Li	 et	 al.,	 2004),	 we	 will	 determine	 whether	 this	 is	 also	 the	 case	 for	 Roquin-1	 by	performing	three	main	experiments.	Pulldown	of	Roquin-1	from	doxycycline-induced	reporter	cells	and	subsequent	detection	of	Usp7	in	immunoblotting	assays	will	reveal	whether	Roquin-1	forms	a	complex	with	Usp7	to	induce	cell	death.	Secondly,	we	will	determine	 the	 protein	 half-life	 of	 Roquin-1	 with	 the	 protein	 synthesis	 inhibitor	cycloheximide,	 and	 evaluate	 whether	 it	 is	 prolonged	 when	 Usp7	 is	 overexpressed.	Finally,	 in	 vitro	 ubiquitination	 assays	 will	 prove	 whether	 ubiquitinated	 Roquin-1	 is	deubiquitinated	 by	 Usp7.	 These	 approaches	 will	 finally	 clarify	 whether	 Usp7	 is	 a	Roquin-1-stabilizing	DUB	during	Roquin-1-induced	cell	death.		
Overall,	 the	 future	 validation	 strategy	 for	 the	 candidates	 arising	 from	 our	CRISPR/Cas9	screen	for	cofactors	of	Roquin-1-induced	cell	death	will	first	of	all	focus	on	 the	 determination	 of	 the	 type	 of	 cell	 death.	 Once	 this	 is	 accomplished,	 literature	search	 will	 identify	 which	 of	 the	 identified	 networks	 of	 candidate	 proteins	 is	 most	likely	 involved	 in	 the	 particular	 type	 of	 cell	 death,	 and	 CRISPR/Cas9	 gene	 knockout	can	 easily	 be	 employed	 in	 order	 to	 show	whether	 loss	 of	 the	 respective	 candidates	interferes	with	the	determined	type	of	cell	death.	In	parallel,	we	will	dissect	the	role	of	Roquin’s	 function	 as	 an	 E3	 ligase	 in	 Roquin-1-induced	 cell	 death,	 and	 evaluate	whether	 the	promising	 candidate	Usp7	 is	 a	Roquin-1-stabilizing	DUB	and	 inducer	of	cell	death	via	p53.			
5.3 Nufip2	 as	 a	 new	 cofactor	 of	 Roquin-1-mediated	 ICOS	
repression	
The	Nufip2	protein	arose	as	a	promising	candidate	from	the	targeted	siRNA	screen	for	cofactors	 of	 Roquin-1-mediated	 ICOS	 repression.	 Except	 for	 the	 known	 cofactor	CNOT1	(Figure	19),	NUFIP2	was	 the	only	RBP	that	passed	the	primary	validation	by	siRNA	deconvolution	(Figure	21).	I	subsequently	confirmed	the	significance	of	Nufip2	for	 Roquin-1-induced	 ICOS	 repression	 in	 two	 rescue	 experiments	 employing	reconstitution	of	Nufip2-knockdown	HeLa	cells	(Figure	24)	and	CRISPR/Cas9	Nufip2	
Discussion	 165	 		knockout	MEF	cells	with	siRNA-	or	sgRNA-resistant	Nufip2	cDNA,	respectively	(Figure	26).	Based	on	 the	 functional	validation	of	Nufip2	 that	was	performed	 in	 this	study,	 I	will	now	discuss	possible	 functions	of	Nufip2	 in	 the	pathway	of	 ICOS	 regulation	and	develop	 strategies	 for	 future	 experimental	 approaches	 helping	 to	 shed	 light	 on	 the	burning	question	how	Nufip2	supports	Roquin-1	function.	Starting	with	the	analysis	of	
cis-elements	 in	 ICOS	 mRNA	 where	 Roquin-1	 binds	 and	 Nufip2	 might	 operate	 as	 a	cofactor,	the	interaction	partners	of	Nufip2	and	Roquin-1	will	be	discussed	building	a	potential	 network	 of	 post-transcriptional	 regulators	 on	 target	mRNAs.	 Finally,	 I	will	suggest	a	model	for	a	temporal	compartmentalization	of	ICOS	regulation	based	on	the	differential	 expression	 of	 Roquin-1	 and	 its	 cofactors	 in	 the	 T	 cell	 activation	 time	course.		
5.3.1 Molecular	 analysis	 of	 Roquin-1	 cis-elements	 in	 human	 ICOS	
mRNA	It	has	been	shown	that	Roquin-1	binds	to	a	highly	conserved	CDE	tri-loop	structure	in	the	 TNF	 3’	UTR,	 and	 induces	 deadenylation-dependent	 mRNA	 decay	 by	 interaction	with	the	CCR4-CAF1-NOT	deadenylase	complex	(Leppek	et	al.,	2013).	An	identical	CDE	was	 found	 at	 the	 3’	end	 of	 ICOS	 mRNA.	 Since	 overexpressed	 Roquin-1	 was	 able	 to	shorten	 the	 half-life	 of	 a	 reporter	 mRNA	 that	 contained	 the	 isolated	 ICOS	 CDE	sequence,	 it	 was	 anticipated	 that	 Roquin-1	 would	 induce	 post-transcriptional	regulation	 of	 ICOS	 mRNA	 in	 a	 CDE-dependent	 manner	 (Leppek	 et	 al.,	 2013).	Nonetheless,	 our	 comprehensive	 analysis	 of	 Roquin-1	 cis-elements	 in	 the	 3’	UTR	 of	
ICOS	mRNA	revealed	in	agreement	with	(Schlundt	et	al.,	2014)	that	the	perfect	CDE	is	negligible	for	Roquin-1-dependent	ICOS	regulation	in	the	context	of	a	reporter	system	employing	full-length	ICOS	mRNA	(Figure	34B,	C).	Instead,	ICOS	regulation	depended	on	a	region	that	was	formerly	assumed	to	be	a	target	of	miR-101.	It	has	been	shown	in	previous	 work	 that	 overexpression	 of	 Roquin-1	 is	 able	 to	 repress	 ICOS	 in	 miRNA-deficient	 cells	 or	 in	 cells	 that	 lack	 argonaute	 proteins	 (Glasmacher,	 2010).	Consistently,	we	could	now	show	that	a	potential	new	tri-loop	structure	folding	at	the	same	 position	 as	 the	 miR-101	 binding	 site	 is	 involved	 in	 Roquin-1-induced	 ICOS	regulation	 (Figure	 36).	 Our	 mutational	 analysis	 allowed	 to	 rule	 out	 Roquin-1	cooperation	with	miR-101	regulation	and	instead	involved	Roquin-1	interaction	with	a	 novel	 stem-loop	 structure.	 Specifically,	 we	 involved	 the	 previously	 published	mutation	that	changed	the	sequence	complementary	to	the	seed	sequence	of	miR-101	in	 the	 ICOS	 3'	UTR	 dissolving	 into	 a	 stem-loop	 structure.	 Most	 importantly,	 we	
166	 Discussion			demonstrated	 a	 functional	 rescue	 by	 introducing	 additional	mutations	 that	 restored	the	base	pairing	of	the	stem-loop.	Additionally,	we	saw	a	contributive	effect	of	a	CDE-like	stem-loop	in	the	5’	part	of	ICOS	3’	UTR.	In	the	following	paragraph,	I	will	discuss	how	 these	 findings	 can	 be	 reconciled	 with	 the	 published	 canonical	 and	 alternative	Roquin-1-bound	stem-loop	structures.		
5.3.1.1 Experimentally	determined	ICOS	cis-elements	compared	to	the	CDE	Based	on	crystal	structures	obtained	from	the	RNA-binding	ROQ	domain	of	Roquin-1	in	complex	with	the	TNF	CDE	and	mutational	analyses	(Codutti	et	al.,	2015;	Schlundt	et	al.,	2014;	Tan	et	al.,	2014),	Codutti	and	colleagues	developed	a	consensus	sequence	for	 Roquin-1-bound	 and	 regulated	 tri-loop	 structures	 (Codutti	 et	 al.,	 2015)	 (Figure	47).	 The	 consensus	 motif	 predicted	 high-affinity	 Roquin-1	 binding	 to	 stem-loop	structures	with	a	5-7	nt	stem	and	a	tri-loop	where	the	first	nucleotide	of	the	loop	is	a	pyrimidine,	followed	by	a	central	purine,	with	no	restrictions	for	the	third	nucleotide	(Y-R-N	loop).	Additionally,	nucleotide	identity	of	bases	in	the	upper	(apical)	part	of	the	stem-loop	 seemed	 to	 be	 an	 important	 determinant	 of	 the	 loop	 conformation	 by	allowing	 purine	 stacking	 interactions	 between	 the	 central	 loop	 purine	 and	 further	purine	residues	in	the	3’	part	of	the	stem.	The	resulting	major	groove	conformation	of	the	 RNA	 was	 found	 to	 be	 essential	 for	 Roquin-1	 binding	 (Codutti	 et	 al.,	 2015).	Comparing	the	former	and	newly	identified	ICOS	cis-elements	(the	CDE-,	CDE-like-	and	miR-101	TS	 stem-loop)	 (Figure	 47)	with	 the	 consensus	 sequence,	 the	 CDE	 is	 a	 near	perfect	match.	It	deviates	from	the	CDE	consensus	only	in	its	lack	of	the	basal	G-C	base	pair,	 while	 all	 four	 required	 purine	 residues	 in	 the	 apical	 3’	 part	 of	 the	 stem	 are	present	and	allow	purine	stacking	(Figure	47B)	(Leppek	et	al.,	2013).		
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Figure	47:	Roquin-1-bound	stem-loop	structures.		
Schematic	 representation	 of	 stem-loop	 structures	 targeted	 by	 Roquin-1	 and	 the	 deduced	 CDE	
consensus	sequence	for	Roquin-1-bound	tri-loops.	Y	=	pyrimidine,	R	=	purine,	N	=	pyrimidine	or	purine.	
Deviations	from	the	consensus	CDE	tri-loop	are	highlighted	in	grey.		
For	the	CDE-like	element	located	at	the	5’	end	of	ICOS	3’	UTR,	however,	the	situation	is	different	(Figure	47).	Although	 fulfilling	 the	main	requirement	of	possessing	a	Y-R-N	loop,	the	CDE-like	stem-loop	deviates	from	the	consensus	in	one	important	criterion.	The	3’	part	of	the	stem	contains	several	pyrimidine	residues	instead	of	purine	bases	at	apical	positions,	including	the	closing	base	pair,	interfering	with	purine	stacking.	Since	purine	stacking	was	considered	to	be	a	central	determinant	of	the	loop	conformation,	the	apical	3’	pyrimidine	bases	could	cause	decreased	Roquin-1	binding	affinity	to	the	CDE-like	stem-loop,	as	compared	to	the	CDE	(Codutti	et	al.,	2015).		
168	 Discussion			Sequence	 inspection	of	 the	newly	 identified	miR-101	TS	stem-loop	revealed	 that	 the	potential	stem-loop	might	actually	be	longer	than	predicted	by	the	LocARNA	software	(Figure	47).	Allowance	of	one	bulge	nucleotide	added	two	more	base	pairs	to	the	stem,	thereby	transforming	it	 into	a	7	nt-stem.	Regarding	the	CDE	consensus	structure,	the	miR-101	TS	stem-loop	again	meets	the	main	requirement	of	possessing	a	Y-R-N	loop,	but	 violates	 the	 consensus	 CDE	 structure	 in	 two	 other	 points.	 The	 closing	 base	 pair	consists	 of	 an	 A-U	 pairing	 instead	 of	 the	 more	 stable	 G-C	 base	 pair,	 and	 three	nucleotides	on	 the	3’	 side	of	 the	stem	 including	 the	closing	base	pair	are	pyrimidine	instead	 of	 purine	 residues.	 Importantly,	 when	 introducing	 compensatory	mutations	into	the	closing	base	pair	and	the	upper	stem	of	the	miR101-TS	stem-loop	or	the	CDE-like	stem-loop,	we	observed	that	regulation	was	fully	restored	(Figure	36).	This	again	is	 in	 contrast	 to	 the	 TNF	 CDE,	 where	 reversion	 of	 the	 two	 stem-closing	 base	 pairs	continued	 to	 strongly	 inhibit	 Roquin-1	 binding	 and	 function	 (Codutti	 et	 al.,	 2015;	Leppek	et	al.,	2013).	Therefore,	the	predicted	purine	stacking	interactions	do	not	seem	to	be	functionally	important	for	regulation	by	the	miR-101	TS	stem-loop	and	the	CDE-like	stem-loop.	I	wondered	how	the	discovery	of	the	CDE-like	and	the	stem-loop	in	the	miR-101	target	sequence	 as	 new	 potential	 Roquin-1-targeted	 cis-elements	 in	 the	 3'	 UTR	 of	 human	
ICOS	mRNA	fit	with	the	proposed	selective	Roquin-1	binding	to	tri-loop	structures	of	a	strict	 CDE	 consensus-type.	 Luckily,	 interesting	 hints	 were	 provided	 by	 recent	publications.	A	detailed	analysis	of	Roquin-1	cis-elements	in	the	Ox40	3’	UTR	revealed	that	more	violations	to	the	consensus	CDE	are	tolerated	by	Roquin-1	than	previously	anticipated	(Janowski	et	al.,	2016).	Functional	assays	demonstrated	that	Roquin-1	was	also	 able	 of	 binding	 a	 non-consensus	 CDE-like	 tri-loop	 (Ox40	 CDE-like)	 with	 lower	affinity,	 and	 most	 surprisingly,	 also	 a	 hexa-loop	 structure	 (Figure	 47)	 with	 high	affinity.	In	the	Roquin-1-bound	hexa-loop	the	Tyr250	of	the	ROQ	domain	emerged	as	a	new	loop-stabilizing	element	engaging	in	stacking	interactions	with	two	nucleotides	of	the	loop	and	a	purine	base	of	the	closing	base	pair.	Purine	stacking	of	the	3’	apical	part	of	the	stem	enforcing	a	specific	conformation	of	hairpin	may	therefore	not	be	required	in	 general.	 The	 configuration	 of	 the	 alternative	 tri-loop	 structure	 of	 the	miR-101	TS	stem-loop	and	recognition	by	the	ROQ	domain	are	therefore	open	questions.	Attempts	of	 crystallization	 and/or	 NMR	 analysis	 of	 the	 ROQ	 domain	 in	 combination	with	 the	CDE-like	stem-loop	and	the	newly	identified	alternative	tri-loop	structure	in	the	miR-101	 target	 site	 will	 be	 informative.	 Identification	 of	 the	 determinants	 of	 loop	conformation	 for	 these	 alternative	 tri-loops	 will	 help	 us	 to	 develop	 a	 new,	 more	
Discussion	 169	 		relaxed	consensus	for	Roquin-1	cis-elements,	which	will	be	useful	for	the	prediction	of	different	target	mRNAs	and	alternative	binding	modes	of	Roquin-1.		
5.3.1.2 Future	aspects	concerning	the	coregulation	of	Roquin-1	cis-elements	
by	Nufip2	Overall,	we	identified	the	CDE-like	stem-loop	and	a	mapped	target	region	(nt	2211	–	2271)	that	includes	the	miR-101	TS	stem-loop	as	a	new	potential	Roquin-targeted	cis-element	 on	 human	 ICOS	 mRNA	 using	 two	 different	 reporter	 systems	 with	overexpressed	and	endogenous	Roquin-1	levels	(Figure	34).	Our	reporter	cell	system	with	endogenous	Roquin-1	expression	can	only	identify	high-affinity	binding	sites	due	to	its	 low	dynamic	range,	however,	the	Roquin-1-overexpression	cell	system	appears	sufficiently	 sensitive	 to	detect	 the	whole	 range	of	 low-and	high-affinity	cis-elements.	For	this	reason	we	think	the	latter	identified	the	CDE-like	stem-loop	as	a	low-affinity	binding	 site	 for	 Roquin-1,	which	 contributes	 to	 a	 repressive	 effect	 that	 requires	 the	miR-101	 TS	 stem-loop.	 However,	 impaired	 ICOS	 regulation	 of	 some	 deletion	constructs	cannot	be	explained	by	those	two	cis-elements,	suggesting	the	presence	of	low-affinity	Roquin-1	binding	sites	distributed	over	 the	whole	 length	of	 ICOS	3’	UTR.	This	 might	 point	 towards	 the	 presence	 of	 several	 different	 high-	 and	 low	 affinity	Roquin-1	binding	sites	 in	the	3’	UTR	of	ICOS,	as	 it	has	recently	been	suggested	in	the	literature	(Jeltsch	&	Heissmeyer,	2016).		After	 identifying	 the	most	 important	 Roquin-1	 target	 regions	 on	 ICOS,	 the	 question	arises	whether	Nufip2,	which	has	been	demonstrated	to	interact	with	mRNA	(Bardoni	et	 al.,	 2003)	 regulates	 ICOS	 through	 the	 same	 or	 different	 cis-elements.	 This	 can	 be	solved	 by	 testing	 all	 available	 ICOS	 deletion	 constructs	 in	 the	 CRISPR/Cas9	 Nufip2	knockout-	 and	 reconstitution	 system	 that	 has	 been	 established	 in	 this	 study	 (Figure	26).	 Moreover,	 it	 would	 be	 highly	 interesting	 to	 evaluate	 whether	 ICOS	 is	 the	 only	target	 that	 is	 coregulated	by	Nufip2	and	Roquin-1.	This	 can	be	evaluated	on	a	 small	scale	 employing	 the	 CRISPR/Cas9	Nufip2	 knockout-	 and	 reconstitution	 system	with	individual	reporters	where	different	Roquin-1-regulated	3’	UTRs	are	fused	to	the	ICOS	CDS	(Jeltsch	et	al.,	2014).	A	complete	picture	on	Nufip2-reguated	mRNAs	and	binding	sites	 would	 be	 obtained	 by	 applying	 high-throughput	 crosslinking-	 and	immunoprecipitation	 (CLIP)	 techniques.	These	 involve	 crosslinking	of	 the	protein	of	interest	to	its	target	mRNAs,	followed	by	protein	pulldown	and	target	identification	by	deep	sequencing	and	have	successfully	been	employed	to	 identify	 target	mRNAs	and	binding	sites	for	Roquin-1	and	Regnase-1	(Mino	et	al.,	2015;	Murakawa	et	al.,	2015).		
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5.3.2 Interactions	 between	 Roquin-1,	 Nufip2	 and	 other	 potential	
cofactors	After	 validation	 of	 Nufip2	 as	 a	 cofactor	 of	 Roquin-1	 in	 post-transcriptional	 gene	regulation	of	 ICOS,	we	set	out	 to	 further	explore	 this	 largely	uncharacterized	protein	and	 its	 role	 in	 Roquin-1-induced	 gene	 repression.	 NUFIP2	 co-immunoprecipitated	with	Roquin-1	in	an	RNase-independent	manner	(Figure	28),	suggesting	the	potential	direct	 protein/protein	 interaction.	 In	 fact,	 a	 binary	 interaction	 of	 purified	 protein	fragments	 in	 surface	 plasmon	 resonance	 experiments	 was	 determined	 (Figure	 20).	Interestingly,	 this	direct	 interaction	 took	place	between	 the	N-terminus	of	Roquin-1,	containing	RING	finger,	ROQ	domain	and	Zinc	finger,	and	the	FMRP-interacting	part	of	the	 NUFIP2	 protein.	 The	 enrichment	 of	 almost	 equal	 parts	 of	 Nufip2	 and	 Roquin-1	proteins	 after	 Roquin-1	 immunoprecipitation	 from	 MEF	 cell	 extracts	 suggests	 that	most	 of	 the	 endogenous	 Roquin-1	molecules	 are	 engaged	 in	 a	 complex	with	Nufip2	(Figure	29).	This	idea	is	further	supported	by	the	fact	that	both	proteins	interact	with	high	 affinity	 in	 in	 vitro	 experiments	 (Kd	 of	 <	200	 nM)	 (Figure	 20).	 Nufip2	was	 thus	demonstrated	as	an	important	direct	binding	partner	of	Roquin-1.		The	same	fragment	of	Nufip2	that	interacts	with	Roquin-1	has	earlier	been	published	to	 engage	 in	 a	 direct	 protein/protein	 interaction	 with	 FMRP	 (Bardoni	 et	 al.,	 2003;	Ramos	 et	 al.,	 2006),	which	 forms	 homo-	 and	 heterodimers	with	 its	 family	members	FXR1	and	FXR2	(Chapter	1.1.4.1)	(Winograd	&	Ceman,	2011).	Furthermore,	Roquin-1	has	 been	 shown	 to	 colocalize	with	 Fmrp	 in	 stress	 granules	 in	 response	 to	 arsenite-induced	oxidative	stress	(Glasmacher,	2010).	Additionally,	FXR1	was	found	to	be	one	of	 the	 few	 proteins	 that	 were	 highly	 enriched	 after	 immunoprecipitation	 of	 an	aptamer-fusion	of	 the	CDE	stem-loop,	 together	with	Roquin-1	and	Roquin-2	(Leppek	et	 al.,	 2013).	 These	 results	 suggest	 that	 FMRP/FXR	 family	 proteins	 are	 linked	 to	Roquin-1-induced	 gene	 repression,	 and	 their	 newly	 discovered	 direct	 interaction	partner	 Nufip2,	 if	 ternary	 complexes	 can	 form,	 might	 be	 the	 missing	 link	 in	 this	connection.		A	 second	 link	 between	 the	 function	 of	 Roquin-	 and	 FMR	 family	 members	 may	 be	provided	 by	Ago2	 and	 the	miRNA	pathway.	 Several	 groups	 have	 reported	 examples	where	Fmrp	or	its	family	members	make	essential	contributions	to	miRNA-mediated	gene	repression	 (Caudy	et	al.,	2002;	Edbauer	et	al.,	2010;	Li	et	al.,	2014b)	and	Fmrp	was	found	to	associate	with	Dicer	and	Ago2	in	mammalian	cells	(Caudy	et	al.,	2002).	A	contribution	 of	 the	 miRNA	 pathway	 to	 Roquin-1-dependent	 target	 regulation	 is,	
Discussion	 171	 		however,	still	under	debate.	It	has	been	shown	earlier	that	miRNAs	are	dispensable	for	Roquin-1	function	(Glasmacher	et	al.,	2010).	I	could	reconfirm	this	result	by	unveiling	that	 the	 formerly	 proposed	miR-101	 target	 site	 gains	 importance	 only	 because	 it	 is	part	of	a	conserved	stem-loop	structure	 that	serves	as	a	new	potential	Roquin-1	cis-element	 in	 the	 ICOS	mRNA	(Chapter	4.1.11.2).	Nonetheless,	 it	was	recently	proposed	that	Roquin-1-induced	post-transcriptional	repression	of	mouse	Icos	may	be	conferred	by	miR-146a,	with	a	direct	interaction	between	the	N-terminus	of	Roquin-1	and	miR-146a	 forming	 a	 complex	 with	 Ago2	 (Srivastava	 et	 al.,	 2015).	 However,	 sequence	alignments	revealed	that	Icos	3’	UTR	sequence	is	~600	nts	longer	in	the	mouse	than	in	24	other	species,	including	humans	(Anne	Hoffmann,	personal	communication).	Since	one	 of	 the	 two	 mapped	 miR-146a	 binding	 sites	 in	 the	 mouse	 Icos	 3’	UTR	 is	consequently	 missing	 in	 most	 other	 species,	 while	 the	 second	 target	 site	 is	 poorly	conserved,	 it	 is	 questionable	 that	 the	 published	 mechanism	 of	 Icos	 regulation	 is	 of	general	 importance.	 Nonetheless,	 miR-146a	 does	 seem	 to	 play	 a	 role	 in	mouse	 Icos	regulation	 (Pratama	 et	 al.,	 2015;	 Srivastava	 et	 al.,	 2015),	 and	 similarly,	 miR-101	overexpression	induced	a	weak	downregulation	of	human	ICOS	(Yu	et	al.,	2007).	Thus,	the	 full	 extent	 of	 Roquin-mediated	 regulation	 may	 involve	 collaboration	 with	 the	miRNA	 pathway	 and/or	 miRNA	 pathway	 components	 in	 the	 regulation	 of	 certain	target	mRNAs.		Considering	 the	protein	 interactions	described	above,	 it	 is	 a	possible	 scenario	 that	a	translational	silencing	complex	consisting	of	Nufip2,	Fmrp/Fxr1/Fxr2	and	the	miRISC	complex	 associates	with	Roquin-1	on	 the	Roquin-1-bound	 target	mRNA	 (Figure	48).	But	 how	 does	 this	 complex	 induce	 post-transcriptional	 repression?	 Roquin-1	 is	thought	to	induce	deadenylation-dependent	mRNA	decay	by	recruitment	of	the	CCR4-CAF1-NOT	 complex	 with	 its	 C-terminal	 domain,	 while	 the	 N-terminal	 domain	 of	Roquin-1	may	be	responsible	for	recruiting	the	mRNA	decapping	complex.	Support	for	this	 model	 comes	 from	 the	 finding	 that	 the	 C-terminus	 of	 Roquin-1	 co-immunoprecipitated	with	CNOT1	and	CNOT7	of	the	deadenylase	complex	(Leppek	et	al.,	2013),	while	the	Roquin-1	N-terminus	interacted	with	Rck	and	Ecd4,	two	cofactors	of	mRNA	decapping	(Glasmacher,	2010).	However,	it	is	unclear	whether	or	not	any	of	these	 interactions	 are	 direct.	 Interestingly,	 both	 NUFIP2	 and	 FXR1/FXR2	 were	recently	identified	as	interactors	of	RCK	(Bish	et	al.,	2015),	suggesting	that	Nufip2	may	support	 or	 even	 induce	 the	 recruitment	 of	 the	 mRNA	 decapping	 complex.	 As	 the	miRISC	 complex	 is	 also	 known	 to	 induce	 deadenylation-dependent	 mRNA	 decay	(Huntzinger	&	Izaurralde,	2011),	it	is	tempting	speculate	that	all	proteins	surrounding	
172	 Discussion			Roquin-1	 in	 a	 complex	may	act	 in	 concert	 to	 initiate	mRNA	decay.	Besides,	RCK	has	been	 shown	 to	 induce	 translational	 inhibition	 (Coller	&	Parker,	 2005),	which	 is	 also	possible	 for	 Roquin-1	 based	 on	 my	 initial	 finding	 of	 Roquin-1-mediated	 repression	being	far	more	pronounced	on	the	protein	compared	to	the	mRNA	level	(Figure	10).		
	
Figure	 48:	 Different	 cofactors	 are	 involved	 in	 Roquin-1-mediated	 post-transcriptional	 gene	
regulation.		
As	 demonstrated	 in	 this	 study,	 the	 N-terminus	 of	 ROQUIN-1	 engages	 in	 a	 direct	 protein/protein	
interaction	with	NUFIP2,	which	itself	has	been	shown	to	directly	 interact	with	FMRP	(Bardoni	et	al.,	
2003;	Ramos	et	al.,	2006).	FMRP	and	ROQUIN-1	were	both	shown	to	interact	with	AGO2	of	the	miRNA-
induced	silencing	complex	(miRISC)	(Li	et	al.,	2014b;	Pratama	et	al.,	2015;	Srivastava	et	al.,	2015).	For	
inducing	mRNA	decay,	the	C-terminus	of	ROQUIN-1	is	thought	to	recruit	the	CCR4-CAF1-NOT	complex	
(Leppek	 et	 al.,	 2013),	 while	 the	 N-terminus	 can	 bind	 to	 the	 cofactors	 of	 decapping	 RCK	 and	 EDC4	
(Glasmacher,	 2010).	 Interaction	with	 RCK	 can	 also	 be	mediated	 by	NUFIP2	 (Bish	 et	 al.,	 2015).	 The	
exonuclease	XRN1	is	recruited	via	interaction	with	EDC4	(Braun	et	al.,	2012;	Chang	et	al.,	2014),	and	
initiates	5’	–	3’	mRNA	decay.		
The	 translational	 silencing	 complex	 assembling	 around	 Roquin-1	might	 thus	 induce	target	gene	repression	by	a	combination	of	mRNA	decay	and	translational	 inhibition.	Regnase-1	was	 left	 out	 in	 this	model	 although	deficiency	 of	 the	Regnase-1	 encoding	gene	 leads	 to	 elevation	of	 ICOS	 levels	 (Jeltsch	 et	 al.,	 2014).	Although	Regnase-1	was	not	essential	for	Roquin-1	dependent	ICOS	regulation	and	did	therefore	not	emerge	as	a	Roquin-1	cofactor	in	our	screen,	 it	turned	out	to	be	highly	important	for	Roquin-1-dependent	regulation	of	the	CDE260	reporter	(Figure	18).	Regnase-1	might	thus	be	a	selective	 cofactor	 for	a	 subset	of	Roquin-1	 targets.	Different	 theories	exist,	 however,	on	how	Roquin-1	and	Regnase-1	cooperate	or	antagonize	in	target	regulation,	making	it	difficult	to	include	in	the	model	(Jeltsch	et	al.,	2014;	Mino	et	al.,	2015).		Although	 my	 model	 (Figure	 48)	 provides	 a	 first	 draft	 of	 how	 Roquin-1	 might	collaborate	with	different	 cofactors	 to	 induce	post-transcriptional	gene	 regulation,	 it	
Discussion	 173	 		still	 requires	 experimental	 validation,	 especially	 concerning	 the	 roles	 of	 Fmrp	 and	Nufip2.	 The	 question	 arises	 how	 Roquin-1	 and	 Fmrp	 can	 directly	 interact	 with	 the	same	domain	of	Nufip2.	This	paradox	cannot	be	answered	yet,	but	will	be	clarified	in	future	experiments.	 In	 collaboration	with	Dr.	Dirk	Niessing’s	group,	we	will	perform	advanced	 surface	 plasmon	 resonance	 studies	 with	 all	 three	 interacting	 protein	fragments	 in	 order	 to	 elucidate	 whether	 Roquin-1	 and	 Fmrp	 indeed	 bind	simultaneously	to	the	same	Nufip2	domain.	An	alternative,	likewise	possible	scenario	would	 be	 mutual	 exclusive	 binding	 of	 both	 proteins,	 which	 would	 require	 an	adaptation	of	our	model.		As	a	burning	question	it	remains	to	be	answered	what	exactly	Nufip2	contributes	to	in	Roquin-1-mediated	 ICOS	 repression.	 Future	 experiments	 discerning	 Nufip2	 cis-elements	 in	 ICOS	 might	 reveal	 whether	 besides	 engaging	 in	 a	 protein/protein	interaction	with	Roquin-1	and	other	post-transcriptional	regulators,	Nufip2	increases	the	 affinity	 of	 Roquin-1	 to	 certain	 target	 mRNAs	 by	 simultaneously	 binding	 to	 the	same	 RNA	 (Chapter	 5.3.1).	 By	 directly	 interacting	 with	 Roquin-1,	 Nufip2	 might	mediate	Roquin-1’s	 interaction	with	 indirect	binding	partners,	 such	as	Rck	or	Fmrp.	This	can	be	evaluated	in	immunoprecipitations	of	Roquin-1	and	systematic	analysis	of	interacting	cofactors	in	cells	that	are	either	deficient	for	EDC4,	NUFIP2,	RCK	and	FMRP	compared	 to	 wildtype	 counterparts.	 With	 the	 advent	 of	 the	 CRISPR/Cas9	 genome	editing	 technology,	 this	 approach	 is	 feasible,	 and	 it	 will	 eventually	 provide	 insights	into	the	order	of	events	during	the	assembly	of	the	mRNP	that	coordinates	Roquin-1-mediated	mRNA	degradation.		Another	 possible	 scenario	 of	 how	 Nufip2	 might	 support	 Roquin-1-dependent	 post-transcriptional	regulation	arises	from	its	ability	to	accumulate	together	with	Roquin-1	in	stress	granules	upon	arsenite-induced	oxidative	stress	(Figure	31).	The	observation	that	Roquin-1,	as	well	as	its	target	mRNA	ICOS	(Yu	et	al.,	2007),	can	localize	to	both	P	bodies	 and	 stress	 granules	 (Athanasopoulos	 et	 al.,	 2010;	 Glasmacher	 et	 al.,	 2010)	favors	 the	 recently	 proposed	 theory	 of	 a	 dynamic	 relationship	 between	 actively	transcribed	mRNAs	and	their	 localization	to	stress	granules	or	P	bodies	for	temporal	storage	 or	 mRNA	 degradation,	 respectively	 (Decker	 &	 Parker,	 2012).	 Sorting	 of	Roquin-1-containing	mRNPs	to	one	of	the	two	respective	sites	may	depend	on	binding	partners.	Recent	literature	suggests	that	P	body	formation	is	initiated	by	recruitment	of	 P	 body	 factors	 to	 the	messenger	 RNA,	while	 aggregation	 of	multiple	mRNPs	 into	cytoplasmic	 granules	 is	 the	 second	 step	 that	 is	mediated	by	Q/N	 rich	 regions	 of	 the	
174	 Discussion			aggregating	 proteins	 (Anderson	 &	 Kedersha,	 2009).	 Since	 Nufip2	 possesses	 such	 a	Q/N	 rich	 protein	 aggregation	 domain,	 it	 was	 recently	 proposed	 to	 take	 part	 in	 the	assembly	 of	 stress	 granules	 (Bish	 et	 al.,	 2015).	 Whether	 Nufip2	 is	 responsible	 for	aggregation	 of	 Roquin-1-mRNPs	 can	 be	 tested	 in	 a	 new	 experimental	 approach	 of	selective	precipitation	(Kato	et	al.,	2012).	Incubation	of	cytoplasmic	cell	lysates	with	a	biotinylated	version	of	 the	chemical	 compound	 isoxazole	 (b-isox)	 leads	 to	 reversible	aggregation	of	RNA	granule-like	 structures,	which	 can	 subsequently	be	pulled	down	with	 streptavidin	beads.	 In	 this	 assay	 aggregation	was	 found	 to	be	mediated	by	 low	complexity	 (LC)	 polypeptide	 sequences,	 which	 were	 found	 in	 most	 of	 the	 106	precipitated	proteins,	including	Nufip2	and	all	members	of	the	FMR	protein	family.	To	address	whether	Nufip2	is	essential	for	Roquin-1-mRNPs	aggregation,	we	will	perform	b-isox	 treatment	 and	 streptavidin	 pulldown	 of	 RNA-granules	 in	 cell	 lysates	 from	arsenite-treated	 Nufip2-wildtype	 and	 -knockout	 cells.	 Western	 blot	 detection	 of	Roquin-1	will	 enable	us	 to	quantify	 the	extent	of	Roquin-1-mRNP	aggregation	 in	 the	presence	and	absence	of	endogenous	Nufip2	and	after	Nufip2	overexpression.		
5.3.3 Roquin-1	 cofactors	 regulate	 ICOS	 in	different	phases	after	T	 cell	
activation	It	 is	now	clear	that	Nufip2	regulates	Icos,	however,	 it	 is	still	elusive	whether	this	is	a	constitutive	contribution	to	Roquin-1	function	or	a	dynamic	one.	Nufip2	might	have	a	general	 impact	 on	 Roquin-1’s	 function	 and	 also	 influence	 the	 regulation	 of	 other	Roquin-1	 targets.	This	 aspect	of	Nufip2	 function	was	not	part	of	 this	 research	work,	which	 focused	 on	 the	 regulation	 of	 Icos	 as	 a	 critical	 costimulatory	 molecule	 of	 the	antibody-dependent	 immune	 response.	Considering	 a	possible	dynamic	 contribution	to	Roquin-1	 function,	we	wondered	whether	 the	known	 trans-acting	 factors	of	post-transcriptional	regulation	of	Icos	were	constantly	expressed	in	T	cells	or	whether	their	expression	was	dynamically	regulated.	The	expression	of	these	proteins	was	therefore	analyzed	 over	 a	 2-week	 Th1	 culture.	 Interestingly,	 they	 showed	 very	 different	expression	maxima	over	the	course	of	differential	Icos	expression	(Figure	33).	Roquin	and	 Nufip2	 were	 coexpressed	 with	 highest	 levels	 at	 day	 1-4	 after	 anti-CD3/CD28	stimulation	so	was	Fxr1.	Ago	proteins	had	their	expression	maxima	earlier,	before	and	shortly	after	stimulation,	while	Fmrp	and	Regnase-1	appeared	later,	from	day	3	till	day	6	 after	 activation.	 Since	 ICOS	 is	 very	dynamically	 regulated	 and	 strongly	 induced	by	transcriptional	upregulation	(Tan	et	al.,	2006),	it	is	not	clear	when	post-transcriptional	regulation	contributes	 the	most.	This	will	 require	 further	 testing,	which	can	be	done	
Discussion	 175	 		by	using	 the	3’	UTR	of	mouse	 Icos	 as	a	 reporter	system.	Although	 it	 still	needs	 to	be	clarified	 which	 of	 the	 changes	 in	 Icos	 expression	 are	 due	 to	 post-transcriptional	regulation,	 the	differential	expression	patterns	of	 the	 Icos	trans-acting	 factors	allows	the	following	interpretation:	Ago	proteins	and	thus	the	miRNA	pathway	can	influence	early	Roquin	regulation,	while	Nufip2	and	Fxr1	can	contribute	later	in	the	course	of	T	cell	activation	and	resting.	The	strongest	coregulation	of	Icos	by	Roquin-1	and	Nufip2	can	thus	be	assumed	between	day	1-3,	the	time	when	ICOS	levels	change	dramatically.	Knowing	 the	 time	 point	where	 the	 coregulatory	 effect	 on	 Icos	 can	 become	maximal	opens	the	way	for	testing	Nufip2-dependency	of	Icos	regulation	in	T	cells.	In	a	future	experiment,	we	will	introduce	Nufip2-targeting	shRNAs	into	CD4+	T	cells	and	analyze	Icos	 expression	 between	 day	 3	 and	 day	 5	 after	 restimulation,	 since	 this	 is	 the	 time	point	where	one	would	expect	maximal	contribution	of	Nufip2.	This	experiment	will	shed	light	on	the	role	of	Nufip2	in	Icos	repression	following	T	cell	activation.		
5.4 Conclusion	
Over	their	whole	lifetime	mRNAs	remain	associated	with	trans-acting	factors	such	as	RNA-binding	proteins	in	the	form	of	mRNA-protein	complexes	(mRNPs).	Although	the	landscape	 of	 active	 RNA-binding	 proteins	 has	 recently	 been	 determined	 in	 human	cells,	the	function	of	many	RBPs	is	still	elusive.	In	this	research	work,	a	new	function	was	attributed	to	 the	previously	uncharacterized	RBP	Nufip2	by	unveiling	 its	critical	importance	 for	 Roquin-1-mediated	 post-transcriptional	 gene	 regulation	 of	 the	inducible	T	cell	costimulatory	receptor	Icos	in	a	high-throughput	screening	approach.	Functional	 validation	demonstrated	 that	Nufip2	 engages	 in	 a	 direct	 interaction	with	the	N-terminus	of	Roquin-1,	and	Nufip2	is	herewith	its	 first	proven	direct	 interactor.	This	 new	 finding	 provides	 a	 starting	 point	 for	 further	 investigation	 of	 the	 mRNP	composition	 that	 directs	 Roquin	 function.	 mRNPs	 are	 remodeled	 during	 different	functional	 stages	 of	 mRNAs	 and	 their	 composition	 is	 believed	 to	 be	 a	 critical	determinant	 of	 the	mRNA	 fate.	 It	 was	 demonstrated	 in	 this	 research	work	 that	 the	known	 post-transcriptional	 regulators	 of	 Icos	 including	 Nufip2	 display	 strikingly	different	 expression	 kinetics	 following	 T	 cell	 activation	 suggesting	 a	 dynamic	contribution	 to	 Roquin-1	 function.	 Since	 composition	 and	 dynamics	 of	 mRNP	formation	 that	 are	 involved	 in	 post-transcriptional	 gene	 regulation	 are	 still	 poorly	investigated,	 this	 finding	 opens	 up	 a	 window	 of	 opportunity	 to	 understand	 the	complex	regulation	of	Icos	by	Roquin-1	and	its	cofactors.		
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Appendix	I:	Validation	of	candidates	from	the	RBP	subset	by	overexpression.		Flow	 cytometric	 analysis	 of	 ICOS	 and	 Thy1.1	 expression	 in	 HeLa	 cells	 with	constitutive	 ICOS	 expression	 upon	 overexpression	 of	 mouse	 or	 human	 cDNA	encoding	12	RNA-binding	candidates	from	the	targeted	Roquin-1	cofactor	screen.	Roquin-1	 full-length	(FL)	was	employed	as	a	positive	control,	while	Roquin-1	(1-509)	 served	 as	 a	 negative	 control.	 Thy1.1	 was	 used	 as	 a	 marker	 for	 retroviral	transduction	with	the	overexpression	constructs.	
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Appendix	II:	Deconvolution	of	siRNA	pools	into	individual	siRNAs	identifies	five	
single	hitters.		Flow	 cytometric	 analysis	 of	 ICOS	 and	 mCherry	 expression	 for	 deconvolution	 of	siRNA	 pools	 into	 individual	 siRNAs	 is	 shown	 for	 5	 candidates,	 where	 only	 one	siRNA	in	the	pool	was	responsible	for	ICOS	derepression.		
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Appendix	III:	Deconvolution	of	siRNA	pools	into	individual	siRNAs	identifies	six	
candidates	with	two	scoring	siRNA.		Flow	 cytometric	 analysis	 of	 ICOS	 and	 mCherry	 expression	 for	 deconvolution	 of	siRNA	pools	 into	 individual	siRNAs	is	shown	for	six	candidates	where	two	siRNA	mediated	the	effect	of	the	pool.		
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Appendix	IV	Deconvolution	of	the	PI4KA	and	STK38	siRNA	pools	shows	a	strong	
correlation	between	knockdown	efficiency	and	ICOS	derepression	for	multiple	
siRNAs.		Flow	 cytometric	 analysis	 of	 ICOS	 and	 mCherry	 expression	 for	 deconvolution	 of	siRNA	pools	into	individual	siRNAs	is	shown	for	the	kinases	STK38	and	PI4KA.		
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Appendix	V:	A	new	monoclonal	Nufip2-antibody	recognizes	 the	N-terminus	of	
Nufip2	with	high	affinity	and	specificity.		Immunoblot	analysis	of	whole	cell	lysates	from	different	cell	lines	probed	with	the	newly	 established	 monoclonal	 Nufip2	 antibody	 (23G8).	 Nufip2	 knockout	 (KO)	HeLa	 and	 MEF	 cells	 were	 created	 by	 transduction	 with	 lentiCRISPR	 encoding	 a	human	or	mouse	Nufip2-targeting	 sgRNA,	 respectively.	From	HeLa	cells,	 a	 stable	clone	was	generated,	showing	no	Nufip2	signal,	while	bulk	cells	with	some	residual	Nufip2	 expression	 are	 shown	 for	 MEF	 cells.	 In	 addition	 to	 the	 specific	 Nufip2	signals	 at	 75	 kDa	 for	 endogenous	 Nufip2	 and	 110	 kDa	 for	 overexpressed	 GFP-NUFIP2	 (black	 arrows),	 the	 antibody	 shows	 two	 unspecific	 bands	 at	 63	 and	 48	kDa.	Detection	of	the	N-terminal	part	of	NUFIP2	was	shown	by	overexpression	of	GFP-NUFIP2	(aa	1-255)	versus	GFP-NUFIP2	full-length	(FL).		
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